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Abstract 
Diabetes is one of the largest global health crises, affecting some 415 million adults 
worldwide, with type 2 diabetes mellitus (T2DM) accounting for at least 90% of all cases of 
diabetes. In line with international statistics, New Zealand has a high prevalence of diabetes 
with around 240,000 New Zealanders living with diabetes. However, therapeutic options for 
T2DM have limited success in restoring normal physiology. The human colon is colonised by 
some 20 trillion bacterial cells, collectively referred to as the gut microbiota. Recent research 
implicates the gut microbiota in energy balance and metabolism, and differences in the gut 
microbiota have been demonstrated between healthy individuals and those with T2DM. 
However, studies to date have not reported consistent changes in the gut microbiota 
composition across the glycaemic spectrum.  
The aim of this thesis was to further investigate the relationship between the gut microbiota, 
diet and glucose tolerance across the glycaemic spectrum. As part of the dietary analysis, 
associations between dietary vitamin C intakes, plasma vitamin C status and glycaemic 
control were also investigated.  
Findings from baseline data of the Canterbury Health, Ageing and Lifecourse (CHALICE) 
study were used to characterise the metabolic profile and self-reported dietary intake of 49-51 
year-olds from Canterbury, New Zealand. Results from this study showed the mean plasma 
vitamin C concentration to decrease with deterioration in blood glucose, despite no significant 
differences in self-reported dietary vitamin C intake.  
A cross-sectional observational pilot study involving well characterised participants was 
undertaken to investigate associations between the gut microbiota, glycaemic control, self-
reported dietary intake, and other indicators of metabolic health. Multiple regression analysis 
showed the class Actinobacteria was independently positively associated with fasting glucose 
and negatively associated with plasma vitamin C concentrations. Congruent with the 
CHALICE results, this study also showed plasma vitamin C concentrations to be significantly 
lower in individuals with T2DM compared to those with normal glucose tolerance (NGT).  
In the search for a novel therapy for T2DM, a logical extension from the observational study 
was to investigate if the gut microbiota could be manipulated by dietary change in people 
with prediabetes. SunGold kiwifruit is both high in vitamin C and is known to alter microbial 
ecology and metabolism in vitro, and therefore, could potentially impact human health. A 
pilot exploratory study was carried out where participants were asked to consume two 
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SunGold kiwifruit daily as part of their usual diet for 12 weeks. Results showed a significant 
increase in the relative abundance (RA) of the class Coriobacteriia with no deterioration in 
HbA1c. It is hypothesised that the polyphenols in the SunGold kiwifruit act as an energy 
source for this class of bacteria. Supplementation with two SunGold kiwifruit per day also 
significantly increased participants’ plasma vitamin C concentrations.   
This thesis posits that the class Actinobacteria is associated with glycaemic control and the 
class Coriobacteriia can be manipulated by SunGold kiwifruit. However, as the study cohorts 
in this thesis were small, findings need to be replicated in larger populations. Furthermore, the 
implications of these results need to be investigated.    
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 Chapter One: Introduction 
1.1 Diabetes 
1.1.1 Definition and Rising Prevalence 
The World Health Organization (WHO) has defined diabetes mellitus as:  
a metabolic disorder of multiple aetiology characterized by chronic 
hyperglycaemia (raised blood glucose concentrations) with disturbances of 
carbohydrate, fat and protein metabolism resulting from defects in insulin 
secretion, insulin action, or both (1). 
Diabetes is one of the largest health crises, with 415 million people between the ages of 20 
and 70 years worldwide estimated as having diabetes in 2015, and the prevalence is 
increasing (2). Diabetes is a major health issue in New Zealand with 245,680 New Zealanders 
diagnosed with diabetes, and significant numbers with undiagnosed diabetes, or prediabetes 
(3). Results from the 2008/2009 New Zealand Adult Nutrition Survey (NZANS) provided 
data on the prevalence of diabetes and prediabetes using the American Diabetes Association 
(ADA) criteria, and found that the prevalence of diabetes and prediabetes was 7.0% and 
25.5% respectively (4). The prevalence of diabetes was higher in men (8.3%) than in women 
(5.8%), and was higher among the obese (14.2%) compared with the normal weight group 
(2.5%) (4). In New Zealand the prevalence of diabetes is greatest for Pacific ethnicities 
(11.1%) and is also greater for Asian (6.5%) and Māori (11.6%) when compared with New 
Zealand European people (4.9%) (5). The 2008/2009 NZANS reported that by 65 years, 35% 
of Māori have been diagnosed with diabetes, compared to 13.2% of individuals identifying as 
New Zealand European or other ethnicity (4). 
There are three main types of diabetes: type 1 diabetes mellitus (T1DM), type 2 diabetes 
mellitus (T2DM) and gestational diabetes mellitus (GDM). T2DM accounts for at least 90% 
of all cases of diabetes (2). People with diabetes are at a higher risk of developing a number 
of disabling and life-threatening health conditions (2). Diabetes is predicted to become the 
seventh leading cause of death by 2030 (6). In addition to this, there is a financial burden for 
individuals and families, and there is a substantial economic impact on countries and national 
health systems (2). People with diabetes require at least two to three times the health-care 
resources of those who do not have diabetes, and diabetes care may account for up to 15% of 
national healthcare budgets (7). In 2008 the cost of publicly provided health services for 
! 2!
T2DM in New Zealand was estimated to be $600 million, and the cost of T2DM was 
expected to rise to $1.8 billion by 2022 (8).  
The increase in the prevalence of diabetes necessitates further research to be carried out 
exploring modifiable causative factors and novel treatment options. Recently, researchers 
have been interested in the gut microbiota as a potential novel contributor to the diabetes 
epidemic. As T2DM accounts for at least 90% of all cases of diabetes the focus of this 
research is on the role of the gut microbiota in the prevention and management of T2DM (2).  
1.1.2 Obesity as a Risk Factor for T2DM  
Epidemiological studies reveal increases in body weight and obesity in virtually all 
populations over the last three decades (9). In 2014 the WHO estimated more than 1.9 billion 
adults (>18 years) were overweight (body mass index (BMI) of 25.0-29.9 kg/m2) and of these 
over 600 million were obese (BMI ≥30 kg/m2) (10). In line with the international statistics 
and prevalence of T2DM, New Zealand also has a high prevalence of obesity, with the 
2015/16 Health of New Zealand Adults survey reporting 31.6% of New Zealand adults to be 
obese and 66.8% to be overweight or obese (>25 kg/m2) (5). In New Zealand, in 2006 the 
annual health care cost attributable to overweight and obesity was estimated to be $624 
million (4.4% of New Zealand’s total health care expenditure in 2006) (11). Therefore, 
identifying novel interventions to reduce energy consumption, absorption and/or storage has 
considerable importance for population health.  
1.1.3 Progression to T2DM 
1.1.3.1 Normal glucose tolerance (NGT) 
Individuals with normal blood glucose concentrations are regulated by a complex interaction 
involving feedback relationships between hormones and circulating glucose concentrations 
(12). Insulin is the primary hormone responsible for glucose uptake from the blood stream in 
insulin-sensitive tissues such as muscle and fat and it helps suppress hepatic glucose 
production, thereby lowering blood glucose concentrations (12, 13). In contrast, glucagon 
stimulates hepatic glucose production, especially in the fasting state, to raise blood glucose 
concentrations (12). Insulin and glucagon originate in the pancreas from the islets of 
Langerhans (α- and β-cells). The rise in glucose from the breakdown of carbohydrates 
stimulates pancreatic β-cells to release insulin. This facilitates the uptake of glucose to tissues 
and inhibits glucagon from being released from the α-cells, thereby suppressing hepatic 
glucose production. In contrast, low plasma blood glucose concentrations stimulate α-cells to 
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release glucagon, mobilize stored glucose from the liver and increase hepatic glucose 
production. In addition to insulin and glucagon, incretins are gut-derived hormones that are 
also released in response to nutrient ingestions (mainly glucose and fat), and they also play an 
important role in pancreatic α- and β-cell responses to rising plasma glucose (14). When 
glucose concentrations rise, the insulin response is influenced by the simultaneous release of 
incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 
peptide (GIP) secreted by the gastrointestinal tract (GI), which amplify glucose-stimulated 
insulin secretion, inhibit glucagon secretion, initiate satiety and delay gastric emptying (15).  
1.1.3.2 Prediabetes, impaired glucose tolerance, impaired fasting glycaemia 
Impaired fasting glucose (IFG) is defined as fasting glucose concentrations in the range 
5.6-6.9 mmol/L measured in a fasting individual (16). Impaired glucose tolerance (IGT) refers 
to delayed clearance of glucose from blood postprandially (16). It is defined as a 2-hour blood 
glucose value in the range 7.8-11.0 mmol/L following a 75 g glucose load, referred to as an 
oral glucose tolerance test (OGTT) (16).  
IGT and IFG are intermediate conditions in the transition between normal glucose control and 
diabetes. People with IGT or IFG are at high risk of progressing to T2DM, although this is not 
inevitable (17). Prediabetes reflects a stage between NGT and diabetes. In routine practice, it 
is characterised by an increase in glycated haemoglobin (HbA1c). If an OGTT has not been 
performed, it is not possible to determine whether an increase in HbA1c reflects IFG, IGT or 
both. Glucose tolerance refers to an individual’s ability to clear glucose from the blood. 
Glucose control refers to the ability of an individual to keep their blood glucose within the 
physiological range.  
1.1.3.3 T2DM 
T2DM is a complex disorder influenced by both genetic and environmental factors; however, 
the genetics of T2DM are complex and not fully defined (16). T2DM is characterised by 
chronic hyperglycaemia, altered insulin secretion, and insulin resistance (16). Although the 
specific aetologies of T2DM are not known, unlike T1DM, autoimmune destruction of β-cells 
does not occur (17). The risk of developing T2DM increases with age, obesity or increased 
percentage of body fat in the abdominal region, and lack of physical activity (16). It occurs 
more frequently in women with prior GDM and in individuals with metabolic syndrome, and 
its frequency varies between different ethnic groups (16). T2DM is a progressive disease, and 
research has shown the decline of β-cell function develops years before diagnostic glucose 
! 4!
values for overt diabetes develop, with individuals having already lost approximately 50% of 
β-cell function at the time of diagnosis (18). It is proposed that β-cell dysfunction may be 
caused by amyloid deposition in the islets, oxidative stress, excess fatty acid or lack of 
incretin effect (19). It has also been suggested that insulin resistance may be caused by an 
insulin signaling defect or lipotoxicity (19). The incretin effect has also been shown to be 
reduced in people with T2DM, with incretin hormones having been shown to be unable to 
increase insulin secretion after glucose ingestion (15, 20). 
In recent years, researchers have been interested in the gut microbiota as a potential novel 
contributor to the diabetes epidemic (21) and this is a major focus of this thesis. T2DM has 
been reported to be associated with an alteration in the usual balance of bowel bacterial 
species, described as a bacterial dysbiosis (22). 
1.1.4 Diagnostic Criteria 
Glucose impairment runs on a continuum, making selection of a specific value where diabetes 
risk begins somewhat arbitrary. The occurrence of diabetes-specific complications across a 
range of plasma glucose concentrations has been used to derive diagnostic cut-off points for 
diabetes. In particular, data from epidemiological studies that have examined both prevalent 
and incident retinopathy were used to define the current diagnostic threshold, which 
corresponds to the glucose level at which the risk of retinopathy increases (23). Since 2011 
the WHO has recommended using HbA1c as a diagnostic test for diabetes, providing that 
stringent quality assurance tests are in place and assays are standardized to criteria aligned 
with the international reference values, and there are no conditions present that preclude the 
accurate measurement of HbA1c, such as variant forms of haemoglobin (24). 
Prior to this, the measurement of plasma glucose in fasting subjects was widely accepted as a 
diagnostic criterion for diabetes and considered the ‘gold standard’ for diagnosis (25). 
Glucose present in the blood binds irreversibly to amino acids on the haemoglobin molecule 
in red blood, forming HbA1c. The lifespan of red blood cells is approximately 120 days, 
consequently HbA1c reflects average plasma glucose levels over 8-12 weeks, and is a 
measure of glucose control (25). Tests can be performed any time of the day and do not 
require special preparation such as fasting (25). HbA1c, therefore, reflects both fasting and 
postprandial blood glucose concentrations, whereas fasting plasma glucose does not take into 
account the postprandial blood glucose concentrations.  
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There are limitations to both methods, as biological variation and pre-analytical variation such 
as prolonged fasting or exercise may impact fasting plasma glucose measurements (25). 
HbA1c measurements may be altered by changes in the red blood cell life cycle span, 
ethnicity, and conditions that interfere with the measurement, such as haemoglobinopathies 
(25). There continues to be considerable debate as to what measure should be used to 
diagnose prediabetes and diabetes, due to the strengths and limitations associated with both 
HbA1c and a glucose-based test.  
In 2003 the ADA modified its recommendations by lowering the threshold for IFG from 
6.1 mmol/L to 5.6 mmol/L (Table 1.1), resulting in discrepancies between the ADA 
recommendations and those of the WHO and New Zealand (23, 26). For the purpose of this 
thesis, the author has used the cut-off values defined by the ADA for normoglycaemia, 
prediabetes (or IFG), and T2DM (Table 1.1). In this thesis, the author used the ADA’s lower 
cut-off value for classifying prediabetes, as population studies have found this cut-off to have 
the highest sensitivity and specificity for predicting future diabetes (27). There is evidence 
that suggests β-cell function starts to alter well before the fasting glucose level of 6.1 mmol/L 
(27). Furthermore, 6.1-6.9 mmol/L is a very narrow band given the day-to-day variability in 
glucose measurements with potential study participants only having one measurement as part 
of screening for studies included in this thesis (27). 
Table 1.1: Diagnostic Criteria for Prediabetes and T2DM 
! HbA1c!
(mmol/mol)!
FG!!
(mmol/L)!
OGTT!2!Hour!
(mmol/L)!
Prediabetes! ! ! !
NZSSD‡! 41!)!49! 6.1!–!6.9! Not!specified!
WHO! Not!specified*! 6.1!–!6.9! !7.8!)11.0!
ADA! 39!)!46! 5.6!–!6.9! !7.8)11.0!
Diabetes! ! ! !
NZSSD! ≥!50! ≥!7.0! Not!specified!
WHO! ≥!48†! ≥!7.0! ≥!11.1!
ADA! ≥!48! ≥!7.0! ≥!11.1!
* In 2011 the WHO concluded that there is currently insufficient evidence to make any formal recommendations 
on the interpretation of HbA1c concentrations below 6.5%. 
† In 2011 the WHO recommended an HbA1c of 6.5% as the cut-off point for diagnosing diabetes (equivalent to 
48 mmol/mol). 
‡ New Zealand Society for the Study of Diabetes (NZSSD) 
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In addition to the discrepancies between countries in diagnostic thresholds, research has 
shown that HbA1c and fasting glucose are not in exact agreement when used for the diagnosis 
of prediabetes and T2DM, because HbA1c is a function of both fasting and postprandial 
hyperglycaemia (28). Monnier et al. (28) reported the relative contribution of postprandial 
glucose excursions to be predominant in fairly controlled patients, whereas the contribution of 
fasting hyperglycaemia was reported to gradually increase as diabetes progressed. A study of 
Korean patients reported that the use of fasting glucose compared to HbA1c may result in an 
underestimation of diabetes and prediabetes (29). Another study in a Palestinian Arab 
population reported only 50% of diabetic patients to be identified by both fasting glucose and 
HbA1c (30). For these reasons, this is a difficult group to study due to discrepancies in 
diagnosis by different methods, and it is also difficult to compare studies where participants 
have been grouped by different diagnostic cut-off values and diagnostic tests. 
1.1.5 Hormones Associated with Body Weight and T2DM 
Body weight reflects the balance between energy intake and energy expenditure (31). Weight 
gain will occur when there is a sustained imbalance between energy intake and energy 
expenditure (positive energy balance) (32). Obesity is characterised by an increase in adipose 
tissue, which in adults comprises white adipose tissue (WAT) and brown adipose tissue 
(BAT) (32). The main role for WAT is to store energy, which can be released as free fatty 
acids when there is food deprivation (32). In contrast, BAT has a role in the regulation of 
body temperature and generates heat via thermogenesis (32). 
1.1.5.1 Adiponectin 
Adipose tissue produces a number of hormones involved in metabolism, including 
adiponectin (33). Adiponectin has pleiotropic effects on pancreatic β-cells, including insulin 
sensitizing and anti-inflammatory effects (34). The production of adiponectin is inversely 
related to obesity and low adiponectin is an independent risk factor for T2DM (35). 
1.1.5.2 Leptin and ghrelin 
Leptin and ghrelin play a key role in energy homeostasis (31). Leptin informs the brain of 
changes in both energy balance and the amount of energy stored as fat (31). An increase in 
circulating leptin concentrations triggers a response to reduce energy intake, and it promotes 
energy expenditure, thereby inducing weight loss (31, 36). In contrast, ghrelin is released 
when nutrient availability is low, and after consumption of a meal, ghrelin levels decrease: 
! 7!
thus it is thought to play a role in meal initiation (36). Obesity is associated with leptin 
resistance, resulting in elevated circulating concentrations of leptin, as well as the inability of 
exogenous leptin to decrease food intake and body weight (36). Conversely, ghrelin is more 
important during negative energy balance than during positive energy balance and is inversely 
related to BMI (36). 
1.1.5.3 Insulin, amylin and glucagon 
Insulin and glucagon are the key mediators in adjustments to glucose production in the liver 
and uptake of glucose by muscles and other tissues in response to dietary intake and changing 
metabolic demands (12) (Section 1.1.3.1). A third hormone, amylin, is a peptide co-secreted 
with insulin from the pancreatic β-cells and is responsible for modulating the rate of nutrient 
delivery (gastric emptying) and suppressing the release of glucagon (12). 
The coordinated response of these hormones to changing blood glucose levels helps to 
maintain blood glucose homeostasis (12). For example, under normal conditions the rise in 
blood glucose after a meal stimulates pancreatic β-cells to release insulin, which facilitates 
tissue uptake of glucose and inhibits glucagon from being released from the α-cells to 
suppress hepatic glucose production (12). In contrast, when plasma glucose levels are low (for 
example, in the fasting state) α-cells release glucagon to mobilize stored glucose from the 
liver and increase hepatic glucose production to increase plasma glucose levels (12).  
The link between insulin resistance and T2DM is well recognized, although the mechanisms 
underlying insulin resistance remain poorly understood. If insulin resistance is present, β-cells 
maintain normal glucose tolerance by increasing insulin output (37). When β-cells cannot 
release sufficient insulin in the presence of insulin resistance, glucose concentrations rise (37), 
also playing an important role in the progressive β-cell failure of T2DM. 
1.1.5.4 Incretins 
Incretins are naturally occurring hormones released by the gut throughout the day in response 
to the presence of glucose in the gut, which also play an important role in the control of 
plasma glucose levels by modulating the activity of pancreatic β- and α-cells (38). Incretins 
facilitate the responses of the pancreas and liver to plasma glucose fluctuations (15). The 
main hormones responsible for the incretin effect are thought to be glucose-dependent GIP 
and GLP-1 (20). GLP-1 and GIP are both released from enteroendocrine cells after oral 
glucose, augmenting glucose-stimulated insulin secretion (39). In addition, the actions of 
these hormones include inhibiting glucagon secretion, induction of satiety, and delay in 
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gastric emptying (40). The incretin effect is severely reduced or absent in patients with T2DM 
(39).  
1.1.6 Plasma Vitamin C and T2DM 
Vitamin C (ascorbic acid) is a water-soluble vitamin that must be obtained from the diet as 
humans are not able to synthesize it (41). Insufficient dietary intake can lead to 
hypovitaminosis C (defined as a plasma concentration ≤ 23 µmol/L) and scurvy (42). Vitamin 
C has many important biological functions, including its ability to act as a potent antioxidant, 
scavenging a wide variety of reactive oxygen and nitrogen species, and regenerating other 
small molecule antioxidants from their respective radicals (43). 
Research suggests that people with T2DM have lower plasma vitamin C concentrations than 
those with normal glucose control (44-46). There are several proposed mechanisms that lower 
plasma vitamin C, including depleted antioxidant stores due to chronic low grade 
inflammation and oxidative stress, which play a pivotal role in the development of insulin 
resistance and T2DM, as well as related complications (44, 47). This relationship will be 
explored further in the trials included as part of this thesis.  
1.1.7 Symptoms, Complications and Treatment for T2DM 
1.1.7.1 Symptoms of T2DM 
Symptoms of T2DM include frequent urination (polyuria), excessive thirst (polydipsia), 
constant hunger, weight loss, vision changes, tingling or numbness in the lower limbs and 
yeast infections (16). In T2DM, symptoms may develop gradually and individuals may even 
be asymptomatic (16). Indeed, there may be a significant delay between glucose levels 
reaching the threshold for diabetes and diagnosis of the disease.  
1.1.7.2 Long-term effects of T2DM 
Hyperglycaemia (raised plasma glucose concentrations) is a common effect of uncontrolled 
diabetes and leads to micro- and macrovascular complications leading to increased morbidity 
and mortality (16).  
Long-term effects of chronic hyperglycaemia may result in the progressive complications of 
retinopathy with potential blindness; nephropathy which may result in renal failure; 
neuropathy and the risk of foot ulcers and amputation; and autonomic dysfunction including 
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sexual dysfunction and/or macrovascular disease including stroke, MI and peripheral artery 
disease (1, 16). 
1.1.7.3 Treatment methods for T2DM  
In managing T2DM, the main goal is to reduce blood glucose concentrations through diet 
(48), exercise, and the administration of insulin or antidiabetic medications. Often individuals 
with T2DM can be managed by a healthy diet, exercise, weight loss, and/or taking oral 
medication such as metformin. Randomized control trials (RCTs) have confirmed the 
potential of lifestyle modification to reduce the risk of progression from prediabetes to T2DM 
over a prolonged period. For example, the Finnish Diabetes Prevention Study aimed to assess 
the efficacy of an intensive diet-exercise programme in delaying or preventing T2DM in those 
with IGT (49). The study included 523 overweight subjects with IGT randomized to an 
intervention group and a control group (49). Those in the intervention group received 
individual dietary advice aimed at reducing weight and were also guided to increase their 
level of physical activity compared to the control group, who received general information 
such as the benefits of weight reduction (49). After one year, the intervention group showed 
significantly greater reductions in weight, measures of glycaemic control (2 hour glucose and 
2 hour insulin), blood pressure and triglycerides compared to the control group (49). 
However, due to the progressive nature of T2DM, once people are diagnosed many will 
require oral medications (such as metformin or sulphonylureas) and insulin to manage their 
diabetes as well as dietary and lifestyle interventions. In New Zealand the first-line drug 
therapy is usually metformin, followed by sulphonylureas and then insulin (50). 
1.1.7.3.1 Oral hypoglycaemic agents 
Metformin is the most commonly used oral anti-hyperglycaemic agent, representing the first-
line therapy for individuals with T2DM (51). The drug is thought to lower blood glucose by 
improving peripheral insulin sensitivity, resulting in increased tissue glucose uptake, and by 
inhibiting hepatic glucose production (52).  
The primary action of sulphonylureas is to stimulate insulin secretion in parallel with the 
normal pattern of insulin response to glucose (53). Sulphonylureas close adenosine 
triphosphate (ATP)-sensitive potassium channels at the beta-cell membrane, which leads to 
the opening of calcium channels (53). This results in exocytosis of insulin from storage 
granules. Sulphonylureas are particularly beneficial when combined with metformin and can 
also be given with insulin to provide enhanced endogenous insulin secretion after meals (53).  
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1.1.7.3.2 Insulin 
Insulin therapy is considered if the individual has unsatisfactory glycaemic control despite the 
optimisation of oral hypoglycaemic agents (50). There are several different types of insulin 
used in New Zealand such as short- and long-acting insulin, mixed insulin and long-acting 
insulin analogues, that differ according to their action (onset of action, peak and duration of 
action) (50).  
1.2 The Human Microbiome 
The human body harbours a large number of microorganisms primarily on the external and 
internal surfaces including the gastrointestinal tracts, skin, saliva, and vagina, with the 
majority of microbes residing in the colon (54). The gut microbiota functions as an extremely 
complex ecosystem, often referred to as an ‘organ’ placed within a host organ (55). It has 
been estimated that the gene content of bacteria in the colon alone is 100 times greater than 
the genes contained in the human genome (56). 
Microbes in the gut are often co-dependent, requiring metabolic support from other members 
of the community for survival, and they must also maintain a symbiotic relationship with the 
host (human) (57). In most cases, the relationship is mutually beneficial; for example, gut 
microbes help with the digestion of nutrients, prevent colonization of the host by pathogens, 
and aid in the development of the intestinal epithelium and immune system, while the host 
provides nutrients and a habitat for bacterial growth (57). The importance of this relationship, 
and its consequences for human health has resulted in a large amount of research in this area. 
The focus of this thesis is on the gut microbiota and metabolic health. 
Until recently, knowledge of the human microbiome was limited, mainly due to a paucity of 
analytical methods to identify microorganisms. Researchers used culture-based methods, 
which posed problems as the majority of gut bacteria are anaerobic, and therefore are a 
challenge to culture, resulting in an underestimation of the complexity of the gut microbiota 
(58). The introduction of culture-independent approaches based on high-throughput 
sequencing of bacterial deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), along with 
bioinformatics, has allowed for the identification of a large number of previously undetected 
microbes along with the functional properties of the bacteria (58). This technology has 
allowed researchers to gain a much more detailed knowledge of the gut microbiota in the 
large bowel (59).  
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Most researchers use faecal samples when investigating the gut microbiota. The faecal 
microbiota represents the situation in the distal colon, and the biochemical activity of the 
microbiota changes from the proximal to distal (60). 
Large-scale projects such as the European Metagenomics of the Human Intestinal Tract 
(MetaHIT), the US Human Microbiome Project (HMP) and many other research groups have 
been working towards characterising microbiota associated with health as well as changes 
associated with disease (56, 61). The human microbiome is currently an area of major 
research interest, with a large number of studies completed over the past decade.  
1.2.1 Taxonomy 
All living organisms are hierarchically classified into eight major levels, with ‘domain’ being 
the most general and ‘species’ being the most specific (Figure 1.1). There are three domains 
of life (archaea, bacteria and eukarya), and the focus of this thesis is bacteria. 
 
Figure 1.1. Hierarchical organization of taxonomic levels used for classifying organisms (Adapted 
from Tyler et al. (58)). 
 
New bacterial species and phyla are still being discovered. Distantly related organisms can 
also share genetic material (horizontal gene transfer), so phylogenetically distinct bacteria can 
appear to be more closely related than would be expected, making the definition of bacterial 
species more difficult (58). The phyla that account for the vast majority of all bacteria in the 
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human large intestine belong to the Gram-negative Bacteroidetes, Proteobacteria and 
Verrucomicrobia as well as the Gram-positive Firmicutes and Actinobacteria (62). 
Bacteroidetes and Firmicutes are the two most abundant bacterial phyla in the large intestine 
(63). However, despite the consistency of these main phyla, their relative abundance (RA) and 
the species present vary considerably across individuals, with the composition of each 
individual’s microbiota being so distinctive it has been suggested it could be used as an 
alternative to fingerprinting (64, 65). For example, inter-individual variation among human 
genes is only 0.5%, while variation among microbial genes is substantially higher (Figure 
1.2).  
 
Figure 1.2. Inter-individual variation among human genes compared to microbial genes (56). 
 
1.2.2 Colonization of the Gut Microbiota 
Until recently it was widely accepted that the placenta barrier kept infants sterile in the uterus 
and that microbial colonization of the newborn occurred during and after birth (66). Although 
some studies have reported the presence of microbes in the healthy placenta, umbilical cord 
and meconium (66, 67), a recent review has concluded that this is most likely due to the 
detection of contaminating DNA from PCR/sequencing reagents (68). During and 
immediately after birth, the baby is also exposed to microorganisms. Researchers have shown 
that vaginally-delivered infants acquire bacterial communities from their mother’s faecal and 
vaginal bacteria, compared to infants born via caesarean section who initially harbour 
bacterial communities similar to those found on the mother’s skin surface (69). A Canadian 
study found that at four months, the prevalence of several groups of intestinal bacteria 
differed in infants born by caesarean delivery compared to vaginally-delivered infants (70). 
Other factors that may impact the exposure of bacteria during birth include the place of birth 
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and the surrounding environment, for example, those born in developed versus developing 
countries, and home versus hospital births. 
Researchers have also reported a low bacterial richness and diversity in infants who were 
breastfed compared to those formula fed (70, 71). Several studies have reported that 
bifidobacteria dominate the microbiota in breastfed infants, while formula-feeding results in a 
more diverse microbial population (72, 73). The dominance of bifidobacteria in breastfed 
infants is thought to be partially due to the composition of human milk, which is rich in 
oligosaccharides resistant to human digestive enzymes, so act as substrates for fermentation in 
the distal gut (73).  
Antibiotic use during infancy is thought to have one of the most significant impacts on the gut 
microbiota composition (72). Multiple use of antibiotics within the first six months of life has 
also been shown to delay the development of the microbiota (74). Fouhy et al. (75) showed 
that infants who had been treated with antibiotics (ampicillin and gentamicin) within 48 hours 
of birth had significantly higher proportions of Proteobacteria (p=0.0049) and significantly 
lower proportions of Actinobacteria (p<0.001) compared to controls four weeks after the 
antibiotic treatment had stopped. At eight weeks the Proteobacteria levels still remained 
significantly higher (p=0.0049) but the Actinobacteria levels were similar to the control 
infants who had not been treated by antibiotics (75).  
Recent research has shown that the microbiota of infants changes once solid foods are 
introduced to the diet (76). The plant polysaccharides in the weaning foods drive the 
establishment of anaerobic bacteria characteristic of the adult microbiota (76). Milk continues 
to provide about 50% of infants’ energy until one year of age (76). It was thought that the gut 
microbiota reaches a relatively stable adult-like state after one to three years (77-79). 
However, recent researchers have suggested that it may actually continue to develop into the 
teenage years (80, 81). 
1.2.3 Bacterial Composition of the Adult GI Tract 
It has been estimated that each individual adult GI tract contains at least 160 bacterial species 
on average (56). The abundance and type of bacteria in the GI tract is influenced by variations 
in pH, oxygen and nutrient availability throughout the gut (82). The lower proportion of the 
GI tract has a higher bacterial count and is mainly populated by anaerobic bacteria, whereas 
the upper portion is populated largely by aerobic bacteria (83). The terminal ileum is thought 
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to represent a transition zone between the aerobic bacteria found in the proximal gut and the 
anaerobic bacteria found in the colon (83). 
Figure 1.3 illustrates the number of bacteria in each region of the gut; however, the 
complexity of the colonic microbiota is not apparent in this diagram. The stomach and the 
small intestine contain a small number of bacteria due to the luminal medium (acid, bile, 
pancreatic secretion), which kill most of the ingested microorganisms, and also due to the 
phasic propulsive motor activity towards the ileal end, which inhibits bacteria being able to 
colonise the lumen (Figure 1.3) (84).  
 
Figure 1.3. Composition and luminal concentrations of dominant microbial species in various regions 
of the gastrointestinal tract. Source: (85).  
 
1.2.3.1  Stability of the gut microbiota 
The intestinal microbiota composition in healthy individuals is relatively stable over time (62, 
86, 87). However, fluctuations in the human microbiota may be associated with dietary 
changes and human health (88-90). For example, David, Materna et al. (90) followed two 
individuals for a year and collected lifestyle information including diet records and a faecal 
sample every day during this time. Results showed the gut microbiota was stable if there were 
no major diseases or drastic changes in diet. One participant travelled from the USA to 
Southeast Asia for approximately two months and so was exposed to a new diet and had two 
episodes of diarrhoea while travelling. During travel the participant had nearly a two-fold 
increase in the Bacteroidetes to Firmicutes ratio, which reversed upon return. The other 
participant had an episode of food poisoning (Salmonella sp.) which resulted in a permanent 
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change in the gut microbiota. There was a decline in most of the gut bacteria taxa, which were 
replaced by genetically similar species, so although the composition changed, the function 
was not affected.  
Researchers often report a dysbiosis, which refers to a perceived imbalance in the proportions 
of bacterial groups making up a microbial community (91). Researchers have reported 
associations between altered abundances of particular bacterial taxa and certain diseases such 
as obesity (92-94) and T2DM (22, 95-97), suggesting that a change in the abundance or the 
loss of particular microbiota may lead to the loss of normal microbiota function. 
1.2.3.2  Functions of the gut microbiota 
1.2.3.2.1.1  Metabolic 
The digestive function of the colon primarily involves fermentation of non-digestible dietary 
components into short chain fatty acids (SCFAs) under anaerobic conditions (98). Other 
products of the fermentation process include gasses (hydrogen and carbon dioxide), small 
amounts of branched-chain fatty acids (BCFAs) (originating from the fermentation of amino 
acids), and ammonia, amines and phenols (99). The gut microbiota also plays an important 
role in the synthesis of vitamins (for example, vitamin K and B group vitamins), the 
absorption of ions (for example, calcium, magnesium and iron) and the metabolism of bile 
acids (84, 98). 
1.2.3.2.1.2  Trophic 
The trophic functions include control of epithelial cell proliferation and differentiation, and 
development and homeostasis of the immune system (84). For example, the SCFA butyrate 
generated in the bowel has an important role in providing energy for the intestinal epithelium 
(84). 
1.2.3.2.1.3  Protective 
The gut microbiota provides protection against pathogens (84). Several protective 
mechanisms have been proposed including preventing the attachment and entry of pathogenic 
bacteria into the epithelial cells, by competing for resources, and by bacteria inhibiting the 
growth of their competitors by the production of SCFAs (84). 
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1.2.4 Factors Known to Influence the Gut Microbiota Composition 
1.2.4.1 Diet and the gut microbiota 
The main substrates for bacterial growth are dietary non-digestible carbohydrates (100). 
Humans are not able to digest many of the dietary plant polysaccharides and oligosaccharides 
(101-103). This is because the cell walls of plants are chemically and structurally highly 
complex, and are arranged in a three-dimensional network that has coevolved to be resistant 
to enzymatic breakdown (104). Since humans lack the digestive enzymes required to break 
down these complex plant polysaccharides, we rely on the gut microbiota to utilize them (55).   
The principal SCFAs (acetic, propionic and butyric acid) are the major end products of 
bacterial fermentation and are produced by different bacteria in the colon. For example, 
butyrate is produced by several bacteria from the phyla Firmicutes such as Faecalibacterium 
prausnitzii, Roseburia spp., Eubacterium rectale, Eubacterium hallii, and Anaerostipes spp. 
(101).  
These SCFAs stimulate salt and water absorption, have a major effect on epithelial cell 
growth, and can bind to free fatty acid receptors which are expressed in intestinal epithelial 
cells and can also be absorbed from the bowel (98, 105, 106). SCFAs are used for a variety of 
different purposes; for example, butyrate is an important energy source for colonic epithelial 
cells, propionate is utilized in the liver as a substrate for the production of glucose by 
gluconeogenesis, and acetate is transformed into acetyl-CoA, is metabolized throughout the 
body (for example, in muscle) and is an important biochemical intermediary in human 
metabolism (98, 100). It is through this symbiosis with bacteria that humans are able to 
harvest energy that would otherwise be inaccessible and lost by excretion from the digestive 
tract (55, 98).  
The second important group of substances for bacterial growth includes proteins, peptides and 
amino acids, and it is estimated that approximately 12-18 g of protein enters the colon daily 
(98). Other sources of protein in the colon include bacterial secretions, proteins and peptides 
released during bacterial lysis, and mucins (98, 100). Proteins reaching and/or produced in the 
colon are fermented to SCFA and BCFAs such as isobutyrate, isovalerate, and a range of 
nitrogenous and sulphur-containing compounds, with some of the products of amino acid 
metabolism potentially being harmful to health, for example ammonia (98, 100). The main 
proteolytic species belong to the genera Bacteroides and Clostridium (100).  
The contribution of the gut microbiota to metabolism is largely dependent on substrate 
availability and retention time (transit) in the colon, thus the gut microbiota composition is 
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largely affected by diet (98). Alterations in the gut intestinal microbiota have been associated 
with alterations in diet; however, often these associations have been with extreme dietary 
differences.  
De Filippo et al. (107) compared the faecal microbiota of 15 healthy European children 
(Florence, Italy) consuming a modern western diet high in animal protein, sugar, starch and 
fat, and low in fibre, to the diet of 14 healthy children from a rural African village in Burkina 
Faso, where the diet is similar to that of early human settlements. The Burkina Faso diet is 
low in fat and animal protein, and rich in starch, fibre and plant polysaccharides, and so is 
predominantly vegetarian (107). The researchers found significant differences in gut 
microbiota between the two groups. The Burkina Faso children showed a significant 
enrichment in the phyla Bacteroidetes and depletion in the phyla Firmicutes compared to the 
Italian children (107). They also had an abundance of bacteria from the genus Prevotella and 
Xylanibacter, known to contain a set of genes encoding enzymes for cellulose and xylan 
hydrolysis, which was completely lacking in the European children (107). However, a 
limitation of this research is that there were many differences other than solely diet, such as 
geographical location and lifestyle factors, between the two study populations.  
A similar result was found in another study which included a cross-sectional analysis of 
individuals (n=98) comparing recent dietary intake (measured by a recent diet recall) and 
long-term dietary intake (measured by a food frequency questionnaire) and the gut microbiota 
composition characterised by clustering faecal communities into enterotypes which were 
distinguished by high levels of Bacteroides and Prevotella (108). Results showed the long-
term dietary data was correlated with enterotype clustering.  The Bacteriodes enterotype was 
found to be highly associated with animal protein, a variety of amino acids and saturated fats, 
and in contrast the Prevotella enterotype was associated with high levels of carbohydrates and 
simple sugars, which is in agreement with the results found by De Filippo et al. 
To separate global environmental difference from dietary influences, Wu et al. (109) 
characterised the gut microbiota and the host metabolome of 15 vegans and 16 omnivores in 
Western society. Vegans consumed more carbohydrates, but less protein and fat than 
omnivores. Twenty five percent of the metabolites tested (92 of 361 metabolites) differed 
between omnivores and vegans. Several metabolites that reflect the plant-based diet of vegans 
were more abundant in vegans than omnivores (q value<0.05) and it was estimated that one 
third of these are composed of products produced by the gut microbiota, for example, the 
benzoate metabolism of plant polyphenolic compounds. Although the plasma metabolome of 
vegans differed markedly from omnivores, results showed only slight differences in the 
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bacterial community composition when the two study groups were compared. No significant 
differences in measures of diversity and evenness was observed between the study groups. 
Furthermore, there were only seven taxa that had a differential presence between groups, all 
of which had a RA <1%. It was concluded that the impact of diet on the plasma metabolome 
of omnivores and vegans is large but the effect of these diets on the composition of the gut 
microbiota is small. The authors also suggested that the production of gut bacteria-derived 
metabolites is constrained by the composition of the gut microbiota.  
David, Maurice et al. (110) investigated whether diet interventions altered gut microbial 
communities in humans in a rapid and diet-specific manner. The study used two diets: a plant-
based diet rich in grains, legumes, fruits and vegetables, and an animal-based diet composed 
of meats, eggs and cheeses (110). Each diet was followed by 10 participants for five 
consecutive days (crossover trial). Results showed shifts in the microbiota occurred within a 
week. The animal-based diet was associated with an increase in the abundance of bile-tolerant 
microorganisms (Alistipes, Bilophila and Bacteroides), and a decreased abundance of 
Firmicutes that metabolize dietary plant polysaccharides (Roseburia, Eubacterium rectale and 
Ruminococcus bromii). The study also found that foodborne microbes can transiently colonize 
the gut (110). For example, bacteria associated with cheese and cured meats became 
significantly more prevalent in faecal samples. The participants’ microbiota reverted to the 
original composition two days after the diet finished (110). 
Wu et al. (108) also investigated the stability of the gut microbiota in a short-term controlled 
feeding experiment where 10 individuals were randomized to high-fat/low-fibre or low-
fat/high-fibre diets and stool samples were collected daily. They also found that changes in 
the microbiota were rapid with shifts detectable within 24 hours and the taxa affected differed 
among individuals. Although the changes in taxa seen were significant and rapid, the 
magnitude of the changes were modest and did not result in a change in enterotype over the 
duration of the study.  
Zhernakova et al. (111) completed systematic metagenomic association analysis of 207 
intrinsic and exogenous factors, which included 63 dietary factors (macronutrients and intake 
of specific food items), in a cohort of 1135 Dutch participants. Increased diversity was 
associated with the consumption of beverages with high polyphenol content (coffee, tea and 
red wine) and low diversity was associated with features of a Western-style diet such as 
higher intake of total energy, sugar-sweetened soft drinks, snacking and high-fat milk. A 
higher amount of carbohydrates in the diet was also associated with lower microbial diversity 
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and in contrast to De Filippo et al.’s (107) and Wu’s (108) results, did not show an association 
of carbohydrate intake to prevotella species (112).  
In summary, diet can have an influence on the composition and diversity of the gut microbiota 
and the metabolites produced and so dietary intake must be considered when investigating 
other associations with the gut microbiota.  
1.2.4.1.1 Prebiotics 
Prebiotics are defined as having the ‘selective stimulation of growth and/or activity(ies) of 
one or a limited number of microbial genus(era)/species in the gut microbiota that confer(s) 
health benefits to the host’ (100). Therefore, any dietary component that reaches the colon 
intact is a potential candidate for a prebiotic attribute; however, it is often not acknowledged 
that evidence for efficacy of prebiotics, such as the stimulation of growth of bacteria 
associated with health in humans (for example, bifidobacteria and lactobacilli) is limited (100, 
113). An example of a fibre with a confirmed prebiotic effect is inulin, with several studies in 
humans reporting it to cause an increase in bifidobacteria (114-116); however, increases in 
gastrointestinal symptoms such as flatulence and bloatedness have also been reported (113, 
114).  
As it is well known that diet alters the gut microbiota, the second part of this thesis involves 
an intervention trial using SunGold kiwifruit for people with prediabetes for reasons detailed 
in the section below.  
1.2.4.2 Probiotics and the gut microbiota 
Probiotics are defined as living microorganisms that, upon digestion in specific numbers, 
exert health benefits on the host (117). Thus a probiotic adds microorganisms to those already 
colonised in the host; however, probiotics do not necessarily colonise the human intestine 
(84). There are already many probiotic products available on the market. Many bacterial 
strains in the Lactobacillus and Bifidobacterium genera are considered to be probiotic (118). 
Most probiotic products are either in foods or beverages (for example, yoghurts or fermented 
milks) or supplied as dietary supplements; however, these products vary considerably in their 
microbial composition and number (dosage) of viable bacteria (119). 
1.2.4.2.1 Probiotics, prebiotics and T2DM 
As discussed in Section 1.1.3.3, oxidative stress is thought to play a role in the pathogenesis 
and progression of diabetes, and lactic acid bacteria such as Lactobacillus acidophilus and 
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Bifidobacterium longum have antioxidant properties (120). Therefore, the addition of bacteria 
known to have antioxidant properties as a probiotic, or a prebiotic that stimulates the growth 
of these bacteria, may provide a novel means of regulating glucose metabolism and oxidative 
stress in T2DM, as already indicated by the results of several clinical trials (121-123). For 
example, Moroti et al. (123) carried out an RCT with 20 volunteers and reported that the 
consumption of a symbiotic shake (containing Lactobacillus acidophilus, Bifidobacterium 
bifidum and oligofructose) over 30 days caused a significant decrease in glycaemia. Ejtahed et 
al. (121) carried out an RCT where 60 patients with T2DM consumed either 300 g/day of 
probiotic yoghurt containing Lactobacillus acidophilus and Bifidobacterium lactis or 
conventional yoghurt for six weeks. Results showed that the probiotic yoghurt significantly 
decreased fasting glucose, HbA1c and increased total antioxidant status compared to the 
control group (121). However, there were limitations with these studies. For example, both 
studies described above had small study cohorts (n=20 and n=60), and the study durations 
were short (30 day and six weeks) (121, 123). Furthermore, the decrease in fasting glucose 
(0.7 mmol/L) and HbA1c (0.12 mmol/mol) reported by Ejtahed et al. would not be considered 
clinically significant, and a duration of three months should be used when measuring HbA1c 
due to the lifecycle of red blood cells (approximately 120 days) (121).  
Phytochemicals are bioactive nonnutritive components of plants (for example flavonoids) that 
may have beneficial health effects (124, 125). Phytochemicals that function as antioxidants 
have the potential to reduce oxidative stress and inflammation, which are implicated in the 
pathogenesis and progression of T2DM (126). The gut microbiota has an important role in 
metabolizing some phytochemicals, such as polyphenols, which have strong antioxidant and 
anti-inflammatory properties, and therefore play a role in regulating the potential health 
benefits (125). For example, it has been reported that a low number of polyphenols can be 
absorbed in the small intestine, with 90-95% of polyphenols reaching the colon where they 
are degraded by microbial enzymes before being absorbed (124). 
1.2.4.2.2 Gold kiwifruit 
SunGold kiwifruit is considered a nutritionally dense fruit, based on the level of nutrients 
present along with being relatively low in calories (Table 1.2). SunGold kiwifruit is one of the 
best sources of vitamin C among fruit and vegetables, containing 161.3 mg/100g of vitamin 
C, almost three times the amount of vitamin C found in oranges (53.2 mg/100g) and 
strawberries (58.8 mg/100g), traditionally known as good sources of vitamin C (127). Other 
key nutrients in SunGold kiwifruit include fibre (1.4 g/100g), polyphenols, folate 
(31 µg/100g), potassium (6.1 µg/100g) and vitamin E (1.4 mg/100g) (Table 1.2).  
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1.2.4.2.2.1 Components of gold kiwifruit relevant to T2DM and metabolic health 
1.2.4.2.2.1.1 Vitamin C 
As discussed in Section 1.1.6, research suggests that people with T2DM have lower plasma 
vitamin C concentrations than those with normal glucose control. It is becoming increasingly 
acknowledged that vitamin C is required at concentrations above those needed for the 
prevention of scurvy for the maintenance of good health (42, 128). For example, marginal 
vitamin C levels (hypovitaminosis C) has been associated with individuals who present with 
fatigue, depression and deficiencies in wound healing (129, 130). Thus, including foods high 
in vitamin C may be an important consideration for those with dysglycaemia. Carr et al. (131) 
showed regular consumption of two SunGold kiwifruit to be an effective vitamin C 
supplement, significantly increasing the plasma vitamin C levels in men with normal levels of 
plasma vitamin C, and causing an even greater increase in those with previous low levels of 
plasma vitamin C.  
1.2.4.2.2.1.2 Non-digestible carbohydrates and phenolics 
Gold kiwifruit comprises about one-third soluble and two-thirds insoluble fibre (132). The 
soluble fibre fraction contains almost exclusively pectic polysaccharides, while the insoluble 
fibre is mostly cellulose and hemicelluloses (133, 134). These non-digestible carbohydrates 
can be fermented by the colonic microbiota and may have prebiotic properties if this results in 
the selective growth of beneficial bacteria (135).  
The ability of the gut bacteria to utilize the fibre in kiwifruit for energy is determined by their 
degradative enzymes (such as glycoside hydrolases, polysaccharide lyases and carbohydrate 
esterases), adhesion factors, and transport systems for each substrate (136), with only a few 
gut bacteria being able to break down insoluble substrates such as plant cell walls. For 
example, cellulolytic bacteria are able to degrade cellulose, making solubilized products 
available for other members of the bacterial community to use through cross-feeding (136). 
Polyphenols (mainly procyanidins and flavonol glycoside) have also been identified in gold 
kiwifruit, and are also likely to transit to the large intestine intact where they can be 
metabolized by the gut microbiota (137).  
There is growing in vitro evidence to suggest that SunGold kiwifruit modulates the gut 
microbiota. Blatchford et al. (138) investigated the impact of pre-digested gold kiwifruit on 
human colonic bacteria using in vitro, pH-controlled, anaerobic batch fermenters, and found 
that gold kiwifruit caused an increase in the RA of the Bacteroides spp. along with an 
increase in organic acids (acetate, butyrate and propionate). The ability of kiwifruit to 
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manipulate the gut microbiota may be of importance to the development of T2DM, as Zhang 
et al. (97) found the abundance of the genus Bacteroides to be lower in people with T2DM 
compared to a prediabetes group and those with NGT. A logical extension of the in vitro trials 
is to investigate the effect of SunGold kiwifruit on the human gut microbiota in a free-living 
situation (Chapter five).  
1.2.4.2.2.1.3 Glycaemic index and glycaemic load 
Maintaining normal blood glucose levels through diet is one of the main goals in the 
management of T2DM (48). In addition to elevated blood glucose levels causing micro- and 
macrovascular damage (139), rapid postprandial increases in blood glucose are also 
considered to be harmful due to the burden placed on the β-cells of the pancreas (140). The 
glycaemic index (GI) refers to the rate of change in blood glucose during carbohydrate 
digestion (141). Therefore, foods that have a lower postprandial response and/or are able to 
reduce the amplitude of the immediate postprandial response could help to improve 
carbohydrate management by the body in individuals with glucose intolerance (142). 
However, GI does not take into account the effect of a typical amount of carbohydrate in a 
food portion on glycaemia (141). The glycaemic load (GL), takes into account both the GI of 
the food and the amount of carbohydrate in a serving (portion size) (141). One of the 
strategies of dietary management of glucose intolerance is to substitute highly glycaemic 
carbohydrates with less glycaemic carbohydrates, taking into account the serving size of the 
food (143). Furthermore, when substituting a highly glycaemic carbohydrate for a less 
glycaemic carbohydrate, the nutritional value of the food should also be considered (144). 
Kiwifruit, eaten as a whole fruit, is nutritionally dense, and has a low glycaemic impact, and 
is therefore considered a suitable choice for those with reduced glucose tolerance (145). 
Researchers have carried out a human intervention study which investigated the effects of 
kiwifruit on the blood glucose response to a breakfast cereal (142). Results showed that when 
a flaked wheat breakfast cereal was consumed with kiwifruit, the blood glucose response was 
lower than when the breakfast cereal was consumed with the same amount of sugars, of the 
same monosaccharide composition, as in the kiwifruit (142). As the sugar composition was 
the same for each meal the researchers proposed several potential mechanisms, for example, 
that the cell wall remnants could have contributed through their effects on diffusion and 
mixing in the gut (142).  
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Table 1.2: Nutrient composition of Zespri SunGold kiwifruit. 
! Zespri!SunGold**!
Per!100g!Edible!Flesh!
Macronutrients! !
Water!(g)! 82.4!
Energy!(kcal)†! 63!
Protein!(g)! 1.02!
Total!fat!(g)! 0.28!
Total!carbohydrate,!available!(g)! 15.8!
Fibre!(g)! 1.4!
Sugars,!total!(g)! 12.3!
Minerals! !
Calcium!(mg)! 17!
Iron!(mg)! 0.21!
Magnesium!(mg)! 12!
Phosphorus!(mg)! 25!
Potassium!(mg)! 315!
Sodium!(mg)! 3!
Zinc!(mg)! 0.08!
Copper!(mg)! 0.151!
Manganese!(mg)! 0.048!
Selenium!(mg)!! 0.4!
Vitamins! !
Vitamin!C,!total!ascorbic!acid!(mg)! 161.3!
Vitamin!B1!–!thiamine!(mg)! 0!
Vitamin!B2!–!riboflavin!(mg)! 0.074!
Vitamin!B3!–!niacin!(mg)! 0.231!
Vitamin!B5!–!pantothenic!acid!(mg)! 0.12!
Vitamin!B6!–!pyridoxine!(mg)! 0.079!
Vitamin!B9!–!folate!(µg)! 31!
Choline!(mg)! 1.9!
Vitamin!B12!(µg)! 0.08!
Vitamin!A!(µg)! N/A!
Vitamin!A,!retinol!activity!equivalents!(RAE)!(µg)! 1!
Vitamin!E!–!α!tocopherol!(mg)! 1.4!
Vitamin!K!(µg)! 6.1!
Other! !
Carotene,!beta!(µg)! 14!
Lutein,!zeaxanthin!(µg)! 24!
Nutrition!adequacy!score! 18.8!
Nutrient!density!(per!100!kcal)! 29.8!
GI! 38!
**Combined data from NVIG2010, Japan market analysis 2010 and Zespri analysis 2011. 
† USDA legislature that calculates energy as total carbohydrate by difference minus insoluble fibre 
http://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/labelingnutrition/ucm20
06828.htm  
Nutrition adequacy score and nutrient density calculated based on the methods of Darmon et al. (146).  
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1.2.4.3 Postprandial glycaemic responses and the gut microbiota 
Although the GI of foods is measured, there are limitations associated with the methodology 
used, including a small number of subjects used given the high variability in the response of 
different people to the same food (147). For example, in New Zealand it is recommended that 
10 individuals are used when testing the GI of a food, in line with the international standard 
method (148).  Zeevi et al. (147) investigated intra- and interpersonal variability in the 
postprandial glycaemic responses to standardised meals of 50 g of available carbohydrate 
(glucose, bread, bread and butter, bread and chocolate, and fructose) of 800 non-diabetic 
adults, and found that although the postprandial glucose response to identical meals was 
reproducible within the same person, they reported high interpersonal variability. 
A number of factors that may affect interpersonal differences in postprandial glycaemic 
responses have been suggested such as genetics (149), insulin sensitivity (150) and exocrine 
pancreatic and glucose transporter activity levels (151) with the gut microbiota being recently 
identified as another possible factor (147).   
To investigate factors affecting interpersonal differences in postprandial glycaemic responses, 
Zeevi et al. (147) also collected additional information including participants’ gut microbiota, 
anthropometric measurements, and lifestyle and medical history.  They reported significant 
positive associations between the postprandial glucose response of participants to the 
standardised meals and metabolic risk factors including HbA1c, BMI, systolic blood pressure, 
CRP and alanine aminotransferase activity. There were also associations seen between the 
postprandial response to the standardised meals and the gut microbiota of individuals. For 
example, the RA of the phylum Actinobactera was positively associated with the postprandial 
glucose response to both glucose and bread, and the RA of the phylum Tenericutes was 
negatively associated with the postprandial glucose response to glucose.  
1.2.4.4 Antibiotics and the gut microbiota in adults 
Although clinicians commonly prescribe antibiotics to treat infections, research has shown 
that antibiotics cause marked short-term disturbances in the human gut microbiota, and in 
some patients the microbiota does not recover to its initial composition following antibiotic 
treatment (152-154). The use of antibiotics that disturb the gut microbiota is also sometimes 
associated with clinical symptoms such as diarrhoea (155). Antibiotics also modulate the gut 
microbiota.  
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Gut bacteria can also become resistant to antibiotics; steadily rising rates of antimicrobial 
resistance, in a range of common bacterial pathogens, are a major threat to human health 
(156). Although there can be great variability in the length of antibiotic courses, most clinical 
courses are seven days or fewer.  
1.2.4.4.1 Effect of antibiotics on the gut microbiota during antibiotic treatment 
Pérez-Cobas et al. (154) analysed the gut microbiota of a single patient on antibiotics for 14 
days and reported various changes in the gut microbiota during this time, such as an early 
reduction in Gram-negative organisms at day six, and the attainment of minimum biodiversity 
and richness on day 11.  
1.2.4.4.2 Short-term effect of antibiotics on the gut microbiota 
Panda et al. (153) investigated the gut microbiota (before and on completion of antibiotic 
treatment [day seven]) in 21 patients who had taken antibiotics for seven days. The two 
broad-spectrum antibiotics (fluoroquinolones and β-lactams) resulted in a significant 25% 
reduction in microbial diversity (153). They also reported a change in the RA of phyla with an 
increase in the Bacteroidetes to Firmicutes ratio (153).  
1.2.4.4.3 Longer term effect of antibiotics on the gut microbiota 
Jakobsson et al. (152) followed six individuals over a four-year period. The study included 
three controls and three people who had antibiotic treatment (clarithromycin and 
metronidazole) for Helicobacter pylori (152). Dramatic shifts in the gut microbiota one week 
after antibiotic treatment were reported, along with reduced bacterial diversity (152). They 
reported that the microbiota of different subjects responded uniquely to the antibiotic 
treatment; there were also some general trends such as a dramatic decline in Actinobacteria 
immediately after treatment (152). In most participants the diversity of the microbiota 
recovered to resemble the pre-treatment states, but in some participants the alterations 
persisted for up to four years (152). 
1.2.4.5 Metformin and the gut microbiota 
Metformin is an oral antihyperglycaemic agent whose primary and dominant metabolic effect 
is inhibition of liver glucose production, though the exact mode of action remains unknown. 
Mild gastrointestinal disturbances (such as diarrhoea, nausea, vomiting, loss of appetite) are 
the most common side effects of metformin, occurring in more than 10% of patients, 
especially during the initial treatment period with underlying mechanisms poorly understood 
(157). Results from one study showed that of 247 participants with T2DM taking metformin 
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and a sulphonylurea, 20.6% reported nausea, 4.5% reported vomiting and 6.5% reported 
diarrhoea (158). These symptoms usually improve or disappear as treatment is continued, and 
the effects can be minimised by starting patients on a low dose of metformin and titrating the 
dose up over several weeks (159). There are studies in both animals and humans that suggest 
some beneficial effects of metformin on glucose metabolism may be microbially mediated 
(160, 161); however, the exact mechanism has not been determined, and the bacteria found to 
be associated and thus their proposed mechanisms differ between studies. Several studies 
have, however, reported metformin to be associated with an increased abundance of 
Akkermansia (160, 162, 163). Although Shin et al. (160) were unable to determine the exact 
mechanism, they found that the oral administration of Akkermansia improves the metabolic 
profile of diet-induced obesity in mice without metformin, via a mechanism mediated by anti-
inflammatory activity of visceral adipose tissue (VAT)-resident regulatory T cells (Tregs).  
A recent study included a reanalysis of two other studies (784 available human gut 
metagenomes) and showed that neglecting to control for antidiabetic medication can 
confound results (164). 
1.2.5 The Gut Microbiota and Obesity 
Disruptions to the normal balance between the gut microbiota and the host have been 
associated with obesity (93, 94) and T2DM (95, 97, 165). 
1.2.5.1 Obesity and the gut microbiota (rodent studies)  
The initial experiments investigating the gut microbiota and obesity were carried out in mice 
and showed a relationship between certain intestinal microorganisms and obesity (Table 1.3). 
As in humans, >90% of the phylogenetic types comprising the mouse distal gut microbiota 
are members of the phyla Bacteroidetes and Firmicutes (62).  
The involvement of the gut microbiota in obesity was first indicated by Bäckhed et al. (166) 
who demonstrated by dual energy x-ray absorptiometry that 8-10-week-old, germ-free (GF) 
mice contained 42% less body fat than mice that harboured a microbiota at birth (CONV-R). 
This was not explained by the diet, as the daily consumption of standard chow diet (57% 
carbohydrates, 5% fat) was 29% lower for the CONV-R mice than for the GF mice. Bäckhed 
et al. (166) then colonized the 8-10-week-old GF mice with the caecal microbiota (distal 
intestine) from a healthy mouse (conventionalized) and after 14 days, despite reduced chow 
consumption and no decrease in energy expenditure, a 57% increase in total body fat content, 
a 61% increase in epididymal fat weight, and a 7% decrease in lean body mass resulted 
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despite no significant difference in total body weight between the two groups. The increase in 
fat was accompanied by elevations in fasting glucose and insulin levels and an insulin-
resistant state (defined by glucose and insulin tolerance tests). These results indicate the 
microbiota of obese individuals may be more efficient at extracting energy from a given diet 
than the microbiota of lean individuals. Several mechanisms may explain these observations 
such as microbial fermentation of dietary polysaccharides that cannot be digested by the host; 
subsequent intestinal absorption of monosaccharide and SCFAs; SCFAs’ conversion to more 
complex lipids in the liver; and microbial regulation of host genes that promote deposition of 
lipids in adipocytes (166). 
Ley et al. (92) analysed 5,088 bacterial 16S rRNA gene sequences from the caecal microbiota 
of genetically obese mice (homozygous for a mutation in the leptin gene), lean mice and wild-
type siblings and their lean mothers, all fed the same diet rich in polysaccharides. Results 
showed the obese mice had a 50% reduction in the abundance of Bacteroidetes and a 
proportional increase in Firmicutes compared to the lean mice, and these differences were not 
attributable to differences in food consumption (92). The relative abundance of Firmicutes to 
Bacteroidetes was therefore higher in obese than in lean mice. 
Turnbaugh et al. (94) characterised the gut microbiomes (caecal microbial DNA) of obese and 
lean littermates by random shotgun sequencing, and then transplanted lean and obese caecal 
microbiota into GF and wild-type mice to validate the predicted increased capacity for dietary 
energy harvest by the obese microbiome. In agreement with Ley et al. (92), they found a 
greater relative abundance of Firmicutes in the obese microbiota along with an increased ratio 
of Firmicutes to Bacteroidetes in obese versus lean mice (94). The obese microbiome was 
also enriched for environmental gene tags (EGTs) encoding enzymes involved in the initial 
steps for the breakdown of indigestible polysaccharides, and was associated with an increased 
concentration of fermentation products (butyrate and acetate) (94). These findings suggest an 
increased capacity for energy harvest from the diet in the obese compared to the lean 
microbiome, consistent with Bäckhed et al. (166) who reported the gut microbiota as affecting 
both energy harvest and energy storage in the host. Fourteen days after colonization of the GF 
mice with either an obese or lean gut microbiota, there was a significantly greater increase in 
total body fat in the mice colonized with an obese microbiota compared to the mice colonized 
with lean microbiota, with no statistically significant difference in chow consumption 
between the groups (94). 
Turnbaugh et al. (167) used a mouse model of diet-induced obesity to investigate the inter-
relationships between diet, gut microbial ecology and energy balance. GF mice were fed a 
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low-fat, high-carbohydrate diet (rich in complex plant polysaccharides) for 12 weeks and then 
were inoculated with the microbiota harvested from conventionally raised mice. Half of the 
mice were then put onto a ‘Western diet’ (high-fat/high-sugar) while the other mice remained 
on the high-carbohydrate diet. Mice on the ‘Western diet’ gained significantly more weight 
than the mice on the carbohydrate diet and had significantly more epididymal fat despite 
consuming fewer calories (167). As with the obese mouse model (ob/ob) (92, 94), the mice 
consuming the Western diet had a significantly higher RA of Firmicutes and lower RA of 
Bacteroidetes (167). The concept of diversity of the gut microbiota was also introduced in this 
research with results showing a reduction in the overall diversity of the ‘Western diet’ 
microbiota due to the bloom in a single class of the Firmicutes (Mollicutes). The results 
therefore indicate that with the administration of a ‘Western diet’ there is a restructuring of 
the gut microbial community, with an increase of the Mollicute lineage from the Firmicutes 
becoming more dominant, accompanied by a suppression of Bacteroidetes (167).  
The development of obesity in genetically or diet-induced obese mice is associated with 
substantial changes in the composition and metabolic function of the gut microbiota that 
allow the obese microbiota to extract more energy from the diet (more effective at 
metabolizing calories not released from food during digestion). The trait has also been shown 
to be transmissible, as colonization of GF mice with gut microbiota from obese mice results in 
a greater increase in total body fat than colonization with gut microbiota from lean mice. The 
RA of the two predominant phyla differs between lean and obese animals; mice that are 
genetically obese have 50% fewer Bacteroidetes, and correspondingly more Firmicutes than 
their lean siblings.  
Energy balance is an equilibrium between the amount of energy taken in as food and the 
amount of energy expended during resting metabolism (basal metabolic rate), diet-induced 
thermogenesis, physical activity, and losses in the faeces and urine (94). It has been suggested 
that an alteration in the efficiency of the microbiota to extract energy from the diet does not 
have to be great to contribute to obesity, a risk factor for T2DM, due to small changes in 
energy balance over long periods of time resulting in significant changes in body weight 
(168). Researchers have attempted to validate the above findings in studies with humans, with 
the added complexities inherent in human studies, such as diet and genotype, which can no 
longer be tightly controlled. 
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Table 1.3: Obesity and the gut microbiota (rodent studies). 
Paper& Methods& Key&Results&
Bäckhed(et(al.((2014)(
(166)&
Aim:&To(investigate(whether(the(microbiota(acts(through(an(
integrated(host(signalling(pathway(to(regulate(energy(
storage(in(the(host.(
B 8B10(week(old(GF(mice(were(compared(to(CONVBR(
mice.(
− Researchers(also(carried(out(a(14Bday(colonization(of(8B
10(week(old(GF(mice(with(an(unfractionated(microbiota(
harvested(from(the(distal(intestines(of(adult(CONVBR(
donors((conventionalization).((
− The(CONVBR(mice(contained(42%(more(total(body(fat(determined(
by(dual(energy(XBray(absorptiometry.(
− After(conventionalization(despite(a(reduced(chow(consumption(
this(resulted(in(a(60%(increase(in(body(fat(content.(The(increase(in(
fat(content(was(accompanied(by(statistically(significant(elevations(
in(fasting(glucose(and(insulin(levels(and(an(insulinBresistant(state,(
as(defined(by(glucose(and(insulin(tolerance(tests.(
Ley(et(al.((2005)(92)& Aim:(to(test(the(hypothesis(that(differences(in(gut(microbial(
ecology(between(2(individuals(may(be(an(important(factor(
affecting(energy(homeostasis.((
− 5,088(bacterial(16S(rRNA(gene(sequences(from(the(
distal(intestinal(microbiota(of(the(mothers((ob/+)(and(
their(obese((ob/ob)(and(lean(offspring([heterozygous(
(ob/+)&and&wild-type&(+/+)](all&fed(the(same(
polysaccharideBrich(diet(were(analysed(using(
polymerase(chain(reaction((PCR)(amplification.(
The(obese(mice(had(a(50%(reduction(in(the(abundance(of(
Bacteroidetes(and(a(proportional(increase(in(Firmicutes.(The(
differences(were(not(attributable(to(differences(in(food(consumption.((
− The(RA(of(Firmicutes(to(Bacteroidetes(was(higher(in(obese(than(in(
lean(mice.((
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Paper& Methods& Key&Results&
Turnbaugh(et(al.((2006)(
(94)&
Aim:&To(determine(if(microbial(community(gene(content(
correlates(with,(and(is(a(potential(contributing(factor(to,(
obesity.(
− The(distal(gut(microbiomes(of(genetically(obese(mice(
(ob/ob)&and(their(lean&littermates([heterozygous((ob/+)&
and(wildBtype&(+/+)](were(characterised(by(random(
shotgun(sequencing(of(their(caecal(microbial(DNA(
(metagenomics(analysis).(
− Researchers(then(transplanted(the(caecal(microbiota(
from(lean(and(obese(mice(to(GF(wildBtype(recipients.(
− The(obese(mice(had(a(greater(abundance&of&Firmicutes.(
− RA(of(Firmicutes(to(Bacteroidetes(was(higher(in(obese(than(in(lean(
mice.(
− The(obese(microbiome(is(enriched(for(EGTs(encoding(enzymes(
involved(in(the(initial(steps(to(break(down(indigestible(
polysaccharides.(Many(Firmicutes(are(butyrate(producers(and(the(
obese(caecum(has(an(increased(concentration(of(fermentation(
products((butyrate(and(acetate).((
− After(14(days,(mice(harbouring(the(microbiota(from(obese(mice(
had(a(significantly(greater(percentage(increase(in(body(fat(than(
mice(colonized(with(lean(microbiota.(There(was(no(statistically(
significant(difference(in(chow(consumption(between(the(groups.((
Turnbaugh(et(al.((2008)(
(167)&
Aim:&To(investigate(the(interrelationship(between(diet,(gut(
microbial(ecology,(and(energy(balance.(
10(germBfree(mice(were(weaned(onto(a(lowBfat(chow(diet(
(carbohydrate(diet)(at(12(weeks;(they(were(
conventionalized((with(the(same(microbiota)(and(after(4(
weeks,(5(of(the(mice(were(switched(to(a(western(diet((high(
in(saturated(fat(and(the(types(of(carbohydrate(commonly(
used(as(food(additives)(and(5(mice(stayed(on(the(
carbohydrate(diet.(
− Mice(on(the(Western(diet(gained(significantly(more(weight(than(
mice(on(the(carbohydrate(diet.((
− Mice(on(the(Western(diet(had(significantly(higher(RA(of(Firmicutes(
and(a(lower(RA(of(Bacteroidetes((
− The(overall(diversity(of(the(Western(diet(microbiota(dropped(
dramatically(due(to(an(increase(in(the(class(Mollicutes(from(the(
Firmicutes.((
!
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1.2.5.2 Obesity and the gut microbiota (human studies) 
As a logical extension of the studies in mice, it has been proposed that the development of 
obesity in humans is influenced by the relative proportions of the two major phyla of bacteria 
(Bacteroidetes and Firmicutes). As with mice, the two dominant phyla in the human gut are 
the Bacteroidetes and Firmicutes (93); however, there is a limited evidence and no clear 
signal given from human studies that suggests the association between adiposity and gut 
microbial ecology seen in mice exists in humans. The findings of several studies in obesity 
and the gut microbiota are outlined in detail below (Table 1.4). 
Turnbaugh et al. (169) characterised the faecal microbiota communities of adult female 
monozygotic and dizygotic twins concordant for leanness or obesity, and their mothers, to 
investigate how host genotype, environmental exposure and host adiposity influence the gut 
microbiome. At the phylum-level, obesity was associated with lower proportions of 
Bacteroidetes (p=0.003) and higher proportions of Actinobacteria (p=0.002) but no difference 
in Firmicutes (p=0.09) in obese compared with lean individuals (169). Alpha diversity 
measures the biodiversity within a sample: it measures the number of species present 
(richness), and some metrics also incorporate a measure of the RA of each species (evenness). 
Obesity was also associated with a significant decrease in diversity, in agreement with 
previous research reporting a decrease in diversity with mice consuming a diet high in 
saturated fat and added sugars (167). The twin study also reported individuals to have a stable 
microbiota, but large inter-personal differences were seen. However, results suggested that the 
gut microbiome is shared to some extent between family members (with a comparable degree 
of covariation between twin pairs) suggesting the microbiota is inherited to some extent (169).  
Zhang et al. (170) compared the microbial community structures from normal weight, obese 
and post-gastric-bypass surgery patients. The earlier studies in mice indicated that obesity was 
associated with a greater abundance of Firmicutes (94), consistent with Zhang et al. (170) 
who found a significant decrease in Firmicutes in post-gastric individuals and in addition, 
reported a proportional increase in Gammaproteobacteria (from the Phylum Proteobacteria). 
Zhang et al. (170) also reported that the number of hydrogen-producing bacteria 
(Prevotellaceae) was highly enriched in obese individuals. This finding, which was associated 
with higher numbers of hydrogen-utilizing methanogenic Archaea, led to the hypothesis that 
this coexistence may reflect interspecies transfer of hydrogen, which might be an important 
mechanism for increasing energy uptake in obese persons, as was reported in the earlier 
studies in mice (94). The shift in bacterial population seen in the post-gastric bypass 
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individuals may, however, reflect the surgical procedure and the consequential changes in 
digestion and dietary intake (170). 
Ley et al. (93) observed differences in the gut microbiota of obese versus lean humans before 
and after being randomly assigned to a fat-restricted (FAT-R) or a carbohydrate-restricted 
(CARB-R) low-calorie diet. As with the obesity studies in mice (92, 94), at baseline the obese 
subjects had fewer Bacteroidetes (p<0.001) and more Firmicutes (p=0.002) than did the lean 
controls. During the period of the low-calorie diets (both FAT-R and CARB-R), the relative 
abundance of the Bacteroidetes progressively increased (p<0.001) proportional to the degree 
of weight loss and the abundance of Firmicutes decreased (p=0.002). Although both study 
groups showed changes in Bacteroidetes and Firmicutes with weight loss, the collections of 
microbial lineages in each division in each individual were distinctive (93). The results from 
this study were in agreement with murine studies which showed a higher RA of Firmicutes 
and a lower RA of Bacteroidetes with the weight gain associated with a ‘Western diet’ (167). 
Duncan et al. (171) investigated the relationship between BMI, weight loss on two different 
reduced carbohydrate regimens and the gut microbiota. In contrast to Ley et al. (93), there 
was no difference between obese and non-obese individuals in the proportion of Bacteroidetes 
nor any significant change in the percentage of Bacteroidetes when obese subjects were on 
the weight-loss diets (171). However, significant reductions in butyrate-producing Firmicutes 
(Roseburia spp. and Eubacterium rectale) and reduced faecal butyrate concentrations were 
reported in the obese patients on the reduced carbohydrate diets (171). 
Payne et al. (172) compared the gut microbial compositions and metabolite concentrations of 
obese versus normal-weight children and, like Duncal et al. (171), reported no significant 
differences in the gut microbiota. Higher concentrations of SCFAs (butyrate and propionate) 
were reported in obese versus normal children which is also consistent with Duncal et al. 
(171), who reported reductions in faecal butyrate concentrations when obese patients were on 
reduced carbohydrate diets. Furthermore, lower concentrations of intermediate compounds 
were detected in the obese children, suggesting exhaustive substrate utilization which could 
reflect an increased energy harvest, as was reported in the earlier mice studies (94). 
Collado et al. (173) characterised the gut microbiota of women based on their BMI prior to 
pregnancy and also looked at the effect of weight gain during pregnancy. Their findings were 
reported at the genus level making results difficult to compare with other studies. The genera 
Bacteroides (from the phylum Bacteroidetes), and Staphylococcus and Clostridium (from the 
phylum Firmicutes) were found to be significantly more prevalent in the overweight 
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compared to the normal-weight women prior to pregnancy. High Bacteroides concentrations 
were also associated with excessive weight gain during pregnancy (p=0.014). 
It is unclear whether the ratio of Bacteroidetes to Firmicutes often reported in studies 
involving mice is apparent in humans. Results have been conflicting, with some researchers 
reporting that obese individuals have a lower ratio of bacteria from the phylum Bacteroidetes 
to Firmicutes than lean individuals (92, 94, 169), and other studies finding no association 
between obesity and the Bacteroidetes: Firmicutes ratio (171, 172). Furthermore, several 
publications actually report a higher ratio of Bacteroidetes to Firmicutes amongst obese 
individuals in contradiction to earlier findings (173, 174).  
Following the studies in mice (167), there is limited evidence from human studies to suggest 
that obese individuals also harbour less diverse bacterial communities (169). A recent meta-
analysis of 10 studies reported that obese individuals have significantly lower diversity 
(p<0.011) than non-obese individuals; however, the effect size was small (2.07% lower 
diversity), and it is questionable whether the difference was biologically significant (175). 
Inter-individual variation is considerable, reflecting unique personal microbiota, leading to the 
suggestion that most studies do not have a large enough sample size and lack the power to 
detect differences in diversity (175).  
Limitations of the human studies investigating obesity and the gut microbiota: 
! Small heterogeneous study cohorts have been used.  
! Researchers have often not measured/reported other factors that may be impacting 
the gut microbiota, such as dietary intake. Varying exclusion criteria have also been 
used by different study groups, for example gastrointestinal diseases and length of 
time since probiotic and antibiotic use.  
! It is difficult to go from animal studies, where diet and other variables can be 
precisely controlled, to free-living human studies.  
! Researchers have used a variety of different methods to collect faecal samples, 
extract and sequence the genomic DNA, and the bioinformatics and statistical 
methods vary, making it difficult to compare papers.  
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Table 1.4: Obesity and the gut microbiota (human studies). 
Paper& Methods& Key&Results/Limitations&
Turnbaugh)et)al.)(2009))(169)) Aim:&to)characterise)the)faecal)microbial)communities)
of)adult)female)monozygotic)and)dizygotic)twin)pairs)
concordant)for)leanness)or)obesity,)and)their)mothers,)
to)address)how)host)genotype,)environmental)exposure)
and)host)adiposity)influence)the)gut)microbiome.)
n=154,)monozygotic)twin)pairs)(31),)dizygotic)twin)pairs)
(23),)where)available,)their)mothers)(46).)
Sequencing&method&
Metagenome)study)
16S)rRNA)sequencing)targeting)the)full)length)gene)with)
an)ABI373xl)capillary)sequencer)+)multiplex)
pyrosequencing)with)a)454)FLX)instrument)to)survey)the)
gene’s)V2)variable)region)and)its)V6)hypervariable)
region.))
− Faecal)samples)from)the)same)individual)were)much)more)similar)to)
each)other)than)samples)from)family)members)or)unrelated)
individuals,)indicating)a)stable)microbiome)within)individuals)and)
large)interVpersonal)differences.)However,)the)study)did)show)that)
the)human)gut)microbiome)is)shared)to)some)extent)among)family)
members,)suggesting)the)microbiota)is)inherited)to)some)extent)
from)the)mother.))
Phylum&
V Lower)proportions)of)Bacteroidetes+(p=0.003))and)higher)proportions)
of)Actinobacteria)(p=0.002))but)no)difference)in)Firmicutes)(p=0.09))
in)obese)compared)with)lean)individuals.&
V Diversity&
− Obesity)was)associated)with)a)significant)decrease)in)alpha)diversity.)
Other&
Metagenomes)of)obese)participants)enriched)in)energy–harvesting)
genes.)
Zhang)et)al.)(2009))(170)) Aim:)To)compare)the)microbial)community)structures)of)
normal)weight,)obese)and)postVgastricVbypass)surgery)
participants.)
n=9)–)healthy)weight)(3),)obese)(3),)postVgastricVbypass)
surgery.)
Sequencing&method&
They)examined)184,094)sequences)of)microbial)16S)
rRNA)genes)from)PCR)amplicons)by)using)the)454)
pyrosequencing)technology.)
Phylum&
− Firmicutes)were)dominant)in)normalVweight)and)obese)individuals)
but)significantly)decreased)in)postVgastric)individuals.)
Class&
− The)postVgastric)individuals)had)an)increase)in)the)class)
Gammaproteobacteria)(from)the)Phylum)Proteobacteria).))
Family&
− Prevotellaceae)(subgroup)of)Bacteroidetes))are)significantly)enriched)
in)obesity.)Prevotellaceae)are)H2Vproducing)bacteria.))
Other&
V Results)showed)significantly)higher)numbers)of)H2Vutilizing)
methanogenic)Archaea)in)obese)individuals.))
!
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Paper& Methods& Key&Results/Limitations&
Ley)et)al.)(2006))(93)) Aim:)To)investigate)the)relation)between)gut)microbial)
ecology)and)body)fat)in)humans.)
n=12)obese)people,)n)=2)controls)
Study&and&sequencing&methods&
Randomly)assigned)to)either)a)FATVR)or)CARBVR)low)
calorie)diet.)The)composition)of)their)gut)microbiota)
was)monitored)over)the)course)of)1)year)(baseline,)12,)
26)and)52)weeks))by)sequencing)16S)ribosomal)RNA)
genes)from)stool)samples.)
Phylum&
− The)relative)proportion)of)Bacteroidetes)is)lower)in)obese)people)
compared)to)lean)people.))
− The)RAs)of)Bacteroidetes)and)Firmicutes)increased)and)decreased,)
respectively,)as)obese)individuals)lost)weight)on)a)FATVR)or)CARBVR)
diet.))
− Increased)abundance)of)Bacteroidetes)correlated)with)%)loss)of)body)
weight)(R2)was)0.8)for)the)CARBVR)diet)and)0.5)for)the)FATVR)diet,)
p<0.05))and)the)correlation)held)only)after)people)had)lost)at)least)
6%)of)their)body)weight)on)the)FATVR)diet)and)at)least)2%)on)the)
CARBVR)diet.))
Duncan)et)al.)(2008))(171)) Aim:)To)examine)the)relationships)between)body)mass)
index,)weight)loss)and)the)major)bacterial)groups)
detected)in)faecal)samples.)
n=13)nonVobese)subjects)(under)conditions)of)weight)
maintenance),)n=23)obese)subjects)who)underwent)
weight)loss)regimes)(4)weeks)of)a)highVprotein)low)
carbohydrate)ketogenic)and)followed)by)4)weeks)of)a)
highVprotein)moderateVcarbohydrate,)nonVketogenic).))
Sequencing&method&
Fluorescent)in)situ)hybridization)(FISH)))
Phylum&
V No)difference)between)obese)and)nonVobese)individuals)in)the)
proportion)of)Bacteroidetes.)
V No)significant)change)in)the)%)of)Bacteroidetes)from)obese)subjects)
on)weight)loss)diets.)
Species&+&SCFA&associations&
V Significant)reductions)in)a)group)of)butyrateVproducing)Firmicutes)
(Roseburia+spp.)and)Eubacterium+rectale))were)detected)in)faecal)
samples)from)obese)subjects)on)weight)loss)diets)(reduced)
carbohydrate)intake).)
V Increased)levels)of)Clostridium+spp.)(phylum:)Firmicutes))also)
correlated)with)reduced)carbohydrate)intake.))
!
!
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Paper& Methods& Key&Results/Limitations&
Payne)et)al.)(2011))(172)) Aim:)to)investigate)differences)in)gut)microbial)
compositions)and)metabolite)concentrations)of)obese)
versus)normalVweight)children.))
n=30,)n=15)(obese),)n=15)(normalVweight))children)8V
14yrs.))
Sequencing&method&
qPCR)and)temperature)gradient)gel)electrophoresis)
(TGGE))and)highVpressure)liquid)chromatography)for)
SCFA)
Phylum&
V No)significant)differences)in)gut)microbiota)communities)of)obese)
and)normalVweight)children.))
V High)degree)of)intraV)and)intergroup)variation.)
SCFA&associations&
V Significantly)higher)concentrations)of)SCFAs)(butyrate)and)
propionate))in)obese)versus)normalVweight)children.))
Collado)et)al.)(2008))(173)) Aim:)to)characterise)the)gut)microbiota)in)women)
according)to)their)BMI)and)the)effect)of)weight)gain)
over)pregnancy)on)the)composition)of)microbiota)
before)delivery.)
n=54,)overweight)(18),)normalVweight)(36))
Excessive)weight)gain)during)pregnancy)>16.0)kg)for)
normalVweight)and)>11.5)kg)for)overweight)candidates.))
Sequencing&method&
Gut)microbiota)analysed)by)FCMVFISH)and)quantitative)
realVtime)polymerase)chain)reaction)(qPCR).))
Genus&
V Higher)levels)of+Bacteroides+(phylum:+Bacteroidetes),+Clostridium+and)
Staphylococcus+(phylum:)Firmicutes)+in)overweight)females)prior)to)
pregnancy.)
V Positive)correlation)between)Bacteroides+concentrations)and)weight)
gain)over)pregnancy)(p=0.014).)
!
!
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Paper& Methods& Key&Results/Limitations&
Schwiertz)et)al.)(2010))(174)) Aim:)to)evaluate)differences)within)the)human)
intestinal)microbiota)and)faecal)SCFA)concentration)of)
lean)and)obese)subjects.)
n=)98,)n=30)lean,)n=35)overweight,)n=33)obese))
Sequencing&
qPCR)and)SCFA)analysis)
Phylum&
V Most)abundant)phyla)were)the)Firmicutes)and)Bacteroidetes)in)lean)
and)obese)subjects.)
V Lower)ratio)of+Firmicutes)to)Bacteroidetes)in)overweight)(P)=)0.001))
and)obese)volunteers)(p=0.005))compared)to)lean)volunteers.))
Genus&
V Methanobrevibacter)(from)phylum)Euryarchaeota))were)detected)in)
a)smaller)proportion)of)overweight)(45.7%,)p=)0.155))and)obese)
volunteers)(33.3%,)p=0.017))compared)to)lean)volunteers)(63.3%).)
V Obese)individuals)had)significantly)lower)Bifidobacterium+
concentrations)(p=0.02).))
SCFA&
V Total)SCFA)content)increased)significantly)from)84.60mmol/L)in)lean)
to)103.87)mmol/L)in)obese)subjects.))
V The)propionate)concentration)increased)significantly)from)lean)to)
obese)subjects)as)well)as)its)proportion)of)total)SCFA.)
Santacruz)et)al.)(2009))(176)) Aim:&to)determine)the)influence)of)an)obesity)
treatment)program)on)the)gut)microbiota)and)body)
weight)of)overweight)adolescents.&
N=)36)adolescents)(13V15)years)on)calorieVrestricted)
diet)(10V40%))and)increased)physical)activity)for)10)
weeks.)
Note:)23)subjects)had)>4.0)kg)weight)loss)(significant)
BMI)reduction))while)the)other)13)subjects)showed)no)
weight)loss)<2.0kg.))
Sequencing&method&
qPCR)of)faecal)samples)before)and)after)the)
intervention)
In&the&high&weightGloss&group:&&
V Levels)of)B.+fragilis)group)(from)genus)Bacteroides))and)Lactobacillus)
group)(genus)from)phylum+Firmicutes))significantly)increased)with)
weight)loss.&
V Clostridium+coccoides)group)(species)from)genus)Clostridium))and)B.+
Longum)counts)(species)from)genus)Bifidobacterium))significantly)
decreased)with)weight)loss.)&
)
&
!
!
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1.2.6 Diabetes and the Gut Microbiota  
1.2.6.1.1 Diabetes and the gut microbiota (human studies) 
Curiously, although few studies have investigated T2DM and the gut microbiota, there is no 
lack of reviews published in this area of research (21, 177-180). There are two metagenome 
studies published, investigating T2DM (or the progression to T2DM) and the gut microbiota 
(22, 96) (Table 1.5). There are only two studies, one of which is a metagenome study, that 
includes an IGT/prediabetes cohort thus covering the glycaemic spectrum (96, 97) (Table 
1.5).  
A comparison of studies investigating the gut microbiota and T2DM have shown inconsistent 
findings with the exception of alpha diversity. Furthermore, researchers have used differing 
bioinformatics and statistical methods and have reported bacterial results at different 
taxonomic levels, making comparisons between the various studies difficult.  
In contrast to previous research where obesity was found to be associated with a significant 
decrease in diversity (169) despite obesity being a strong risk factor for T2DM, researchers 
have found no association between T2DM and alpha diversity (95, 97, 181).  
Qin et al. (22) and Karlsson et al. (96) combined metagenomic analysis with clinical data 
known as a metagenome-wide association study (MGWAS) (Table 1.5) (22, 96). Both studies 
reported a lower presence of Clostridiales bacteria that produce the SCFA butyrate 
(Roseburia intestinalis and F. prauznitzii) in those with T2DM. However, several associations 
differed between the two studies (Table 1.5). For example, Karlsson et al. (96) identified an 
enrichment of Lactobacillus gasseri and Streptococcus mutans in their T2DM cohort, and Qin 
et al. (22) reported an enrichment of Proteobacteria in their T2DM cohort. 
At the phylum-level, Larsen et al. (95) reported the ratio of Bacteroidetes to Firmicutes to be 
significantly positively correlated with reduced glucose tolerance, whereas Zhang et al. (97) 
reported no correlation between plasma glucose and the ratio of Bacteroidetes to Firmicutes. 
Larsen et al. (95) also reported that the relative abundance (RA) of Firmicutes was 
significantly lower (p=0.03) in the diabetes cases compared to the controls (95); however, this 
was not reported in the other studies investigating the gut microbiota and T2DM (165, 181, 
182) (Table 1.5). At the class-level, a significant increase in Betaproteobacteria in those with 
T2DM/increased plasma glucose was reported by two studies (95, 97). Conflicting results 
were reported for the RA of the class Clostridia, with Zhang et al. (97) reporting significantly 
higher RA in the T2DM group compared to the prediabetes group, in contrast to Larsen et al. 
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(95), who reported significantly lower RA in those with T2DM than in the controls. A number 
of different bacteria at the genus- and species-level were reported to have an association with 
T2DM but there was no consistency between studies (Table 1.5).  
Limitations of the human studies investigating diabetes and the gut microbiota: 
The inconsistency in findings of the above studies investigating T2DM and the gut microbiota 
could be due to a variety of reasons including:  
! Small heterogeneous study cohorts. 
! Limited information reported on other factors that may be impacting the gut 
microbiota, such as dietary intake, and varying exclusion criteria used by different 
research groups, for example, gastrointestinal diseases and length of time since 
probiotic and antibiotic use. 
! Researchers have used a variety of different methods to extract and sequence the 
genomic DNA, and the bioinformatics and statistical methods have also differed, 
making it difficult to compare papers.  
! A complication of investigating the progression to T2DM is the disagreement in 
diagnostic values and tests worldwide for diagnosing people with prediabetes and 
T2DM. For example, the WHO and ADA recommend different diagnostic values for 
prediabetes. Furthermore, researchers to date have used a variety of diagnostic 
thresholds and a variety of tests including fasting glucose, HbA1c and oral glucose 
tolerance test (OGTT) to stratify their participants.  
! A further issue around investigating those with T2DM is the variety of 
antihyperglycaemic agents used to improve glycaemic control, and that metformin, the 
most commonly used drug in those with T2DM, may also impact the gut microbiota.  
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Table 1.5: Diabetes and the gut microbiota (human studies). 
Paper& Methods& Key&Results/Limitations&
Qin$et$al.$(2012)$(22)& Aim:&To$develop$a$protocol$for$a$metagenome9wide$
association$study.$
n=345$–$Chinese$males$and$females$(normal$glucose$
tolerance$(NGT)$and$T2DM)$
Medications$not$reported.$$
Sequencing&method:&
Deep$shotgun$sequencing$of$gut$microbial$DNA$&$Illumina$
GAIIx$and$HiSeq2000$were$used$to$sequence$the$samples.$
Phylum&
9 Proteobacteria$higher$in$the$T2DM$group.$$
Species&+&SCFA&associations&
9 butyrate9producing$bacteria$(Roseburia-intestinalis$and$F.-
prauznitzii)$lower$in$T2DM$group.$
9 Increase$in$the$number$of$opportunistic$pathogens$in$those$
with$T2DM.$$
Karlsson$et$al.$(2013)$(96)& Aim:&To$characterise$the$faecal$metagenome$of$145$
European$women$with$normal,$impaired$or$diabetic$glucose$
control.$
n$=$145,$NGT$(43),$IGT$(49),$T2DM$(53)$70$yr$old$European$
females$
Some$participants$on$medication$
Sequencing&method:&&
Shotgun$sequencing$9$Genomic$DNA$was$extracted$and$
sequenced$on$Illumina$HiSeq$2000.$$
Species&+&SCFA&associations&&
9 butyrate9producing$bacteria$(Roseburia-intestinalis$and$F.-
prauznitzii)$lower$in$T2DM$group$
9 Lactobacillus-gasseri$and$Streptococcus-mutants$higher$in$
the$T2DM$cohort.$$
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Paper& Methods& Key&Results/Limitations&
Zhang$et$al.$(2013)$(97)& Aim:$To$investigate$associations$between$gut$microbiota$and$
different$glucose$intolerance$statuses.$$
n$=$121,$NGT$(44),$prediabetes$(64),$T2DM$(13)$
9 WHO$criteria$used$for$the$diagnosis$of$diabetes.$Fasting$
glucose$and$OGTT$results$reported.$$
Exclusion&criteria:&&
9 antihyperglycaemic$agents,$probiotics,$antibiotics$
hormones,$antiobesity$agents,$lipid9lowering$drugs$<1$
month$prior$to$the$study.$
9 Renal$and/or$hepatic$diseases,$GI$tract$diseases,$
psychiatric$disorders,$neoplasia$and$other$diseases$that$
may$interfere$with$the$conduct$of$the$study.$$
Sequencing&method:&&
9 16S$rDNA9based$high9throughput$sequencing.$
Amplication$of$the$V39V5$region$of$the$16S$rRNA$gene$
from$each$DNA$sample.$
Dietary&intake:$not$measured.$
Analysis:&
9 RA$of$gut$microbiota$were$compared$between$groups.$$
9 Richness$and$diversity$estimations$used$the$Shannon$
diversity$and$Chaol$index.$$
9 Principal$component$analysis$(PCA)$used$for$beta$
diversity$between$the$3$groups.$$
9 PERMANOVA$and$co9inertia$(CIA)$analysis$tested$
relationships$between$microbiota$and$clinical$
parameters.$$
Diversity&
9 No$significant$differences$were$found$between$the$3$groups$
for$the$Chaol$index$and$Shannon$index.$$
Phylum&
9 Firmicutes$and$Bacteroidetes$were$the$dominant$taxa$at$the$
phylum$level.$
9 Ratio$of$Bacteroidetes$to$Firmicutes$was$not$correlated$with$
plasma$glucose$concentration.$$
Class&
9 RA$of-Betaproteobacteria-was$significantly$increased$in$the$
prediabetes$group$in$comparison$to$the$NGT$group$and$was$
even$higher$in$the$T2DM$group.$$
9 RA-of-Clostridia-was$significantly$higher$in$the$T2DM$group$
compared$to$the$prediabetes$group.-$
9 RA$of$Verrucomicrobiae$was$significantly$lower$in$
prediabetes$compared$to$the$NGT$group.$$
Genus&
9 Bacteroides$in$the$T2DM$were$only$half$that$of$the$NGT$and$
prediabetes$groups.$$
Species&+&SCFA&associations&
9 Butyrate9producing$bacteria$(e.g.$Akkermansia-municiphila)$
had$a$higher$abundance$in$the$NGT$compared$to$the$
prediabetes$groups.$
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Paper& Methods& Key&Results/Limitations&
Wu$et$al.$(2015)$(181)& Aim:&To$complete$molecular$analyses$of$the$faecal$
microbiota$in$people$with$T2DM.$
n=28,$NGT$(16),$T2DM$(12)$
9 12$T2DM$participants$were$new$cases$with$unstable$
blood$glucose$levels$and$4$were$treated$cases$with$stable$
blood$glucose$levels.$$
9 No$mention$of$diagnostic$criteria$used.$
Exclusion&criteria:&
9 History$of$GI$diseases$and$use$of$antibiotics,$probiotics$or$
prebiotics$within$30$days$prior$to$sampling.$$
Sequencing&method:&
9 PCR9denaturing$gradient$gel$electrophoresis$(DGGE)$with$
primers$specifically$targeting$V3$region$of$the$16S$rRNA$
gene,$as$well$as$being$sequenced$for$excised$gel$bands.$
Dietary&intake:$dietary$habits$measured.$$
Analysis:&
9 Bacterial$diversity$(evaluated$by$the$number$of$bands$
and$the$band$intensity$of$DGGE$profiles$and$the$
Shannon9Weaver$index).$$
9 Targeted$bacteria$groups$–$Bifidobacterium,-Bacteroides-
vulgatus,-Clostridium-leptum-subgroup$
Diversity))
9 No$significant$difference$in$diversity$between$the$two$
groups.$$
Phylum&
9 Bacteroidetes$and$Firmicutes$were$the$dominant$bacteria$for$
both$groups.$$
Genus&
Bifidobacterium$were$less$represented$in$the$microbiota$of$the$
T2DM$group$than$the$NGT$group.$$
Dietary&
Limited$dietary$information$reported$‘similar$consumption$of$
patterns$of$grain$(rice,$wheat),$vegetables$and$a$little$meat$in$
both$groups’.$‘The$only$difference$was$that$the$daily$amount$of$
food$in$diabetes$patients$was$limited’.$
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Paper& Methods& Key&Results/Limitations&
Larsen$et$al.$(2010)$(95)& Aim:&To$characterise$the$composition$of$faecal$microbiota$in$
adults$with$T2DM$compared$to$non9diabetic$controls.$
n=36,$NGT$(18),$T2DM$(18)$–$All$male$participants$
9 Diagnosed$with$OGTT.$Diagnostic$value$not$mentioned.$$
Exclusion&criteria:&
9 No$exclusion$criteria$reported.$$
Sequencing&method:&
9 qPCR$by$tag9encoded$amplicon$pyrosequencing$of$the$V4$
region$of$the$16S$rRNA$gene.$
Dietary&intake:$not$measured.$$
Analysis:&
9 diversity$was$estimated$by$Chaol$indices$
9 RA$of$phylum$and$classes$reported$
9 Correlations$between$OUT$or$BMI$and$bacteria$
Diversity&
9 No$difference$in$the$mean$bacterial$diversity,$as$estimated$
by$Chaol$indices.&
Phylum&
9 RA$of$Firmicutes$was$significantly$lower$(p=0.03)$in$the$
diabetic$group$compared$to$the$controls.$$
9 The$ratio$of$Bacteroidetes$to$Firmicutes$was$significantly$
positively$correlated$with$reduced$glucose$tolerance.$
Although$not$significant$the$reverse$was$seen$for$BMI.$The$
researchers$suggested$that$being$overweight$and$having$
diabetes$are$associated$with$different$groups$of$intestinal$
microbiota.$
Class&
9 The$RA$of$Clostridia$in$diabetes$was$significantly$lower$than$
in$controls$(p=0.03).$
9 Betaproteobacteria-was$significantly$positively$correlated$
with$plasma$glucose$(p=0.04).$$
Other&
9 Ratio$of$BacteroidesBPrevotella$group$to-C.-coccoidesBE.-
rectale$group$was$significantly$correlated$with$plasma$
glucose$(p=0.02)$but$not$BMI.$$
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Paper& Methods& Key&Results/Limitations&
Sato$et$al.$(2014)$(165)& Aim:&To$investigate$gut$microbiota$and$‘live$gut$bacteria’$in$
the$systemic$circulation$of$Japanese$patients$with$T2DM.$
n=100,$NGT$(50),$T2DM$(50)$
9 Healthy$controls$diagnosed$by$HbA1c$levels$<6.0%$(42$
mmol/mol).$$
Exclusion&criteria:&
9 Proliferative$retinopathy,$age$≥$80$years,$serious$liver$
disease,$serious$kidney$disease,$acute$heart$failure,$
malignancy,$inflammatory$bowel$disease$(IBD),$history$of$
treatment$with$antibiotics$within$3$months$of$study$
participation.$$
Sequencing&method:&
9 16S$rRNA9Targeted$Reverse$Transcription9Quantitative$
PCR$(RT9qPCR)$$
Dietary&intake:&
9 Self9administered$diet$history$questionnaire$measuring$
dietary$habits$during$the$preceding$month.$$
Genus&and&Species&&
9 Clostridium-coccoides$group$(species),$Atopobuim-cluster$
(genus),$and$Prevotella$(genus)$were$significantly$lower$
(p<0.05),$while$the$counts$of$total$Lactobacillus-(genus)$were$
significantly$higher$in$faecal$samples$in$T2DM$patients$than$
those$of$control$subjects.$
Analysis&with&and&without&metformin&
9 Enterobacteriaceae$and$Staphylococcus$were$significantly$
higher$in$the$patients$receiving$metformin$(p<0.05)$$
Correlations&
9 C.coccoides$(species)$correlated$negatively$with$hs9CRP,$
energy$intake,$saturated$fatty$acid$intake$and$BMI.$
9 Aptobium-cluster$(genus)$correlated$negatively$with$hs9CRP$
and$BMI$and$positively$with$HDL9cholesterol.$$
Dietary&
9 They$reported$no$significant$differences$in$total$energy,$
carbohydrates,$fat$and$protein$between$groups$(same$as$our$
study).$$
9 They$reported$a$similar$intake$of$yoghurt$between$groups.$$
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Paper& Methods& Key&Results/Limitations&
Lambeth$et$al.$(2015)$(182)$ Aim:&to$investigate$the$characteristics$of$the$gut$microbiota$
in$prediabetes$and$T2DM$compared$to$non9diabetic$subjects.$
n=49.$NGT$(15),$prediabetes$(20),$T2DM$(14)$
9 Participants$characterised$by$the$ADA$criteria$using$
HbA1c$with$<5.7%$for$NGT,$5.796.4%$prediabetes$and$
>6.5%$T2DM.$
Exclusion&criteria:&
9 Patients$who$were$acutely$ill$or$actively$taking$antibiotics$
were$excluded.$No$mention$of$diabetes$medications.$$
Sequencing&method:&
9 PCR$amplification$and$high9throughput$sequencing$of$the$
V4$region$of$the$16S$rRNA$gene.$$
Dietary&intake:&survey$questionnaire$for$dietary$intake.&&
Class&
The$prediabetes$group$had$a$higher$RA$of$the$class$
chloracidobacteria$(p=0.04)$
Genus&
The$T2DM$group$had$higher$levels$of$the$genus$Collinsella$and$
an$unknown$genus$belonging$to$the$family$Enterobacteriaceae.$$
Dietary&–&participants$reported$whether$they$were$vegetarian,$
lactose9free,$or$gluten9free$but$other$details$of$dietary$habits$
were$not$explored.&&
Metformin&–&authors$noted$that$the$patients$in$this$study$were$
not$questioned$about$metformin$and$assumed$that$some$of$the$
T2DM$group$and$possibly$some$of$the$prediabetes$group$would$
have$been$taking$metformin.&&
Probiotics&–&One$participant$in$each$of$the$study$groups$
reported$taking$probiotics$but$were$not$excluded$from$analysis.&&
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1.2.6.2 Mechanisms linking the gut microbiota to T2DM 
Despite the inconsistent findings, several mechanisms have been proposed linking the gut 
microbiota and the progression to and management of T2DM.  
Researchers have reported that the gut microbiota affects energy metabolism (94, 166, 169) as 
an increase in energy harvested could lead to weight gain and therefore insulin resistance. It 
has also been suggested that altered intestinal microbiota and reduced SCFA production (for 
example, a decrease in butyrate-producing bacteria in those with T2DM) may lead to 
increased intestinal permeability, eventually leading to the translocation of bacterial 
lipopolysaccharides (LPS) which may result in metabolic endotoxemia and insulin resistance 
(183). Individuals with low bacterial richness have also been shown to have greater overall 
adiposity, insulin resistance and dyslipidaemia and a more pronounced inflammatory 
phenotype when compared to individuals with high bacterial richness (184). 
It has also been suggested that associations between the gut microbiota and metabolic health, 
such as insulin resistance, may be mediated through the serum metabolome (185). Pedersen et 
al. (185) investigated associations between the gut microbiota, the serum metabolome and 
insulin resistance. Consistent with previous research (186), Pedersen et al. found increased 
levels of branched chain amino acids (BCAA) in the serum metabolome of individuals with 
insulin resistance and metabolic syndrome. The increase in BCAA in the serum metabolome 
was linked to the gut microbiota and was attributed to both an increase in the RA of species 
containing genes coding for BCAA synthesis and a decrease in the RA of species containing 
genes for bacterial BCAA uptake (inwards transport). Prevotella copri and Bacteroides 
vulgatus were identified as the main species driving the association between the biosynthesis 
of BCAAs and insulin resistance. The reduced capacity for bacterial BCAA uptake was 
driven by reduced abundance of multiple species, including Butyrivibrio crossotus and 
Eubacterium siraeum. 
Although some researchers are convinced that there is a connection between the gut 
microbiota, obesity and glucose intolerance, studies are equivocal. This may be due to 
differences in methodologies as discussed in this review. In the first part of this thesis, the 
author has addressed some of the issues around methodology in an observational trial 
investigating the gut microbiota of people across the glycaemic spectrum. For example, 
participants were carefully stratified according to metabolic and clinical criteria to create 
homogenous groups. Other factors that may impact the gut microbiota were also taken into 
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account, including dietary intake, probiotic, antibiotic and metformin use, and gastrointestinal 
disease. 
1.3 Aims and Hypotheses 
Overall aims of this thesis:  
This thesis will investigate differences in metabolic markers, dietary intake and vitamin C 
status and the gut microbiota of individuals across the glycaemic spectrum.  
The final part of this thesis investigates whether the consumption of SunGold kiwifruit (as 
part of the normal diet of a free-living individual) is associated with alterations in the gut 
microbiota, and can potentially improve glucose tolerance and other markers of metabolic 
health.   
The hypotheses that are explored in this thesis are that:  
• Improved glycaemic control is positively associated with markers of metabolic health. 
• Plasma vitamin C is negatively associated with glycaemic control and other markers 
of metabolic health.  
• The gut microbiota composition is associated with glycaemic control. 
• There will be no change in glycaemic control in people with prediabetes consuming 
two SunGold kiwifruit per day over 12 weeks in a free-living situation.  
• The consumption of two SunGold kiwifruit per day will alter the gut microbiota 
composition in people with prediabetes in a free-living situation.   
• The consumption of two SunGold kiwifruit per day over 12 weeks will increase 
plasma vitamin C concentrations and improve markers of metabolic health.  
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 Chapter Two: Methods 
This chapter includes the general methods used for each of the studies included in this thesis. 
Methodology details specific to each study such as ethics, inclusion and exclusion criteria, 
and what happened at participant study visit(s) are detailed in each of the study chapters.  
2.1 Author’s Role in each Study Included in this Thesis.  
2.1.1 Canterbury Health, Ageing and Lifecourse (CHALICE) Study 
The role of the author in the CHALICE study was to calculate the macro- and micronutrient 
intake of participants and to interpret the metabolic data and dietary data that had previously 
been entered into Kai-culator, a nutrient analysis programme. The author was not involved in 
protocol development or collection of the clinical data. During data collection for CHALICE, 
the author had been involved in checking the four-day estimated food diaries (4DEFD) for 
completeness and requesting additional dietary data where necessary as part of a master’s 
degree. The author had also previously entered a portion of the food diaries into Kai-culator 
and oversaw other experienced nutritionists who also entered the data into Kai-culator, which 
involved checking for accuracy and making necessary changes to ensure consistency of data.  
2.1.2 Metabolic Health Cross Sectional Study (MHCSS) 
The role of the author in the MHCSS was to design the study protocol and methodology,!
complete the Health and Disability Ethics Committees (HDEC) applications and obtain 
locality assessment including consultation with local Māori, arrange and conduct participant 
recruitment and study visits, administration of the questionnaires, collection of clinical data 
(with the exception of blood samples), aliquot and storage of faecal samples, participant 
training for food diary data collection, review of food diaries and entry of missing data, 
development of methodology for entering the food diaries into Kai-culator, data entry of some 
food diaries and overseeing the data entry for the other food diaries, and entering, managing 
and presenting study data. 
2.1.3 Kiwifruit Intervention Study (KIS) 
The role of the author in the KIS was to design the study protocol and methodology, complete 
the HDEC applications and obtain locality assessment including consultation with local 
Māori, arrange and conduct participant recruitment and study visits, administration of the 
questionnaires, collection of clinical data (with the exception of blood samples), aliquot and 
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storage of faecal samples, participant training for food diary data collection, review of food 
diaries and entry of missing data, development of methodology for entering the food diaries 
into Kai-culator, overseeing the food diary data entry, and entering, managing and presenting 
study data. 
There are some differences in methodologies used to collect the same data for each of the 
studies included in this thesis. The type of data collected and methodologies used to collect 
the data for CHALICE differed, as the author of this thesis was not involved in protocol 
development or collection of clinical data. The KIS was completed after the MHCSS and 
therefore there are some slight differences in the two methodologies. The author of this thesis 
adapted the KIS methodology based on experiences from the MHCSS.  
2.2 Demographic Information 
Information on demographics used in this thesis included gender, ethnicity, educational 
qualifications, smoking status and current medication and supplements for the CHALICE, 
MHCSS and KIS. Alcohol consumption was also reported in the KIS. Demographic 
information was collected by the interviewer-administered questionnaires (187) in CHALICE 
and was obtained from self-reported questionnaires in the MHCSS and KIS.  
2.2.1 Additional Questionnaires included only in the KIS  
Gastrointestinal Symptom Rating Scale (GSRS). The author of this thesis obtained a 
licence (Microbiota Metabolic Health Kiwifruit Intervention U1111-1183-9874) to use the 
Australia-Australasian version of the GSRS questionnaire. Participants completed the 
questionnaire the evening before or during their study appointment. The questionnaire is a 
rating scale for gastrointestinal symptoms in patients and asks a series of questions about 
gastrointestinal symptoms over the previous week. A total GSRS score was calculated for 
each participant at baseline, week 6 and 12.  
Bowel movements. As with the lead-in week, participants were asked to record the number of 
bowel movements they had on three non-consecutive days during the week prior to their study 
appointment. They were also asked to classify their faeces using the Bristol Stool Chart. If 
participants reported taking a laxative during this time, the information was excluded in 
analyses. 
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2.3 Anthropometric Data 
Height (m). Height was measured using a fixed stadiometer with a sliding horizontal 
headpiece. Participants stood straight against the wall, looking ahead, without shoes, while the 
headpiece was lowered and rested firmly on the top of their head. Height was measured once 
to the nearest mm.  
Weight (kg). In the MHCSS and KIS, participants were asked to remove their footwear and 
heavy outer clothing such as belts and jackets, and were weighed once to the nearest 0.1 kg on 
calibrated Tanita scales (Model BWB-800A, Tanita Corporation, Tokyo, Japan). In 
CHALICE, weight was measured to the nearest 0.1 kg on calibrated Tanita Body 
Composition Analyser TBF 300 scales (Tanita Corporation, Tokyo, Japan). 
Body composition analysis. As a higher percentage of body fat is associated with a greater 
risk of obesity-related illnesses, it was considered an important measure to include in this 
thesis. BMI cannot discriminate between fat and muscle and although waist circumference 
and waist-to-hip ratio can be used to describe distribution, these measures do not quantify fat 
mass. Body composition was measured using bioimpedance analysis in CHALICE, MHCSS 
and KIS.  
MHCSS and KIS - In MHCSS and KIS the Biodynamics BIA 450 (Biodynamics Corporation, 
Seattle, Washington, USA) machine was used to measure body composition. The information 
entered into the machine included gender, age (years), height (m) and weight (kg). Patient 
assessments were conducted using a connection between the individual’s wrist and ankle and 
the analyser using standard ECG sensor pad electrodes (CONMED Corporation, Utica, New 
York, USA). The machine used a 50-kilohertz electrical current to measure the two 
components of impedance, resistance (R) and reactance (X), in the body (188). The machine 
uses resistance and reactance along with the patient’s gender, age, height and weight, and uses 
regression analysis to compute results (188). The body is modelled as a series of tissue and 
fluid compartments (Figure 2.1).  The measurements used in the MHCSS and KIS included 
fat mass (%) and basal metabolic rate (BMR). One participant in the KIS had a pacemaker 
and so was excluded from the bioimpedance analyses.  
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Figure 2.1. Relationship of mass and water distribution (188).  
 
Fat mass (%) (188). Fat mass is the total amount of stored lipids in the body and consists of 
subcutaneous fat and visceral fat. Subcutaneous fat is located directly beneath the skin and 
serves as an energy reserve and insulation against the cold. Visceral fat is located deeper 
within the body and serves as an energy reserve and as a cushion between organs.  
Calculations used for fat mass (188): 
Fat mass (kg) = weight – fat-free mass  
Fat mass (%) = fat mass / weight 
where fat-free mass = a * height2 + b * weight + c * age + d * resistance + e 
Resistance is a direct measure and is determined by the potential (V) and the current (I) which 
are correlated, integrated, digitalized, and divided to determine resistance. Values for 
resistance are stored and used to perform subsequent equations. Variables a, b, c, d, and e 
represent constant coefficients calculated by regression analysis.  
CHALICE - Body composition was measured by calibrated Tanita Body Composition 
Analyser TBF 300 scales (Tanita Corporation, Tokyo, Japan). Participants were asked to 
remove heavy items like belts and jackets. The information entered into the scales for each 
participant was: age (years), height (m), weight for clothes (set at 0.0 kg) and body type 
entered as standard male or standard female. Participants stood on the weighing platform with 
their bare feet positioned so that their heels were placed on the posterior electrodes, and the 
front parts of the feet in contact with the anterior electrode. The Body Composition Analyser 
circulates 50-kilohertz electrical current through the lower part of the body to measure 
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impedance (electrical resistance). The impedance is greatest in fat tissue, which contains only 
10-20% water, while fat- free mass that contains 70-75% water allows the current to pass 
through much more easily (189). This resistance is measured and input into scientifically 
validated Tanita equations to calculate body composition measurements. Only fat mass (%) 
data was utilized for this thesis from the CHALICE dataset.  
BMI (kg/m2). Widely accepted as an appropriate population-level indicator of excess body 
fat (190), BMI is calculated by weight in kilograms divided by height squared in metres. In 
each of the studies included in this thesis, BMI was automatically calculated for each 
participant by the bioimpedance equipment.  
Waist circumference and the waist-to-hip ratio are alternative anthropometric measures that 
also indicate whether excess body fat is centrally or peripherally located. 
Waist circumference (cm). In the MHCSS and KIS the WHO STEPwise Approach to 
Surveillance (STEPS) protocol for measuring the waist circumference was used. The 
measurement was made at the approximate midpoint between the lower margin of the last 
palpable rib and the top of the iliac crest (191). The measurement was made against the skin 
or over light clothing. The tightness of the tape was controlled by using a Gulick II Measuring 
tape (Model 67020, Country Technology Inc, Gays Mills Wisconsin, USA). Measurements 
were made to the nearest 0.1 cm. In the MHCSS, two measures were recorded, and if the 
difference between the measurements exceeded 1.5 cm, a third measure was taken. The 
measures for each participant were averaged. In the KIS the method was adapted with three 
measurements taken at each study visit for each participant and the three measurements were 
averaged. In the KIS the coefficient of variation associated with the measurement error for 
waist circumference was 0.65%. 
In CHALICE, waist circumference was also measured at the midpoint between the lowest rib 
and the top of the hip bone iliac crest. The measurement was made over light clothing.  One 
measurement was made to the nearest 0.1 cm.   
Hip circumference (cm).  In the MHCSS and KIS, hip circumference was measured to the 
nearest 0.1 cm around the widest portion of the buttocks with the tape parallel to the floor 
using a Gulick II Measuring tape, as described above. In the KIS the coefficient of variation 
associated with the measurement error for hip circumference was 1.86%. Hip circumference 
was not measured in CHALICE. 
Waist-to-hip ratio. In the MHCSS and KIS, waist-to-hip ratio was calculated by dividing the 
waist circumference by the hip measurement. 
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Blood pressure (mmHg). In the MHCSS and KIS, blood pressure was measured using an 
automated blood pressure monitor (Bp TRU, BTM-300, Omron Healthcare Co., Ltd, Muko, 
Kyoto, Japan). In the MHCSS, the measurement was repeated if the results were outside the 
normal range. If there was an obvious outlier, this result was removed and the other results 
were averaged. In the KIS, three blood pressure measurements were taken at each study visit 
and the measurements were averaged for each participant. In the KIS, the coefficient of 
variation associated with the measurement error for systolic and diastolic blood pressure were 
2.99% and 5.16% respectively.  
In CHALICE, one manual reading and two automated (Livingston Digital 
Sphygmomanometer with a Welch-Allyn cuff) readings were used to measure blood pressure 
and these three readings were averaged.  
2.4 Blood Parameters 
Venous blood samples were collected after a 10-12 hour fast without food or drinks (other 
than water). For each of the studies included in this thesis, additional fasting EDTA blood was 
collected and centrifuged to separate plasma, which was removed and stored at -80 °C prior to 
analysis. The blood was centrifuged at: 4000 rpm for 10 min at 4 °C for CHALICE and at 
1000 g (2500 rpm) for 15 minutes at 4 °C for the MHCSS. In the KIS, a slightly different 
protocol was used for the EDTA blood that was stored for batch analysis of vitamin C as a 
measure of compliance. The EDTA blood was stored immediately on ice (and kept cool at all 
times) prior to centrifuging for 10 minutes at 1000 g (2500 rpm) at 4 °C.  
For all studies in this thesis, vitamin C was analysed by the Department of Pathology and 
Biomedical Science, University of Otago Christchurch; leptin and ghrelin were analysed by 
the Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch 
and all other blood tests were completed by an International Accreditation New Zealand 
(IANZ) laboratory  
2.4.1 CHALICE 
Blood tests from the CHALICE data included in this study were the markers of metabolic 
health and comprised lipids (total cholesterol, triglycerides, high-density lipoprotein (HDL) 
cholesterol, low-density lipoprotein (LDL) cholesterol, and cholesterol (total/HDL) ratio), the 
inflammatory marker high-sensitivity C-reactive protein (hs-CRP), glucose, HbA1c and 
insulin. Plasma vitamin C was also measured for this study. 
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2.4.2 MHCSS and KIS 
Blood tests comprised lipids (total cholesterol, triglycerides, HDL-cholesterol, LDL-
cholesterol, and cholesterol (total/HDL) ratio), ghrelin, leptin, adiponectin, insulin, glucose, 
HbA1c and plasma vitamin C.   
Lipid parameters. Total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglycerides 
were determined in lithium heparin blood by standard methods (Abbott c series analyser, 
Abbott Park, Illinois, USA) at an IANZ laboratory. 
hs-CRP. The inflammatory marker hs-CRP was measured using end-point nephelometry at 
an IANZ laboratory.  
HbA1c. Determined in blood collected in ethylenediaminetetraacetic acid (EDTA) 
anticoagulant tubes by standard methods (Bio-rad Variant HPLC, Bio-Rad, Hercules, 
California, USA) at an IANZ laboratory. The coefficient of variation associated with the 
measurement for HbA1c is 0.66% at HbA1c of 38 mmol/mol (192). 
Glucose. Fasting glucose was measured in blood collected in fluoride oxalate venoject tubes 
for the MHCSS and KIS and in EDTA anticoagulant tubes for the CHALICE study by 
standard methods (Glucose Hexokinase Enzymatic Assay, Abbott c series analyser, Abbott 
Park, Illinois, USA) at an IANZ laboratory. The coefficient of variation associated with the 
measurement of glucose in plasma is 1.5% at 6.78 mmol/L (193).  
Plasma ghrelin. Measured by an in-house radioimmunoassay (RIA) following extraction 
from plasma using Sep Pak C18 cartridges, as described previously (194). The assay 
recognises the total circulating ghrelin (that is, both octanoyl and non-octanoyl forms). The 
cross reactivities of other peptides in the assay, including vasointestinal peptide, prolactin, 
galanin, growth hormone releasing hormone, neuropeptide Y, brain natriuretic peptide, atrial 
natriuretic peptide, endothelin-1, and angiotensin II, were all less than 0.03%. The RIA had a 
mean detection limit of 10.8 ± 0.8 pmol/L and mean ED50 of 136.2 ± 10.0 pmol/L over 23 
consecutive assays. 
Plasma leptin and adiponectin. Measured using commercial enzyme-linked immunosorbent 
assays (ELISA) from BioVendor (Brno, Czech Republic), Research and Diagnostic products 
(RD191001100 Human Leptin ELISA and RD191023100 Human Adiponectin ELISA) 
according to the manufacturer’s instructions.  
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Plasma insulin. Measured using the Roche Cobas e411 method in an IANZ laboratory. After 
storage at –80 ˚C, thawed plasma was pre-treated using 25% polyethylene glycol to 
precipitate any unwanted antibodies. 
Plasma vitamin C. Stored EDTA-plasma was rapidly thawed and a 500 µL aliquot was 
treated with an equal volume of ice-cold 0.54 M high performance liquid chromatography 
(HPLC)-grade perchloric acid solution (containing 100 µmol/L of the metal chelator DTPA) 
to precipitate protein and stabilize the vitamin C (195). Samples were mixed, incubated on ice 
for a few minutes, then centrifuged. A 100 µL aliquot of the deproteinated supernatant was 
treated with 10 µL of the reducing agent TCEP (100 mg/mL stock) for 2 h at 4 °C to recover 
any oxidized vitamin C (196). Samples were further diluted with an equal volume of ice-cold 
77 mM perchloric acid/ diethylenetriaminepentaacetic acid (DTPA) solution for HPLC 
analysis. 
The total vitamin C content (ascorbic acid plus dehydroascorbic acid) of the samples was 
determined by HPLC with electrochemical detection. Samples (20 µL) were separated on a 
Synergi 4 µ Hydro-RP 80A column 150 mm × 4.6 mm (Phenomenex NZ Ltd, Auckland, New 
Zealand) using a Dionex Ultimate 3000 HPLC unit (with autosampler chilled to 4 °C and 
column temperature set at 30 °C) and an ESA coulochem II detector (+200 mV electrode 
potential and 20 µA sensitivity). The mobile phase comprised 80 mM sodium acetate buffer, 
pH 4.8, containing DTPA (0.54 mmol/L) and freshly added ion pair reagent n-octylamine 
(1 µmol/L), delivered at a flow rate of 1.2 mL/min. A standard curve of sodium-L-ascorbate, 
standardized spectrophotometrically at 245 nm (ε = 9860), was freshly prepared for each 
HPLC run in 77 mmol/L HPLC-grade perchloric acid containing DTPA (100 µmol/L). 
Plasma vitamin C content is expressed as µmol/L.  
Fasting plasma vitamin C concentrations were classified as follows; deficient <11 µmol/L, 
marginal 11-23 µmol/L, inadequate 24-49 µmol/L, adequate 50-69 µmol/L and saturated 
≥70 µmol/L (42).  
2.5 Self-Reported Dietary Intake Data  
Food diaries are one method used to measure the food consumption of individuals, 
particularly in large epidemiological studies (197). Food diaries are a method used to quantify 
individual foods consumed (197). When deciding on the number, selection and spacing of 
days, the food intake, nutrients of interest, day-to-day variation in nutrient intake, and the 
level of precision required must be considered (197).  
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In this thesis, several different methods were used to collect self-reported dietary data; 
however, all methods were used with the aim to obtain information on participants’ usual 
dietary intake. In CHALICE a four-day estimated food diary (4DEFD) and in the KIS a three-
day estimated food diary were chosen rather than a weighed food diary to reduce participant 
burden. The use of an estimated rather than weighed food diary was used, as detailed dietary 
analysis with the gut microbiota was not carried out in these studies. In the KIS a three-day 
estimated food diary (3DEFD) was used as the aim was to investigate major changes in 
dietary intake during the intervention trial, which may act as confounding factors. In the 
MHCSS trial, a four-day weighed food diary (4DWFD) was chosen to gain more detail about 
the dietary intake and in particular around the quantity of foods/beverages consumed by 
participants.  
For all three studies included in this thesis, the food diaries were entered into Kai-culator 
(version 1.08d), a nutrient analysis programme developed by the Department of Human 
Nutrition at the University of Otago, New Zealand. Kai-culator uses the 2014 version of the 
New Zealand food composition database ‘NZ FOODfiles’ (198). 
2.5.1 CHALICE 
CHALICE included self-reported 4DEFD, which was pretested in a convenience sample of 
eight men aged 50 years and older before use in CHALICE. A group of men were chosen 
based on the assumption they may be less likely to know about food preparation and so would 
provide more feedback and recommendations on how best to collect this information. The 
participants who took part in the pretesting were asked to complete the 4DEFD and attend a 
group interview to discuss the 4DEFD layout and the content of the instructions. Based on the 
returned 4DEFD and feedback received from this group, the 4DEFD was modified to produce 
more specific instructions, with regard to reporting food portion sizes. 
CHALICE participants were asked to complete a self-reported 4DEFD (non-consecutive 
including one weekend day) during the week after their study interview. A self-reported 
4DEFD was chosen as it is shown to be accurate by allowing sufficient time to gather data to 
estimate usual intake without the high respondent burden of a longer duration food record 
(197). The CHALICE researchers provided verbal instructions, including examples showing 
how to complete the 4DEFD and written instructions were also included in the 4DEFD. For 
example, detailed instructions were given to explain how to estimate portion sizes using 
common household measures. Participants’ dietary intake was calculated as an average of the 
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four days. The 4DEFD included detailed instructions on how to record portion sizes, using 
common household measures.  
The completed 4DEFDs were checked by the author of this thesis and other trained 
nutritionists soon after the diaries were returned and additional information obtained from 
participants was added where necessary, before the data was entered into Kai-culator. This 
process of checking involved going through each day of the food diary and highlighting 
where details needed to be clarified or added, such as the information on type of 
food/beverage consumed, portion sizes and to check if data was missing: for example, if a 
spread was used on bread or if fat/oil was used when cooking. The CHALICE study 
interviewer would then contact the participant and add the details to the food diary. Data entry 
was undertaken by the author of this thesis and other experienced nutritionists, who used 
agreed assumptions and standardised protocols. All diaries were further checked for accuracy 
by the author of this thesis, who also made any necessary changes to reduce bias and ensure 
consistency of data entry. The author of this thesis did not develop the methods used to enter 
the food diary data into Kai-culator, with mixed meals not being entered as individual 
ingredients, as was done for the MHCSS and KIS.  
Average total daily energy and fibre were calculated along with percent energy values for fat 
(including saturated, monounsaturated, polyunsaturated), carbohydrate (including sugar and 
starch) and protein. Percentage energy from macronutrients per day was calculated from the 
average total daily dietary intake (Section 2.5.4). Micronutrient intake was calculated as well 
as information on high-dose vitamin C supplement use (>500 mg vitamin C). 
2.5.2 MHCSS 
Participants completed a self-reported four-day (non-consecutive) weighed food diary 
(4DWFD) (including one weekend day) prior to their study visit. A weighed food diary was 
chosen for this study as it is the most precise method available for estimating usual food and 
nutrient intakes of individuals (197). Participants’ daily dietary intake was calculated as an 
average of the four days. Participants received training using the Salter digital scales and on 
how to record the data, either at home or in the clinic, prior to the diary being completed. 
Once completed, the diary was also reviewed at their second study visit to add any missing 
information if necessary. The food diaries were entered into Kai-culator. 
Data entry protocols for the diaries were developed by the author of this thesis, and data entry 
was undertaken by an experienced dietitian and an experienced nutritionist who cross-
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checked each other’s data and were overseen by an experienced nutritionist and the author of 
this thesis. A further 16% of the diaries were checked again for accuracy.  
Participants were asked to record and weigh all food and beverages separately. They were 
also asked to provide recipes for mixed dishes and to record the weight (or percentage) of the 
recipe they consumed. As the author had a particular interest in fruit and vegetables for this 
study, in order to group these accurately, all recipes containing >50% fruit or vegetables (for 
example, fruit crumble) were entered as individual ingredients. In contrast, foods containing 
<50% such as a fruit muffin were added as a normal recipe (not individual ingredients) and 
grouped appropriately, for example cakes and muffins. When entering cooked recipes, the 
ingredients had to be changed from raw values (stated in the recipe) to cooked values as 
recorded in the diaries. To do this, all ingredients were multiplied by the appropriate moisture 
retention factor using United States Department of Agriculture (USDA) moisture retention 
values (199).  
In the case of ready-made composite foods such as a purchased sandwich, the ingredients 
were entered separately if the participant stated what the sandwich contained, or if not, a 
standard sandwich was created (for example, chicken salad sandwich) and used for all 
participants who did not indicate the exact ingredients. If participants were eating out and 
unable to weigh their meal, they were asked to take a photograph and provide a description of 
the meal along with estimated amounts of each food. Participants either took photos of 
packages/beverages or attached the empty food packets to their diary if they could not 
describe them or thought the item was not commonly eaten.  
If the food/beverage consumed did not exist in Kai-culator, another food close in nutrient 
composition was substituted, and a list of food substitutions was kept to ensure this was 
consistent for all participants. If there was no close match, either the system administrator 
added the food item or a recipe was created for the food item.  
Average total daily energy and fibre were calculated along with percent energy values for fat 
(including saturated, monounsaturated, polyunsaturated), carbohydrate (including sugar and 
starch) and protein. Percent energy from macronutrients per day was calculated from the 
average total daily dietary intake for the MHCSS-gut microbiota and MHCSS-Vit C chapters 
(Section 2.5.4). Dietary vitamin C intake was also analysed for both the MHCSS-gut 
microbiota and MHCSS-Vit C chapters but selected food groups (Table 2.1) were only 
analysed with the gut microbiota data (Chapter four, Section two). 
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The exclusion of dried fruit, and fruit and vegetable juices from the fruit and vegetable food 
groups did not materially alter the study results. Therefore, for the purposes of the analysis, 
the dried fruit, and fruit and vegetable juices are included in their respective food groups 
(Table 2.1).  
Participants were asked to record the name of dietary supplements taken within the last 
month, the amount per dose, and the frequency, as well as the first and last dose.  
Table 2.1: Food Groups 
Food$Group$ Examples$of$food$items$included$
Total&fruit&& Raw,&frozen,&dried,&canned/stewed&and&real&fruit&juice&(≥50%&
fruit&juice).&
Fresh&fruit& All&raw&fruit.&
Kiwifruit& Green&and&gold&kiwifruit.&
Total&vegetables&& Starchy&vegetables,&nonHstarchy&vegetables&and&vegetable&juices&
(see&below&group&descriptions).&
NonHstarchy&vegetables&& All&vegetables&(fresh/frozen/canned)&including&mixes,&coleslaw,&
green&salads,&tomatoes&(including&pasta&sauces&and&salsa),&corn,&
avocado,&olives,&green&peas&and&beans,&legumes&and&pulses,&
legume&products&and&dishes&(e.g.&hummus,&lentil&curry,&baked&
beans,&tofu,&bean&salad).&&
Starchy&vegetables&& Potatoes&(e.g.&mashed,&boiled,&baked,&hot&chips,&potato&crisps,&
wedges)&kumara,&parsnip,&taro,&yams.&
Total&fruit&and&vegetables&& Total&fruit&(raw,&frozen,&dried,&canned/stewed&and&real&fruit&
juice),&vegetables&(total&starchy&and&nonHstarchy&vegetables).&&
Probiotics&& Probiotic&yoghurt&(e.g.&Yoplait&Yoplus,&Symbio&Probalance,&
Yoplait&Elivae,&Activate,&Bio&Farm&Organic,&The&Collective&
Pourable&Yoghurt&–&Kefir&Tummy&Love,&Doctors&Choice&Bio&
yoghurt,&EasiYo,&Piako,&Cyclops,&De&Winkel,&Naturalea,&Bliss),&
probiotic/fermented&drinks&(Activate,&miso&soup)&and&fermented&
foods&(sauerkraut,&tempeh).&&
Grainy&foods&(bread,&breakfast&
cereals&(all&types),&pasta,&grains&
Bread&(e.g.&white,&wholemeal,&grain,&rye,&garlic,&wraps,&fruit&
toast/currant&bun,&pita,&English&muffins,&pizza&base),&crackers&
(rice,&wheat,&corn),&grains&(e.g.&rice,&quinoa,&wheatgerm,&wheat&
bran&taco&shells/corn&chips),&breakfast&cereals&(e.g.&muesli,&
wheat&biscuits,&porridge,&puffed/flaked/extruded&cereals),&
pasta/noodles&(cooked&from&fresh&or&dried).&
Nuts&and&seeds& Peanuts,&walnuts,&almonds,&cashew&nuts,&brazil&nuts,&hazel&nuts,&
pine&nuts,&pumpkin&seeds,&sunflower&seeds,&linseed,&mixed&nuts,&
peanut&butter.&
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2.5.3 KIS 
Participants completed a three-day (two weekdays and one weekend day) self-reported 
estimated food diary (3DEFD) during their lead-in week and during their final week of 
consuming the SunGold kiwifruit (week 12). A shorted estimated food diary was chosen for 
this study to reduce participant burden, as participants were required to complete a food diary 
both at baseline and at the end of the study. Furthermore, less detail was required on dietary 
intake as the aim was to assess whether participants had made major changes to their dietary 
intake that could confound results. Participants’ daily dietary intake was calculated as an 
average over the three days. Participants were asked to record everything they ate or drank 
over the three days. They were asked to describe each item in detail, including cooking details 
and any salt, sugar, spices and sauces they may have added before eating. They were also 
asked to record the brand name of each food, drink or cooking ingredient and also, if possible, 
to attach the wrappers of foods to provide the nutrition information. They were provided with 
some tips to help them estimate the portion sizes such as using household measures, for 
example, two rounded teaspoons of sugar. They were also given a book with photos of 
commonly eaten foods of different portions that they could relate their meal to. Participants 
were also encouraged to take photos of their meals in addition to completing the food diary 
with estimated portions. Once completed, the diary was reviewed during their study 
appointment to add any missing information if necessary.  
The food diaries were entered into Kai-culator. The methodology for entering the food diaries 
is the same as was used for the MHCSS (Section 2.5.2). Average total daily energy and fibre 
intake were calculated along with percent energy values for total fat, carbohydrate and 
protein. Percent energy from macronutrients per day was calculated from the average total 
daily dietary intake (Section 2.5.4). Dietary vitamin C was also analysed. Food groups for 
fresh fruit and total fruit were created and analysed for comparison of fruit intake prior to 
(lead-in phase) and when consuming the two SunGold kiwifruit daily (week 12). At week 12, 
both fresh and total fruit with and without the SunGold kiwifruit were calculated for 
comparison with baseline fruit intake.  
2.5.4 Percentage of Energy from Macronutrients 
In New Zealand, the Acceptable Macronutrient Distribution Range (AMDR) for protein is 
15–25% of total energy, total fat 20−35% of total energy, and carbohydrate 45–65% of total 
energy (200). 
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For all dietary data included in this thesis, the percent energy from macronutrients per day 
was calculated from the average total daily dietary intake as follows (200): 
• percent energy from fat = (fat (g/day) × 37.7 kJ/g) / energy (kJ/day)  
• percent energy from carbohydrate = (carbohydrate (g/day) × 16.7 kJ/g) / energy 
(kJ/day)  
• percent energy from protein = (protein (g/day) × 16.7 kJ/g) / energy (kJ/day)  
2.5.5 Precision of Kai-culator and Self-Reported Dietary Intake Data 
As Kai-culator uses the electronic version of the New Zealand Food Composition database as 
its base, which is developed by Plant and Food Research, the precision and accuracy of the 
Kai-culator database is therefore reliant on the methods used by Plant and Food Research to 
evaluate the composition of foods included in their database (198).  
Although dietary intake was not weighed in CHALICE or the KIS, participants were provided 
with tips to help them estimate the portion sizes such as using standard household measuring 
cups and spoons where possible. In the KIS, they were also given a book with photos of 
commonly-eaten foods of different portions that they could relate their meal to. Participants 
were also encouraged to keep wrappers of foods and in the KIS they were encouraged to take 
photos of their meals in addition to completing the food diary to help with estimated portions. 
The accuracy of dietary intake information recorded by participants was improved by 
checking the food diaries once they were returned and asking the participants for further 
information where details were missing; this was added to the food diary before it was entered 
into Kai-culator. Participants were asked to record foods/beverages as consumed to avoid 
relying on memory.  
Weekend days were proportionally included in the dietary survey period for each person, to 
account for potential day-of-the-week effects on food and nutrient intakes (197). 
In the MHCSS and KIS, where participant recipes were entered specifically for participants, a 
protocol was followed to ensure accuracy and consistency. The ingredients as recorded by the 
participant were located in the Kai-culator database and recorded as a recipe. Moisture losses 
or gains on cooking were accounted for as well as nutrient losses due to cooking, using the 
USDA conversion data as described above (199).  
In each of the studies, the food diaries were entered by more than one person. To reduce bias 
and to ensure consistency of the data entry, all studies used agreed upon assumptions and 
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standardised protocols. A list of food substitutions was kept to ensure consistency for all food 
diaries. In all studies, data entry was undertaken by experienced dietitians and nutritionists. In 
the MCHSS and KIS, they cross checked each other’s data and were overseen by an 
experienced nutritionist and the author of this thesis. A proportion of diaries were also 
checked again for accuracy. In the CHALICE study, although the food diaries were not cross-
checked by those entering them, all the food diaries were checked for accuracy by the author 
of this thesis.   
2.5.6 Limitations of Self-Reported Dietary Intake Data 
Despite the efforts made to improve the precision and accuracy of the data collected and 
analysed on participants’ self-reported dietary intake, measuring dietary intake is a difficult 
endeavour with several possible limitations described below.   
2.5.6.1 Respondent bias  
Respondent bias refers to the systematic over-reporting or under-reporting of foods (197).  It 
is well recognised that under-reporting bias is increased in obese cohorts and is characterised 
by a tendency to report relatively low intakes of foods high in fat and simple carbohydrates 
that may be perceived as socially undesirable (201-205). Therefore, under-reporting is 
potentially problematic for the studies included in this thesis, as associations between diet and 
T2DM, an obesity-related disorder, are explored. Under-reporting of usual energy intakes 
may also arise from participants eating less than usual while recording their dietary intake 
(197). Other factors associated with low-energy reporting include: age and sex; 
socioeconomic status; health-related activities such as smoking status; behavioural effects 
such as the burden of recording the food intake resulting in individuals adapting their diet in 
order to simplify the recording of food intake and may be responsible for energy under-
reporting associated with under-eating; and psychological effects including those linked with 
eating disorders (197). Some participants can experience difficulties in writing down the 
foods and beverages consumed. Over-reporting is not as prevalent as under-reporting but it 
also occurs (197). 
2.5.6.2 Respondent memory lapses 
Although participants were asked to record all foods and beverages at the time of 
consumption, this may not have always been possible. Memory failure can impact the results 
both by participants failing to recall foods/beverages actually consumed (unintentional 
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omission) or reporting foods/beverages that were not consumed (unintentional addition) 
(197). In an attempt to reduce this limitation, all food diaries were checked by an experienced 
nutritionist or dietitian on completion and participants were queried if it appeared as though 
foods/beverages may be missing.   
2.5.6.3 Incorrect estimation of the portion size consumed  
The errors associated with quantifying the portion of food consumed are suggested as the 
largest measurement error in most dietary assessment methods (197). This occurs if 
individuals fail to quantify accurately the food consumed, or from misconceptions of an 
average portion size (197). To overcome this issue, weighed food diaries were used in the 
MHCSS where detailed data on amounts of food consumed was required. In CHALICE and 
the KIS, participants were encouraged to use household measures to estimate portion sizes. In 
CHALICE, participants were shown photographs with a description of the amount of food 
consumed as examples before they started the food diary (for example, different amounts of 
spreads on toast were quantified in a photograph). In the KIS, participants were provided with 
a booklet containing food photographs of different foods quantified as small, medium and 
large portions and they were also encouraged to take photographs of the foods/beverages they 
consumed.  
Despite the errors listed above, there is no better tool in community studies for assessing 
dietary intake unless there is a relevant biomarker.  
2.6 Physical Activity  
In the MHCSS and the KIS, physical activity participants completed the self-administered 
short form version of the International Physical Activity Questionnaire (IPAQ-Short) (206). 
The questionnaire asks about physical activity over the previous seven days. A continuous 
score was calculated for participants as per the IPAQ scoring protocol (Appendix A). The 
total minutes of walking, moderate and vigorous intensity activity per week were calculated 
by multiplying the minutes of an activity per day by the number of days per week the activity 
was reported. The Metabolic Equivalent of Task (MET) scores of 3.3, 4.0 and 8.0 for 
walking, moderate and vigorous intensity activity were assigned as per the IPAQ scoring 
protocol (Appendix A). There is currently no scoring system for the physical activity data 
collected as part of CHALICE and so this information could not be included in this thesis.  
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2.7 Faecal Microbiota Analysis for the MHCSS and the KIS 
2.7.1 Faecal Sample Collection 
At their study appointment, participants provided a faecal sample, which they had collected at 
home in a sterile collection pottle no more than 24 hours prior to their study visit. The sample 
was either stored in an insulated bag with an ice pack or in a home refrigerator. Samples were 
transported in a coolie bag with an ice pack to their study appointment. All samples were 
processed within 24 hours of the patient collecting their sample. The samples were processed 
in a microbiological sterile hood into four aliquots of 0.5–1.0 g of faeces and stored in sterile 
1.5 mL Eppendorf tubes at –80°C for batched analyses. Faecal sample collection 
methodology was adapted from the Human Microbiome Project methodology 
(www.ncbi.nlm.nih.gov/ projects/gap/cgi-
bin/document.cgi?study_id=phs000228.v3.p1&phd=3190#sec114). We deviated from the 
sample pre-processing methods by homogenising samples with a metal spatula before 
aliquoting into the Eppendorf tubes. We also washed the aliquots with TN150 buffer (Tris-
HCl, pH 8.0 (10mM), NaCl (150mM) rather than the MoBio lysis buffer. We also did not 
store samples for RNA extraction. 
The faecal microbiota analysis was completed at the Department of Microbiology and 
Immunology, University of Otago, Dunedin. The faecal DNA extraction was completed by 
Alan Hughes and the preparations of the DNA sequencing, management of the DNA 
sequencing process and the phylogenetic analysis of the DNA sequences was completed by 
Dr Blair Lawley.   
2.7.2 DNA Extraction and Sequence Analysis 
DNA was extracted from stool using the MoBio PowerSoil DNA Isolation kit according to 
the Human Microbiome Project standard operating procedures (www.ncbi.nlm.nih.gov/ 
projects/gap/cgi-bin/document.cgi?study_id=phs000228.v3.p1&phd=3190#sec114).  
Sequencing was carried out at Argonne National Laboratories with 2 × 250 base paired-end 
reads on an Illumina Miseq platform using Nextera libraries according to their own standard 
procedures. Primers used were the 515F/806R set, targeting the 16S rRNA gene V4 region. 
Three sequence files were returned for both the MHCSS and KIS from Argonne National 
Laboratories, comprising forward reads, reverse reads and index (barcode) reads. These reads 
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were processed according to the following skeleton protocol (details of each step can be found 
in Appendix B for the MHCSS and KIS). 
DNA sequences were processed using the QIIME v. 1.9.1 and vsearch v. 2.0.2 suite of 
programs (207, 208). Paired reads were joined and passed through a quality control step in 
which very short or very long reads, reads with low quality or reads with barcode errors were 
excluded. This step also associates reads with the original samples (demultiplexing). Reads 
were then dereplicated (identical reads were clustered and representative sequences used for 
further processing), sorted by cluster size, singleton reads were removed, reads were clustered 
with a 97% identity threshold, chimeras were detected and removed (using both denovo and 
reference-based approaches), original reads were mapped back to the chimera filtered repset, 
an Operational Taxonomic Unit (OTU) table was built from the mapped reads, taxonomy was 
assigned to representative OTU sequences (using the SILVA 123 database), representative 
sequences were aligned and a tree was built from this alignment. 
In the MHCSS, all the T2DM participant samples were submitted as duplicates and in the 
kiwifruit intervention trial all of the participant samples were submitted as duplicates (to 
avoid depletion of this study group through sequence failure), and jackknifed clustering was 
used to ensure that technical repeats clustered together. After ensuring technical repeats were 
not divergent, these repeat samples were combined. The final output OTU table was filtered 
for non-bacterial targets (chloroplast and mitochondria). 
The entire OTU table was collapsed based on assigned taxonomy to five levels (Phylum, 
Class, Order, Family and Genus). Each collapsed table includes data from all OTUs. Taxa 
summaries (where the OTU table was collapsed to various taxonomic levels) was carried out 
on the full OTU table and on an OTU table in which filtering had removed OTUs present in 
fewer than 25% of samples as per QIIME script (http://qiime.org/scripts/ 
group_significance.html). Relative abundances were then recalculated using the filtered 
tables. This reduced the OTU table from 1250 OTUs to 485 OTUs in the MHCSS and from 
1095 OTUs to 427 OTUs in the KIS. 
2.7.3 Diversity 
Rarefaction was set to the sample with the minimum sequence count. With few samples 
available for the study, it seemed wise to retain as many samples as possible. Rarefaction 
curves also indicate that little advantage would be obtained by extending sampling further; the 
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curves do not flatten completely but are approaching plateau and there is a balance between 
increasing sampling and reducing sample numbers. 
Core diversity analyses were carried out in QIIME v 1.9 using a rarefaction level of 6000 
sequences per sample (after combining sequences from technical replicates of the T2DM 
participants, the minimum sequence count was 6993) for the MHCSS and at a rarefaction 
level of 35,000 sequences per sample (after combining sequences from technical replicates of 
all of the study participants the minimum sample sequence coverage was 39,216 and 36,699 
after filtering) in the KIS to avoid loss of any samples. Alpha diversity measures were carried 
out on multiply rarefied tables, whilst beta diversity metrics were applied to a single 
rarefaction table (according to defaults in QIIME v1.9). 
2.7.3.1 Alpha diversity - MHCSS and KIS 
Alpha diversity analysis of phylogenetic data allows estimations of microbial community 
richness (number of phylotypes) and evenness (distribution of phylotype abundance). These 
measurements are collected for each individual and then can be used to compare treatment 
groups. In this thesis Observed species, Whole tree (phylogenetic diversity [PD]), Shannon 
index, Simpson’s diversity and Chao index were included as measures of diversity. These 
were included for the following reasons: Observed species is purely a measure of richness 
(i.e. presence/absence of OTUs); Whole Tree (PD) considers the taxonomy of the community 
and adjusts based on this taxonomy (so it is not just presence/absence but gives a higher 
diversity value to a sample where the bacteria are more distantly related); Shannon index and 
Simpson’s diversity are similar, but different, methods of measuring richness and evenness 
(thus taking into account the abundance of each OTU); and Chao index is a predictive metric 
and is purely a richness measure. 
2.7.3.2 Beta diversity - KIS 
Beta diversity (unique fraction metric [Unifrac] weighted and unweighted) was used to 
compare similarities in microbiota composition over time in the KIS. Beta diversity measures 
were also obtained (using unifrac distances) for the MHCSS but were not considered robust 
from a statistical point of view.  
2.7.4 Faecal Water Content - KIS  
Faecal water content was only calculated for the KIS as a reflection of gut transit time. 
Shorter transit time means more water in faeces. Shorter transit time means less time for 
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bacterial replication and might favour species with shorter doubling times. For each faecal 
sample, approximately 200 mg of faeces was placed in a pre-weighed microfuge tube, the 
weight was recorded, and the tube with cap open was placed in a 37 oC incubator. The tubes 
were dried until a constant dry weight was obtained, and percentage water content was then 
calculated. 
2.7.5 Limitations of Faecal Microbiota Analysis 
2.7.5.1 Faecal sample 
Faeces are used as a non-invasive proxy to study gut microbiota (209). Whilst faeces may be 
fairly representative of the luminal content of the distal large intestine, they may not be ideal 
for studies of mucosal communities (and are certainly not representative of small intestine 
communities) (210). However, faeces are by far the easiest and least invasive sample type to 
collect and are accepted by the wider scientific community. Transit time also has a significant 
impact on the microbial species found in the faecal samples, so any variation in bowel 
movement or transit time between study participants could alter the composition of the gut 
microbiota (211). Sample collection and storage prior to DNA extraction can also lead to 
biases. Ideally a sample will be collected as soon as there is a bowel motion and then stored at 
–20°C prior to shipping to a laboratory for processing (212). Methodological consistency is 
important.    
2.7.5.2 DNA extraction 
A large number of DNA extraction protocols have been described in the literature, each with 
purported advantages and disadvantages. Most methods utilize a combination of chemical and 
physical approaches to break cells open and release genomic DNA (gDNA). Subsequent 
purification of gDNA and removal of inhibitory chemicals (that is, substances that may 
interfere with the generation of sequencing libraries or other downstream analysis protocols) 
may include, for example, inhibitor and/or nucleic acid precipitation, trapping of gDNA on 
silica membranes or binding of gDNA to magnetic particles. Choice of protocol can lead to 
bias in output results. Some protocols perform poorly when extracting DNA, as a number of 
Gram-positive bacteria have tough cell walls, and can thus bias population structure analyses 
towards certain bacterial subsets (213, 214).  
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2.7.5.3 Sequencing 
High throughput sequencing technologies currently focus on large numbers of fairly short 
reads. Many microbiota analysis studies also identify population structure by focusing on 
marker genes (or short regions of marker genes) such as the 16S ribosomal RNA gene. If 
using the 16S rRNA gene, the region targeted will determine the level of phylogenetic 
information available (some bacteria share sequence identity across short regions of the gene). 
Additionally the primer sequences used to amplify the region of interest may introduce biases 
if they do not target all species with equal efficiency (215) (primers used in this study for the 
16A rRNA gene variable region 4 have been developed to amplify most known gut bacteria 
and are widely employed for human gut microbiota analyses (216)) 
(www.ncbi.nlm.nih.gov/projects/gap/ cgi-bin/document.cgi?study_id=phs000228.v3. 
p1&phd=3190#sec114). Library preparation for sequencing also involves a number of 
polymerase chain reaction (PCR) protocols. PCR uses a DNA-specific DNA polymerase 
to generate new DNA strands. These enzymes will occasionally introduce errors when 
extending strands (different enzymes have different error rates). Errors occurring early in the 
PCR process can expand exponentially and impact on community structure. PCR-based errors 
can lead to over-estimations of alpha diversity and can impact on the ability to identify 
bacteria at a lower taxonomic level. 
The sequencing process itself also employs PCR and thus further errors can be incorporated 
during the generation of sequencing strands. Different technologies have different error rates. 
Illumina MiSeq and HiSeq instruments have low error rates, whilst pyrosequencing and long-
read sequencers tend to have higher associated error rates. 
2.7.5.4 Bioinformatics 
Bioinformatic pipelines are constantly under development and are often employed to 
minimize the impact of errors introduced during wet-lab sample preparation and sequencing. 
These protocols must be employed carefully to ensure that low quality or aberrant reads are 
not included, and clustering approaches are relevant to the sample set and sequencing 
technology being employed. Identification of bacterial phylogeny also requires large curated 
databases. As these databases grow, identification of bacterial taxonomy improves. 
2.8 Statistical Analyses 
All statistical analyses for this thesis were completed under the supervision of the 
departmental biostatistician, Professor Chris Frampton.  
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There was no imputation of missing data in any of the analyses and individual missing data 
are presented throughout the thesis with each table. Across all three studies reported in the 
thesis there is very little missing data. Of the 239 participants who had a dietary intake data 
and were analysed for the associations with vitamin C and glucose levels, there was no 
missing data. Of the 89 participants, one participant did not complete the dietary data and one 
participant did not have gut microbiota data. Of the participants completing the KIS, the data 
was largely completed. There was one participant who had a pacemaker, so bioimpedance 
could not be measured. 
2.8.1 Under-reporting  
Resting metabolic rate (RMR) or basal metabolic rate (BMR) is the number of calories 
metabolized at rest during 24 hours and represents the largest component (60–75%) of total 
daily energy expenditure in sedentary humans (217). For all studies, BMR was calculated 
using the Schofield equations as outlined in Table 2.2.  
In all studies included in this thesis to assess under-reporting, low energy reporters were 
determined using the Goldberg method. The ratio between reported energy intake (EI) and 
BMR was calculated by dividing EI by BMR. EI was converted from kJ to kcal in line with 
the units for the BMR calculation used. The revised Goldberg cut-off values by Black (218) 
of 1.00 for a three-day food diary and 1.02 for a four-day food diary were used. Thus the cut-
off limit of EI:BMR <1.00 and EI:BMR <1.02 was used to classify individuals as under-
reporters in the KIS and the CHALICE and MHCSS studies respectively. 
Table 2.2: Schofield equations for estimating BMR (kcal/day) from weight (kg) and height (m) (219) 
Gender/Age$(years)$ BMR$(kcal/day)$
Males$ $
10H17& 16.2&*&Wt&+&137&*&Ht&+&516&
18H29& 15.0&*&Wt&H&10&*&Ht&+&706&
30H59& 11.5&*&Wt&–&2.6&*&Ht&+&877&
60+& 9.1&*&Wt&+&972&*&Ht&H&834&
Females$ &
10H17& 8.4&*&Wt&+&466&*&Ht&+&200&
18H29& 13.6&*&Wt&+&283&*&Ht&+&98&
30H59& 8.1&*&Wt&+&1.4&*&Ht&+&844&
60+& 7.9&*&Wt&+&458&*&Ht&+&17.7&
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2.8.2 CHALICE 
Standard descriptive statistics including means and standard deviations, frequencies and 
percentages were used as appropriate to summarise the demographic, anthropometric, 
laboratory and dietary results across participants, grouped by fasting glucose. From the three 
study groups, these features were compared by one-way analysis of variance (ANOVA) or 
chi-square tests as appropriate. When these analyses showed significant (p<0.05) differences 
between groups, pairwise analyses were undertaken. The association between anthropometric, 
demographic and laboratory measures, and vitamin C concentrations and fasting glucose were 
tested by one-way ANOVA or Pearson’s correlation coefficients as appropriate. Significant 
univariate associations identified from the above analyses were then further tested using 
multiple regression to determine independent associations with plasma vitamin C and fasting 
glucose. All statistical analyses were undertaken using SPSS (version 25.0, IBM Corp., 
Armonk, New York, USA). The sample size available for correlation analysis of dietary data 
(n=239) had greater than 80% power to detect as statistically significant (two tailed α=0.05) 
correlation coefficients >0.18. The sample size available for correlation analysis of plasma 
vitamin C and fasting glucose (n=368) had >80% power to detect as statistically significant 
(two tailed α=0.05) correlation coefficients >0.15.  
2.8.3 MHCSS 
2.8.3.1 MHCSS-Vit C 
Standard descriptive statistics including means, standard deviations, frequencies, and 
percentages were used as appropriate to summarise the demographic, anthropometric, and 
laboratory results across participants grouped by fasting glucose and T2DM treatment. Four 
of the laboratory measures (hs-CRP, ghrelin, leptin, and adiponectin) showed a strong 
positive skew and were therefore loge transformed prior to analyses. These variables are 
described using geometric means and 95% confidence intervals. Associations between the 
clinical characteristics of the cohorts grouped by fasting glucose (including those treated with 
metformin) were tested using one-way ANOVA and chi-squared tests as appropriate. Where 
significant associations were identified, these were further explored with pair-wise 
comparisons amongst the fasting glucose groups. The univariate associations between plasma 
vitamin C and demographic, anthropometric, and laboratory measures were tested using 
Pearson’s correlation coefficients and one-way ANOVA. Significant predictors identified 
from these univariate analyses were then combined in a multiple-regression analysis to 
identify significant independent associations with plasma vitamin C. The two-tailed p-value 
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<0.05 was taken to indicate statistical significance. All statistical analyses were undertaken 
using SPSS (version 25.0, IBM Corp., Armonk, New York, USA). The sample size available 
for correlation analysis of fasting glucose and plasma vitamin C (n=89) had >80% power to 
detect as statistically significant (two tailed α=0.05) correlation coefficients >0.30. 
2.8.3.2 MHCSS-gut microbiota 
Standard descriptive statistics including means, medians, standard deviations, interquartile 
ranges frequencies and percentages were used as appropriate to summarise the demographic, 
anthropometric, laboratory, dietary and microbiota results across participants, grouped by 
fasting glucose. Four of the laboratory measures (hs-CRP, ghrelin, leptin, and adiponectin) 
showed strong positive skew and were therefore loge transformed prior to analyses. These 
variables are described using geometric means and 95% confidence intervals. Associations 
between the clinical characteristics of the cohorts grouped by fasting glucose were tested 
using one-way ANOVA and chi-squared tests as appropriate. Where significant associations 
were identified, these were further explored with pair-wise comparisons amongst the study 
groups.  
Comparisons of dietary and microbiota data across fasting glucose groups and demographic 
groups (gender, ethnicity and smoking status) were undertaken using the non-parametric 
Wilcoxon summed ranked test. Where these indicated significant differences among the 
groups they were further explored using Mann-Whitney U tests. The results from these tests 
are summarised as medians and interquartile ranges. The associations between age, clinical 
characteristics, diet, microbial RA and alpha diversity were tested using Spearman’s non-
parametric correlation coefficients. Significant univariate associations identified from the 
above analyses were then further tested using multiple regression to determine independent 
associations with the microbial RA. A two-tailed p-value <0.05 was taken to indicate 
statistical significance. All statistical analyses were undertaken using SPSS V25.0. The 
sample size available for correlation analysis of plasma glucose and the RA of bacteria (n=61) 
had >80% power to detect as statistically significant (two tailed α=0.05) correlation 
coefficients >0.35. 
2.8.4 KIS 
2.8.4.1 KIS-gut microbiota and KIS-Vit C 
Standard descriptive statistics, including means, medians, standard deviations, interquartile 
ranges, frequencies and percentages, were used to describe the baseline demographic, 
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anthropometric, laboratory and questionnaire data. The changes in these measures over time 
were compared by paired t-tests and Wilcoxon signed-rank tests as appropriate. Changes in 
taxonomic RA and diversity data was statistically analysed using Wilcoxon signed-rank tests 
and are presented as medians and interquartile ranges. The association between vitamin C 
concentrations and intakes and demographic, dietary, laboratory and anthropometric measures 
were tested by Pearson’s correlation coefficients. Changes in anthropometric and laboratory 
measures were compared between the two vitamin C adequacy groups by one-way ANOVA. 
A two-tailed p<0.05 was taken to indicated statistical significance. The sample size available 
for pre- and post-comparisons (n=24) had >80% power to detect as statistically significant 
(two-tailed α=0.05) within participant effect sizes >0.65. 
 

! 75!
 Chapter Three:  
Canterbury Health, Ageing and Lifecourse  
Study (CHALICE) 
3.1 Background 
As part of this thesis, the author was involved in the analysis of dietary and metabolic health 
aspects of the CHALICE study. The CHALICE study involves a cohort of 49-51 year-olds 
from Canterbury, New Zealand who undertook comprehensive health, dietary and social 
assessments (187). With age being a risk factor for developing prediabetes and T2DM (16), 
associations from the dietary and metabolic health aspects of CHALICE were used to provide 
direction for this thesis before undertaking research in the area of glycaemic control.  
Individuals’ plasma vitamin C concentrations are not routinely checked in the New Zealand 
population, therefore there is only information from small New Zealand studies that measured 
the plasma vitamin C concentrations of specific, non-representative groups (220, 221). For 
that reason, both dietary intake of vitamin C and plasma vitamin C as a biomarker of vitamin 
C intake were measured in the CHALICE population (222).  
Plasma vitamin C is required for a number of important biological functions via acting as an 
enzymatic cofactor and reducing agent (128, 223). Because humans are unable to synthesize 
their own vitamin C, it must be obtained from the diet. Vitamin C is naturally present in fruit 
and vegetables, is often added as a preservative to foods/beverages, and is also used as a 
dietary supplement (128). Approximately 90% of the daily intake of vitamin C in the general 
population comes from fruit and vegetables; however, it is important to note that the content 
of vitamin C in fruit and vegetables varies, with citrus fruits, kiwifruit, mango and vegetables 
such as broccoli, tomatoes and peppers being rich sources of vitamin C (223). It is also 
important to consider the degradation of vitamin C when heated and during storage, making 
the processing and preparation procedures an important consideration when estimating dietary 
intake of vitamin C (223). 
The limitations of self-reported dietary data have been described in detail in Chapter two.  
Consequently, plasma vitamin C was measured as a biomarker of vitamin C intake in the 
CHALICE cohort. Measuring vitamin C concentrations in the plasma has a number of 
advantages over measuring dietary vitamin C intake. For example, it is not reliant on 
participants’ recall of their diet, it takes into account vitamin C supplements and it accounts 
for confounders of vitamin C status such as smoking, prescription medications and health 
! 76!
conditions which may affect turnover of the vitamin (222). Both plasma vitamin C and the 
nutrient analysis programme used in CHALICE account for the potential impact of vitamin C 
losses due to food processing and preparation. 
There is some evidence to suggest that people with T2DM have lower plasma vitamin C 
concentrations compared to those with normal glucose tolerance (NGT) (44-46). One 
proposed mechanism is that vitamin C, being a potent antioxidant, may have a role in 
moderating the inflammatory effect of adipose tissue, with obesity being a major risk factor 
for diabetes (222). 
3.2 Aims and Hypotheses  
The aim of this study was to investigate associations between dietary intake, markers of 
dietary intake, and metabolic health in a cohort of 49 to 51-year-olds in Canterbury, New 
Zealand.  
It was hypothesised that: 
• Improved glycaemic control is positively associated with markers of metabolic health. 
• Plasma vitamin C is negatively associated with markers of metabolic health.  
3.3 Protocol 
This study used data collected as part of the baseline assessment in the CHALICE study, a 
prospective, longitudinal study examining the health and well-being of 50-year-olds in 
Canterbury. Participation in the study comprised a four- to six-hour assessment with data 
obtained from interviews, self-completed questionnaires, laboratory tests and procedures. 
Data collected by CHALICE researchers as part of the wider CHALICE study included: 
demographic information, anthropometric measures, eye health measurements, fasting blood 
and urine samples, health history, heart health measurements, cognitive and mental health 
evaluation, family and social history, physical function and physical activity, and home food 
availability and dietary intake data. Details included in this thesis on the rationale, design and 
methodology for CHALICE have previously been published (187).  
The cross-sectional (baseline) data included in this thesis were the metabolic and dietary 
intake collected via self-completed questionnaires and food diaries, and from blood tests. 
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3.3.1 Study Population 
Ethical approval was obtained from the Upper South A Regional Ethics Committee 
(URA/10/03/021). In New Zealand there are compulsory electoral roles (one Māori roll and a 
general roll) for people aged ≥ 18 years, which are actively maintained and provide up-to-date 
lists known as health research extracts. The health research extracts were requested annually 
during recruitment for CHALICE and included adults who were 49 to 50 years old, registered 
in the following territorial authorities that align with the Canterbury District Health Board 
(CDHB) catchment area: Kaikoura District, Hurunui District, Waimakariri District, 
Christchurch City, Selwyn District, and Ashburton District.  
Random sampling was completed by an independent biostatistician. Potential participants 
(adults 49-50 years registered in the CDHB catchment area) were randomly ordered and 
participants were selected in a ratio of 4:1 non-Māori to Māori so that Māori represented 15% 
of the CHALICE study sample to reflect the wider demographic make-up of New Zealand. 
Enrolment statistics estimated that in 2012, 94.9% of the target population were registered to 
vote in the Christchurch City Council area (224). Those selected were then assigned to one of 
four specially trained CHALICE researchers who then contacted them.  
CHALICE researchers used the addresses recorded in the electoral role to send those selected 
a letter of invitation and an information sheet that outlined the study, and invited them to 
contact the research team (by free-post). If they did not respond to the letter, the CHALICE 
researchers telephoned them up to four times at various days/times (including evenings and 
weekends) over 10 to 20 days using numbers sourced from the White Pages and the internet. 
If contact was unsuccessful, then a second invitation letter was sent approximately four to six 
weeks later. In a final attempt to contact the person, CHALICE researchers scheduled two 
home visits (where practical). There was no set time limit for these home visits. If they were 
unable to make contact through the letters, phone calls and home visits, these potential 
participants were designated ‘unable to contact’. 
If contact was made, the study was re-outlined and potential participants who expressed an 
interest were screened for eligibility. The eligibility criteria for the study were adults who 
were currently 49 to 51 years old, and registered in territorial authorities that align with the 
Canterbury District Health Board (CDHB) catchment area. Participants had to live in the 
community (for example, not in a prison or a rest home), and be able to complete the 4-6 hour 
assessment (for example, speak English proficiently). Written informed consent was obtained 
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from all participants (187). The full CHALICE cohort includes baseline data for 404 
individuals (Figure 3.1).  
 
Figure 3.1. Participant flow for the CHALICE cohort (figure adapted from Spittlehouse J. (225)). 
 
A comparison between CHALICE and the New Zealand Census data for people of a similar 
age and region has been published (222). The CHALICE participants had higher rates of 
Māori ethnicity and higher qualifications than the Canterbury average, whereas 
socioeconomic status and smoking were within stochastic limits (222). This suggests the 
sample is reasonably representative of 50-year-olds in Canterbury and hence the national 
cohort allowing for regional bias (222). The CHALICE cohort also had typical levels of 
health for a community sample (222). Anthropometric measures were close to those of the 
New Zealand population and average metabolic and cardiac markers for the CHALICE cohort 
were generally within the healthy range (222). Agreement between the study data and national 
demographics provides confidence that the study is representative of the health of 50-year-old 
New Zealanders in 2010 (222). 
From the CHALICE cohort (n=404), participants were excluded if they did not have a plasma 
vitamin C value, or if they were not fasting for their blood test for this study. This resulted in 
368 participants being included in this study, of whom 239 participants had dietary intake 
data.  
As the focus of this thesis is glycaemic control, these participants were grouped using the 
ADA fasting glucose cut-off criteria for prediabetes (5.6 to 6.9 mmol/L) and T2DM (≥ 
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7.0 mmol/L) (16). Those who reported being previously diagnosed with T2DM by a doctor 
were also included in the T2DM group. 
3.3.1.1 Inclusion criteria:  
H NGT (fasting glucose ≤ 5.5 mmol/L) (n=287). 
H Prediabetes (fasting glucose 5.6 mmol/L to 6.9 mmol/L) (n=61). 
H T2DM taking no diabetes medication (fasting glucose ≥ 7.0 mmol/L) or those who 
reported a previous diagnosis of T2DM from a doctor (n=20).  
Individuals who reported a previous diagnosis of T2DM were using a range of diabetes 
medications including one or a combination of medications such as metformin, 
sulphonylureas and insulin, or no diabetes medication at all. 
3.4 Results 
3.4.1 Participant Characteristics 
Demographic characteristics are detailed in Table 3.1. Each study group (NGT, prediabetes 
and T2DM), and the entire cohort comprised approximately 50% females, and so there were 
no significant differences in gender between the groups (p=0.440). The majority of 
participants were European (around 80%), and as Māori were over-sampled they comprised 
15% of the population, higher than what would be expected with Māori comprising 5.5% of 
the New Zealand Census 2013 data of 50 to 54-year-olds from the same region (226). There 
were no significant differences in ethnicity between the three study groups (p=0.937). 
Participants who identified themselves as current smokers comprised 15% of the study 
population, and there were no significant differences between the study groups (p=0.776). 
There was a mix of qualifications, which reflects the age group of participants (49-51 years), 
and there were no significant differences between the level of education of the study groups 
(p=0.705).  
Anthropometric measures are also detailed in Table 3.1. Weight, BMI, fat mass and waist 
circumference all increased from NGT to prediabetes to T2DM. Those with prediabetes and 
T2DM were on average 8.2 kg and 17.6 kg heavier, had a higher BMI by 3 kg/m2 and 
7 kg/m2, and a larger waist circumference by 6 cm and 17 cm, respectively compared to those 
with NGT, and these measures were significantly different between groups (Table 3.1). The 
mean BMI for the NGT group (28 kg/m2) reflects the international BMI cut-off for 
overweight (25.0–29.9 kg/m2), and the prediabetes (30 kg/m2) and T2DM (35 kg/m2) groups 
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were obese (≥30.0 kg/m2). Those with T2DM also had a significantly greater fat mass by 6% 
than those with NGT. Blood pressure did not differ significantly between study groups.  
Table 3.1: General characteristics of participants classified as having NGT, prediabetes and T2DM. 
Characteristics$ NGT$
(n=287)$
Prediabetes$
(n=61)$
T2DM$
(n=20)$
Total$
(n=368)$
Sex& & & & &
Female&%&(n)$ 55&(157)& 46&(28)& 50&(10)& 53&(195)&
Male&%&(n)& 45&(130)& 54&(33)& 50&(10)& 47&(73)&
Ethnicity$ & & & &
European&%&(n)& 79&(227)& 75&(46)& 85&(17)& 79&(290)&
Māori&%&(n)& 15&(44)& 15&(9)& 10&(2)& 15&(55)&
Pacific&Island&%&(n)& 1&(4)& 3&(2)& 0&(0)& 2&(6)&
Asian&%&(n)& 3&(9)& 5&(3)& 5&(1)& 4&(13)&
Other&%&(n)& 1&(3)& 2&(1)& 0&(0)& 1&(4)&
Qualification$ & & & &
No&qualification&%&(n)& 13&(37)& 11&(7)& 35&(5)& 13&(49)&
Secondary&school&%&(n)& 29&(82)& 26&(16)& 25&(5)& 28&(103)&
PostHsecondary&certificate,&
diploma&or&trade&diploma&%&(n)&
40&(114)& 46&(28)& 40&(8)& 41&(150)&
University&%&(n)& 19&(54)& 16&(10)& 10&(2)& 18&(66)&
Anthropometry$ & & & &
Weight*&(kg)& 80.5&±&17.5
a
& 88.7&±&18.6
b
& 98.1&±&22.8
c
& 82.8&±&18.6&
BMI*&(kg/m
2
)& 28&±&5
a
& 30&±&7
b
& 35&±&10
c
& 28&±&6&
Fat&mass*&(%)& 33&±&10
a
& 34&±&10
ab
& 39&±&10
b
& 33&±&10&
Waist&circumference*&(cm)& 93&±&14
a
& 99&±&14
b
& 110&±&18
c
& 95&±&15&
Blood&pressure&diastolic&
(mmHg)&
83&±&10& 85&±&9& 83&±&8& 84&±&10&
Blood&pressure&systolic&(mmHg)& 132&±&15& 135&±&15& 133&±&18& 132&±&15&
Smoking$Status$ & & & &
Current&smoker&%&(n)& 15&(43)& 11&(7)& 15&(3)& 14&(53)&
Values presented as mean ± SD unless stated otherwise. * p values from ANOVA tests.  
Groups sharing a common superscript letter denote the study groups that do not differ significantly from each 
other at the 0.05 level from post hoc analysis.  
Waist circumference was missing for one participant (1 × NGT). 
 
3.4.2 Laboratory Measures 
Fasting glucose, used as the basis for defining prediabetes and T2DM, increased from NGT 
(4.8 mmol/L) to prediabetes (5.9 mmol/L) to T2DM (8.8 mmol/L) as expected and differed 
significantly between the study groups (p<0.001, Table 3.2). Although fasting glucose was 
used as the basis for classifying participants in the analysis, the mean HbA1c of 37 mmol/mol 
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for the NGT group, 40 mmol/mol for the prediabetes group, and 60 mmol/mol for the T2DM 
group were also consistent with the ADA guidelines for the classification of prediabetes and 
T2DM based on HbA1c (16). The mean insulin concentrations were consistent, with the 
glycaemic measures, increasing from NGT (52 pmol/L) to prediabetes (84 pmol/L) to T2DM 
(123 pmol/L) and differed significantly between groups (p<0.001) (Table 3.2). High-
sensitivity CRP (hs-CRP) also increased from NGT (1.8 mg/L) to prediabetes (2.1 mg/L) to 
T2DM (4.6 mg/L), and the T2DM group had a significantly higher mean hs-CRP compared to 
the NGT and prediabetes groups (p=0.005) (Table 3.2). 
The mean total cholesterol concentration was lower in the T2DM group (4.9 mmol/L) than 
the prediabetes and NGT groups (5.4 mmol/L), but did not differ significantly between groups 
(p=0.058) (Table 3.2). All study groups had a total cholesterol level above the recommended 
cut-off in New Zealand of 4.0 mmol/L.  
The mean HDL- and LDL-cholesterol concentrations were significantly lower in the T2DM 
group (1.1 and 2.9 mmol/L) compared to the prediabetes group (1.3 and 3.4 mmol/L) and 
NGT group (1.4 and 3.5 mmol/L) (Table 3.2). All groups had a greater mean LDL 
concentration than the recommended cut-off in New Zealand of 2.0 mmol/L; however, all 
groups also met the recommended cut-off of greater than 1.0 mmol/L for HDL-cholesterol.  
Due to the lower HDL concentrations in the T2DM group, the cholesterol (total/HDL) ratio 
was higher in the T2DM group (4.7) compared to the prediabetes (4.5) and NGT groups (4.1). 
The cholesterol (total/HDL) ratio was significantly lower in the NGT group compared to the 
prediabetes and T2DM groups (p=0.009), and was the only group below the recommended 
cut-off in New Zealand of 4.5. 
The mean concentration of triglycerides was significantly higher in those with T2DM 
(2.4 mmol/L) compared to the prediabetes (1.8 mmol/L) and NGT (1.3 mmol/L) groups 
(p<0.001) (Table 3.2). The mean of both the prediabetes and T2DM groups was above the 
recommended cut-off in New Zealand (<1.7 mmol/L).  
The mean plasma vitamin C concentration decreased from the NGT (45 µmol/L) to 
prediabetes (41 µmol/L) and T2DM (35 µmol/L) groups and was significantly lower in the 
T2DM group compared to the NGT group (p=0.015). 
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Table 3.2: Laboratory measures of participants classified as having NGT, prediabetes and T2DM. 
Laboratory$Measures$ NGT$
(n=287)$
Prediabetes$
(n=61)$
T2DM$
(n=20)$
Total$
(n=368)$
Glucose*&(mmol/L)& 4.8&±&0.4
a
& 5.9&±&0.3
b
& 8.8&±&3.0
c
& 5.2&±&1.2&
HbA1c*&(mmol/mol&)& 37&±&4
a
& 40&±&5
b
& 60&±&18
c
& 39&±&8&
Total&cholesterol&(mmol/L)& 5.4&±&1.0& 5.4&±&0.9& 4.9&±&8& 5.4&±&1.0&
HDLHcholesterol*&(mmol/L)& 1.4&±&0.3
a
& 1.3&±&0.3
a
& 1.1&±&0.3
b
& 1.3&±&0.3&
LDLHcholesterol*&(mmol/L)& 3.5&±&0.9
a
& 3.4&±&0.8
a
& 2.9&±&0.6
b
& 3.4&±&0.8&
Triglycerides*&(mmol/L)& 1.3&±&0.7
a
& 1.8&±&1.5
b
& 2.4&±&2.3
c
& 1.4&±&1.1&
Cholesterol&(total/HDL)&ratio*& 4.1&±&1.1
a
& 4.5&±&1.3
b
&& 4.7&±&1.2
b
& 4.2&±&1.1&
hsHCRP*&(mg/L)& 1.8&±&3.7
a
& 2.1&±&2.5
a
& 4.6&±&6.2
b
& 2.0&±&3.7&
Insulin*&(pmol/L)& 52&±&36
a
& 84&±&54
b
& 123&±&102
c
& 61&±&49&
Plasma&vitamin&C*&(µmol/L)& 45&±&17
a
& 41&±&19
ab
& 35&±&21
b
& 44&±&17&
Values presented as mean ± SD. * p values from ANOVA tests.  
Groups sharing a common superscript letter denote the study groups that do not differ significantly from each 
other at the 0.05 level from post hoc analysis.  
There are missing data from two individuals for HbA1c (2 × prediabetes) and one individual for LDL-
cholesterol.  
 
3.4.3 Fasting Glucose Correlations 
If significant differences were seen between fasting groups for demographic, anthropometric 
and laboratory measures (Tables 3.1-3.2), univariate correlation analyses were carried out for 
these variables (Table 3.3). The three anthropometric measures (weight, BMI and waist 
circumference) were all significantly positively associated with fasting glucose 
concentrations.  HDL- and LDL-cholesterol were negatively associated with fasting glucose, 
and triglycerides and cholesterol (total/HDL) ratio were positively associated with fasting 
glucose. Plasma insulin concentration was positively associated with fasting glucose, and 
plasma vitamin C was negatively associated with fasting glucose.  
A final multiple regression showed insulin (p<0.001), triglycerides (p=0.002), waist 
circumference (p=0.024) and LDL-cholesterol (p<0.001) to be significant independent 
predictors of fasting glucose concentrations (Table 3.4). Insulin, triglycerides and waist 
circumference were positively associated with glucose concentrations, and LDL-cholesterol 
was negatively associated with fasting glucose concentrations.  
  
! 83!
Table 3.3: Pearson’s correlation of fasting glucose, anthropometric measures, lipids, hs-CRP, insulin 
and plasma vitamin C (n=368).   
Measure$ Pearson$Correlation$Glucose$(n=368)$
Weight&(kg)& 0.241**&
BMI&(kg/m
2
)& 0.241**&
Fat&mass&(%)& 0.095&
Waist&circumference&(cm)& 0.301**&
HDLHcholesterol&(mmol/L)& H0.265**&
LDLHcholesterol&(mmol/L)& H0.141**&
Triglycerides&(mmol/L)& 0.307**&
Cholesterol&(total/HDL)&ratio& 0.217**&
hsHCRP&(mg/L)& 0.094&
Insulin&(pmol/L)& 0.350**&
Plasma&vitamin&C&(µmol/L)& H0.166**&
**Correlation is significant at the 0.01 level (2-tailed). 
*Correlation is significant at the 0.05 level (2-tailed). 
 
Table 3.4: Multiple regression analysis showing significant associations with glucose concentrations. 
Measure$ B$$ Lower$95%$CI$ Upper$95%$CI$ p$$
Insulin&(pmol/L)& 0.005& 0.002& 0.008& <0.001&
Triglycerides&(mmol/L)& 0.301& 0.115& 0.486& 0.002&
LDLHcholesterol&(mmol/L)& H0.257& H0.393& H0.121& <0.001&
Waist&circumference&(cm)& 0.011& 0.001& 0.020& 0.024&
B: coefficient from the multiple linear regression model. 
 
3.4.4 Self-Reported Dietary Intake 
There were no significant differences in self-reported macronutrient intake or dietary vitamin 
C intake across the groups (Table 3.5). Although not presented in this table, all other 
macronutrients, micronutrients, vitamins and minerals that were available from the Kai-
culator output were analysed and dietary vitamin D intake was the only other nutrient that 
differed significantly between groups (p=0.021). The T2DM group had a mean daily intake of 
6.6 µg, which was significantly higher than the NGT group that had a mean daily intake of 
4.4 µg. The prediabetes group had a mean daily intake of 5.0 µg, which was not significantly 
different when compared with the NGT or T2DM groups. Vitamin D was not a focus of this 
thesis so was not discussed further. 
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All study groups had a mean protein (18% for all study groups) and carbohydrate intake (46-
47% for all study groups) (as % of energy) that met the AMDR recommendations for protein 
(15-25%) and carbohydrate (45-65%). The mean fat intake of all groups (34-35% for all study 
groups) was at the upper end of the AMDR recommendation as percent of energy of 20-35%.  
The adequate intake (AI) of dietary fibre in New Zealand is 25 g for women and 30 g for men 
(200). Although fibre intake was not reported by sex, all three study groups had a mean intake 
(26, 26 and 25 g) similar to the recommendation. 
The mean dietary intake of vitamin C decreased from the NGT group (116 mg/day) to the 
prediabetes (102 mg/day) and T2DM groups (73 mg/day) but did not differ significantly 
between groups (p=0.055). All groups met the current New Zealand Recommended Dietary 
Intake (RDI) of 45 mg/day (200). There were a small number of participants (5%) who 
reported taking a high-dose vitamin C supplement (>500 mg vitamin C), and intake of 
vitamin C supplements did not differ significantly between groups (p=0.438). 
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Table 3.5: Self-reported dietary intake of participants classified as having NGT, prediabetes and 
T2DM. 
Total$Daily$Dietary$Intake$ NGT$
(n=186)$$
Prediabetes$
(n=40)$$
T2DM$
(n=13)$
Total$
(n=239)$
Energy&(kJ)& 8997&±&2501& 9681&±&3927& 8928&±&2495& 9108&±&2787&
Fibre&(g)& 26&±&9& 26&±&10&& 25&±&12& 26&±&10&
Protein&(%&of&energy)&& 18&±&3& 18&±&4& 18&±&5& 18&±&3&
Protein&(g)& 91&±&26& 102&±&62& 93&±&30& 93&±&35&
Total&fat&(%&of&energy)& 35&±&7& 34&±&7& 35&±&8& 35&±&7&
Total&fat&(g)& 82&±&27& 84&±&33& 82&±&33& 82&±&28&
Saturated&fat&(%&of&energy)& 13&±&3& 13&±&3& 13&±&3& 13&±&3&
Saturated&fat&(g)& 31&±&12& 32&±&13& 31&±&13& 31&±&13&
Monounsaturated&fatty&acids&(%&
of&energy)&
13&±&3& 12&±&3& 12&±&4& 13&±&3&
Monounsaturated&fatty&acids&(g)& 31&±&11& 31&±&13& 30&±&14&& 31&±&12&
Polyunsaturated&fatty&acids&(%&of&
energy)&
5&±&2& 5&±&2& 5&±&2& 5&±&2&
Polyunsaturated&fatty&acids&(g)& 12&±&6& 12&±&6& 12&±&6& 12&±&6&
Total&carbohydrate&(%&of&energy)& 46&±&7& 47&±&7& 47&±&7& 46&±&7&
Total&carbohydrate&(g)& 242&±&77& 263&±&116& 243&±&79& 256&±&85&
Sugar&(%&of&energy)& 21&±&6& 21&±&8& 21&±&7& 21&±&7&
Sugar&(g)& 112&±&49& 126&±&90& 110&±&51& 115&±&58&
Starch&(%&of&energy)& 24&±&6& 25&±&7& 25&±&8& 24&±&6&
Starch&(g)& 130&±&45& 137&±&47& 133&±&62& 131&±&46&
Dietary&vitamin&C&intake&(mg)& 116&±&69& 102&±&64& 73&±&30& 111&±&67&
Vitamin&C&supplements&%&(n)& 5&(15)& 3&(2)& 0&(0)& 5&(17)&
Values presented as mean ± SD unless stated otherwise. 
There were no significant differences between the study groups for any of the dietary intake measures.  
 
The percentage of individuals estimated to be under-reporting their energy intake was 18% 
(Table 3.6). The percentage of individuals estimated to be under-reporting their energy intake 
was 7% higher in the prediabetes and T2DM groups compared to the NGT group (Table 3.6).   
Table 3.6: Percentage of individuals in each study group estimated to be under-reporting dietary 
intake. 
NGT$(n=186)$ Prediabetes$(n=40)$ T2DM$(n=13)$ Total$(n=239)$
16&(30)& 23&(9)& 23&(3)& 18&(42)&
Values presented as % (n). 
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3.4.5 Plasma Vitamin C Status of Study Groups 
The T2DM group had a significantly lower mean plasma vitamin C concentration 
(35 µmol/L) than the NGT group (45 µmol/L). Furthermore, there was a higher proportion of 
people in the T2DM group with deficient (15%) and marginal (15%) vitamin C 
concentrations compared to the NGT group (1.7% deficient and 9.8% marginal) (Figure 3.2). 
However, all groups had mean vitamin C concentrations less than the recommendation for 
adequate plasma vitamin C concentrations (≥ 50 µmol/L).  
 
Figure 3.2. Plasma vitamin C status of individuals within study groups. Percentage of individuals from 
each study group (NGT, prediabetes and T2DM (T2DM includes those with a fasting glucose of 
≥ 7.0 mmol/L and/or a previous diagnosis of T2DM)) classified as having saturating (≥70 µmol/L), 
adequate (50–69 µmol/L), inadequate (24–49 µmol/L), marginal (11–23 µmol/L), and deficient 
(<11 µmol/L) plasma vitamin C concentrations (42). 
 
3.4.6 Self-Reported Dietary Vitamin C Intake of Study Groups 
Although plasma vitamin C was significantly lower in individuals with T2DM compared to 
those with NGT, there were no significant differences in self-reported dietary vitamin C 
intake between study groups determined from the 4DEFD. The majority of participants met 
the New Zealand RDI of 45 mg/day (Figure 3.3). There were no participants in the T2DM 
group who had intakes below the New Zealand Estimated Average Requirement (EAR) of 
30 mg/day (Figure 3.3). In contrast, no individuals in the T2DM group and few individuals in 
the NGT (8.1%) and prediabetes (7.5%) groups were reaching the New Zealand Ministry of 
Health’s suggested dietary targets (SDT) to reduce chronic disease risk, which is 220 mg/day 
for men and 190 mg/d for women (Figure 3.3) (200). 
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Figure 3.3. Individuals meeting New Zealand dietary intake recommendations for vitamin C. 
Percentage of individuals from each study group (NGT, prediabetes and T2DM (T2DM includes those 
with a fasting glucose of ≥ 7.0 mmol/L and/or a previous diagnosis of T2DM)) meeting the estimated 
average requirement (EAR) (30 mg/day), recommended dietary intake (RDI) (45 mg/day), and 
suggested dietary target (SDT) to reduce chronic disease risk (220 mg/day for men and 190 mg/day 
for women) for dietary vitamin C intake using the nutrient reference values for Australia and New 
Zealand (200). 
 
3.4.7 Plasma Vitamin C Correlations 
Due to the significant decrease in the mean plasma vitamin C in the T2DM group compared 
to NGT group, correlations with vitamin C and markers of metabolic health were measured 
(Table 3.7).  
Plasma vitamin C concentrations were significantly lower in males compared to females by 
6 µmol/L (F=14.5, df=1,366, p<0.001). There was a significant association between smoking 
status and plasma vitamin C concentration (F=22.2, df=1,366, p<0.001), with current smokers 
having a mean vitamin C concentration of 34 µmol/L compared to 46 µmol/L for those that 
reported not currently smoking. There was also a significant association between education 
and plasma vitamin C (F=3.3, df=3,364, p=0.020), for example, the mean plasma vitamin C 
concentration of those with a university degree (48 µmol/L) was significantly higher than 
those with no qualification (mean 39 µmol/L). There were no significant differences between 
ethnicity and plasma vitamin C concentrations (F=0.8, df=4,363, p=0.532). 
Three of the four anthropometric measures (weight, BMI and waist circumference) were 
significantly negatively associated with plasma vitamin C concentrations (Table 3.7). 
Glycaemic indices (glucose and HbA1c), insulin, hs-CRP, triglycerides and the cholesterol 
(total/HDL) ratio were also negatively associated with plasma vitamin C concentrations 
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(Table 3.7). In contrast, HDL-cholesterol was positively associated with plasma vitamin C 
concentrations. Self-reported dietary vitamin C intake was positively associated with plasma 
vitamin C concentrations.  
A final multiple regression showed BMI (p=0.016), waist circumference (p=0.002), smoking 
status (p=0.010), insulin (p=0.003) and self-reported dietary vitamin C intake (p<0.001) to be 
significant independent predictors of plasma vitamin C (Table 3.8). Waist circumference and 
insulin were negatively associated with plasma vitamin C and, in contrast, BMI and self-
reported dietary vitamin C intake were positively associated with plasma vitamin C 
concentrations. Current smokers had reduced plasma vitamin C concentrations compared to 
those not currently smoking.  There was a strong positive association between insulin and 
fasting glucose (r=0.350, p<0.001). Accordingly, fasting glucose does not feature as an 
independent predictor of plasma vitamin C in this dataset. 
Table 3.7: Pearson’s correlation of plasma vitamin C, glycaemic indices, insulin, lipids, hs-CRP, and 
anthropometric measures (n=368). 
Measure$ Pearson$Correlation$
Plasma$Vitamin$C$(n=368)$
Glucose&(mmol/L)& H0.166**&
HbA1c&(mmol/mol)& H0.183**&
Insulin&(pmol/L)& H0.218**&
Total&cholesterol&(mmol/L)& 0.020&
Triglycerides&(mmol/L)& H0.224**&
HDLHcholesterol&(mmol/L)& 0.210**&
LDLHcholesterol&(mmol/L)& 0.054&
Cholesterol&(total/HDL)&ratio& H0.183**&
hsHCRP&(mg/L)& H0.014&
Diastolic&blood&pressure&(mmHg)& H0.119*&
Systolic&blood&pressure&(mmHg)& H0.087&
Weight&(kg)& H0.191**&
BMI&(kg/m
2
)& H0.158**&
Fat&mass&(%)& H0.005&
Waist&circumference&(cm)& H0.249**&
Dietary&vitamin&C&intake&(mg)&(n=239)& 0.272**&
**Correlation is significant at the 0.01 level (2-tailed). 
*Correlation is significant at the 0.05 level (2-tailed). 
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Table 3.8: Multiple regression analysis showing significant associations with plasma vitamin C 
concentrations. 
Measure$ B$$ Lower$95%$CI$ Upper$95%$CI$ p$$
BMI& 0.8& 0.2& 1.5& 0.016&
Waist&circumference& H0.4& H0.7& H0.2& 0.002&
Current&smoker& H8.4& H14.7& H2.1& 0.010&
Insulin& H0.1& H0.12& H0.02& 0.003&
Dietary&vitamin&C&& 0.1& 0.02& 0.08& <0.001&
B: coefficient from the multiple linear regression model. 
 
3.5 Discussion 
This study included a sub-group of the CHALICE cohort, with participants grouped as having 
NGT, prediabetes and T2DM. These groups were characterised by other markers of metabolic 
health (including anthropometric and laboratory measures), and differences between groups 
were investigated. The CHALICE study is the first representative study of plasma vitamin C 
status within the New Zealand population.  
In agreement with the hypothesis for this study, results showed that markers of metabolic 
health including weight, BMI, waist circumference, triglycerides, cholesterol (total/HDL) 
ratio and plasma insulin levels were all positively associated with fasting glucose. Results 
from this study are consistent with known risk factors for T2DM, such as obesity and insulin 
resistance (16). Dyslipidemia is also common in those with T2DM, consistent with the results 
of this study (227).  
Insulin, triglycerides and waist circumference were found to be independently positively 
associated with fasting glucose concentrations. In contrast LDL-cholesterol was found to be 
independently negatively associated with fasting glucose concentrations and may reflect the 
use of lipid-lowering medications, which are commonly used in individuals with T2DM. 
There were no significant differences in the mean daily self-reported dietary intake of the 
NGT, prediabetes or T2DM groups. All three groups had mean dietary intakes that were 
within the AMDR range for protein, total fat and carbohydrate intake. In addition, all three 
groups had a mean daily fibre intake in line with New Zealand recommendations. The mean 
daily intake of energy, and percent energy from protein, total fat, and total carbohydrate 
intake in the current study, were similar to results from the 2008/2009 New Zealand Adult 
Nutrition Survey (NZANS) (4), despite differences in dietary data collection methods 
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(24-hour recall versus 4DEFD). The appropriate comparator for the results from the current 
study are males and females aged 31-50 years in the 2008/09 NZANS (4). The mean daily 
energy intake for males and females was 11,493 kJ and 7,921 kJ respectively in the NZANS 
compared to 9,108 kJ for individuals in the current study. The mean daily percent energy 
from protein for males and females was 16.7% and 17.0% respectively in the NZANS 
compared to 18% in the current study. The mean daily percent energy from total fat for males 
and females was 34.3% and 34.5% respectively in the NZANS compared to 35% in the 
current study. The mean daily percent energy from carbohydrate for males and females was 
44.8% and 45.5% respectively in the NZANS compared to 46% in the current study.  
The percentage of individuals estimated to be under-reporting their energy intake in this study 
was calculated to be 18%, similar to what has been reported in New Zealand national surveys 
(228, 229). As BMI was higher in the prediabetes and T2DM groups compared to the NGT 
group, it was surprising to find no significant differences in the mean total daily energy intake 
across the groups. However, results only showed a slightly higher percentage (7% higher) of 
under-reporting in the prediabetes and T2DM groups compared to the NGT group.  Previous 
research including New Zealand adult nutrition surveys has also shown under-reporting bias 
to be increased in obese cohorts (201-203, 205, 229). If the slightly higher level of under-
reporting in the prediabetes and T2DM groups is due to social desirability, it is unlikely 
individuals are under-reporting foods they consider to be ‘healthy’ such as fruit and 
vegetables (197, 230) and it therefore would have little impact on the dietary vitamin C 
results.  
Results from this study did find a correlation of dietary vitamin C intake to be a significant 
independent predictor of plasma vitamin C. Although this correlation was not perfect, we 
would not expect it to be, as they are measuring different things; for example, dietary intake is 
from diet only and does not take into account supplements and utilization and, most 
importantly, dietary vitamin C does not account for confounders of vitamin C status such as 
smoking and health conditions, which may affect turnover of the vitamin. 
It is also possible that those with prediabetes and T2DM are actually not under-reporting, as a 
recent study has shown RMR and therefore energy requirements are often over-estimated in 
obesity-susceptible individuals (217). Furthermore, studies often attract motivated individuals 
and it is unknown whether participants in the prediabetes or T2DM groups were currently 
dieting at the time of study. Since obesity results from interaction of genetic and 
environmental factors, there are other factors that need to be considered that could have 
contributed to the differences seen in BMI. For example, physical activity was not measured, 
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and could have therefore contributed. Individuals may also have a genetic predisposition to 
obesity with genome-wide association (GWA), studies having identified multiple loci 
robustly associated with BMI and risk of obesity (231, 232).  
Results from this study showed that the mean plasma vitamin C concentration decreased with 
deterioration in blood glucose control, with a higher proportion of people in the T2DM group 
with deficient and marginal vitamin C concentrations compared to the NGT group. Although 
the mean daily self-reported dietary vitamin C intake was lower (by 43 mg/day) in the T2DM 
compared to the NGT, and so may have contributed to the lower plasma vitamin C 
concentration in the T2DM group, there were no statistically significant differences in self-
reported dietary vitamin C intake between groups. Furthermore, the majority of participants in 
each group had self-reported dietary intakes above the New Zealand RDI for vitamin C 
(45 mg/day). Other researchers have also reported lower plasma vitamin C concentrations to 
be associated with poorer blood glucose control (44, 45). 
Consequently, plasma vitamin C was further investigated and correlated with other markers of 
metabolic health. In agreement with the hypothesis for this chapter, plasma vitamin C was 
negatively associated with markers of metabolic health including glycaemic control measures, 
adiposity, plasma insulin, triglycerides, cholesterol (total/HDL) ratio and diastolic blood 
pressure. Plasma vitamin C was also associated with gender, smoking status, and level of 
education.  
Men had significantly lower plasma vitamin C concentrations than women, which could be a 
matter of weight, as individuals with higher weight are prone to vitamin C deficiency and are 
known to require higher intakes of vitamin C to reach adequate plasma concentrations (233). 
Those with a higher level of education also had higher vitamin C concentrations, which could 
be due to healthier dietary habits such as a greater consumption of fruit and vegetables, and so 
the level of education of participants should be considered when investigating predictors of 
plasma vitamin C concentrations. 
From the significant associations with plasma vitamin C mentioned above (gender, education, 
smoking status, adiposity, glycaemic measures, insulin, lipids and dietary vitamin C) BMI, 
waist circumference, smoking status, plasma insulin and, as expected, dietary vitamin C 
intake were all found to be independently associated with plasma vitamin C concentrations. It 
was surprising that the multiple regression analyses showed BMI to be positively associated 
and, in contrast, waist circumference to be negatively associated with plasma vitamin C 
concentrations. This could reflect the differences in measurements as BMI takes weight into 
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account, and individuals with a higher weight need higher intakes of vitamin C (111, 233), 
whereas waist circumference measures central obesity and a higher waist circumference is 
associated with lower plasma vitamin C concentrations. There was a strong positive 
association between insulin and fasting glucose and accordingly fasting glucose does not 
feature as an independent predictor of plasma vitamin C in this dataset.  
Consistent with previous research, plasma vitamin C concentrations were significantly lower 
in current smokers compared to non-smokers (234, 235). This may be partly due to poorer 
dietary habits, but may also be due to the oxidizing properties of tobacco smoke, which 
results in an increase turnover of vitamin C (223). 
The association of lower plasma vitamin C with increased body weight and an increased risk 
of the metabolic syndrome has also been reported by other researchers and is investigated 
further in Chapter four of this thesis (236-239).  
3.5.1 Strengths 
The CHALICE study included a comprehensive range of measures and so the cohort used in 
this study were metabolically well-characterised.  
3.5.2 Limitations 
• Although this study included a large cohort of individuals (n=368), there were limited 
numbers of participants with T2DM (n=20) because participants were randomly recruited, 
rather than being selected based on their glycaemic control. 
• A limitation of this study is the observational design, in which associations do not imply 
causations. Vitamin C could be a marker for fruit and vegetable intake and may be 
associated with other positive dietary and lifestyle factors. Many factors that impact on the 
health status of individuals interact and correlate with each other, as seen in this cohort. 
This has been addressed by multiple regression models. 
• The slightly increased percentage of individuals under-reporting in the prediabetes and 
T2DM groups is a potential limitation of this study. However, if under-reporting was 
related to social desirability, it is unlikely that fruit and vegetable intake, and thus dietary 
vitamin C intake, was affected. There are also several other possible explanations for the 
lower energy intakes estimated for those with prediabetes and T2DM, such as individuals 
currently dieting, physical activity levels may be higher, and individuals in these groups 
may have a genetic predisposition for obesity (240). Furthermore, research has suggested 
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the energy prediction equations overestimate the energy requirements more for obesity-
susceptible individuals (217). 
• A limitation of the blood pressure results included in this study was that one manual 
reading and two automated reading were taken for each participant and these three 
readings were averaged rather than discarding the first reading (which is often higher) and 
averaging the second two readings. 
3.6 Conclusion 
Improved glycaemic control is associated with markers of metabolic heath. Plasma vitamin C 
concentration appears to be associated with glycaemic control and other markers of metabolic 
health, and therefore vitamin C and its potent antioxidant properties will continue to be a 
focus of this thesis. 
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 Chapter Four: Metabolic Health Cross  
Section Study (MHCSS)  
4.1 Section One: MHCSS-Vit C 
4.1.1 Background 
Vitamin C (ascorbate) is an essential micronutrient in humans, required for a number of 
important biological functions via acting as an enzymatic cofactor and reducing agent (43). 
Research suggests that chronic low-grade inflammation and oxidative stress play a pivotal 
role in the development of insulin resistance and T2DM, as well as related complications (47). 
Vitamin C has potent antioxidant properties (128). Vitamin C can protect important 
biomolecules from oxidation through participating in oxidation-reduction reactions whereby it 
is readily oxidized to dehydroascorbic acid, which in turn is rapidly reduced back to ascorbate 
(43). Vitamin C is naturally present in fruit and vegetables, is often added as a preservative to 
foods/beverages, and is also used as a dietary supplement (128). As a result of being water-
soluble, vitamin C has a relatively short half-life in the body due to rapid renal clearance, and 
therefore a regular and adequate intake is required to prevent deficiency.  
Previous research and results from Chapter four suggests that people with T2DM have lower 
plasma vitamin C concentrations than those with NGT (44-46). There are several proposed 
mechanisms including: (1) increased ascorbate excretion in those with microalbuminuria, 
(2) competition of blood glucose with vitamin C for uptake into cells due to its structural 
similarity to the oxidised form (dehydroascorbic acid), and (3) increased oxidative stress 
depleting antioxidant stores (44). Glucose-dependent inhibition of dehydroascorbic acid 
uptake into erythrocytes may contribute to enhanced erythrocyte fragility and could 
potentially contribute to complications such as diabetic microvascular angiopathy (241).  
As dietary vitamin C directly contributes to plasma vitamin C concentrations, potential 
differences in the intake between those with NGT and T2DM must also be considered. A 
prospective study of 48,850 men revealed that while the baseline consumption of fruit and 
vegetables was similar, men who developed T2DM then increased their consumption of fruit 
and vegetables by 1.6 serves/week compared to an increase of 0.7 serves/week in those who 
remained diabetes-free (242). Therefore, it seems that people with T2DM are altering their 
diet in an attempt to manage their blood sugar. Indeed, clinical advice to those newly-
diagnosed with T2DM focuses on improving the diet. However, the dietary changes appear to 
be small (difference of 0.9 serves of fruit and vegetables/week) (242).  
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The lower plasma vitamin C concentrations reported in people with T2DM has led to a 
growing interest in the role that vitamin C may afford against the development of T2DM and 
associated complications. A prospective survey of the Dutch and Finnish cohorts within the 
Seven Countries Study (SCS), a longitudinal study of cardiovascular risk factors among 16 
cohorts of middle-aged men, revealed an inverse association between dietary vitamin C intake 
and glucose intolerance, suggesting that antioxidants such as vitamin C may play a protective 
role against the development of IGT and T2DM (243). Further, the European Prospective 
Investigation of Cancer (EPIC)-Norfolk Study of some 21,000 individuals ascertained 735 
cases of T2DM after a 12-year follow-up, and demonstrated a strong inverse association 
between plasma vitamin C concentration and T2DM risk (244).  
However, studies investigating plasma vitamin C and glycaemic control have often failed to 
account for factors such as smoking status and dietary vitamin C intake, which are known to 
impact plasma vitamin C concentrations. When dietary intake is taken into account, there are 
conflicting results, with one study showing a low plasma vitamin C concentration in people 
with diabetes consuming a similar amount of dietary vitamin C as those without diabetes 
(245), compared to another study that reported no differences in serum vitamin C 
concentrations in people grouped by T2DM status after adjustment for dietary vitamin C 
intake (246). Therefore, the objective of this study was to determine the association between 
plasma vitamin C status and glycaemic control accounting for vitamin C intake in adults. 
4.1.2 Aims and Hypothesis 
The aim of this study was to investigate plasma vitamin C concentrations across the 
glycaemic spectrum and to explore correlations with indices of metabolic health.  
It was hypothesised that:  
• Plasma vitamin C will be associated with glycaemic control and other markers of 
metabolic health.  
4.1.3 Study Protocol 
4.1.3.1 Study participants  
This study was approved by the New Zealand Central Health and Disability Ethics Committee 
(consent no. 14/CEN/34). Written informed consent was obtained from all participants. 
Individuals aged ≥ 18 years meeting the inclusion criteria detailed below were recruited from 
general practice, prediabetes and diabetes services, retinal screening services, pharmacies, and 
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from local advertisements. Fasting glucose and HbA1c cut-off values for NGT, prediabetes 
and T2DM were based on the ADA criteria (16). A total of 101 individuals underwent a 
screening questionnaire to ascertain eligibility for the study. Ninety participants were enrolled 
and 89 participants completed the study.  
4.1.3.2 Study design 
This was a cross-sectional observational pilot study. At their study appointment, participants 
completed demographic and physical activity questionnaires. Anthropometric data were 
collected including BMI, waist and hip circumference and bioelectrical impedance. The four-
day weighed food diary completed during the previous 1-2 weeks was reviewed and 
additional information from the participant was added if necessary. A venous blood sample 
and a urine sample were collected after an overnight fast, and blood pressure was measured. 
Participants provided a faecal sample collected within 24 hours of their study appointment.!
4.1.3.3 Inclusion criteria of individuals aged ≥18 years with:  
• NGT (fasting glucose ≤ 5.5 mmol/L) (n = 35).  
• Prediabetes (fasting glucose 5.6 mmol/L to 6.9 mmol/L) (n = 25). 
• T2DM taking no diabetes medication (fasting glucose ≥ 7.0 mmol/L) or on a regimen 
of metformin only (n = 29). 
4.1.3.4 Exclusion criteria 
Excluded from the study were individuals unable to give informed consent, those who had 
taken antibiotics in the last month, those with a medical history of significant gastrointestinal 
disease (for example inflammatory bowel disease), those who had undergone a previous 
bowel resection, and individuals taking diabetes medication other than metformin. For this 
study participants taking metformin were not excluded from the analyses as metformin is not 
considered to impact plasma vitamin C concentrations.  
4.1.4 Results 
4.1.4.1 Participant characteristics 
Demographic characteristics are detailed in Table 4.1. The NGT group was slightly younger 
(55 years) than the prediabetes (63 years) and T2DM (61 years) groups. The ratio of females 
in each study group differed significantly, comprising 74% in the NGT group, 52% in the 
prediabetes group and 35% in the T2DM group. The majority of participants were European 
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(90%) and there were a mix of qualifications, as would be expected given the age of the 
participants (Table 4.1). There were no significant differences in physical activity between the 
study groups, although those in the NGT and prediabetes groups were slightly more active 
than those with T2DM. 
The mean BMI for the NGT (27.6 kg/m2) and prediabetes (29.9 kg/m2) groups reflects the 
international BMI cut-off points for overweight (25.0–29.9 kg/m2), and the T2DM group were 
obese (≥30.0 kg/m2). The waist circumference and waist-to-hip ratio increased across the 
groups from NGT to T2DM along with fat mass (%), as would be expected given that obesity 
is a risk factor for T2DM (Table 4.1).  
4.1.4.2 Metabolic and inflammatory biomarkers 
Fasting glucose, used as the basis for defining prediabetes and T2DM, increased from NGT 
(5.0 mmol/L) to prediabetes (6.2 mmol/L) to T2DM (7.2 mmol/L) as expected and differed 
significantly between the study groups (p<0.05, Table 4.2). Although fasting glucose was 
used as the basis for classifying participants in the analysis, the mean HbA1c of 35 mmol/mol 
for the NGT group and 40 mmol/mol for the prediabetes group were consistent with the ADA 
guidelines for the classification of NGT and prediabetes based on HbA1c (16). The mean 
HbA1c of 47 mmol/mol for the T2DM group is slightly lower than the current threshold for 
the diagnosis of diabetes (48 mmol/mol) because some of the individuals in this category 
were treated with the biguanide oral hypoglycaemic drug metformin. Fasting and postprandial 
glucose were likely reduced in these treated individuals. The mean HbA1c for all participants 
was 41 mmol/mol (Table 4.2).  
The mean fasting insulin concentrations were consistent with the glycaemic measures and 
were significantly higher in the T2DM group (95 pmol/L) compared to the NGT group 
(53 pmol/L). The increasing BMI across the groups (NGT=28 kg/m2, prediabetes=30 kg/m2 
and T2DM=33 kg/m2) was associated significantly with the increase in leptin concentrations 
(NGT=27 ng/mL, prediabetes and T2DM=33 ng/mL), and the reduction in ghrelin 
concentrations (NGT=171 pmol/L, prediabetes=111 pmol/L and T2DM=112 pmol/L). 
The total, HDL- and LDL-cholesterol decreased from the NGT (5.3 mmol/L, 1.5mmol/L and 
3.4 mmol/L respectively) to the T2DM group (4.3 mmol/L, 1.1 mmol/L and 2.5 mmol/L) 
(Table 4.2), which may reflect the use of lipid-lowering medications which are routinely used 
in individuals with T2DM. 
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There was a slight increase in triglycerides across the groups (NGT=1.1 mmol/L, 
prediabetes=1.3 mmol/L and T2DM=1.4 mmol/L), with the mean for each group remaining 
below the recommended cut-off in New Zealand (<1.7 mmol/L) (Table 4.2). There were no 
significant differences in the cholesterol (total/HDL) ratio between groups, and each group 
was below the recommended cut-off in New Zealand of 4.5. 
4.1.4.3 Self-reported dietary data 
There were no significant differences in the self-reported macronutrient intake and dietary 
vitamin C intake across the groups (Table 4.3). The AMDR range for protein is 15–25% of 
total energy, total fat 20−35% of total energy, and carbohydrate 45–65% of total energy 
(200). All study groups had slightly higher mean total fat intakes and slightly lower 
carbohydrate intakes than recommended, but the mean protein intake for all groups fell within 
the recommended range.  
The AI for dietary fibre in New Zealand and Australia is set at the median for dietary fibre 
intake recorded in the 1995 National Nutrition Survey of Australia (ABS 1998) and the 1997 
National Nutrition Survey of New Zealand (MOH 1999) (200). The AI is 25 g for women and 
30 g for men. Although fibre intake is not reported by sex in Table 4.3, the mean daily fibre 
intake for each group of 24 g, 25 g, and 27 g for the NGT, prediabetes, and T2DM groups 
respectively was similar to recommendations.  
Six participants reported taking a high-dose vitamin C supplement (≥500 mg vitamin C). The 
plasma vitamin C concentration of five of these participants ranged from 36–59 µmol/L, 
which reflects inadequate to adequate plasma vitamin C concentrations and suggests that they 
did not take the supplement close to their study appointment. The other participant had a 
plasma vitamin C concentration of 74 µmol/L, which is a saturating concentration, and was 
consistent with a high mean dietary vitamin C intake of 194 mg/day, known to saturate 
plasma (195). 
The percentage of individuals estimated to be under-reporting their energy intake was 27% 
(Table 4.4). The percentage of individuals estimated to be under-reporting their energy intake 
was only 4% higher in the prediabetes group compared to the NGT group, but was 28% 
higher in the T2DM groups compared to the NGT group (Table 4.4).   
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Table 4.1: General characteristics of participants classified as having normal glucose tolerance (NGT) (n= 35), prediabetes (n = 25), and T2DM (n = 29). 
Characteristics* NGT* Prediabetes* T2DM* Total*
Age**(years)* 55"±"13a" 63"±"9b* 61"±"11b" 59"±"11"
Sex** " " " "
Female"%"(n)" 74"(26)a" 52"(13)ab" 35"(10)b" 55%"(49)"
Male"%"(n)" 26"(9)" 48"(12)" 66"(19)" 45%"(40)"
Ethnicity** " " " "
European"%"(n)" 86"(30)" 88"(22)" 97"(28)" 90%"(80)"
Māori"%"(n)" 9"(3)" 4"(1)" 3"(1)" 6%"(5)"
Pacific"Island"%"(n)" 0"(0)" 4"(1)" 0"(0)" 1%"(1)"
Asian"%"(n)" 3"(1)" 4"(1)" 0"(0)" 2%"(2)"
Other"%"(n)" 3"(1)" 0"(0)" 0"(0)" 1%"(1)"
Qualification** " " " "
No"qualification"%"(n)" 96"(3)" 20"(5)" 25"(7)" 17%"(15)"
Secondary"school"%"(n)" 20"(7)" 24"(6)" 32"(9)" 25%"(22)"
PostMsecondary"certificate,"diploma"
or"trade"diploma"%"(n)"
43"(15)" 20"(5)" 25"(7)" 31%"(27)"
University"%"(n)" 27"(10)" 36"(9)" 18"(5)" 27%"(24)"
Physical*Activity*(MET"min/week)* 1723"±"1687" 2496"±"3671" 1320"±"1490" 1772"±"2327"
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Characteristics* NGT* Prediabetes* T2DM* Total*
Anthropometry* " " " "
Weight*"(kg)" 76.0"±"17.7a" 88.6"±"19.1b* 96.1"±"20.2b" 86.1"±"20.6"
BMI*"(kg/m2)" 27.6"±"5.9a" 29.9"±"7.0ab" 33.3"±"6.3b" 30.1"±"6.7"
Fat"mass"(%)" 31.5"±"8.0" 33.2"±"8.4" 34.7"±"7.1" 33.0"±"7.9"
Waist"circumference*"(cm)" 89.4"±"16.2a" 99.4"±"13.9b" 110.1"±"14.6c" 99.0"±"17.3"
WaistMtoMhip"ratio*" 0.85"±"0.09a" 0.91"±"0.08b" 0.96"±"0.10b" 0.91"±"0.10"
Blood"pressure"diastolic"(mmHg)" 77.9"±"8.6" 83.1"±"8.4" 79.3"±"9.0" 79.7"±"9.0"
Blood"pressure"systolic*"(mmHg)" 124.7"±"14.4a" 131.8"±"13.9ab" 135.2"±"15.1b" 130.3"±"15.1"
Smoking*Status"" " " " "
Current"smoker"%"(n)" 7"(2)" 5"(1)" 3"(1)" 5%"(4)"
ExMsmoker"%"(n)" 28"(8)" 439"(9)" 38"(11)" 35%"(28)"
NonMsmoker"%"(n)" 66"(19)" 52"(11)" 59"(17)" 60%"(47)"
Values represented as mean ± SD unless stated otherwise. *p values from ANOVA tests.  
Groups sharing a common superscript letter denotes the study groups that do not differ significantly from each other at the 0.05 level from post hoc analysis.  
There are missing data from one individual for qualification (1 × T2DM), 12 individuals for physical activity (7 × NGT and 5 × prediabetes), five individuals for waist-to-hip ratio (2 
× NGT and 3 × prediabetes), nine individuals for blood pressure measures (4 × NGT and 5 × prediabetes), and 10 individuals did not provide smoking status data (6 × NGT, 4 × 
prediabetes). 
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Table 4.2: Laboratory measures of participants classified as having normal glucose tolerance (NGT) (n = 35), prediabetes (n = 25), and T2DM (n = 29). 
Laboratory*Measures* NGT* Prediabetes* T2DM* Total*
Fasting"glucose*"(mmol/L)" 5.0"±"0.4a" 6.2"±"0.4b" 7.2"±"1.3c" 6.0"±"1.2"
HbA1c*"(mmol/mol)" 35"±"4a" 40"±"5b" 47"±"9c" 41"±"8"
hsMCRP"(mg/L)"Mean"(95%"CI)" 1.2"(0.9–1.6)" 1.6"(1.0–2.3)" 2.1"(1.4–2.8)" 1.6"(1.31.9)"
Total"cholesterol*"(mmol/L)" 5.3"±"0.9"a" 5.9"±"1.2a" 4.3"±"1.1b" 5.0"±"1.1"
HDLMcholesterol*"(mmol/L)" 1.5"±"0.4"a" 1.3"±"0.3b" 1.1"±"0.2b" 1.3"±"0.3"
LDLMcholesterol*"(Calc)"(mmol/L)" 3.4"±"0.8a" 3.3"±"1.0a" 2.5"±"1.0b" 3.1"±"1.0"
Triglycerides*"(mmol/L)" 1.1"±"0.4a" 1.3"±"0.7ab" 1.4"±"0.6b" 1.3"±"0.6"
Cholesterol"(total/HDL)"ratio" 3.8"±"0.8" 4.2"±"0.8" 3.9"±"1.1" 4.0"±"0.9"
Insulin*"(pmol/L)" 53"±"37a" 89"±"53b" 95"±"48b" 77"±"49"
Ghrelin*"(pmol/L)"Mean"(95%"CI)" 171"(142–207)a" 111"(88–140)b" 112"(91–139)b" 132"(117–150)"
Leptin"(ng/mL)"Mean"(95%"CI)" 27"(20–38)" 33"(20–54)" 33"(23–47)" 31"(25–38)"
Adiponectin*"(µg/mL)"Mean"(95%"CI)" 11"(9–13)a" 9"(7–11)a" 7"(6–8)b" 9"(8–10)"
Plasma"vitamin"C*"(µmol/L)" 57"±"14a" 48"±"16b" 41"±"18b" 49"±"17"
Values represented as mean ± SD unless stated otherwise. *p values from ANOVA tests.  
Groups sharing a common superscript letter denotes the study groups that do not differ significantly from each other at the 0.05 level from post hoc analysis.  
hs-CRP, ghrelin, leptin and adiponectin were loge transformed prior to analysis. Results are presented as geometric means and 95% confidence intervals.  
There are missing data from three individuals for plasma vitamin C (2 × NGT and 1 × prediabetes). 
!
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Table 4.3: Self-reported dietary intake of participants classified as having normal glucose tolerance (NGT) (n = 35), prediabetes (n = 25), and T2DM (n = 29). 
Total*Daily*Dietary*intake* NGT* Prediabetes* T2DM* Total*
Energy"(kJ)"" 8192"±"2336" 8430"±"2260" 8033"±"2416" 8204"±"2321"
Fibre"(g)"" 24"±"9" 25"±"8" 27"±"9" 25"±"9"
Protein"(%"of"energy)"" 17"±"3" 18"±"4" 17"±"3" 17"±"3"
Fat"(%"of"energy)"" 37"±"6" 39"±"8" 36"±"7" 37"±"7"
Carbohydrate"(%"of"energy)"" 44"±"6" 40"±"8" 44"±"8" 43"±"7"
Dietary"vitamin"C"intake"(mg)" 103"±"76" 94"±"58" 101"±"61" 100"±"66"
Values represented as mean ± SD.  
There were no significant differences between the study groups for any of the self-reported dietary intake measures.  
There are missing data from one individual for dietary information (1 × prediabetes).  
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Table 4.4: Percentage of individuals in each study group estimated to be under-reporting dietary 
intake. 
NGT$(n=35)$ Prediabetes$(n=24)$ T2DM$(n=29)$ Total$(n=88)$
17#(6)# 21#(5)# 45#(13)# 27#(24)#
Values presented as % (n) 
 
4.1.4.4 Plasma vitamin C status and dietary vitamin C intakes 
A significant decrease in the mean plasma vitamin C concentration was observed between the 
NGT (57 µmol/L) and the prediabetes group (48 µmol/L) (p=0.035) and the T2DM (41 
µmol/L) group (p<0.001) (Table 4.2). Furthermore, there was a higher proportion of 
individuals with deficient (3% in T2DM group), marginal (14% in T2DM group and 4% in 
prediabetes group), and inadequate (48% in T2DM group and 58% in prediabetes group) 
plasma vitamin C concentrations in the T2DM and prediabetes groups, compared with the 
NGT group (3% marginal and 18% inadequate) (Figure 4.1). 
!
Figure 4.1. Plasma vitamin C status of individuals within study groups. Percentage of individuals from 
each study group (NGT, prediabetes, and T2DM, including those taking no diabetes medication 
(fasting glucose ≥ 7.0 mmol/L or on a regimen of metformin only (T2DM)), classified as having 
saturating (≥70 µmol/L), adequate (50–69 µmol/L), inadequate (24–49 µmol/L), marginal (11–23 
µmol/L), and deficient (<11 µmol/L) plasma vitamin C concentrations (42). 
 
Although plasma vitamin C was significantly lower in individuals with T2DM compared to 
those with NGT, there were no significant differences in dietary vitamin C concentrations 
between study groups determined from the four-day weighed food diaries (Table 4.3). The 
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majority of participants met the New Zealand Recommended Dietary Intake (RDI) of 
45 mg/day (Figure 4.2). Furthermore, there were no participants in the T2DM group who had 
intakes below the New Zealand EAR (30 mg/day). At the group level, it appears that most 
participants had sufficient fruit and vegetables to meet the recommended vitamin C intakes. 
However, few participants were reaching the New Zealand Ministry of Health’s suggested 
dietary targets (SDT) to reduce chronic disease risk, which is 220 mg/day for men and 
190 mg/day for women (Figure 4.2). 
!
Figure 4.2. Individuals meeting New Zealand dietary intake recommendations for vitamin C. 
Percentage of individuals from each study group (NGT, prediabetes, and T2DM, including those 
taking no diabetes medication (fasting glucose ≥7.0 mmol/L or on a regimen of metformin only 
(T2DM)), meeting the estimated average requirement (EAR) (30 mg/day), recommended dietary 
intake (RDI) (45 mg/day), and suggested dietary target (SDT) to reduce chronic disease risk 
(220 mg/day for men and 190 mg/day for women) for dietary vitamin C intake using the nutrient 
reference values for Australia and New Zealand (200). 
 
4.1.4.5 Plasma vitamin C correlations 
There were no significant associations between age, gender, ethnicity, education level, and 
plasma vitamin C concentrations. There was a significant association between smoking 
history and plasma vitamin C concentration (p=0.035), with current (mean 31 µmol/L) and 
ex-smokers (mean 47 µmol/L) having lower concentrations than non-smokers (mean 
53 µmol/L). There was a significant linear association between vitamin C intake and plasma 
vitamin C concentration (r=0.353, p=0.001). 
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The three anthropometric measures (BMI, fat mass, and waist-to-hip ratio) were all 
significantly negatively associated with plasma vitamin C (p<0.05) when conducting 
univariate analyses (Table 4.5). When these three variables were included in a multiple 
regression, however, only BMI was independently negatively associated with plasma vitamin 
C (p<0.001). Laboratory measurements (HbA1c, fasting glucose, triglycerides, cholesterol 
(total /HDL) ratio, insulin, and hs-CRP) were negatively associated with plasma vitamin C 
(p<0.05), and HDL-cholesterol and ghrelin were positively associated with plasma vitamin C 
(p<0.05) in the univariate analysis (Table 4.5). When these variables were included in a 
multiple regression, only hs-CRP and fasting glucose were independently negatively 
associated with plasma vitamin C (p<0.05).  
A final multiple regression showed fasting glucose (p=0.001), BMI (p=0.001) and smoking 
history (p=0.003) to be significant independent predictors of plasma vitamin C (Table 4.6). 
Fasting glucose and BMI were negatively associated with plasma vitamin C, and current and 
ex-smokers had reduced plasma vitamin C concentrations compared to non-smokers. There 
was a strong positive association between hs-CRP concentrations and BMI (r=0.618, 
p<0.001). Accordingly, hs-CRP does not feature as an independent predictor of plasma 
vitamin C. Including dietary vitamin C intake in the above model showed that this was a 
significant independent predictor (p=0.032) of plasma vitamin C concentrations, and BMI, 
fasting glucose, and smoking history remained as significant independent predictors 
(R2=0.43) (Table 4.6). 
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Table 4.5: Pearson correlations of plasma vitamin C, glycaemic indices, hormones, lipids, high 
sensitivity C-reactive protein, and anthropometric measures. 
Measure$ Pearson$Correlation$
Fasting#glucose#(mmol/L)# −0.411***#
HbA1c#(mmol/mol)# −0.334***#
Total#cholesterol#(mmol/L)# 0.093#
Triglycerides#(mmol/L)# −0.322**#
HDLHcholesterol#(mmol/L)# 0.295**#
Cholesterol#(total/HDL)#ratio# −0.214*#
LDLHcholesterol#(mmol/L)## 0.086#
Insulin#(pmol/L)# −0.353**#
hsHCRP#(mg/L)# −0.333**#
Ghrelin#(pmol/L)# 0.295**#
Leptin#(ng/mL)# −0.183#
Adiponectin#(µg/mL)# 0.202#
BMI#(kg/m
2
)# −0.446***#
WaistHtoHhip#ratio# −0.274*#
Fat#mass#(%)# −0.295**#
*** correlations significant at 0.001 level (2-tailed); ** correlations significant at the 0.01 level (2-tailed);  
* correlations significant at the 0.05 level (2-tailed) 
 
Table 4.6: Multiple regression analysis showing significant associations with plasma vitamin C 
concentrations. 
Measure$ B$$ Lower$95%$CI$ Upper$95%$CI$ p$$
BMI# −0.9# −1.4# −0.4# 0.001#
Current#smoker# −21.9# −35.8# −7.9# 0.003#
ExHsmoker# −4.9# −11.2# 1.5# 0.128#
Fasting#glucose# −4.4# −7.1# −1.8# 0.001#
Dietary#vitamin#C## 0.05# 0.01# 0.10# 0.032#
B: coefficient from the multiple linear regression model. 
 
4.1.5 Discussion 
4.1.5.1 Predictors of plasma vitamin C 
In agreement with the hypothesis for this study, results showed fasting glucose, BMI, 
smoking history, and dietary vitamin C intake to be significant independent predictors of 
plasma vitamin C concentrations. The inverse association between fasting glucose and plasma 
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vitamin C concentration shown in this study is in agreement with earlier studies (44-46) and 
also the results from Chapter three. In addition, the mean plasma vitamin C concentration was 
significantly lower in the prediabetes group (compared to the NGT group), suggesting that a 
reduction in plasma vitamin C concentration occurs in parallel with the decline in glucose 
tolerance during the progression to T2DM. It has been proposed that the uptake of 
dehydroascorbic acid, the oxidized form of vitamin C, by the glucose transporters (GLUTs) 
could be competitively inhibited by elevated blood glucose levels (247). This could contribute 
to complications such as diabetic microvascular angiopathy due to erythrocyte fragility, as 
erythrocytes lack the sodium-dependent vitamin C transporters (SVCTs) and are dependent 
on the GLUTs for the uptake of vitamin C (241). The present study also found plasma vitamin 
C concentration to be inversely related to BMI, which concurs with previous research (238). 
Individuals with a higher weight are prone to vitamin C inadequacy and are known to require 
higher intakes of vitamin C in order to reach adequate plasma concentrations (111, 233).  
Oxidative stress is defined as a significant imbalance between the production of reactive 
oxygen species (ROS) and antioxidant defences, and leads to alterations in signalling 
pathways and to potential tissue damage (248). ROS activate nuclear factor кB (NFкB), a pro-
inflammatory transcription factor, which triggers a signalling cascade that leads to the 
continued synthesis of oxidative species and low-grade chronic inflammation (248). High-
sensitivity CRP, produced by the liver, indicates the presence of inflammation in the body. In 
the present study the concentration of hs-CRP increased with the deterioration of glycaemic 
control and increase in BMI. This result is consistent with the evidence suggesting that 
obesity can lead to chronic activation of the innate immune system and low-grade systemic 
inflammation and oxidative stress, which have been implicated in the development of insulin 
resistance and T2DM (47, 249, 250). Hyperglycaemia, increased plasma concentrations of 
free fatty acids (FFAs), and hyperinsulinaemia have all been linked to an increased production 
of ROS (248, 250). The data from the present study showed an inverse relationship between 
hs-CRP and plasma vitamin C. It is therefore hypothesised that lower plasma vitamin C 
concentrations in those with higher BMI, prediabetes, and T2DM reflects depletion of vitamin 
C due to its antioxidant and anti-inflammatory activities. 
Consistent with the role of vitamin C as an antioxidant, data from the present study showed a 
significant inverse relationship between plasma vitamin C concentration and smoking status. 
Ex- and current smokers had lower plasma vitamin C concentrations than non-smokers, which 
is consistent with previous research (234, 235). It has long been recognised that smokers and 
passive smokers have a lower vitamin C status than non-smokers partly due to poor dietary 
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habits, but also due to the oxidizing properties of tobacco smoke, resulting in an increased 
turnover of vitamin C (223).  
As expected, dietary vitamin C was found to be a predictor for plasma vitamin C 
concentration. However, when the dietary intake of the vitamin was corrected for by covariate 
analysis, fasting glucose, BMI and smoking status remained as significant independent 
predictors of plasma vitamin C concentration. That is, the associations observed were not 
solely explained by differences in dietary intake. This result is at odds with one study that 
reported no differences in serum vitamin C concentrations in people grouped by diabetes 
status after adjustment for dietary vitamin C intake (246). 
4.1.5.2 Metabolic hormones 
The mean fasting insulin concentrations were consistent with the glycaemic measures and 
were significantly higher in the T2DM group compared to the NGT group. A higher fasting 
insulin concentration indicates insulin resistance, a well-known contributor to impaired 
glucose tolerance and T2DM. Leptin and ghrelin are two hormones that have a major 
influence on energy balance (251). Leptin is a mediator of long-term regulation of energy 
balance, suppressing food intake and thereby inducing weight loss. Ghrelin, on the other 
hand, is a fast-acting hormone, seemingly playing a role in meal initiation. In obese patients, 
the circulating concentration of leptin is increased, whereas, surprisingly, ghrelin is decreased 
(251). It is now established that obese patients are leptin-resistant (251). Indeed, in the present 
study, the increasing BMI across the groups was associated with an increase in leptin 
concentrations and a reduction in ghrelin concentrations. There was an inverse relationship 
between insulin and leptin and plasma vitamin C, and a positive relationship between ghrelin 
and plasma vitamin C; however, these hormones were also associated with fasting glucose 
and were thus not included as independent predictors of plasma vitamin C. 
4.1.5.3 Clinical significance 
As hyperglycaemia is associated with increased oxidative stress, a role for antioxidants such 
as vitamin C in the prevention of T2DM and/or the reduction of complications is a reasonable 
proposition. Indeed, a recent meta-analysis of 15 RCTs, investigating vitamin C 
supplementation and insulin resistance and biomarkers of glycaemic control (fasting glucose, 
HbA1c), found that doses of ≥200 mg/day vitamin C significantly reduced glucose 
concentrations in patients with T2DM, particularly if the intervention was for more than 30 
days and in older individuals (252). Furthermore, a recent 12-month RCT found that treating 
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those with T2DM with both metformin and vitamin C was more effective at reducing HbA1c 
and risk factors for diabetes-related long-term complications than treating with metformin 
alone (253). 
Although T2DM is not traditionally considered a risk factor for vitamin C deficiency, 
research, including the present study, indicates that those with prediabetes or T2DM are more 
likely to have inadequate or deficient plasma vitamin C concentrations. This did not appear to 
be due to a lower dietary vitamin C intake, so dietary advice needs to emphasise the 
importance of consuming high vitamin C foods, aiming for an intake of at least 200 mg/day 
(200). This is particularly relevant in light of the associated T2DM risk factors of higher BMI 
and smoking status, both of which impact vitamin C status. In addition to the growing interest 
of the role of vitamin C may afford against the development of T2DM and associated 
complications, vitamin C deficiency (plasma concentration ≤11 µmol/L) will increase a 
person’s risk of developing the potentially fatal disease of scurvy. Furthermore, researchers 
have also suggested that vitamin C is required at concentrations above those needed to 
prevent scurvy for the maintenance of good health (42, 128). For example, individuals with 
marginal plasma vitamin C concentrations (≤23 µmol/L) are known to present with fatigue, 
depression and deficiencies in wound healing (129, 130). 
Further research into the possibility of a higher RDI for vitamin C for those with prediabetes 
and T2DM is warranted, in line with what has been recommended in some countries for 
smokers (254). 
4.1.5.4 Study strengths and limitations 
The study used robust methodology for dietary intake, plasma vitamin C, and statistical 
analysis, and accounted for other factors that are known to impact plasma vitamin C 
concentration such as smoking status, dietary vitamin C intake, and supplement use. The 
participants with T2DM were clinically well described and were either not treated with 
diabetes medication or treated with a single oral hypoglycaemic agent only (metformin). 
Those taking metformin were included in the overall analysis. When the metformin-treated 
cases were excluded, the correlation between fasting glucose and plasma vitamin C 
concentrations was similar in direction and magnitude (n=64, r=−0.477, p<0.001) to the entire 
cohort (n=86, r=−0.411, p=0.001). Further, the current norm is for metformin treatment to be 
initiated at diagnosis, rather than after the failure of diet and lifestyle changes to optimize 
glucose control. As such, it will become increasingly difficult to recruit treatment-naïve 
individuals with T2DM into clinical studies.  
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A limitation of this study is the observational design, in which associations do not imply 
causations. T2DM has been shown to increase the urinary excretion of vitamin C, leading to 
reduced plasma vitamin C concentrations in a rodent model (255). Whether this also occurs in 
humans is unknown. In addition, the duration of T2DM was not reported in the present study. 
Indeed, many individuals have undiagnosed T2DM for a significant period of time prior to 
formal diagnosis, making it very difficult to interpret data concerning the duration of disease.  
The percentage of individuals estimated to be under-reporting their dietary intke was slightly 
higher (9% higher) than what was estimated in Chapter three but was still similar to national 
surveys in New Zealand (228, 229). The higher percentage of under-reporting estimated in 
this study may reflect the differences in methodology used. The weighed food diary used in 
this study may have imposed a greater burden to individuals!compared to the estimated food 
diary used in CHALICE. Thus, in this study, individuals may have adapted their diet in order 
to simplify the weighing of food intake (197).  
Results showed the highest percentage of under-reporting to be in the T2DM group. As 
discussed in Chapter three, if the under-reporting is related to social desirability it is unlikely 
that fruit and vegetable intake, and thus dietary vitamin C intake, was affected. Accordingly, 
in this study dietary vitamin C intake was found to be an independent predictor of plasma 
vitamin C concentration and although the association is not perfect this would not be expected 
as diet records take account of intake whereas plasma vitamin C concentration takes into 
account other factors such as utilization and confounders such as smoking.  There are also 
other possible reasons for the lower energy intakes than what was estimated for those with 
prediabetes and T2DM, such as individuals currently dieting, physical activity levels may be 
higher, individuals in these groups may have a genetic predisposition for obesity, and recent 
research has suggested the energy prediction equations overestimate the energy requirements 
more for obesity-susceptible individuals (217). 
The study cohort was relatively small with 89 participants. This study did not use standard 
protocol for measuring blood pressure, with measurements only repeated if the initial reading 
was outside the normal range, which is therefore a limitation of these results. The study had 
only one measure of plasma vitamin C per participant and so future research should ideally 
incorporate repeated samples to account for any temporal fluctuations. There was a limitation 
around the lack of detail with regards to vitamin C supplement use; however, only six 
participants reported taking high-dose vitamin C supplements and the use was sporadic.  
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4.1.6 Conclusions 
This cross-sectional observational study has identified a moderate inverse relationship 
between plasma vitamin C and both fasting glucose and BMI in adult subjects across the 
glycaemic spectrum. One possible explanation for this observation is that the depletion of 
vitamin C may be due to oxidative stress and inflammation resulting from dysglycaemia, 
overweight/obesity, and smoking, rather than lower dietary intakes. Further research is 
required to determine whether those with an increased dietary intake through fruit and 
vegetables and/or vitamin C supplementation have a decreased risk of progression to T2DM 
and/or complications associated with the metabolic syndrome and T2DM. 
4.2 Section Two: MHCSS-gut Microbiota 
4.2.1 Background 
T2DM is a complex disorder defined by elevated blood glucose, reflecting relative insulin 
deficiency (16). The underlying feature is insulin resistance, and additional metabolic 
abnormalities such as inflammation and dyslipidaemia are common. The disorder is 
influenced by genetic and environmental factors, with diet and lifestyle as significant 
precipitants (16).  
T2DM accounts for at least 90% of all cases of diabetes (2), has a high prevalence in the New 
Zealand population, and the prevalence is increasing significantly with time (256). The 
complications of diabetes, including microvascular complications such as eye, kidney and 
nerve damage, as well as increased morbidity and mortality attributable to cardiovascular 
disease and cancer, contribute significantly to the burden of ill health of New Zealanders 
(257). Researchers have recently been interested in the gut microbiota as a potential novel 
contributor to the diabetes epidemic (21). 
The gut microbiota contributes to energy balance in humans by fermenting undigested dietary 
components that reach the large bowel, providing additional metabolic capability to the host 
(258). Among the metabolites produced are SCFAs, such as acetate, propionate and butyrate 
which host cells can use as substrates for energy production (98). SCFAs have anti-
inflammatory effects by reducing the release of proinflammatory cytokines by adipose tissue 
and weakening leukocyte activation, which improves insulin resistance, tissue glucose uptake, 
and blood glucose levels (Figure 4.3) (259). Furthermore, SCFAs have been shown to affect 
pancreatic beta-cell function by directly acting as histone deacetylases (HDAC) inhibitors 
(promoting !-cell development, proliferation, differentiation and function), and can directly 
! 113!
influence glucose uptake and insulin production by stimulating release of GLP-1 from the 
endocrine cells in the gut (259) (Figure 4.3).  
Accordingly, the extent to which the bowel microbiota contributes in a positive or negative 
way to energy balance and to human health or disease may be determined by microbiota 
composition. The total metabolite output, or metabolome, of the gut microbiota will vary 
according to the range of species present (richness or diversity) and the extent to which 
species are represented in the gut (relative abundance). 
 
Figure 4.3. SCFAs improve metabolic functions in T2DM (259). 
 
T2DM has been reported to be associated with an alteration in the usual balance of bowel 
bacterial species, described as a bacterial dysbiosis (22). Differences in the gut microbiota 
have been demonstrated between individuals with T2DM and healthy individuals (95, 165, 
181). Further, the finding of differences in gut microbiota between healthy individuals, 
individuals with prediabetes and T2DM implicates gut ecology in the progression from 
normal glucose tolerance (NGT) to T2DM (97). A logical extension is the suggestion that 
manipulation, by dietary change, of the RAs of particular bacterial taxa within the gut 
microbiota could be a therapy for T2DM (260). Studies to date have been conducted in 
heterogeneous cohorts, ranging from individuals who manage diabetes by diet alone, to those 
requiring insulin therapy. For example, metformin is an oral antihyperglycaemic agent whose 
primary and dominant metabolic effect is inhibition of liver glucose production, but the exact 
mode of action remains unknown. Gastrointestinal disturbances are the most common side 
effect of metformin treatment (157).  
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There are studies in both animals and humans that suggest some beneficial effects of 
metformin on glucose metabolism may be microbially mediated (160-163, 261). A recent 
study investigating the gut microbiota in Japanese patients with T2DM reported 
Enterobacteriaceae and Staphylococcus to be significantly higher in the patients receiving 
metformin (165). A recent study included a reanalysis of two other studies (784 available 
human gut metagenomes) and showed that neglecting to control for antidiabetic medication 
can confound results (164). It is possible that consistent changes in microbiota composition 
has not been demonstrated across studies because of these confounding factors. 
The major determinant of gut microbiota composition is diet (108, 109). Marked differences 
in gut microbiota were observed between children raised on a rural African diet compared 
with children consuming a European ‘Western’ style diet (107). Further, the gut microbiota 
responds very rapidly to dietary change, as shown in a recent cross-over design study in 
healthy individuals allocated to either a predominantly plant-based diet or a predominantly 
animal-based diet for five days (110). This interval was sufficient to establish an altered gut 
microbiota composition. Diets high in plant fibre result in predominance of Bacteroidetes 
bacteria and a relative reduction in the prevalence of!Firmicutes and are associated with a 
different pattern of SCFA production (107). Obesity is associated with the converse finding: 
reduction in the RA of Bacteroidetes and an increase in the numbers of Firmicutes (92, 170). 
It is possible that differences in the diet, for instance a difference in fibre intake, account for 
the differences in gut microbiota observed in obesity and T2DM, but to date this has not been 
demonstrated. Food ingredients that promote the proliferation of particular gut bacteria are 
termed ‘prebiotics’ (100). Kiwifruit is an important example of a New Zealand food with 
potential prebiotic activity and may therefore have a role to play in T2DM therapy. 
Therapeutic options for T2DM have limited success in restoring normal physiology. Further 
research is required to tease out the relationship between the gut microbiota and its 
metabolites, and diet and glucose tolerance across the glycaemic spectrum. The possibility 
that the impact of the disease could be reduced by manipulating gut microbiota by diet is 
worthy of investigation. 
4.2.2 Aims and Hypothesis 
The aim of this study was to explore the relationship between diet, microbial ecology and 
metabolic indices across the spectrum from normal glucose tolerance to T2DM: 
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• To define gut microbiota composition associated with normal glucose tolerance, 
prediabetes and T2DM.  
• To explore factors (anthropometric, laboratory measures, demographics, dietary 
intake) potentially confounding the association between glycaemic control and the gut 
microbiota composition.  
It was hypothesised that: 
• The gut microbiota composition is associated with glycaemic control. 
4.2.3 Protocol 
See Chapter four, Section one for details on ethics and study design. Participants were 
grouped based on the ADA criteria for fasting glucose cut-off values for NGT, prediabetes 
and T2DM (16).  
4.2.3.1 Inclusion criteria based on fasting glucose grouping: individuals aged ≥ 18 
years with: 
• NGT (fasting glucose ≤ 5.5 mmol/L) (n=33) 
• Prediabetes (fasting glucose  5.6 mmol/L to 6.9 mmol/L) (n=22)  
• T2DM taking no antihyperglycaemic agents (fasting glucose ≥ 7.0 mmol/L) 
(n=6) 
4.2.3.2 Exclusion criteria  
Exclusion criteria included individuals unable to give informed consent, those who had taken 
antibiotics in the last month, those with a medical history of significant gastrointestinal 
disease (inflammatory bowel disease or a previous bowel resection) and those taking 
antihyperglycaemic agents. Due to the exclusion criteria for this study, a total of 61 
participants were included in the analysis for this chapter. 
4.2.3.3 Blood parameters 
Fasting glucose and HbA1c were measured in this study as indicators of glycaemic control. 
Although these correlate strongly (Figure 4.4), fasting glucose and HbA1c reflect different 
aspects of glucose metabolism (29, 262). In this study, for comparison between groups (NGT, 
prediabetes and T2DM) participants have been grouped by fasting glucose, in keeping with 
the vitamin C study (Chapter four, Section one). Both fasting glucose and HbA1c have also 
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been used as continuous variables in correlation analyses due to worldwide discrepancies in 
the diagnostic criteria for prediabetes and T2DM (23, 263, 264). 
4.2.4 Results 
For the microbiota analyses, those currently taking probiotics (n=4) were excluded from 
analysis with the gut microbiota. One participant was also excluded due to not having 
genomic DNA sequencing data from their faecal sample and one participant was excluded as 
they had no dietary data.  
Those with a diagnosis of T2DM taking metformin (n=22) were also excluded from the main 
analyses of this section, as results suggested metformin may have been confounding 
associations (Section 4.2.4.3.1.2). Unfortunately, the group of participants with T2DM not 
taking metformin is small (n=6), and anecdotally most New Zealanders are being prescribed 
metformin immediately following a diagnosis of T2DM. This left a total of 61 participants in 
the main analyses of this section.   
4.2.4.1 Glycaemic measures and inflammation 
Glycaemic measures (fasting glucose and HbA1c), used as the basis for defining prediabetes 
and T2DM, increased from NGT to T2DM as expected (Figure 4.4). Although fasting glucose 
was used as the basis for classifying participants in the analysis, the mean HbA1c of 
35 mmol/mol for the NGT group, 41 mmol/mol for the prediabetes group and 49 mmol/mol 
for the T2DM group were consistent with the ADA guidelines for the classification of 
diabetes based on HbA1c (16).  
!
Figure 4.4. Fasting glucose versus HbA1c showing the American Diabetes Association (ADA) 
diagnostic cut-off values for prediabetes and T2DM (n=61). 
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4.2.4.2 Participant characteristics  
Demographic characteristics and anthropometric measures are detailed in Table 4.7. The NGT 
group was slightly younger (56.0 years) than the prediabetes (63.5 years) and T2DM (65.5 
years) groups, and there were more females in the NGT group (72.7%) compared to the 
prediabetes and T2DM groups, where there were equal numbers of males and females. The 
majority of participants were European (85.2%) and there was a mix of qualifications as 
would be expected given the age of the participants (Table 4.7). There were no significant 
differences in physical activity between the study groups, although individuals in the T2DM 
group were less active than those in the NGT and prediabetes groups (861, 1723 and 2580 
MET minutes/week respectively).  
The mean BMI (kg/m2) and fat mass (%) increased from NGT (27.9 kg/m2 and 31.2%) to 
prediabetes (30.2 kg/m2 and 33.8%) to T2DM (32.4 kg/m2 and 35.6%), as would be expected 
with obesity being a risk factor for T2DM. The BMI for the NGT group reflects the 
international BMI cut-offs for overweight (25.0-29.9 kg/m2) and the prediabetes and T2DM 
groups were obese (≥30 kg/m2). The waist circumference (cm) and waist-to-hip ratio were 
also significantly greater in those with prediabetes (100.5 cm and 0.92) and T2DM (104.3 cm 
and 0.92) compared to those with NGT (89.5 cm and 0.85). Blood pressure was slightly 
higher in those with prediabetes (133/83 mmHg) and T2DM (134/84 mmHg) compared to 
those with NGT (125/78 mmHg), as was the use of antihypertensive medication, which was 
masking the expected increase. Around 50% of individuals were current or ex-smokers in the 
prediabetes and T2DM groups, whereas there was a lower proportion in the NGT group 
(35%).  
Laboratory measures are detailed in Table 4.8. Total, HDL- and LDL-cholesterol were lower 
in the prediabetes (5.08, 1.23 and 3.2 mmol/L) and T2DM (5.07, 1.24 and 3.2 mmol/L) 
groups compared to those with NGT (5.28, 1.44 and 3.4 mmol/L), which reflects the 
increased use of lipid-lowering medication in those with prediabetes and T2DM. 
Triglycerides were slightly higher in the prediabetes (1.4 mmol/L) and T2DM (1.5 mmol/L) 
groups compared to those with NGT (1.1 mmol/L) although the average for each group 
remained below the recommended cut-off in New Zealand (<1.7 mmol/L). There were no 
significant differences in the cholesterol (total/HDL) ratio between groups, and each group 
was below the recommended cut-off in New Zealand of 4.5. 
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The average fasting insulin concentrations were consistent with the glycaemic measures and 
were significantly higher in the prediabetes (93 pmol/L) and T2DM (107 pmol/L) groups 
compared to the NGT group (54 pmol/L). The increasing BMI from NGT to T2DM was 
associated with an increase in leptin concentrations (increase of 13 ng/mL), and a reduction in 
ghrelin concentrations (decrease of 62 pmol/L). Plasma vitamin C levels were significantly 
lower in those with prediabetes (47.2 µmol/L) and T2DM (34.3 µmol/L) compared to those 
with NGT (58.7 µmol/L) (p<0.05, Table 4.8). 
Participants’ self-reported dietary intake is detailed in Table 4.9. Results show a similar 
dietary intake for most participants in the study. The only significant difference in dietary 
intake across the groups was a significantly lower intake of sugar as a percentage of energy 
intake in the prediabetes group (17%) compared to the NGT group (21%) (p<0.05, Table 4.9). 
The AMDRs are the recommendations for the balance of protein, fat and carbohydrate in the 
diet with respect to relative contribution to dietary energy (200). The AMDR range for protein 
is 15–25% of total energy, total fat 20−35% of total energy, and carbohydrate 45–65% of total 
energy (200). All study groups had slightly higher average total fat intakes and slightly lower 
carbohydrate intakes than recommended, but the average protein intake for all groups fell 
within the recommended range.  
The AI for dietary fibre in New Zealand and Australia is set at the median for dietary fibre 
intake recorded in the 1995 National Nutrition Survey of Australia (ABS 1998) and the 1997 
National Nutrition Survey of New Zealand (Ministry of Health (MOH) 1999) (200). The AI is 
25 g for women and 30 g for men. Although fibre intake is not reported by sex in Table 4.9, 
the average daily fibre intake for each group of 25 g, 25 g, and 24 g for the NGT, prediabetes, 
and T2DM groups respectively was similar to recommendations.  
Although not significantly different, the daily consumption of fruit decreased from NGT to 
T2DM (decrease of 70 g) and the consumption of vegetables increased from NGT to T2DM 
(increase of 15 g). This resulted in an overall slight decrease in the consumption of fruit and 
vegetables from the NGT to T2DM (decrease of 49 g). Probiotic (food and beverage) 
consumption was low in all groups and was not consumed at all by those with T2DM. 
Although not significant, the consumption of grainy foods (breads/breakfast cereals/pasta) 
decreased from the NGT to T2DM groups (decrease of 28 g). Nuts and seed consumption was 
similar between groups.  
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The percentage of individuals’ under-reporting their dietary intake in each study group was 
calculated to be 11% and 38% higher in the prediabetes and T2DM groups compared to the 
NGT group respectively (Table 4.10).  
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Table 4.7: General characteristics of participants classed as having normal glucose tolerance (NGT) (n=33), prediabetes (n=22) and T2DM (n=6) grouped by fasting 
glucose. 
Characteristics** NGT* Prediabetes* T2DM* Total*
Age*(years)** 56.0%±%12.5a% 63.5%±%9.06b% 65.5%±%14.3ab% 59.6%±12.0%
Sex* % % % %
Female% %(n)* 72.7%(24)% 50.0%(11)% 50.0%(3)% 62.3%(38)%
Male% %(n)% 27.3%(9)% 50.0%(11)% 50.0%(3)* 37.7%(23)%
Ethnicity* % % % %
European% %(n)* 84.8%(28)% 86.4%(19)% 83.3%(1)% 85.2%(52)%
Māori% %(n)% 9.1%(3)% 4.5%(1)% 16.7%(1)% 8.2%(5)%
Pacific%Island% %(n)% 0.0%(0)% 4.5%(1)% 0.0%(0)% 1.6%(1)%
Asian% %(n)% 3.0%(1)% 4.5%(1)% 0.0%(0)% 3.3%(2)%
Other% %(n)% 3.0%(1)% 0.0%(0)% 0.0%(0)% 1.6%(1)%
Qualification* % % % %
No%qualification% %(n)% 9.1%(3)% 18.2%(4)% 33.3%(2)% 14.8%(9)%
Secondary%school% %(n)% 18.2%(6)% 27.3%(6)% 50.0%(3)% 24.6%(15)%
PostNsecondary%certificate,%diploma%or%trade%
diploma% %(n)%
42.4%(14)% 22.7%(5)% 0.0%(0)% 31.1%(19)%
University% %(n)% 30.3%(10)% 31.8%(7)% 16.7%(1)% 29.5%(18)%
Physical*Activity*(MET*minutes/week)* 1723%±%1687% 2580%±%3910% 861%±%647% 1907%±%2603%
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Characteristics** NGT* Prediabetes* T2DM* Total*
Anthropometry* % % % %
Weight*%(kg)%% 76.8%±%17.9
a
% 88.5%±%19.0
b
% 92.7%±%16.9
ab
% 82.6%±%19.0%
BMI%(kg/m
2
)% 27.9%±%6.0% 30.2%±%7.0% 32.4%±%6.3% 29.1%±%6.5%
Fat%mass%(%)% 31.2%±%8.1% 33.8%±%8.1% 35.6%±%8.0% 32.6%±%8.1%
Waist%circumference*%(cm)% 89.5%±%16.4
a
% 100.5%±%13.5
b
% 104.3%±%13.1
b
% 94.9%±%16.0%
WaistNtoNhip%ratio*% 0.85%±%0.10
a
% 0.92%±%0.07
b
% 0.92%±%0.09
ab
% 0.88%±%0.09%
Blood%pressure%diastolic%(mmHg)% 78.1%±%8.9% 83.0%±%9.2% 84.3%±%9.3% 80.4%±%9.2%
Blood%pressure%systolic%(mmHg)% 125.1%±%14.9% 133.2%±%11.4% 134.1%±%16.4% 128.8%±%14.3%
Antihypertensive%medication% %(n)% 21.2%(7)% 45.5%(10)% 33.3%(2)% 31.1%(19)%
Smoking*Status* % % % %
Current%smoker% %(n)* 6.9%(2)% 5.6%(1)% 0.0%(0)% 5.7%(3)%
ExNsmoker% %(n)% 27.6%(8)% 50.0%(9)% 50.0%(3)% 37.3%(20)%
NonNsmoker% %(n)% 65.5%(19)% 44.4%(8)% 50.0%(3)% 56.6%(30)%
Values presented as mean ± SD unless stated otherwise. * p values from ANOVA tests.  
Groups sharing a common superscript letter denotes the study groups that do not differ significantly from each other at the 0.05 level from post hoc analysis.  
There are missing data from 10 individuals for physical activity (5 × NGT and 5 × prediabetes), five individuals for waist-to-hip ratio (2 × NGT and 3 × prediabetes), nine 
individuals for blood pressure (4 × NGT and 5 × prediabetes) and eight individuals for smoking history (4 × NGT, 4 × prediabetes). 
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Table 4.8: Laboratory measures of participants classed as having normal glucose tolerance (NGT) (n=33), prediabetes (n=22) and T2DM (n=6) grouped by fasting 
glucose 
Laboratory*Measures* NGT* Prediabetes* T2DM* Total*
Fasting%glucose*%(mmol/L)% 5.0%±%0.4
a
% 6.3%±%0.4
b
% 7.9%±%1.1
c
% 5.8%±%1.0%
HbA1c*(mmol/mol)% 35%±%4
a
% 41%±%4
b
% 49%±%6
c
% 39%±%6%
Total%cholesterol%(mmol/L)% 5.28%±%0.88% 5.08%±%1.22% 5.07%±%1.05% 5.19%±%1.01%
HDLNcholesterol*%(mmol/L)% 1.44%±%0.35
a
% 1.23%±%0.28
b
% 1.24%±%0.22
ab
% 1.35%±%0.33%
LDLNcholesterol%(mmol/L)% 3.4%±%0.8% 3.2%±%1.0% 3.2%±%1.1% 3.3%±%0.9%
Triglycerides%(mmol/L)% 1.1%±%0.4% 1.4%±%0.7% 1.5%±%0.7% 1.2%±%0.6%
Cholesterol%(total/HDL)%ratio% 3.8%±%0.8% 4.2%±%0.8% 4.2%±%1.1% 4.0%±%0.8%
Lipid%lowering%medication*% %(n)% 9.1%(3)
a
% 31.8%(7)
ab
% 66.7%(4)
b
% 23.0%(14)%
hsNCRP%(mg/L)%Mean%(95%%CI)% 1.19%(0.84–1.62)% 1.61%(1.03N2.34)% 2.70%(0.89N6.24)% 1.46%(1.13N1.83)%
Fasting%insulin*%(pmol/L)% 54%±37
a
% 93%±%22
b
% 107%±%63
b
% 73%±%50%
Ghrelin%(pmol/L)*%Mean%(95%%CI)% 169.1%(138.7N206.1)
a
% 105.4%(81.5N136.1)
b
% 107.6%(43.1N268.9)
ab
% 136.4%(115.9N160.4)%
Leptin%(ng/mL)%Mean%(95%%CI)% 27.1%(19.3N38.1)% 34.1%(20.5N56.8)% 40.2%(11.3N143.1)% 30.6%(23.4N40.0)%
Adiponectin%(µg/mL)%(95%%CI)% 11%(9N13)% 9%(7N11)% 10%(6N18)% 10%(9N12)%
Plasma%vitamin%C*%(µmol/L)% 58.7%±%13.1
a
% 47.2%±%16.0
b
% 34.3%±%12.7
b
% 52.0%±%16.1%
Values presented as mean ± SD unless stated otherwise. * p values from ANOVA tests.  
Groups sharing a common superscript letter denotes the study groups that do not differ significantly from each other at the 0.05 level from post hoc analysis.  
hs-CRP, ghrelin, leptin and adiponectin were loge transformed prior to analysis. Results appear as geometric means and 95% confidence intervals.  
There is missing data for three individuals for plasma vitamin C (2 × NGT and 1 × prediabetes). 
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Table 4.9: Self-reported daily dietary intake of participants classed as having NGT (n=33), prediabetes (n=22) and T2DM (n=6) grouped by fasting glucose. 
Daily*Dietary*Intake* NGT* Prediabetes* T2DM* Total* p"
Energy%(kJ)% 8372%±%2278% 8268%±%2291% 8479%±%3068% 8374%±%2322% 0.974%
Fibre%(g)% 25%±%9% 25%±%8% 24%±%7% 25%±%8% 0.917%
Protein%(%%of%energy)%% 17%±%3% 18%±%4% 16%±%4% 17%±%3% 0.245%
Protein%(g)% 84%±%26% 88%±%22% 78%±%28% 85%±%24% 0.667%
Total%fat%(%%of%energy)% 37%±%6% 39%±%7% 39%±%7% 38%±%7% 0.449%
Total%fat%(g)% 82%±28% 88%±%37% 92%±%44% 85%±%33% 0.743%
Saturated%fat%(%%of%energy)% 13%±%3% 14%±%4% 15%±%4% 14%±%4% 0.659%
Saturated%fat%(g)% 30%±%13% 32%±%16% 34%±%16% 31%±%14% 0.816%
Monounsaturated%fat%(%%of%energy)% 14%±%3% 14%±%4% 14%±%3% 14%±%3% 0.713%
Monounsaturated%fat%(g)% 30%±%11% 33%±%17% 34%±%19% 32%±%14% 0.762%
Polyunsaturated%fat%(%%of%energy)% 6%±%2% 6%±%2% 6%±%1% 6%±%2% 0.477%
Polyunsaturated%fat%(g)% 12%±%4% 13%±%6% 13%±%6% 13%±%5% 0.654%
Total%carbohydrate%(%%of%energy)% 44%±%6% 40%±%8% 41%±%6% 42%±%7% 0.118%
Total%carbohydrate%(g)% 220%±%66% 197%±%55% 201%±%51% 209%±%61% 0.370%
Sugar%(%%of%energy)*% 21%±%6
a
% 17%±%5
b
% 19%±%3
ab
% 19%±%6% 0.037%
Sugar%(g)% 104%±%42% 80%±%26% 90%±%21% 94%±%36% 0.059%
Starch%(%%of%energy)% 23%±%5% 24%±%5% 22%±%3% 23%±%5% 0.858%
Starch%(g)% 115%±%39% 116%±%41% 110%±%31% 115%±%38% 0.940%
Dietary%vitamin%C%intake%(mg)% 81%(69N124)% 76%(66N112)% 78%(52N127)% 79%(66N124)% 0.800%
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Daily*Dietary*Intake* NGT* Prediabetes* T2DM* Total* p"
Fresh%fruit%(g)% 131%(53N202)% 111%(65N170)% 81%(30N195)% 128%(55N195)% 0.889%
Kiwifruit%(g)% 0%(0N14)% 0%(0N0)% 0%(0N55)% 0%(0N12)% 0.500%
Kiwifruit%consumption% %(n)% 33.3%(11)% 18.2%(4)% 33.3%(2)% 27.9%(17)% 0.448%
Total%fruit%(g)% 176%(112N247)% 143%(75N239)% 106%(78N236)% 151%(91N239)% 0.501%
Total%vegetables%(g)% 318%(204N368)% 259%(193N412)% 333%(178N409)% 312%(197N379)% 0.936%
NonNstarchy%vegetables%(g)% 53%(41N66)% 46%(32N75)% 78%(45N121)% 50%(39N75)* 0.193%
Starchy%vegetables%(g)% 100%(86N142)% 91%(54N139)% 107%(72N118)% 98%(72N139)% 0.416%
Total%fruit%and%vegetables%(g)% 487%(360N586)% 460%(317N632)% 438%(393N646)% 476%(350N614)* 0.913%
Probiotics%(g)% 0%(0N21)% 0%(0N4)% 0%(0N0)% 0%(0N12)* 0.239%
Grainy%foods%(g)% 169%(135N241)% 166%(124N237)% 141%(115N182)% 164%(131N238)% 0.408%
Nuts%and%seeds%(g)% 5%(0N14)% 3%(0N20)% 4%(0N20)% 5%(0N15)% 0.860%
Values presented as mean ± SD or median and interquartile range (25th to 75th percentiles). *p values from ANOVA tests.  
Groups sharing a common superscript letter denotes the study groups that do not differ significantly from each other at the 0.05 level from post hoc analysis.  
There was no missing dietary data. 
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Table 4.10: Percentage of individuals in each study group estimated to be under-reporting dietary 
intake. 
NGT$(n=33)$ Prediabetes$(n=22)$ T2DM$(n=6)$ Total$(n=61)$
12#(4)# 23#(5)# 50#(3)# 20#(12)#
Values presented as % (n). 
 
4.2.4.3 Section two: part one - the gut microbiota  
Two samples failed to sequence (2/112 = 1.8%, well within accepted rate of 4%); however, 
one of these samples included a duplicate reaction which sequenced well. Thus, only a single 
submitted sample did not generate good sequence data. The total number of sequences for 
analysis following quality procedures was 2,607,801. Each sample generated an average of 
29,220 sequences (range 0–105594). 
The operational taxonomic unit (OTU) tables were filtered by prevalence (any OTUs not 
present in at least 25% of the sample set were removed). At the phylum-level taxa were not 
analysed if they had a RA of <1%. At the other taxonomic levels presented in this study 
(class, order, family and genus), very low abundance taxa (RA of <0.1%) were also not 
analysed.  
OTUs were assigned taxonomy via the SILVA v. 123 database. This database provides seven 
taxonomic levels (kingdom, phylum, class, order, family, genus and species). Raw sequence 
counts were normalised by conversion to RA, and the original OTU table was collapsed to 
each taxonomic level. Realistically only five of these collapsed tables provide data for 
analysis (phylum to genus). The kingdom-level table provides only two points (Bacteria and 
Archaea), whilst taxonomic assignment to species level is often not robust, using short 
amplicon sequence data. For this reason, those two taxonomic levels are not considered 
further. The phylum-level data were analysed first, followed by lower taxonomic ranks. In 
many cases a single lineage was observed through multiple taxonomic ranks. In these cases, 
the highest taxonomic rank and the ranks where the taxonomy diverges are reported (for 
example, phylum and then family if there is a single lineage through the class and order 
rankings).  
4.2.4.3.1 The gut microbiota and glycaemic control 
4.2.4.3.1.1 Phylum  
There were ten phyla identified from the 61 faecal samples (Euryarchaeota, Actinobacteria, 
Bacteroidetes, Cyanobacteria, Firmicutes, Fusobacteria, Proteobacteria, Synergistetes, 
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Tenericutes and Verrucomicrobia). Actinobacteria, Bacteroidetes and Firmicutes were the 
only phyla present with a RA of greater than 1% and so were the only phyla included in the 
main body of the thesis. Five of the phyla (Euryarchaeota, Cyanobacteria, Fusobacteria, 
Synergistetes and Tenericutes) not considered for further analysis were present at a RA of less 
than 0.1%. Statistical analysis for the phyla Proteobacteria and Verrucomicrobia can be 
found in Appendix C. 
Firmicutes and Bacteroidetes were the dominant phyla comprising 76% and 10% of all 
bacterial taxa detected respectively (Table 4.11). When comparing the study groups, 
Actinobacteria had a significantly greater RA in those with T2DM compared to those with 
NGT and prediabetes (p=0.023, Table 4.11, Figure 4.5).  
Table 4.11: RA of bacteria present by participants grouped by fasting glucose at the phylum-level. 
RA$of$Bacteria$
(%)$
NGT$$
(n=33)$
Prediabetes$
(n=22)$
T2DM$$
(n=6)$
Total$
(n=61)$
p$$
Actinobacteria+ 5.3#(1.8,8.5)a# 5.6#(3.1,10.7)a# 21.0#(16.8,25.5)b# 5.7#(2.8,11.2)# 0.023#
Bacteroidetes+ 12.5#(6.0,15.4)# 9.2#(7.4,15.0)# 4.5#(1.5,11.8)# 10.3#(4.8,15.0)# 0.139#
Firmicutes+ 76.2#(68.6,80.3)# 76.4#(67.8,84.3)# 72.4#(69.8,73.9)# 75.8#(68.5,82.0)# 0.654#
Firmicutes#to#
Bacteroidetes#
(ratio)#
6.0#(4.5,13.3)# 8.1#(4.3,11.3)# 16.3#(6.8,45.3)# 7.4#(4.6,16.3)# 0.184#
Data presented as median and interquartile range (25th to 75th percentiles). p values from Wilcoxon summed rank 
tests.  
Groups sharing a common superscript letter denotes the study groups that do not differ significantly from each 
other at the 0.05 level from post hoc analysis.  
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Figure 4.5. RA of the phylum Actinobacteria (%) in participants grouped by fasting glucose. Bars 
represent median and interquartile range.  
 
There was a significant positive association (p<0.05) between fasting glucose and the RA of 
Actinobacteria (Table 4.12, Figure 4.6). HbA1c shows a similar trend but did not reach 
statistical significance. There were no other significant associations between the RA of phyla 
and glycaemic control. 
Table 4.12: Spearman’s correlation coefficient of bacteria at the phylum-level and measures of 
glycaemic control. 
# Fasting$Glucose$(mmol/L)$ HbA1c$(mmol/mol)$
RA$of$Bacteria$(%)# rs# p+ rs# p+
Actinobacteria++ 0.281# 0.028# 0.247# 0.055#
Bacteroidetes+ ,0.143# 0.273# ,0.155# 0.234#
Firmicutes+ ,0.140# 0.284# ,0.138# 0.290#
Firmicutes#to#Bacteroidetes#(ratio)# 0.123# 0.344# 0.137# 0.292#
 
N
G
T
P
r e
d
i a
b
e
t e
s
T
2
D
M
0
1 0
2 0
3 0
4 0
P a r t i c i p a n t s  G r o u p e d  b y  F a s t in g  G l u c o s e  ( m m o l / L )
R
A
 o
f
P
h
y
lu
m
 A
c
ti
n
o
b
a
c
te
ri
a
 (
%
)
! 128!
!
Figure 4.6. RA of phylum Actinobacteria (%) with fasting glucose concentrations (n=61). 
 
4.2.4.3.1.2 Justification for the exclusion of participants taking metformin 
Those in the T2DM group taking metformin had a previous diagnosis for diabetes, but the 
range of fasting glucose levels at the study visit included values lower than 7 mmol/L due to 
the action of the metformin lowering blood glucose levels (Figures 4.7 and 4.8).  
 
Figure 4.7. Fasting glucose levels of participants in the NGT, prediabetes and T2DM not taking/taking 
metformin grouped by the ADA diagnostic cut-of values (n=84). Those taking probiotics (n=4) and 
missing sequencing data (n=1) were excluded from this analysis.  
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Figure 4.8. Fasting glucose versus HbA1c including those with T2DM taking metformin showing the 
ADA diagnostic cut-off values for prediabetes and T2DM (n=84). Those taking probiotics (n=4) and 
missing sequencing data (n=1) were excluded from this analysis.  
 
When individuals with a previous diagnosis of T2DM taking metformin are included in the 
correlation of fasting glucose with the RA of Actinobacteria, the correlation is no longer 
significant (Tables 4.13 and 4.14). This is due to low levels of Actinobacteria in the T2DM 
group taking metformin, which may be partially disrupting the association (Table 4.13, 
Figures 4.9 and 4.10). In addition, as discussed above, the glycaemic control of those taking 
metformin is being manipulated (Figures 4.7 and 4.8). 
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Table 4.13: RA of bacteria by participants grouped by fasting glucose and metformin use at the 
phylum-level (n=84). 
RA$of$Bacteria$
(%)$
NGT$$
(n=33)$
Prediabetes$$
(n=23)$
T2DM$No$
Metformin$
(n=6)$
T2DM$Taking$
Metformin$
(n=22)$
p"
Actinobacteria++ 5#(2,8)ac# 5#(3,11)ab# 21#(17,26)b# 3#(2,7)c# 0.008#
Bacteroidetes+ 12#(6,15)# 8#(6,15)# 4#(2,12)# 12#(8,21)# 0.096#
Firmicutes+ 76#(69,80)# 77#(68,84)# 72#(70,74)# 77#(67,83)# 0.829#
Verrucomicrobia+ 0.83#(0.05,3.78)# 0.90#(0.01,2.41)# 0.30#(0.06,2.06)# 0.01#(0.00,1.26)# 0.395#
Firmicutes+to+
Bacteroidetes+
(ratio)+
6.0#(4.50,13.3)# 8.3#(4.3,13.6)# 16.3#(6.8,45.3)# 6.0#(3.2,10.5)# 0.145#
      
Data presented as median and interquartile range (25th to 75th percentiles). p values from Wilcoxon summed rank 
tests.  
Groups sharing a common superscript letter denotes the study groups that do not differ significantly from each 
other at the 0.05 level from post hoc analysis.  
Participants taking probiotics (n=4) and missing sequencing data (n=1) were excluded from this analysis.   
 
Table 4.14: Spearman’s correlation coefficient of the RA of the phylum Actinobacteria and measures 
of glycaemic control including (n=84) and excluding (n=61) individuals taking metformin. 
$ Including$those$on$
metformin$(n=84)$
Excluding$those$on$
metformin$(n=61)$
Measure$of$Glycaemic$Control$ rs# p## rs$ p#$
Fasting#glucose#(mmol/L)# 0.107# 0.334# 0.281# 0.028#
HbA1c#(mmol/mol)# 0.063# 0.570# 0.247# 0.055#
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Figure 4.9. RA of the phylum Actinobacteria (%) in individuals grouped by fasting glucose 
concentrations and metformin use (n=84). Bars represent median and interquartile range.  
 
 
Figure 4.10. Fasting glucose with the RA of the phylum Actinobacteria (%) (n=84). 
 
As the focus of this chapter is to explore the effect of glycaemic control (participants were 
deliberately targeted to provide a spectrum from NGT to prediabetes and T2DM) on the gut 
microbiota, those with a diagnosis of T2DM taking metformin (n=22) have been removed 
from all further microbiota analysis. Metformin may be confounding associations for two 
reasons. The glycaemic control of those taking metformin is being manipulated, and the 
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results above suggest that metformin potentially impacts the gut microbiota which has also 
been reported in previous studies (160-162, 164, 261).  
4.2.4.3.1.3 Class  
At the class-level, two phyla (Actinobacteria and Firmicutes) branched into two classes each 
(Figures 4.11 and 4.12). From these four classes there was one significant association seen. 
When participants are grouped by fasting glucose concentrations, the class Actinobacteria had 
a significantly greater RA in those with T2DM compared to those with NGT and prediabetes 
by 15.7% and 14.8% respectively (Table 4.15, Figure 4.13). The RA of the class 
Coriobacteriia was also higher in those with T2DM compared to those with NGT, but this 
was not statistically significant (Table 4.15, Figure 4.14). The correlation analysis also shows 
a significant positive association with the class Actinobacteria and fasting glucose (r=0.286, 
p=0.025) (Table 4.16, Figure 4.15). HbA1c shows a similar trend but did not reach statistical 
significance (Table 4.16). Coriobacteriia and fasting glucose also showed a non-significant 
positive trend (Table 4.16, Figure 4.16). With the low abundance not analysed, there was only 
one genus associated with each class, so results below the class level are not presented. 
Bifidobacterium was the only genus present for the class Actinobacteria (Figure 4.11). 
Collinsella was the only genus in the Coriobacteriia class (Figure 4.11). The class 
Actinobacteria comprised approximately 80% of the phylum Actinobacteria. 
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Figure 4.11. Bacteria for the phylum Actinobacteria (class, order, family, and genus) present in the 
study dataset. 
 
 
!
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Figure 4.12. Bacteria for the phylum Firmicutes (class, order, family, and genus) present in the study dataset. 
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Table 4.15: RA of bacteria present by participants grouped by fasting glucose at the class-level. 
RA#of#Bacteria#(%)#
NGT##
(n=33)#
Prediabetes#
(n=22)#
T2DM##
(n=6)#
p"
Actinobacteria;,Actinobacteria,, 3.1$(0.6(7.3)a$ 4.0$(2.1(8.9)a$ 18.8$(15.1(22.7)b$ 0.025$
Actinobacteria;,Coriobacteriia, 1.3$(0.8(2.3)$ 1.8$(1.2(2.4)$ 2.5$(1.3(2.8)$ 0.075$
Firmicutes;,Clostridia, 69.2$(64.0(75.0)$ 70.9$(62.2(77.9)$ 64.8$(60.6(68.8)$ 0.431$
Firmicutes;,Erysipelotrichia, 2.6$(1.3(4.7)$ 4.0$(1.5(6.5)$ 3.1$(2.6(5.8)$ 0.368$
Data presented as median and interquartile range (25th to 75th percentiles). p values from Wilcoxon summed rank 
tests.  
Groups sharing a common superscript letter denotes the study groups that do not differ significantly from each 
other at the 0.05 level from post hoc analysis.  
 
!
Figure 4.13. RA of the class Actinobacteria (%) in participants grouped by fasting glucose. Bars 
represent median and interquartile range. 
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Figure 4.14. RA of the class Coriobacteriia (%) in participants grouped by fasting glucose. Bars 
represent median and interquartile range. 
 
Table 4.16: Spearman’s correlation coefficient of bacteria at the class-level and measures of glycaemic 
control. 
RA#of#Bacteria#(%)$
Fasting#Glucose#(mmol/L)# HbA1c#(mmol/mol)#
rs$ p, rs$ p,
Actinobacteria;,Actinobacteria, 0.286$ 0.025$ 0.249$ 0.053$
Actinobacteria;,Coriobacteriia, 0.223$ 0.084$ 0.062$ 0.635$
Firmicutes;,Clostridia, (0.152$ 0.243$ (0.203$ 0.117$
Firmicutes;,Erysipelotrichia, 0.020$ 0.876$ 0.238$ 0.065$
 
!
Figure 4.15. RA of class Actinobacteria (%) with fasting glucose concentrations. 
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Figure 4.16. RA of class Coriobacteriia (%) with fasting glucose concentrations. 
 
4.2.4.3.1.4 Order 
Data are not presented at the order level as all classes contained only a single order.  
4.2.4.3.1.5 Family  
Two orders (Bacteroidales and Clostridiales) branch into eight families (Figures 4.17 and 
4.12). Of these eight families, there was one significant association seen between family RA 
and fasting glucose groups. Those with T2DM had a significantly lower RA of 
Ruminococcaceae compared to those with NGT and prediabetes (p=0.027) (Table 4.17 and 
Figure 4.18). A trend was also seen in the correlation with fasting glucose and the RA of 
Ruminococcaceae, but this did not reach statistical significance (Table 4.18). 
!
Figure 4.17. Bacteria for the phylum Bacteroidetes (class, order, family, and genus) present in the 
study dataset. 
!
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Table 4.17: RA of bacteria present by participants grouped by fasting glucose at the family-level. 
RA#of#Bacteria#(%)#
NGT##
(n=33)#
Prediabetes#
(n=22)#
T2DM##
(n=6)#
p"
Bacteroidetes;,Bacteroidia;,
Bacteroidales;,Bacteroidaceae, 5.4$(2.8(10.0)$ 5.9$(4.2(7.8)$ 2.8$(0.8(3.8)$ 0.166$
Bacteroidetes;,Bacteroidia;,
Bacteroidales;,
Porphyromonadaceae,
1.1$(0.5(1.5)$ 1.1$(0.6(1.7)$ 0.3$(0.1(1.2)$ 0.265$
Bacteroidetes;,Bacteroidia;,
Bacteroidales;,Rikenellaceae, 2.5$(0.9(4.7)$ 1.8$(0.9(2.5)$ 1.3$(0.2(2.0)$ 0.306$
Firmicutes;,Clostridia;,
Clostridiales;,Clostridiaceae,1,
0.5$(0.1(1.4)$ 0.3$(0.0(2.5)$ 0.1$(0.0(1.2)$ 0.558$
Firmicutes;,Clostridia;,
Clostridiales;,Lachnospiraceae,
34.3$(26.5(45.3)$ 37.9$(28.8(40.1)$ 41.7$(34.5(46.2)$ 0.559$
Firmicutes;,Clostridia;,
Clostridiales;,
Peptostreptococcaceae,
1.1$(0.3(2.6)$ 0.6$(0.1(3.9)$ 1.4$(0.1(4.2)$ 0.916$
Firmicutes;,Clostridia;,
Clostridiales;,Ruminococcaceae,
27.9$(25.1(31.2)a$ 26.6$(23.6(30.7)a$ 17.1$(12.8(21.7)b$ 0.027$
Firmicutes;,Clostridia;,
Clostridiales;,Unknown,
1.5$(0.4(4.2)$ 1.2$(0.4(3.3)$ 0.3$(0.0(5.4)$ 0.572$
Data presented as median and interquartile range (25th to 75th percentiles). p values from Wilcoxon summed rank 
tests.  
Groups sharing a common superscript letter denotes the study groups that do not differ significantly from each 
other at the 0.05 level from post hoc analysis.  
!
!
Figure 4.18. RA of the family Ruminococcaceae (%) in participants grouped by fasting glucose. Bars 
represent median and interquartile range. 
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Table 4.18: Spearman’s correlation coefficient of bacteria at the family-level and measures of 
glycaemic control. 
RA#of#Bacteria#(%)$
Fasting#Glucose#(mmol/L)#
HbA1c##
(mmol/mol)#
rs$ p, rs$ p,
Bacteroidetes;,Bacteroidia;,Bacteroidales;,
Bacteroidaceae,
(0.029$ 0.825$ (0.112$ 0.390$
Bacteroidetes;,Bacteroidia;,Bacteroidales;,
Porphyromonadaceae, (0.185$ 0.154$ (0.095$ 0.446$
Bacteroidetes;,Bacteroidia;,Bacteroidales;,
Rikenellaceae,
(0.207$ 0.110$ (0.070$ 0.590$
Firmicutes;,Clostridia;,Clostridiales;,
Clostridiaceae,1,
(0.065$ 0.621$ (0.092$ 0.480$
Firmicutes;,Clostridia;,Clostridiales;,
Lachnospiraceae,
0.057$ 0.663$ (0.057$ 0.661$
Firmicutes;,Clostridia;,Clostridiales;,
Peptostreptococcaceae, (0.145$ 0.264$ (0.176$ 0.175$
Firmicutes;,Clostridia;,Clostridiales;,
Ruminococcaceae,
(0.242$ 0.060$ (0.146$ 0.261$
Firmicutes;,Clostridia;,Clostridiales;,
Unknown,
(0.225$ 0.081$ (0.156$ 0.230$
 
4.2.4.3.1.6 Genus  
Only three families (Ruminococcaceae, Lachnospiraceae and Erysipelotrichaceae, all from 
Firmicutes phyla) from the classes analysed above contained more than one genera, and these 
branched into 14 genera (Figure 4.12). Of these 14 genera, there were three significant 
associations seen between genera RA and fasting glucose groups. Dorea had a significantly 
greater RA in those with T2DM compared to NGT and prediabetes (p=0.038, Table 4.19, 
Figure 4.19). Those with prediabetes had a significantly greater RA of Subdoligranulum 
compared with those who had NGT and T2DM (p=0.005, Table 4.19, Figure 4.20). In 
contrast, Ruminococcaceae UCG-002 had a significantly lower RA in those with T2DM 
compared to NGT and prediabetes (p=0.014, Table 4.19).  
In line with the grouped analysis, correlations with fasting glucose also showed the RA of 
Ruminococcaceae UCG-002 to be negatively associated with fasting glucose (r=−0.340,        
p=0.007, Table 4.20. Figure 4.21). In agreement with the grouped analysis results, the RA of 
Dorea increased with increasing fasting glucose but this was not statistically significant 
! 140!
(r=0.239, p=0.064, Table 4.20). However, there was no association between the RA of 
Subdoligranulum and fasting glucose (r=−0.011, p=0.932, Table 4.20).  
 
!
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Table 4.19: RA of bacteria present by participants grouped by fasting glucose at the genus-level. 
RA#of#Bacteria#(%)#
NGT##
(n=33)#
Prediabetes#
(n=22)#
T2DM##
(n=6)#
p"
Firmicutes;+Clostridia;+Clostridiales;+Lachnospiraceae;+Anaerostipes+ 1.5$(0.8(3.3)$ 1.1$(0.6(2.5)$ 4.5$(0.7(6.1)$ 0.162$
Firmicutes;+Clostridia;+Clostridiales;+Lachnospiraceae;+Blautia+ 7.9$(5.3(14.0)$ 9.2$(6.3(10.8)$ 9.8$(7.4(13.6)$ 0.878$
Firmicutes;+Clostridia;+Clostridiales;+Lachnospiraceae;+Dorea+ 1.4$(0.8(2.0)a$ 1.8$(1.3(3.0)ab$ 2.4$(1.8(8.4)b$ 0.038$
Firmicutes;+Clostridia;+Clostridiales;+Lachnospiraceae;+Eubacterium+ 7.8$(5.0(12.4)$ 9.8$(7.6(12.8)$ 11.0$(2.9(15.1)$ 0.466$
Firmicutes;+Clostridia;+Clostridiales;+Lachnospiraceae;+Fusicatenibacter+ 1.7$(0.9(3.2)$ 2.3$(1.3(3.2)$ 1.9$(1.1(3.1)$ 0.800$
Firmicutes;+Clostridia;+Clostridiales;+Lachnospiraceae;+Roseburia+ 1.4$(0.7(1.8)$ 1.2$(0.7(1.9)$ 0.6$(0.2(1.9)$ 0.565$
Firmicutes;+Clostridia;+Clostridiales;+Ruminococcaceae;+Faecalibacterium+ 8.8$(7.1(13.8)$ 8.4$(5.7(11.5)$ 8.8$(8.2(11.4)$ 0.602$
Firmicutes;+Clostridia;+Clostridiales;+Ruminococcaceae;+Ruminococcaceae+UCG=002+ 1.7$(0.5(2.6)a$ 0.8$(0.5(1.7)a$ 0.2$(0.0(0.3)b$ 0.014$
Firmicutes;+Clostridia;+Clostridiales;+Ruminococcaceae;+Ruminococcaceae+UCG=014+ 0.4$(0.0(2.2)$ 0.9$(0.0(2.8)$ 0.0$(0.0(1.1)$ 0.217$
Firmicutes;+Clostridia;+Clostridiales;+Ruminococcaceae;+Ruminococcus+2+ 2.4$(0.5(5.2)$ 3.1$(1.8(4.5)$ 1.1$(0.1(4.2)$ 0.573$
Firmicutes;+Clostridia;+Clostridiales;+Ruminococcaceae;+Subdoligranulum+ 3.0$(1.4(3.7)a$ 3.9$(2.1(5.6)b$ 1.2$(0.6(2.1)a$ 0.005$
Firmicutes;+Clostridia;+Clostridiales;+Ruminococcaceae;[Eubacterium]+coprostanoligenes+
group+
1.6$(0.9(2.5)$ 1.4$(0.6(2.9)$ 1.1$(0.6(2.1)$ 0.958$
Firmicutes;+Erysipelotrichia;+Erysipelotrichales;+Erysipelotrichaceae;+Erysipelotrichaceae+
UCG=003+
1.2$(0.5(3.1)$ 1.8$(0.8(2.6)$ 2.3$(1.1(3.0)$ 0.614$
Firmicutes;+Erysipelotrichia;+Erysipelotrichales;+Erysipelotrichaceae;+Holdmanella+ 0.0$(0.0(0.2)$ 0.0$(0.0(3.0)$ 0.0$(0.0(0.0)$ 0.726$
Data presented as median and interquartile range (25th to 75th percentiles). p values from Wilcoxon summed rank tests.  
Groups sharing a common superscript letter denotes the study groups that do not differ significantly from each other at the 0.05 level from post hoc analysis.  
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Figure 4.19. RA of the genus Dorea (%) in participants grouped by fasting glucose. Bars represent 
median and interquartile range. 
!
 
Figure 4.20. RA of the genus Subdoligranulum (%) in participants grouped by fasting glucose. Bars 
represent median and interquartile range. 
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Table 4.20: Spearman’s correlation coefficient of bacteria at the genus-level and measures of glycaemic control. 
Bacteria(at(the(Genus(Level!
Fasting(Glucose((mmol/L)( HbA1c((mmol/mol)(
rs! p" rs! p"
Firmicutes;"Clostridia;"Clostridiales;"Lachnospiraceae;"Anaerostipes" $0.053! 0.684! $0.090! 0.488!
Firmicutes;"Clostridia;"Clostridiales;"Lachnospiraceae;"Blautia" 0.045! 0.733! 0.021! 0.871!
Firmicutes;"Clostridia;"Clostridiales;"Lachnospiraceae;"Dorea" 0.239! 0.064! 0.119! 0.363!
Firmicutes;"Clostridia;"Clostridiales;"Lachnospiraceae;"Eubacterium" 0.141! 0.278! $0.009! 0.945!
Firmicutes;"Clostridia;"Clostridiales;"Lachnospiraceae;"Fusicatenibacter" 0.008! 0.949! $0.066! 0.613!
Firmicutes;"Clostridia;"Clostridiales;"Lachnospiraceae;"Roseburia" $0.113! 0.386! $0.201! 0.120!
Firmicutes;"Clostridia;"Clostridiales;"Ruminococcaceae;"Faecalibacterium" $0.047! 0.721! $0.115! 0.376!
Firmicutes;"Clostridia;"Clostridiales;"Ruminococcaceae;"Ruminococcaceae"UCG=002" $0.340! 0.007! $0.180! 0.165!
Firmicutes;"Clostridia;"Clostridiales;"Ruminococcaceae;"Ruminococcaceae"UCG=014" $0.090! 0.492! $0.123! 0.346!
Firmicutes;"Clostridia;"Clostridiales;"Ruminococcaceae;"Ruminococcus"2" 0.069! 0.596! 0.041! 0.754!
Firmicutes;"Clostridia;"Clostridiales;"Ruminococcaceae;"Subdoligranulum" $0.011! 0.932! $0.018! 0.889!
Firmicutes;"Clostridia;"Clostridiales;"Ruminococcaceae;[Eubacterium]"coprostanoligenes"group" $0.039! 0.766! 0.055! 0.675!
Firmicutes;"Erysipelotrichia;"Erysipelotrichales;"Erysipelotrichaceae;"Erysipelotrichaceae"UCG=003" $0.058! 0.658! 0.042! 0.749!
Firmicutes;"Erysipelotrichia;"Erysipelotrichales;"Erysipelotrichaceae;"Holdmanella" 0.010! 0.942! 0.112! 0.388!
!
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Figure 4.21. RA of the genus Ruminococcaceae UCG-002 (%) with fasting glucose concentrations. 
 
4.2.4.3.2 Glycaemic control and alpha diversity  
Figure 4.22 shows that sampling is heading towards saturation as the curves are approaching 
plateau. This shows that at 6000 sequences (reads/sample) the species accumulation is 
reaching a plateau, therefore the analysis of the microbiota data captures most of the species 
present.  
!
Figure 4.22. Number of sequences versus number of observed species. Values shown are mean ± SE.  
 
Although all of the diversity measures were decreased in those with T2DM, this was not 
statistically significant (Tables 4.21, Figure 4.23 and Table 4.22, Figure 4.24).  
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Table 4.21: Diversity (at 6000 sequences/sample) of participants grouped by fasting glucose. 
Diversity)Measures)
NGT))
(n=33))
Prediabetes)
(n=22))
T2DM))
(n=6))
p"
Observed(species( 233((1952253)( 242((2112267)( 171((1592235)( 0.067(
Whole(tree((PD)( 19((17222)( 20((18222)( 17((14222)( 0.348(
Shannon(index( 5.7((5.225.9)( 5.6((5.426.0)( 4.9((4.525.9)( 0.290(
Simpson’s(diversity( 0.96((0.9520.97)( 0.96((0.9520.97)( 0.93((0.9220.97)( 0.400(
Chao(index( 310((2672368)( 337((2962374)( 265((2232323)( 0.087(
Data presented as median and interquartile range (25th to 75th percentiles). p values from Wilcoxon summed rank 
tests. 
 
!
Figure 4.23. Observed species (at a rarefaction level of 6000 sequences/sample) of participants 
grouped by fasting glucose. Bars represent median and interquartile range. 
 
Table 4.22: Spearman’s correlation coefficient of alpha diversity (at 6000 sequences/sample) and 
measures of glycaemic control.  
( Fasting)Glucose) HbA1c)
( rs( p" rs( p"
Observed(species( 20.125( 0.338( 20.127( 0.331(
Whole(tree((PD)( 20.075( 0.565( 20.053( 0.688(
Shannon(index( 20.162( 0.213( 20.136( 0.298(
Simpson’s(diversity( 20.133( 0.307( 20.115( 0.376(
Chao(index( 20.109( 0.405( 0.017( 0.896(
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Figure 4.24. Graph of the number of observed species according to fasting glucose concentrations and 
study groups. 
 
4.2.4.4 Section two: part two - the gut microbiota and participant characteristics  
The results for this section include both continuous and grouped data (gender, ethnicity and 
smoking status). Ethnicity was analysed as two categories, European and non-European 
(Māori, Pacific Island, Asian and other), and smoking history was also analysed as two 
categories, those who have never smoked and those who are current or ex-smokers. Smoking 
history was not significantly associated with the RA of bacteria at any taxonomic level. 
The aim of part two and three is to investigate participant characteristics and self-reported 
dietary intake that could be potentially confounding the association between glycaemic 
control and the gut microbiota composition. If there was no association seen with the RA of 
bacteria and fasting glucose as a continuous or grouped variable (i.e. participants grouped by 
fasting glucose concentrations) in part one, then no further analyses with participant 
characteristics and self-reported dietary intake were included in this chapter. Refer to 
Appendix D for all significant associations found between the RA of bacteria and participant 
characteristics and self-reported dietary intake. 
Associations with participant characteristis were therefore explored with Actinobacteria at the 
phylum-level, Actinobacteria at the class-level, Ruminococcaceae at the family-level and 
Dorea, Ruminococcaceae UCG-002 and Subdoligranulum at the genus-level, as the RA of 
these bacteria were associated with glycaemic control.! 
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4.2.4.4.1 Phylum  
Weight (r=0.267, p=0.038) and fasting insulin concentrations (r=0.314, p=0.014) were 
positively associated with the phylum Actinobacteria, and plasma vitamin C concentration 
was negatively associated with Actinobacteria (Table 4.23, Figures 4.25-4.27). There were no 
significant associations with gender, ethnicity or smoking history and the RA of 
Actinobacteria at the phylum-level.  
Table 4.23: Spearman’s correlation coefficients of Actinobacteria at the phylum-level and other 
characteristics of the study population. 
Phylum) Actinobacteria"
Characteristics) rs(
Age) 20.144(
Anthropometry) (
Weight((kg)( 0.267*(
BMI((kg/m2)( 0.212(
Waist(circumference((cm)( 0.205(
Waist2to2hip(ratio(( 0.169(
Fat(mass((%)( 0.182(
Laboratory)Measures) (
hs2CRP((mg/L)(( 0.090(
Total(cholesterol((mmol/L)( 20.047(
HDL2cholesterol((mmol/L)( 20.180(
LDL2cholesterol((mmol/L)( 20.023(
Triglycerides((mmol/L)( 0.245(
Cholesterol((total/HDL)(ratio( 0.124(
Fasting(insulin((pmol/L)( 0.314*(
Ghrelin((pmol/L)(( 20.140(
Leptin((ng/mL)(( 0.187(
Adiponectin((µg/mL)(( 20.148(
Plasma(vitamin(C((µmol/L)( 20.450**(
*Significant at the 0.05 level, **significant at the 0.01 level  
There are missing data for 5 individuals for waist-to-hip ratio (2 × NGT and 3 × prediabetes) and 3 individuals 
for plasma vitamin C (2 × NGT and 1 × prediabetes). 
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Figure 4.25. RA of the phylum Actinobacteria (%) with weight. 
 
!
Figure 4.26. RA of the phylum Actinobacteria (%) with plasma insulin concentrations.  
 
!
Figure 4.27. RA of the phylum Actinobacteria (%) with plasma vitamin C concentrations.  
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4.2.4.4.2 Class 
At the class-level, the RA of Actinobacteria is positively associated with insulin (r=0.280, 
p=0.029) and negatively associated with plasma vitamin C concentrations (r=−0.427, 
p=0.001) (Table 4.24, Figures 4.28-4.29). There were no significant associations with gender, 
ethnicity or smoking history and the RA of Actinobacteria at the class-level.  
Table 4.24: Spearman’s correlation coefficients of Actinobacteria at the class-level associated with 
characteristic(s) of the study population. 
Phylum;)Class) Actinobacteria;"Actinobacteria"
Characteristics) rs(
Age) 20.117(
Anthropometry) (
Weight((kg)( 0.206(
BMI((kg/m2)( 0.165(
Waist(circumference((cm)( 0.162(
Waist2to2hip(ratio(( 0.150(
Fat(mass((%)( 0.160(
Lab)Measures) (
hs2CRP((mg/L)(( 0.053(
Total(cholesterol((mmol/L)( 20.044(
HDL2cholesterol((mmol/L)( 20.182(
LDL2cholesterol((mmol/L)( 20.031(
Triglycerides((mmol/L)( 0.246(
Cholesterol((total/HDL)(ratio( 0.139(
Fasting(insulin((pmol/L)( 0.280*(
Ghrelin((pmol/L)(( 20.124(
Leptin((ng/mL)(( 0.164(
Adiponectin((µg/mL)(( 20.164(
Plasma(vitamin(C((µmol/L)( 20.427**(
*Significant at the 0.05 level, ** significant at the 0.01 level 
There are missing data for 5 individuals for waist-to-hip ratio (2 × NGT and 3 × prediabetes) and 3 individuals 
for plasma vitamin C (2 × NGT and 1 × prediabetes) 
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Figure 4.28. The RA of the class Actinobacteria (%) with plasma insulin concentrations. 
 
!
Figure 4.29. The RA of the class Actinobacteria (%) with plasma vitamin C concentrations. 
 
4.2.4.4.3 Family  
At the family-level, the RA of Ruminococcaceae was negatively associated with waist 
circumference (r=−0.279, p=0.030), waist-to-hip ratio (r=−0.329, p=0.013), and insulin 
(r=−0.265, p=0.029) (Table 4.25, Figures 4.30-4.32). There were no significant associations 
with gender, ethnicity or smoking history and the RA of Ruminococcaceae at the family-
level. 
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Table 4.25: Spearman’s correlation coefficients of Ruminococcaceae at the family-level associated 
with other characteristic(s) of the study population. 
Phylum;)Class;)Order;)Family) Firmicutes;"Clostridia;"Clostridiales;"
Ruminococcaceae"
Characteristics) rs(
Age) 0.077(
Anthropometry) (
Weight((kg)( 20.180(
BMI((kg/m2)( 20.155(
Waist(circumference((cm)( 20.279*(
Waist2to2hip(ratio(( 20.329*(
Fat(mass((%)( 20.094(
Lab)Measures) (
hs2CRP((mg/L)(( 20.110(
Total(cholesterol((mmol/L)( 0.015(
HDL2cholesterol((mmol/L)( 0.175(
LDL2cholesterol((mmol/L)( 20.035(
Triglycerides((mmol/L)( 20.246(
Cholesterol((total/HDL)(ratio( 20.173(
Fasting(insulin((pmol/L)( 20.265*(
Ghrelin((pmol/L)(( 0.064(
Leptin((ng/mL)(( 20.141(
Adiponectin((µg/mL)(( 0.114(
Plasma(vitamin(C((µmol/L)( 0.115(
*Significant at the 0.05 level, **significant at the 0.01 level 
There are missing data for 5 individuals for waist-to-hip ratio (2 × NGT and 3 × prediabetes) and 3 individuals 
for plasma vitamin C (2 × NGT and 1 × prediabetes). 
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Figure 4.30. RA of the family Ruminococcaceae (%) with waist circumference. 
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Figure 4.31. RA of the family Ruminococcaceae (%) with waist-to-hip ratio. 
 
!
Figure 4.32. RA of the family Ruminococcaceae (%) with plasma insulin concentrations. 
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(r=−0.355, p=0.005), and positively associated with HDL-cholesterol (r=0.292, p=0.022) 
(Table 4.26, Figure 4.34). The RA of Ruminococcaceae UCG-002 was also significantly 
lower in non-European compared to European participants (p=0.008) (Table 4.27, Figure 
4.34).  
The RA of Subdoligranulum was negatively associated with HDL-cholesterol (r=−0.275, 
p=0.032) and ghrelin (r=−0.262, p=0.041) and positively associated with triglycerides 
(r=0.345, p=0.006) and cholesterol (total/HDL) ratio (r=0.360, p=0.004) (Table 4.26, Figure 
4.35).  
Table 4.26: Spearman’s correlation coefficients of Dorea, Ruminococcaceae UCG-02 and 
Subdoligranulum at the genus-level associated with other characteristic(s) of the study population. 
Phylum;)Class;)Order;)Family)
Firmicutes;"
Clostridia;"
Clostridiales;"
Lachnospiraceae"
Firmicutes;"Clostridia;"Clostridiales;"
Ruminococcaceae"
Genus) Dorea" Ruminococcaceae"UCG;002" Subdoligranulum"
Characteristics) rs( rs( rs(
Age) 0.027( 0.038( 0.173(
Anthropometry) ( ( (
Weight((kg)( 0.311*( 20.263*( 0.058(
BMI((kg/m2)( 0.323*( 20.236( 0.075(
Waist(circumference((cm)( 0.324*( 20.249( 0.156(
Waist2to2hip(ratio(( 0.256( 20.293*( 0.130(
Fat(mass((%)( 0.238( 20.076( 0.040(
Lab)Measures) ( ( (
hs2CRP((mg/L)(( 0.175( 20.142( 20.018(
Total(cholesterol((mmol/L)( 0.018( 20.053( 0.046(
HDL2cholesterol((mmol/L)( 20.199( 0.292*( 20.275*(
LDL2cholesterol((mmol/L)( 0.037( 20.086( 0.066(
Triglycerides((mmol/L)( 0.283*( 20.333**( 0.345**(
Cholesterol((total/HDL)(ratio( 0.298*( 20.362**( 0.360**(
Fasting(insulin((pmol/L)( 0.439**( 20.355**( 0.209(
Ghrelin((pmol/L)(( 0.109( 0.233( 20.262*(
Leptin((ng/mL)(( 0.301*( 20.089( 0.060(
Adiponectin((µg/mL)(( 20.095( 0.224( 20.095(
Plasma(vitamin(C((µmol/L)( 20.235( 0.303*( 0.059(
*Significant at the 0.05 level, **significant at the 0.01 level 
There are missing data for 5 individuals for waist-to-hip ratio (2 × NGT and 3 × prediabetes) and 3 individuals 
for plasma vitamin C (2 × NGT and 1 × prediabetes). 
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Figure 4.33. Figures A-G show the RA of the genus Dorea (%) with weight, BMI, waist 
circumference, triglycerides, cholesterol (total/HDL) ratio, plasma insulin and leptin.   
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Table 4.27: RA of Ruminococcaceae UCG-02 at the genus-level with gender, ethnicity and smoking 
status. 
Phylum;)Class;)Order;)Family;)
Genus)
)
Characteristics)
Firmicutes;"Clostridia;"Clostridiales;"
Ruminococcaceae;""
Ruminococcaceae"UCG;002"
Sex)(n=61)) (
Female((n=38)( 1.0((0.522.7)(
Male((n=23)( 0.7((0.221.6)(
Ethnicity)(n=61)) (
Non2European((n=9)( 0.3((0.020.5)*(
European((n=52)( 1.0((0.622.5)(
Smoking)History)(n=53)) (
Current/ex2smoker((n=23)( 1.0((0.522.5)(
Non2smoker((n=30)( 1.0((0.322.7)(
Data presented as median and interquartile range (25th to 75th percentiles). *Significant at the 0.05 level from 
Mann Whitney U Test. 
There are missing data for 8 individuals for smoking history (4 × NGT and 4 × prediabetes) 
!
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Figure 4.34. Figures A-G show the RA of the genus Ruminococcaceae UCG-002 (%) with weight, 
waist-to-hip ratio, triglycerides, cholesterol (total/HDL) ratio, plasma insulin, HDL-cholesterol, and 
ethnicity. 
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Figure 4.35. Figures A-D show the RA of the genus Subdoligranulum (%) with HDL-cholesterol, 
ghrelin, triglycerides and cholesterol (total/HDL) ratio. 
4.2.4.5 Section two: part three, the gut microbiota and self-reported dietary intake  
4.2.4.5.1 Phylum 
The RA of the phylum Actinobacteria is positively associated with non-starchy vegetable 
intake (r=0.319, p=0.012) (Table 4.28, Figure 4.36).  
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Table 4.28: Spearman’s correlation coefficients of Actinobacteria at the phylum-level and daily 
dietary intake of the study population. 
Phylum) Actinobacteria"
Daily)Dietary)Intake) rs(
Energy((kJ)( 0.044(
Fibre((g)( 20.026(
Protein((%(of(energy)(( 0.001(
Protein((g)( 0.010(
Total(fat((%(of(energy)( 20.006(
Total(fat((g)( 20.010(
Saturated(fat((%(of(energy)( 20.024(
Saturated(fat((g)( 20.008(
Monounsaturated(fatty(acids((MUFA)((%(of(energy)( 20.072(
MUFA((g)( 20.031(
Polyunsaturated(fatty(acids((PUFA)((%(of(energy)( 0.075(
PUFA((g)( 0.054(
Total(carbohydrate((CHO)((%(of(energy)( 0.053(
Total(CHO((g)( 0.059(
Sugar((%(of(energy)( 20.113(
Sugar((g)( 20.094(
Starch((%(of(energy)( 0.216(
Starch((g)( 0.211(
Dietary(vitamin(C((mg)( 20.111(
Fresh(fruit((g)( 20.175(
Kiwifruit((g)( 20.184(
Total(fruit((g)( 20.220(
Total(vegetables((g)( 20.082(
Non2starchy(vegetables((g)( 0.346*(
Starchy(vegetables((g)( 20.066(
Total(fruit(and(vegetables((g)( 20.197(
Probiotics((g)( 20.055(
Grainy(foods((g)( 0.208(
Nuts(and(seeds((g)( 20.065(
*Significant at the 0.05 level.  
There are no missing data.  
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Figure 4.36. RA of the phylum Actinobacteria (%) with non-starchy vegetable intake. 
 
4.2.4.5.2 Class  
The RA of the class Actinobacteria is positively associated with non-starchy vegetable intake 
(r=0.319, p=0.012) (Table 4.29, Figure 4.37). !
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Table 4.29: Spearman’s correlation coefficients of Actinobacteria at the class-level and the daily 
dietary intake of the study population.  
Phylum;)Class) Actinobacteria;"Actinobacteria"
Daily)Dietary)Intake) rs(
Energy((kJ)( 0.025(
Fibre((g)( 20.014(
Protein((%(of(energy)(( 0.032(
Protein((g)( 0.041(
Total(fat((%(of(energy)( 20.047(
Total(fat((g)( 20.034(
Saturated(fat((%(of(energy)( 20.042(
Saturated(fat((g)( 20.023(
MUFA((%(of(energy)( 20.091(
MUFA((g)( 20.046(
PUFA((%(of(energy)( 0.008(
PUFA((g)( 0.008(
Total(CHO((%(of(energy)( 0.048(
Total(CHO((g)( 0.035(
Sugar((%(of(energy)( 20.123(
Sugar((g)( 20.114(
Starch((%(of(energy)( 0.212(
Starch((g)( 0.201(
Dietary(vitamin(C((mg)( 20.103(
Fresh(fruit((g)( 20.176(
Kiwifruit((g)( 20.189(
Total(fruit((g)( 20.226(
Total(vegetables((g)( 20.090(
Non2starchy(vegetables((g)( 0.319*(
Starchy(vegetables((g)( 20.075(
Total(fruit(and(vegetables((g)( 20.212(
Probiotics((g)( 20.033(
Grainy(foods((g)( 0.248(
Nuts(and(seeds((g)( 20.029(
*Significant at the 0.05 level, ** significant at the 0.01 level 
There are no missing data. 
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Figure 4.37. RA of the class Actinobacteria (%) with non-starchy vegetable intake 
 
4.2.4.5.3 Family 
The RA of the family Ruminococcaceae was positively associated with kiwifruit intake 
(r=0.322, p=0.011) (Table 4.30, Figure 4.38). 
  
0 1 0 0 2 0 0 3 0 0 4 0 0
0
1 0
2 0
3 0
4 0
N o n - S t a r c h y  V e g e t a b le  I n t a k e  ( g / d a y )
R
A
 o
f 
 C
la
s
s
A
c
ti
n
o
b
a
c
te
ri
a
 (
%
)
r = 0 . 3 1 9 ,  p = 0 . 0 1 2
! 162!
Table 4.30: Spearman’s correlation coefficients of Ruminococcaceae at the family-level and the daily 
dietary intake of the study population. 
Phylum;)Class;)Order) Firmicutes;"Clostridia;"Clostridiales;"
Family) Ruminococcaceae"
Daily)Dietary)Intake) rs(
Energy((kJ)( 0.027(
Fibre((g)( 0.132(
Protein((%(of(energy)(( 0.092(
Protein((g)( 0.055(
Total(fat((%(of(energy)( 0.115(
Total(fat((g)( 0.115(
Saturated(fat((%(of(energy)( 0.072(
Saturated(fat((g)( 0.064(
MUFA((%(of(energy)( 0.118(
MUFA((g)( 0.125(
PUFA((%(of(energy)( 20.092(
PUFA((g)( 20.004(
Total(CHO((%(of(energy)( 20.114(
Total(CHO((g)( 20.128(
Sugar((%(of(energy)( 20.110(
Sugar((g)( 20.094(
Starch((%(of(energy)( 20.175(
Starch((g)( 20.137(
Dietary(vitamin(C((mg)( 0.227(
Fresh(fruit((g)( 0.095(
Kiwifruit((g)( 0.322*(
Total(fruit((g)( 0.095(
Total(vegetables((g)( 0.234(
Non2starchy(vegetables((g)( 20.165(
Starchy(vegetables((g)( 20.084(
Total(fruit(and(vegetables((g)( 0.237(
Probiotics((g)( 0.224(
Grainy(foods((g)( 20.147(
Nuts(and(seeds((g)( 0.099(
*Significant at the 0.05 level.  
There are no missing data.  
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Figure 4.38. RA of the family Ruminococcaceae (%) with kiwifruit intake. 
 
4.2.4.5.4 Genus 
The RA of the genus Ruminococcaceae UCG-002, is positively associated with dietary 
vitamin C (r=0.276, p=0.031) and probiotic intake (r=0.298, p=0.020) (Table 4.31, Figure 
4.39). 
The RA of the genus Subdoligranulum is negatively associated with kiwifruit consumption 
(r=−0.265, p=0.039) (Table 4.31, Figure 4.39). 
The RA of the genus Dorea is negatively associated with fibre (r=−0.288, p=0.024), total 
vegetable (r=−0.453, p<0.001), total fruit and vegetable (r=−0.318, p=0.012) and probiotic 
intake (r=−0.340, p=0.007) (Table 4.31, Figure 4.39). 
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Table 4.31: Spearman’s correlation coefficients of Dorea, Ruminococcaceae UCG-02 and Subdoligranulum at the genus-level and the daily dietary intake of the 
study population. 
Phylum;(Class;(Order;(Family(
Firmicutes;Clostridia;Clostridiales;0
Lachnospiraceae;0
Firmicutes;Clostridia;Clostridiales;0
Ruminococcaceae;0
Genus( Dorea0 Ruminococcaceae0UCG90020 Subdoligranulum0
Daily(Dietary(Intake! rs! rs! rs!
Energy!(kJ)! -0.008! -0.036! -0.022!
Fibre!(g)! -0.288*! 0.019! 0.056!
Protein!(%!of!energy)!! 0.048! 0.059! -0.010!
Protein!(g)! 0.030! 0.029! 0.000!
Total!fat!(%!of!energy)! 0.068! 0.001! -0.046!
Total!fat!(g)! -0.021! 0.030! -0.054!
Saturated!fat!(%!of!energy)! 0.073! -0.027! -0.201!
Saturated!fat!(g)! 0.032! -0.031! -0.130!
MUFA!(%!of!energy)! 0.032! 0.037! -0.048!
MUFA!(g)! -0.019! 0.056! -0.046!
PUFA!(%!of!energy)! -0.059! -0.033! 0.212!
PUFA!(g)! -0.104! 0.008! 0.096!
Total!CHO!(%!of!energy)! -0.121! -0.040! 0.102!
Total!carbohydrate!(g)! 0.039! -0.213! 0.027!
Sugar!(%!of!energy)! 0.005! 0.021! -0.021!
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Phylum;(Class;(Order;(Family(
Firmicutes;Clostridia;Clostridiales;0
Lachnospiraceae;0
Firmicutes;Clostridia;Clostridiales;0
Ruminococcaceae;0
Genus( Dorea0 Ruminococcaceae0UCG90020 Subdoligranulum0
Sugar!(g)! 0.087! -0.042! -0.067!
Starch!(%!of!energy)! -0.200! -0.120! 0.120!
Starch!(g)! -0.069! -0.215! 0.047!
Dietary!vitamin!C!(mg)! -0.171! 0.276*! -0.086!
Fresh!fruit!(g)! -0.079! 0.109! 0.065!
Kiwifruit!(g)! -0.030! 0.181! -0.265*!
Total!fruit!(g)! -0.056! 0.065! 0.082!
Total!vegetables!(g)! -0.453**! 0.210! -0.074!
Non-starchy!vegetables!(g)! -0.137! -0.163! -0.111!
Starchy!vegetables!(g)! -0.167! 0.006! 0.020!
Total!fruit!and!vegetables!(g)! -0.318*! 0.163! -0.005!
Probiotics!(g)! -0.340**! 0.298*! -0.003!
Grainy!foods!(g)! -0.126! -0.134! 0.150!
Nuts!and!seeds!(g)! -0.105! 0.022! 0.062!
*Significant at the 0.05 level, **significant at the 0.01 level 
There are no missing data 
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Figure 4.39. Figures A-B show the RA of the genus Ruminococcaceae UCG-002 (%) with dietary 
vitamin C and probiotic intake, Figure C shows the RA of the genus Subdoligranulum (%) with 
kiwifruit intake and Figures D-G show the RA of Dorea (%) with fruit, total vegetable, total fruit and 
vegetable and probiotic intake. 
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4.2.5 Multiple Regression Analysis 
To identify whether there is an independent association of fasting glucose with the RA of the 
phylum Actinobacteria, class Actinobacteria, family Ruminococcaceae and genera Dorea,-
Ruminococcaceae-UCG1002-and-Subdoligranulum, multiple regression analyses were 
undertaken using variables (demographic, anthropometric, laboratory measures, dietary 
intake) that showed significant univariate associations with the RA of these bacteria.!
4.2.5.1 Phylum 
From the univariate analyses above, fasting glucose, insulin, plasma vitamin C, weight and 
non-starchy vegetable intake were significantly associated with the RA of the phylum 
Actinobacteria. Multiple regression analysis indicated that fasting glucose (p=0.018) and 
plasma vitamin C concentration (p=0.026) are independently associated with the RA of the 
phylum Actinobacteria (Table 4.32). Fasting glucose was positively associated and, in 
contrast, plasma vitamin C concentration was negatively associated with the RA of the 
phylum Actinobacteria (Table 4.32).   
Table 4.32: Multiple regression analysis showing significant associations with the RA of the phylum 
Actinobacteria.   
Measure' B' Lower'95%'CI' Upper'95%'CI' p''
Fasting(glucose( 0.022( 0.004( 0.040( 0.018(
Plasma(vitamin(C( 80.001( 80.003( 0.000( 0.026(
B: coefficient from the multiple linear regression model. 
 
4.2.5.2 Class 
From the univariate analyses above, glucose, insulin, plasma vitamin C and non-starchy 
vegetable intake were significantly associated with the RA of the class Actinobacteria. 
Multiple regression analysis indicated that fasting glucose (p=0.018) and plasma vitamin C 
(p=0.035) are independently associated with the RA of the class Actinobacteria (Table 4.33). 
Fasting glucose was positively associated and in contrast plasma vitamin C concentration was 
negatively associated with the RA of the class Actinobacteria (Table 4.33).    
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Table 4.33: Multiple regression analysis showing significant associations with the RA of the class 
Actinobacteria.   
Measure' B' Lower'95%'CI' Upper'95%'CI' p'
Fasting(glucose( 0.021( 0.004( 0.039( 0.018(
Plasma(vitamin(C( 80.001( 80.002( 0.000( 0.035(
B: coefficient from the multiple linear regression model. 
 
4.2.5.3 Family 
From the univariate analyses fasting glucose groups, waist circumference, waist-to-hip ratio, 
insulin and kiwifruit intake were significantly (p<0.05) associated with the RA of the family 
Ruminococcaceae. Multiple regression analysis indicated that fasting glucose groups 
(p=0.021) and waist-to-hip ratio (p=0.013) are independently associated with the RA of the 
family Ruminococcaceae (Table 4.34). The RA of the family Ruminococcaceae is 
significantly lower in the T2DM group compared with the NGT and prediabetes groups 
(Table 4.34). Waist-to-hip ratio is negatively associated with the RA of the family 
Ruminococcaceae (Table 4.34).  
Table 4.34: Multiple regression analysis showing significant associations with the RA of the family 
Ruminococcaceae.   
Measure' B' Lower'95%'CI' Upper'95%'CI' p'
Fasting(glucose(groups*1( 0.078( 0.020( 0.137( 0.010(
Fasting(glucose(groups*2( 0.082( 0.022( 0.141( 0.008(
Waist8to8hip(ratio( 80.258( 80.458( 80.057( 0.013(
B: coefficient from the multiple linear regression model. 
* By comparison with reference group T2DM where 1 = NGT and 2 = prediabetes 
 
4.2.5.4 Genus 
From the univariate analyses fasting glucose groups, weight, BMI, waist circumference, 
triglycerides, cholesterol (total/HDL) ratio, insulin, leptin, fibre, total vegetable, total fruit and 
vegetable and probiotic intake were significantly (p<0.05) associated with the RA of the 
genus Dorea. Multiple regression analysis indicated that fasting glucose groups (p<0.001) and 
total vegetable intake (p=0.001) are independently associated with the RA of the genus Dorea!
(Table 4.35). The RA of the genus Dorea is significantly higher in the T2DM compared to the 
NGT and prediabetes groups. Total vegetable intake was negatively associated with the RA of 
the genus Dorea.   
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Table 4.35: Multiple regression analysis showing significant associations with the RA of the genus 
Dorea.   
Measure' B' Lower'95%'CI' Upper'95%'CI' p'
Fasting(glucose(groups*1( 80.031( 80.043( 80.018( <0.001(
Fasting(glucose(groups*2( 80.026( 80.039( 80.013( <0.001(
Total(vegetable(intake( 80.000( 80.000( 80.000( 0.001(
B: coefficient from the multiple linear regression model. 
* By comparison with reference group T2DM where 1 = NGT and 2 = prediabetes 
 
From the univariate analyses above, fasting glucose, weight, waist-to-hip ratio, HDL-
cholesterol, triglycerides, cholesterol (total/HDL) ratio, insulin, plasma vitamin C, ethnicity, 
dietary vitamin C and probiotic intake were significantly (p<0.05) associated with the RA of 
the genus Ruminococcaceae UCG-002. Multiple regression analysis indicated that fasting 
glucose (p=0.013) and probiotic intake (p=0.046) are independently associated with the RA of 
the genus Ruminococcaceae-UCG1002!(Table 4.36). Fasting glucose was negatively 
associated and in contrast probiotic intake was positively associated with the RA of the genus 
Ruminococcaceae-UCG1002.  
Table 4.36: Multiple regression analysis showing significant associations with the RA of the genus 
Ruminococcaceae UCG-002.   
Measure' B' Lower'95%'CI' Upper'95%'CI' p'
Fasting(glucose( 80.004( 80.008( 80.001( 0.013(
Probiotic(intake( 0.000( 0.000( 0.000( 0.046(
B: coefficient from the multiple linear regression model. 
 
From the univariate analyses fasting glucose groups, HDL-cholesterol triglycerides, 
cholesterol (total/HDL) ratio, ghrelin and kiwifruit were significantly (p<0.05) associated 
with the RA of the genus Subdoligranulum. Multiple regression analysis indicated that 
fasting glucose groups (p=0.046) and cholesterol (total/HDL) ratio (p<0.001) are 
independently associated with the RA of the genus Subdoligranulum-(Table 4.37). The RA of 
the genus Subdoligranulum is significantly lower in the T2DM group compared with the NGT 
and prediabetes groups. The cholesterol (total/HDL) ratio is positively associated with the RA 
of the genus Subdoligranulum. 
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Table 4.37: Multiple regression analysis showing significant associations with the RA of the genus 
Subdoligranulum.   
Measure' B' Lower'95%'CI' Upper'95%'CI' p'
Fasting(glucose(groups*1( 0.024( 0.003( 0.045( 0.026(
Fasting(glucose(groups*2( 0.027( 0.006( 0.049( 0.015(
Cholesterol((total/HDL)(ratio( 0.014( 0.006( 0.021( <0.001(
B: coefficient from the multiple linear regression model. 
* By comparison with reference group T2DM where 1 = NGT and 2=prediabetes 
 
4.3 Discussion 
This is the first study to investigate associations between the gut microbiota and glycaemic 
control and other indicators of metabolic health in participants who have been well-
characterised and have provided detailed dietary data. This study is also novel because it 
investigates these relationships across the spectrum of glycaemic control rather than just those 
defined as having NGT and T2DM. Associations of both taxonomy and diversity are reported.  
4.3.1 Self-Reported Dietary Intake  
The average daily dietary intake of macronutrients in the present study were similar to the 
results from the CHALICE cohort (Chapter three), with slight variances potentially due to 
differences in the methods used to collect the dietary data (weighed versus estimated food 
diary):  
• energy intake for those with NGT (8,997 kJ versus 8,372 kJ), prediabetes (9,681 kJ 
versus 8,268 kJ) and T2DM (8,928 kJ versus 8,479 kJ) 
• fibre intake for those with NGT (26 g versus 25 g), prediabetes, (26 g versus 25 g) and 
T2DM (25 g versus 24 g) 
• protein intake (as % of energy) for those with NGT (18% versus 17%), prediabetes (18% 
for both studies) and T2DM (18% versus 16%) 
• total fat intake (as % of energy) for those with NGT (35% versus 37%), prediabetes (35% 
versus 39%) and T2DM (35% versus 39%) 
• total carbohydrate intake (as % of energy) for those with NGT (46% versus 44%), 
prediabetes (47% versus 40%) and T2DM (47% versus 41%) 
Consistent with results from the CHALICE cohort and the entire cohort for the MHCSS 
(Chapter four, Section one), BMI was higher in the prediabetes and T2DM groups compared 
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with the NGT group, despite there being no significant difference in total energy intake across 
the study groups. It was estimated that a greater percentage of those in the prediabetes (11% 
higher than the NGT group) and T2DM (38% higher than the NGT group) groups were 
under-reporting their dietary intake. This is a potential limitation of the dietary intake data, 
particularly for the T2DM group. If social desirability influenced under-reporting, the food 
groups mainly affected would be those considered to be ‘unhealthy’ such as foods and 
beverages high in fat and/or sugar. There are also several other possible explanations for this 
observation other than the individuals under-reporting. For example, those individuals 
estimated to be under-reporting could have been currently dieting. It is possible that the 
individuals with prediabetes were highly motivated and were currently dieting in order to 
prevent developing T2DM. There are also other possible explanations such as individuals 
may have had a genetic predisposition to obesity (231, 232) and recent research has also 
suggested the energy prediction equations overestimate the energy requirements more for 
obesity-susceptible individuals (217). 
In the present study, the dietary intake of macronutrients across the study groups was similar 
with only a significantly lower consumption of sugar (sum of the free individual 
monosaccharides (glucose, fructose) and disaccharides (lactose, maltose, and sucrose)) as a 
percentage of energy consumed in those with prediabetes compared to NGT. 
This similarity in diet may in part explain why there were few significant associations seen 
with the gut microbiota and dietary intake, as previous research has often investigated the gut 
microbiota in populations with marked differences in diet (107, 109, 110).  
4.3.2 The Gut Microbiota and Glycaemic Control  
In agreement with the hypothesis for this study, the RAs of the phylum Actinobacteria, class 
Actinobacteria, family Ruminococcaceae and genera Dorea, Subdoligranulum and 
Ruminococcaceae UCG-002 were found to be independently associated with glycaemic 
control as detailed below.  
4.3.2.1 Taxonomy results 
4.3.2.1.1 Phylum and class 
In this study population, at the phylum-level Firmicutes and Bacteroidetes were the dominant 
taxa comprising 76% and 10% of all bacterial taxa detected respectively. Previous researchers 
have also reported these to be the dominant phyla when investigating the gut microbiota and 
glycaemic control (97, 181). 
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Researchers investigating the gut microbiota and T2DM and obesity often report associations 
with the ratio of Firmicutes and Bacteroidetes due to earlier findings in rodent studies 
reporting the RA of Firmicutes to Bacteroidetes to be higher in obese than lean mice (92, 94, 
167). However, the association seen in rodent studies has not been consistently reported in 
human studies, which are equivocal. Schwiertz et al. (174) reported a lower ratio of 
Firmicutes to Bacteroidetes in overweight (p=0.001) and obese volunteers (p=0.005) 
compared to lean volunteers. Zhang et al. (97) reported no relationship between the ratio of 
Bacteroidetes to Firmicutes and plasma glucose concentration, whereas Larsen et al. (95) 
found that the ratio of Bacteroidetes to Firmicutes was significantly positively correlated with 
reduced glucose tolerance. Although not significant, the current study showed the RA of 
Bacteroidetes and Firmicutes was lower in the T2DM group compared to those with NGT and 
prediabetes. Larsen et al. (95) also reported the RA of Firmicutes to be lower (p=0.03) in 
those with T2DM compared to those with NGT. 
When comparing the study groups at the phylum- and class-level, Actinobacteria were found 
to have a significantly greater RA in those with T2DM compared to those with NGT and 
prediabetes. Multiple regression analysis showed both fasting glucose and plasma vitamin C 
concentration to be independently associated with the RA of the phylum and class 
Actinobacteria. Fasting glucose was found to be positively associated, and in contrast, plasma 
vitamin C concentration was found to be negatively associated, with the RA of the phylum 
and class Actinobacteria. 
This association was not further explored at the family- or genus-level as the class 
Actinobacteria did not split into multiple orders, families or genera in this dataset. 
Bifidobacterium was the only genus present in the class Actinobacteria. Although there could 
have been other genera included within the phylum, which were not analysed due to having 
very low RA, Bifidobacterium was the most dominant genus and so it is most likely to be 
driving the associations seen at the class-level. 
Results from the current study are also consistent with Sasaki et al. (265) who demonstrated a 
significantly increased Bifidobacterium population in those with T2DM compared to healthy 
individuals; however, the result is inconsistent with Wu et al. (181) who reported 
Bifidobacterium to be less prevalent in the microbiota of those with T2DM compared to NGT.  
Bifidobacterium are Gram-positive, non-sporulating, anaerobic rods (266). A critical feature 
of this genus is their ability to metabolize a variety of carbohydrates encountered in the GT 
tract, including oligosaccharides (266). Bifidobacteria is one of the most commonly used 
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strains in probiotic foods and supplements and is thought to have anti-inflammatory properties 
(118). In this study, probiotic consumption did not explain the increase in the genus 
Bifidobacterium (from the class Actinobacteria) found in those with T2DM. Participants who 
reported taking a probiotic capsule were excluded from the analyses and there were no 
participants in the T2DM group who reported consuming probiotic yoghurts or beverages.  
It is speculated that pathological changes related to T2DM may have affected the bowel 
ecosystem. Zeevi et al. (147) investigated factors affecting interpersonal differences in 
postprandial glycaemic responses and found associations between the postprandial response 
to the standardised meals and the gut microbiota of individuals. They reported the RAs of 
Actinobacteria to be positively associated with the postprandial glucose response to both 
glucose and bread. Results from the current study also showed a positive association with 
Actinobacteria and fasting glucose, and HbA1c with the latter also taking into account 
postprandial glucose levels. Therefore, further investigation into postprandial glucose and the 
RA of Actinobacteria may help explain the association seen in this study.  
The phylum and class Actinobacteria were also negatively associated with plasma vitamin C 
concentrations and, although not significant, were also negatively associated with total fruit 
and total fruit and vegetable intake. Although plasma vitamin C is a biomarker for dietary 
vitamin C, differences in intake and plasma results may be due to plasma vitamin C also 
taking into account supplements and utilization of vitamin C and it is not reliant on 
participant’s recall of their diet. Wu et al. (108) found high levels of the phylum 
Actinobaceria to be associated with a high-fat, low-fibre diet, which is likely to represent a 
diet low in fruit and vegetables.  
4.3.2.1.2 Family 
At the family-level, the RA of Ruminococcaceae was found to have a significantly lower RA 
in those with T2DM compared to those with NGT and prediabetes. This association has not 
been previously reported. A similar pattern was seen in the correlation of Ruminococcaceae 
and fasting glucose but was not statistically significant. Multiple regression analysis showed 
both fasting glucose groups and waist-to-hip ratio to be independently associated with the RA 
of the family Ruminococcaceae. As waist-to-hip ratio increased, the RA of the family 
Ruminococcaceae decreased. This is consistent with previous research, as Beaumont et al. 
(267) have also shown Ruminococcaceae to be negatively associated with visceral adiposity. 
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4.3.2.1.3 Genus 
The genera Dorea, Ruminococcaceae UCG-002 and Subdoligranulum were found to be 
independently associated with fasting glucose. The independent associations seen in this study 
at the genus-level have not been previously reported in the literature. 
The RA of Dorea was higher in those with T2DM compared to those with prediabetes and 
NGT. The RA of Dorea was also found to be independently associated with vegetable intake. 
A lower intake of vegetables was associated with an increased RA of Dorea.  
The RA of Ruminococcaceae UCG-002 was found to be negatively associated with fasting 
glucose. The RA of Ruminococcaceae UCG-002 was also found to be independently 
associated with probiotic intake. A higher RA of Ruminococcaceae UCG-002 was associated 
with a greater intake of probiotics.  
The RA of Subdoligranulum was lower in those with T2DM than those with prediabetes and 
NGT. The RA of Subdoligranulum was also found to be independently associated with 
cholesterol (total/HDL) ratio. A higher RA of Subdoligranulum was associated with an 
increased cholesterol (total/HDL) ratio.  
4.3.3 Metformin and the Gut Microbiota 
When individuals with a previous diagnosis of T2DM taking metformin were included in the 
correlation of fasting glucose with the RA of the phylum Actinobacteria, the correlation is no 
longer significant. This is due to low levels of Actinobacteria in the T2DM group taking 
metformin. This may be due to the fasting glucose levels of the metformin groups being 
therapeutically lowered, or the presence of metformin may be impacting the RA of bacteria 
from the phylum Actinobacteria.  
Previous research in both animal and human studies suggests that some beneficial effects of 
metformin on glucose metabolism may be microbially mediated (112, 160, 161). However, 
the exact mechanism(s) has not been determined as the bacteria found to be associated, and 
thus the proposed mechanisms, differ between studies.  
Wu et al. (261) reported an increase in the abundance of Bifidobacterium with the 
commencement of metformin individuals with treatment-naïve T2DM and in the current 
study Bifidobacterium was the most dominant genus for the phylum Actinobacteria. 
A number of studies have reported a higher RA of Akkermansia muciniphila (known for 
mucin degrading) in those with T2DM taking metformin (162, 261), and also in rodent studies 
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(160, 163). In contrast, in the current study the RA of Verrucomicrobia, for which 
Akkermansia was the only genus, was lower in those with T2DM taking metformin compared 
to those with T2DM not taking metformin, although this was not statistically significant.  
Although not seen in the current study, Zhernakova et al. (112) reported an increased 
abundance of Escherichia coli in those with T2DM using metformin (n=15) compared to 
those with T2DM not using metformin (n=9) and found that metformin can affect the 
microbiome through SCFA production with concentrations of SCFAs and in particular 
propionate being significantly higher in metformin users.   
A recent study included a reanalysis of two other studies (784 available human gut 
metagenomes) also showed that neglecting to control for antidiabetic medication can 
confound results (164). Therefore, those taking metformin in the current study were excluded 
for the microbiota analyses. 
4.3.3.1 Diversity results 
Alpha diversity measures the biodiversity within a sample. It measures the number of species 
present (richness), and some metrics also incorporate a measure of the RA of each species 
(evenness). Although there was some suggestion of reduced diversity seen in those with 
T2DM compared to those with NGT and prediabetes, this was not statistically significant for 
any of the diversity measures, which is consistent with previous studies (95, 97, 181). There is 
considerable inter-individual variation in the gut microbiota, and it has been suggested that 
most studies do not have a large enough sample size (sufficient power) to detect significant 
differences in diversity (175).  
4.3.3.2 Butyrate-producing bacteria 
Previous research shows a lower abundance of butyrate-producing bacteria in those with 
T2DM (22, 96, 97). For example, Qin et al. (22) and Karlsson et al. (96) reported a lower 
abundance of the butyrate-producing species Roseburia intestinalis and F. prauznitzii in 
T2DM groups. In the current study, no difference was found in prevalence of the genus 
Roseburia or Faecalbacterium according to fasting glucose concentrations. Zhang et al. (97) 
reported a lower abundance of the class Verrucomicrobiae and the butyrate-producing species 
Akkermansia municiphila in those with prediabetes compared to NGT. However, in the 
current study the RA of Verrucomicrobia was low and was not related to glycaemic control, 
and so was not presented in the main results (Appendix C).  
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There is limited literature on the gut microbiota and T2DM/glycaemic control for comparison 
of results from this study, and furthermore the reported results are inconsistent. This 
inconsistency may be explained by small study cohorts and variability in the methodology: 
• Previous studies report limited information on other factors that may be impacting the 
gut microbiota, such as dietary intake, lifestyle and medications. For example, Zhang 
et al. (97) and Larsen et al. (95) reported no information on dietary intake.  
• Previous research employs different exclusion criteria, such as those relating to 
concomitant gastrointestinal diseases, medications, prebiotics and length of time since 
probiotic and antibiotic use. For example, Sato et al. (165) excluded those using 
antibiotics within three months of the study and did not exclude participants based on 
probiotic use, in contrast to Zhang et al. (97), who excluded those taking probiotics 
and antibiotics within one month of the study.  
• Researchers have also used a variety of different methods to extract and sequence the 
genomic DNA, and bioinformatics and statistical methods have also differed, making 
it difficult to compare results. For example, Wu et al. (181) used PCR-denaturing 
gradient gel electrophoresis (DGGE) and Zhang et al. (97) used 16S rDNA-based 
high-throughput sequencing.  
• A complication of investigating the progression to T2DM is the disagreement in 
diagnostic values and tests worldwide for diagnosing people with prediabetes and 
T2DM. For example, the WHO and ADA recommend different diagnostic values for 
prediabetes (23, 26). Furthermore, researchers to date have used a variety of diagnostic 
thresholds and a variety of tests to classify their participants, including fasting glucose, 
HbA1c and the OGTT. For instance, Sato et al. (165) used HbA1c whereas Larsen et 
al. (95) used an OGTT. One possible solution for this issue is to look at the actual 
fasting glucose and HbA1c concentrations (continuous variables) and test for 
associations of these with the RA of the gut microbiota, as was done in this study, thus 
avoiding problems with worldwide discrepancies in cut-off values used to group 
participants.  
• A further consideration when studying the content of the microbiota is the use of 
antihyperglycaemic agents to improve glycaemic control, like metformin, a common 
drug that impacts the gut microbiota, used to treat those with T2DM (161, 162, 164, 
261). Zhang et al. (97) excluded those taking antihyperglycaemic agents and Sato et 
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al. (165) reported a variety of antihyperglycaemic agents to be used by participants in 
their study. 
4.3.4 Study Strengths  
The study used robust methodology, the population was metabolically well-characterised 
(age, sex, ethnicity, education, physical activity, anthropometry, smoking status, glycaemic 
measures, inflammatory marker, lipids and metabolic hormones), and the study accounted for 
other factors known to impact the gut microbiota such as gastrointestinal disease, metformin, 
antibiotic and probiotic use and dietary intake.  
This was an exploratory study with participants selected to provide variability in glycaemic 
control. The weighed food diary used in this study allows for precision of portion sizes.  
4.3.5 Study Limitations 
4.3.5.1 Cohort size 
This study had a relatively small study cohort of 61 participants. There were limited numbers 
of treatment-naïve participants with high fasting glucose levels meeting the diagnostic criteria 
for T2DM (n=6), as the majority of individuals with T2DM commence metformin therapy at 
diagnosis. This means the statistical power may not be sufficient to identify some clinically 
relevant associations with the gut microbiota, particularly amongst those with high fasting 
glucose. The differences in the gut microbiota seen between those with T2DM and the larger 
study groups (NGT and prediabetes) need to be validated in a larger study population. The 
very low numbers of non-European individuals (n=9) may also be influencing associations of 
the RA of bacteria with ethnicity. 
4.3.5.2 Blood pressure 
A limitation of the blood pressure results in this study is that only one measure was made for 
some individuals, as often the first measurement can be higher. Ideally three measurements 
should be taken and the last two measurements averaged.    
4.3.5.3 Dietary intake  
As mentioned in the discussion, there was a greater percentage of individuals estimated to be 
under-reporting their dietary intake in the prediabetes and T2DM groups compared to those in 
the NGT group. This is a potential limitation of the dietary intake data; however, there are 
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also other possible explanations for this observation, as recent research has also suggested the 
energy prediction equations overestimate the energy requirements more for obesity-
susceptible individuals (217). It is also possible that the individuals with prediabetes and 
T2DM were highly motivated and were currently dieting in order to manage or prevent 
developing T2DM.  
4.3.5.4 Statistical analyses 
The combination of the number of OTUs and the number of parameters explored in relation to 
these OTUs is very large in the current study (approximately 1530). Given this large number 
of statistical tests, it is highly likely that many of the statistically significant results represent 
Type I errors. For this reason, significant associations found from the univariate analyses 
were subject to multiple regression analyses to determine independent associations. 
Furthermore, conclusions from this study are based on associations seen at the higher 
taxonomic levels (phylum and class).  
4.4 Conclusions 
Results from this study suggest that participants with T2DM have a significantly greater RA 
of the phylum and class Actinobacteria compared to those with NGT or prediabetes. It is 
possible that this may be associated with higher postprandial glucose levels in those with 
T2DM.  A greater RA of the phylum and class Actinobacteria was also independently 
associated with a lower level of plasma vitamin C and although non-significant was also 
negatively associated with self-reported fruit and vegetable intake.  
4.5 Future Research 
This was a pilot exploratory study and a larger cohort is required to validate the findings. This 
research focused on characterising the gut microbiota, and so further research is required to 
investigate the function/metabolites of the bacteria. The next step would be investigating 
whether there is something different about the bowels of those with T2DM that influences the 
gut microbiota, such as promoting an increased RA of Actinobacteria. As previous research 
has shown Actinobacteria to be associated with postprandial glucose, this is one possible area 
that could be investigated further.  
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 Chapter Five: Kiwifruit Intervention  
Study (KIS) 
Section One: KIS–Gut Microbiota  
5.1 Background 
Hyperglycaemia (elevated blood glucose concentrations) and insulin resistance are implicated 
in the pathogenesis of micro- and macrovascular complications (139). Maintaining normal 
blood glucose levels through diet is one of the main goals in the management of a glucose 
metabolism disorder (diabetes or prediabetes) (48). Virtually all fruits represent a source of 
sugars, and therefore moderate consumption is recommended in people with T2DM.  
However, there are differing amounts of sugar and other nutrients in various fruit, and portion 
sizes vary markedly.  
Kiwifruit (originally known as Chinese gooseberry) is the genus Actinida. Despite the name, 
kiwifruit are not native to New Zealand, with seeds brought to New Zealand from China in 
1904. Most New Zealand kiwifruit is now marketed under the brand name Zespri. The 
kiwifruit used in this study are marketed as Zespri SunGold kiwifruit and the species is 
Actinidia chinesis var chinesis. 
Kiwifruit, eaten as a whole fruit, have a low glycaemic impact and are therefore thought to be 
a suitable choice for those with diabetes (145). Zespri SunGold kiwifruit has a glycaemic 
index (GI) of 38 (268). Furthermore, kiwifruit have been shown to reduce the amplitude of 
the postprandial blood glucose ‘spike’ when eaten with a wheat biscuit cereal, independent of 
available carbohydrate composition (142). This research suggests that replacing some 
carbohydrate at breakfast with kiwifruit may improve the acute blood glucose response in 
healthy people; however, longer term research needs to be carried out to investigate the effect 
of kiwifruit consumption on glycaemic control. Researchers have proposed several potential 
mechanisms as to how non-carbohydrate kiwifruit components, such as cell wall remnants,  
reduce the postprandial response to the breakfast cereal, possibly contributing through their 
effects on diffusion and mixing in the gut (269). In addition to investigating the mechanisms 
involved, further research needs to be carried out on those who are free-living and are glucose 
intolerant.  
In addition to having a positive effect on glycaemic control, gold kiwifruit contain dietary 
fibre (1.4 g/100 g in raw Zespri SunGold kiwifruit) (270) and polyphenols which resist 
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digestion by human enzymes and are degraded by bacteria in the digestive tract, stimulating 
the growth or activity of certain bacteria in the colon. The fibre in kiwifruit comprises both 
soluble (for example, pectin) and insoluble (for example, hemicelluloses and celluloses) 
components which make up cell walls (132).  
T2DM has been reported to be associated with an alteration in the usual balance of bowel 
bacterial species, described as a bacterial dysbiosis (22). Differences in the gut microbiota 
have been demonstrated between individuals with T2DM and healthy individuals in Chapter 
four and in previous research (95, 96). Further, the finding of differences in gut microbiota 
between healthy individuals, individuals with prediabetes, and those with T2DM suggest a 
potential association between gut ecology and the progression from normal glucose tolerance 
to T2DM (97). A logical extension is the hypothesis that manipulation, by dietary change, of 
the RAs of particular bacterial taxa within the gut microbiota could play a role in managing 
T2DM (260). 
On the basis of in vitro experiments, it has been speculated that SunGold Kiwifruit 
consumption may affect the composition and functioning of the bowel microbiota (138, 271). 
However, the outcomes of this study need to be confirmed in human intervention studies.  
SunGold kiwifruit are also one of the best sources of vitamin C (161.3 mg/100g) among fruit 
and vegetables (270). Regular consumption of two SunGold kiwifruit has been shown to 
significantly increase the plasma vitamin C levels in men with inadequate levels of plasma 
vitamin C (195).  
Results from Chapters three and four showed that those with prediabetes and T2DM have 
lower plasma vitamin C levels. Since hyperglycaemia is associated with increased oxidative 
stress, a role for antioxidants such as vitamin C in the prevention of T2DM and/or the 
reduction of complications is a reasonable proposition. However, there have been mixed 
findings reported in randomised controlled trials (RCTs) of supplementation with vitamin C 
on glycaemic control and insulin sensitivity (272-274).  
A recent meta-analysis of 15 RCTs investigating vitamin C supplementation and insulin 
resistance and biomarkers of glycaemic control (fasting glucose, HbA1c) found that doses of 
≥200 mg/day vitamin C significantly reduced fasting glucose concentrations in patients with 
T2DM, particularly if the intervention was for more than 30 days and in older individuals 
(252). Furthermore, a recent 12-month RCT found that treating those with T2DM with both 
metformin and vitamin C was more effective at reducing HbA1c and risk factors for diabetes-
related long-term complications than treating with metformin alone (253). 
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SunGold kiwifruit consumption could, therefore, manipulate gut ecology, increase plasma 
vitamin C concentrations, and reduce the postprandial response to a carbohydrate-containing 
meal to improve glycaemic control or to prevent deterioration of glucose intolerance.  
5.2 Aims and Hypotheses 
The aim of this study was to investigate the effect of consuming two SunGold kiwifruit per 
day over 12 weeks on vitamin C status, clinical and anthropometric measures and faecal 
microbiota composition in people with prediabetes.  
It is hypothesised that:  
• There will be no change in glycaemic control in people with prediabetes consuming 
two SunGold kiwifruit per day over 12 weeks in a free-living situation.  
• The consumption of two SunGold kiwifruit per day will alter the gut microbiota 
composition in people with prediabetes in a free-living situation.   
5.3 Protocol 
5.3.1 Study Participants 
The study was approved by the Southern Health and Disability Ethics Committee (consent no. 
16/STH/87) and was included in the Australian New Zealand Clinical Trials Registry 
(ACTRN12616000858493). Written informed consent was obtained from all participants. 
Individuals ≥ 18 years meeting the inclusion criteria detailed below were recruited by a range 
of methods including: 
• advertisements in local newspapers (The Star and The Press) 
• flyers in general practice and other primary care health settings 
• e-mailing staff at local large businesses and organisations including the Canterbury 
District Health Board (CDHB) 
• contacting participants from previous studies  
• posting study information to those who had attended prediabetes education classes 
• placing flyers at local businesses 
A total of 41 individuals underwent a screening questionnaire and venous blood test to 
measure HbA1c to ascertain eligibility for the study (Figure 5.1). Twenty-six participants 
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were enrolled and 24 participants completed the study. Four participants (one of whom did 
not complete the trial) were excluded from the gut microbiota analysis due to starting a course 
of antibiotics during the trial. One patient left the study due to a family bereavement. Another 
participant was admitted to hospital for a pre-existing condition and had to conclude 
involvement in the study. 
 
Figure 5.1. Participant flow for the study cohort. 
 
Inclusion criteria: Selection criteria for trial participants (≥ 18 years) was the requirement to 
meet the ADA diagnostic criteria for prediabetes (HbA1c result of 39-46 mmol/mol) at 
baseline. HbA1c was used in this study for screening because the public are more familiar 
with this measurement; the NZSSD recommends using the HbA1c as the preferred diagnostic 
test for diabetes (275). A three month trial period was therefore chosen, as the red blood cell 
has a 90-120 day lifespan and during this time haemoglobin is glycated in proportion to the 
mean exposure to glucose (275).  
Exclusion criteria: Individuals unable to give informed consent, those with an HbA1c outside 
the diagnostic range for prediabetes (HbA1c result of 39-46 mmol/mol), those with a previous 
diagnosis of diabetes, those on diabetes medications such as metformin, those who had taken 
antibiotics in the last month, those with a medical history of significant gastrointestinal 
disease (for example, inflammatory bowel disease), previous bowel resection, those with a 
known kiwifruit allergy, women who were pregnant, breastfeeding or planning a pregnancy, 
and those planning to travel overseas in the three months post selection (trial period) were 
excluded. 
5.3.2 Study Design 
This was a pilot intervention trial where baseline measurements were used as the control 
measures for comparison. Participants were screened with a questionnaire and venous blood 
Individuals!Screened!(n=41)!
Individuals!enrolled!(n=26)!
Ineligible!(n=15)!
Individuals!who!completed!the!
study!(n=24)!
Individuals!who!didn’t!complete!
the!study!(n=2)!
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test to measure HbA1c. If eligible, they started a lead-in phase where they were asked to not 
eat any kiwifruit (green or gold) for seven days. During this time they also completed an 
estimated food diary over three non-consecutive days (two weekdays and one weekend day) 
to analyse their usual dietary intake (Table 5.1). On the same three days, participants recorded 
their number of bowel movements and the type of bowel movements using the Bristol Stool 
Chart. If participants reported taking a laxative during this time, the information was excluded 
in analyses. 
After the lead-in phase, Zespri SunGold kiwifruit (Actinidia chinesis var chinesis) were 
delivered to participants weekly. The kiwifruit were selected to be of the same size and 
quality. The average weight of the SunGold fruit was 132 g (whole fruit) and 95 g for the 
flesh (28% accounts for the skin (276)). Participants were asked to consume the flesh of two 
SunGold kiwifruit every day for twelve weeks. Strategies to avoid them forgetting the fruit 
were discussed such as eating them at the same time every day and having two kiwifruit out 
on the bench every day so the participants knew whether they had eaten them. Participants 
were asked not to eat any kiwifruit other that the two study fruit during the 12 weeks. As the 
study was a free-living situation, participants were asked to consume the fruit as part of their 
usual diet. Participants were asked not to eat the skin, and to eat the flesh raw and not crushed 
or blended in a smoothie. Participants were asked to maintain their normal dietary and 
lifestyle habits for the duration of the trial.  
Following screening and the lead-in week, there were three study visits: baseline, week six 
and week twelve (Figure 5.2). Table 5.1 shows the information collected at each study visit. 
 
Figure 5.2. Study Timeline 
 
  
Screening!
LeadIIn!
Phase!
(1!week)!
Baseline!!
(week!0)!
MidIPoint!
(week!6)!
Study!
Completion!
(week!12)!
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Table 5.1: Information and samples collected at each study visit. 
' Lead4In'
Phase'
Week'0'
(baseline)'
Week'6'
(study(mid8point)(
Week'12'
(study(completion)(
Questionnaires' 8Food(diary(
(3DEFD)(
8Bowel(
movements((
(
8Demographic(
8Medical(history(
8Medications(
8Supplements(
8Anthropometric(
8Physical(Activity(
8GSRS*(
8Bowel(movements(
8Changes(to(
medications(and(
supplements(
8Anthropometric(
8GSRS(
8Bowel(movements(
(
8Changes(to(
medications(and(
supplements(
8Anthropometric(
8Physical(Activity(
8GSRS(
8Bowel(movements((
8Food(Diary((
(3DEFD)(
8Adverse(events(
Blood'Tests' (
(
8Fasting(glucose†(
8vitamin(C‡(
8HbA1c(
8Lipids(
8Hormones(
8hs8CRP(
8Fasting(glucose(
(
(
8Fasting(glucose(
8vitamin(C(
8HbA1c(
8Lipids(
8Hormones(
8hs8CRP(
Samples' ( 8Faecal(sample( 8Faecal(sample( 8Faecal(sample(
* Gastrointestinal symptom rating scale (GSRS) 
† fasting glucose was measured as an additional measure of glycaemic control 
‡ vitamin C was included as a measure of compliance 
 
Medication and supplement use. At baseline, participants were asked to record any 
medications (prescription or non-prescription) they were currently taking, the dose, the 
number per day and the length of time they had been taking the medication. They were also 
asked if they were taking any dietary supplements, how frequently they took the supplement 
and when their last dose was. At weeks 6 and 12 they were asked if they had stopped taking 
any medications/supplements, if they had changed the dose, or if they had started taking 
something new, and, if so, the details around this. 
5.4 Results 
5.4.1 Participant Characteristics  
The average age of the participants was 66 years and ranged from 44 to 85 years old. There 
was an equal number of male and female participants and the majority of participants were 
European (80.8%) (Table 5.2). There was a mix of qualifications which is expected given the 
age of the participants. There were fewer participants currently smoking (14.4%) compared to 
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the number of participants who reported being ex- (38.5%) or non-smokers (46.2%). The 
majority of participants reported consuming alcohol (73.1%) (Table 5.2).  
Table 5.2: General characteristics of participants. 
Characteristics' n=26'
Age'(years)'(mean(±(SD)' 66(±(9(
Sex' (
( Female(%((n)( 50((13)(
( Male(%((n)( 50((13)(
Ethnicity' (
( European(%((n)( 80.8((21)(
( Māori(%((n)' 7.7((2)(
( Samoan(%((n)( 3.8((1)(
( Asian/Chinese(%((n)( 3.8((1)(
( Other(%((n)( 3.8((1)(
Qualification' (
( No(qualification(%((n)( 26.9((7)(
( Secondary(school(%((n)( 19.2((5)(
( Post8secondary(certificate,(diploma(or(trade(diploma(%((n)( 42.3((11)(
( University(%((n)( 11.5((3)(
Smoking'Status' (
( Current(smoker(%((n)( 15.4((4)(
( Ex8smoker(%((n)( 38.5((10)(
( Non8smoker(%((n)( 46.2((12)(
Alcohol'Status' (
( Current(drinker(%((n)(
( Ex8drinker(%((n)(
73.1((19)(
11.5((3)(
( Non8drinker(%((n)( 15.4((4)(
 
From baseline to the end of the study there were no significant changes in weight, BMI or fat 
mass. There was a significant decrease in waist circumference at week 6, of 0.9 cm (p=0.019) 
and 3.1 cm at week 12 (p=0.001) compared to baseline (Table 5.3, Figure 5.3 A-B). Although 
waist-to-hip ratio was significantly lower at week 12 compared to baseline (p=0.032), the 
difference was small and not clinically significant (Table 5.3, Figure 5.3 C-D). Blood pressure 
also decreased over the duration of the study (Table 5.3, Figure 5.4). At week 6, diastolic and 
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systolic blood pressure had decreased from baseline by 3 mmHg (p=0.040) and 5 mmHg 
(p=0.026) respectively (Table 5.3, Figure 5.4 C). At week 12, systolic and diastolic blood 
pressure were 4 mmHg (p=0.029) and 6 mmHg (p=0.003) lower than baseline (Table 5.3, 
Figure 5.4 A). At baseline, 42% (n=11) of participants recorded taking medication that lowers 
blood pressure. There were changes to blood pressure medication for only two of these 
participants during the trial. One participant had their blood pressure medication dose reduced 
by half from week 6 to 12 and another participant had it increased between baseline and week 
6 but then reduced back to the baseline dose between week 6 and 12.  
Although fasting glucose significantly increased by 0.2 mmol/L at week 6 (p=0.001), it was 
only 0.1 mmol/L higher than baseline at week 12 (p=0.046) which is not clinically significant 
(Table 5.3, Figure 5.5 A-B). There were no significant differences in the average number of 
bowel motions measured over three non-consecutive days or gastrointestinal symptoms 
measured by the GSRS questionnaire (Table 5.3). However, at week 12, participants were 
asked if they experienced any positive effects/symptoms while consuming the SunGold 
kiwifruit during the trial and 12 participants (50%) reported improvements in bowel motions 
and/or GI symptoms such as increased frequency/more regular bowel motions, no 
constipation, reduced gas, softer stools, improved digestion and reduced irritable bowel 
syndrome symptoms.  
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Table 5.3: Anthropometric, blood pressure, laboratory measures and questionnaires completed at week 
0, 6 and 12. 
Characteristics' Week'0'(n=26)' Week'6'(n=26)' Week'12'(n=24)'
Anthropometry' ( ( (
Weight((kg)( 80.2(±(19.8( 80.1(±(20.0( 77.9(±(18.6(
BMI((kg/m2)( 29.4(±(7.3( 29.4(±(7.4( 28.6(±(7.0(
Fat(mass((%)( 34.3(±(6.6( 34.4(±(6.6( 34.0(±(6.9(
Waist(circumference((cm)( 98.6(±(15.3( 97.7(±(15.2*(( 95.5(±(14.6***((
Waist8to8hip(ratio( 0.90(±(0.09( 0.90(±(0.09( 0.89(±(0.09*((
Blood'Pressure'' ( ( (
Diastolic((mmHg)( 76(±(8( 73(±(9*(( 72(±(10*((
Systolic((mmHg)( 129(±(14( 124(±(17*( 123(±(18**((
Laboratory'Measures' ( ( ((
Fasting(glucose((mmol/L)( 5.4(±(0.7( 5.6(±(0.7**(( 5.5(±(0.8*((
Questionnaires' ( ( (
GSRS( 21(±(5( 21(±(6( 23(±(7(
Average(daily(bowel(movements( 1.2((1.081.3)( 1.3((1.082.0)( 1.0((0.782.0)(
Values presented as mean ± SD or median and interquartile range (25th to 75th percentiles). Wilcoxon Signed 
Ranks tests were used to compare the daily bowel motions measurements between times. Paired sample t-tests 
were used for all other variables.  
*Significant at the 0.05 level, ** significant at the 0.01 level, ***significant at the 0.001 level 
In addition to the missing data for the two participants who did not complete week 12 there was missing data at 
baseline and week 6 for fasting glucose (1 participant), plasma vitamin C (1 participant) and fat mass (1 
participant). 
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Figure 5.3. (A) Average waist circumference. Bars represent standard error of the mean. (B) Waist circumference of individuals. (C) Average waist-to-hip ratio. 
Bars represent standard error of the mean. (D) Waist-to-hip ratio of individuals. 
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Figure 5.4. (A) Average systolic blood pressure. Bars represent standard error of the mean. (B) Systolic blood pressure of individuals. (C) Average diastolic blood 
pressure. Bars represent standard error of the mean. (D) Diastolic blood pressure of individuals. 
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Figure 5.5. (A) Average fasting glucose. Bars represent standard error of the mean. (B) Fasting glucose of individuals. (C) Average HbA1c. Bars represent standard 
error of the mean. (D) HbA1c of individuals. 
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There was a small statistically significant decrease in HbA1c of 1 mmol/mol at week 12 
compared to baseline (p=0.005) (Table 5.4, Figure 5.5 C-D). The decrease is, however, small 
and would not be considered clinically significant. Figures 5.3-5.5 show the overall effect 
across the cohort, and also the somewhat variable response of all individuals.  
Plasma vitamin C concentrations were significantly higher at 12 weeks compared to baseline 
(p<0.001), indicating compliance with kiwifruit consumption (Table 5.4, Figure 5.6 A-B). 
Table 5.4: Laboratory measures and physical activity of participants at week 0 and week 12. 
Characteristics* Week*0*(n=26)* Week*12*(n=24)*
Laboratory*Measures* ! !
HbA1c!(mmol/mol)!! 43!±!2! 42!±!2**!
Total!cholesterol!(mmol/L)! 5.2!±!1.3! 5.1!±!1.3!
HDL=cholesterol!(mmol/L)! 1.35!±!0.23! 1.35!±!0.23!
LDL=cholesterol!(mmol/L)! 3.3!±!1.0! 3.3!±!1.1!
Triglycerides!(mmol/L)! 1.1!±!0.5! 1.1!±!0.4!
Cholesterol!(total/HDL)!ratio! 3.9!±!0.9! 3.8!±!0.9!
hs=CRP!(mg/L)! 1.8!(0.6=3.2)! 0.9!(0.5=2.2)!
Insulin!(pmol/L)!! 51!(31=73)! 42!(31=67)!
Ghrelin!(pmol/L)! 162!(110=204)! 154!(119=206)!
Leptin!(ng/mL)! 38!(27=71)! 35!(25=75)!
Adiponectin!(µg/mL)! 9!(6=11)! 10!(7=12)!
Plasma!vitamin!C!(µmol/L)! 50!±!19! 64!±!13***!
Physical*Activity*(met=minutes/week)** 3598!±!5273! 3493!±!4062!
Values presented as mean ± SD or median and interquartile range 25th to 75th percentiles). Wilcoxon Signed 
Ranks tests were used to compare hs-CRP, hormones (insulin, ghrelin, leptin and adiponectin) and physical 
activity between times. Paired sample t-tests were used for all other variables.  
*Significant at the 0.05 level, ** significant at the 0.01 level, ***significant at the 0.001 level 
In addition to the two participants who did not complete the trial there was missing data for one participant for 
physical activity and insulin at week 12. 
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Figure 5.6. (A) Plasma vitamin C concentration of participants. Bars represent the median and interquartile range. (B) Plasma vitamin C concentration of 
individuals. 
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5.4.2 Self-Reported Dietary Intake 
5.4.2.1 Macronutrients 
There were no significant differences in daily energy, fibre, protein, total fat and total 
available carbohydrate when week 12 was compared to baseline (Table 5.5). There was a non-
significant trend towards an increase in total available sugars, and when investigated further 
results showed the daily intake of fructose and glucose to be significantly higher at week 12 
compared to baseline (p<0.001), and the intake of sucrose to be significantly lower at week 12 
compared to baseline (p=0.018). Starch intake was not significantly different at week 12 
compared to baseline. 
5.4.2.2 Micronutrients 
Significant changes in micronutrient intake are included in Table 5.5. There was a significant 
increase in vitamin C (p<0.001) (Table 5.5, Figure 5.7) and E (p=0.037) (Table 5.5).  There 
was a significantly higher intake of folate at week 12 compared to baseline (p=0.012), and 
when investigated further this was attributed to folate naturally occurring in foods (p=0.002).  
5.4.2.3 Under-reporting 
The total daily energy intake of 7.4 MJ at baseline is lower than may be expected for a cohort 
of individuals with a mean body weight of 80 kg and BMI of 29 kg/m2 at baseline. The 
percentage of participants’ under-reporting at baseline and week 12 was similar and was 
estimated to be 33% and 25% respectively using the Goldberg method.    
5.4.2.4 Fruit intake 
At baseline the amount of fruit eaten (fresh and total) is the same whether or not kiwifruit is 
excluded from the anaylsis, as participants were instructed not to eat any kiwifruit during the 
lead-in phase of the trial, during which time the baseline food diaries were completed (Table 
5.5). 
5.4.2.4.1 Fresh fruit 
The amount of fresh fruit consumed daily was significantly higher (by 106 g) at week 12 
compared to baseline when SunGold kiwifruit was included in the dietary data at week 12 
(p<0.001) (Table 5.5). When the consumption of SunGold kiwifruit at week 12 was excluded 
from the dietary data, the intake of fresh fruit was significantly lower (by 59 g) at week 12 
compared to baseline (p<0.001). 
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5.4.2.4.2 Total fruit 
Total fruit intake was also significantly higher (by 90 g) at week 12 compared to baseline 
when kiwifruit consumption was included at week 12 (p=0.003) (Table 5.5). When analysis 
was completed excluding the SunGold kiwifruit consumed at week 12, the intake of fruit at 
week 12 was significantly lower (by 76 g) compared to fruit intake at baseline.  
5.4.2.5 Kiwifruit questionnaire at study completion 
At the end of the study all participants said that it was manageable to consume two SunGold 
kiwifruit every day for three months. All participants also confirmed that they would continue 
to eat two SunGold kiwifruit every day if there was a health benefit for them, even if they had 
to purchase the fruit.  
Eleven participants said that they replaced fruit they previously ate with the SunGold 
kiwifruit. Half of the participants reported eating both kiwifruit together (Table 5.6). Most 
participants (79%) reported eating the kiwifruit at the same time every day, suggesting they 
were in a routine. 
As this trial was a free-living situation, participants chose when they ate one or both of the 
kiwifruit (Table 5.6). The most common time of day was breakfast, with 11 participants who 
reported eating kiwifruit with breakfast and four participants who reported eating the kiwifruit 
prior to breakfast. Supper was the second most common time of day (9 participants), followed 
by lunch (7 participants). More participants ate the kiwifruit as a mid-afternoon snack (5 
participants) as opposed to a mid-morning snack (3 participants). Only one participant 
reported eating kiwifruit with dinner.  
In this study participants were asked not to consume the skin for consistency in fibre 
consumption amongst participants. There were only two participants who said it would be 
more convenient to eat the skin (Table 5.6). 
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Table 5.5: Dietary intake of participants at week 0 and week 12. 
Daily&Dietary&Intake& Week&0&(n=26)& Week&12&(n=24)&
Macronutrients& & &
Energy'(kJ)' 7407'±'2759' 7176'±'1683'
Fibre'(g)' 23'±'8' 23'±'8'
Protein'(g)' 81'±'24' 80'±'22'
Protein'(%'of'energy)' 19'±'4' 19'±'4'
Total'fat'(g)' 72'±'35' 68'±'18'
Total'fat'(%'of'energy)' 35'±'6' 36'±'6'
Total'carbohydrate'(g)' 190'±'71' 184'±'49'
Total'carbohydrate'(%'of'energy)' 43'±'5' 43'±'6'
Total'available'sugars'(g)' 82'±'33' 86'±'23'
Fructose'(g)' 16'±'8' 22'±'6***'
Glucose'(g)' 14'±'6' 20'±'5***'
Sucrose'(g)' 35'±'25' 29'±'16*'
Lactose'(g)' 14'±'8' 20'±'5'
Maltose'(g)' 3.0'±'1.8' 2.8'±'1.5'
Total'starch'(g)'' 108'±'43' 97'±'34'
Micronutrients& ' '
Vitamin'C'(mg)' 79'±'35' 347'±'70***'
Vitamin'E'(mg)' 8.5'±'3.9' 10.3'±'3.3*''
Total'folate'(µg)' 271'±'126' 337'±'119*'
Folate'(naturally'occurring)'(µg)' 236'±'105' 291'±'98**'
Food&Groups& ' '
Fresh'fruit'including'kiwifruit'(g)' 131'±'91' 237'±'68***'
Fresh'fruit'excluding'kiwifruit'(g)' 131'±'91' 72'±'55***'
Total'fruit'including'kiwifruit'(g)' 184'±'101' 274'±'104**'
Total'fruit'excluding'kiwifruit'(g)' 184'±'101' 108'±'94**'
Values presented as mean ± SD.  
Paired sample t-tests were used to compare dietary data between times.  
*Significant at the 0.05 level, ** significant at the 0.01 level, ***significant at the 0.001 level 
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Table 5.6: Information on kiwifruit consumption collected at week 12. 
Participants&(n=24)& n&(%)&
Kiwifruit'consumption'was'manageable'' 24'(100)'
Replaced'fruit'previously'eaten'with'kiwifruit' 11'(46)'
Kiwifruit'eaten'at'the'same'time' 12'(50)'
Timing&of&kiwifruit&consumption& '
Consumption'of'fruit'at'the'same'time'every'day' 19'(79)'
Before'breakfast' 4'
With'breakfast' 11'
MidYmorning' 3'
With'lunch' 7'
MidYafternoon' 5'
With'dinner' 1'
Supper' 9'
More'convenient'to'eat'the'skin'' 2'(8)'
Continue'kiwifruit'if'there'is'a'health'benefit' 24'(100)'
 
 
Figure 5.7. Daily dietary vitamin C intake of participants at week 0 and week 12 (n=24). 
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effective at increasing plasma vitamin C levels, consistent with previous research (195). At 
week 12 from the food diary data, compliance was calculated to be 91%. This was calculated 
for every individual as the percentage of the six kiwifruit consumed over three days.  
5.4.2.5.2 Adverse events  
At week 12, participants were asked if they experienced any negative effects/symptoms when 
eating the gold kiwifruit. Only three participants reported adverse events. One participant 
reported feeling slightly bloated at times, one participant found the kiwifruit too sweet at the 
beginning of the trial but adapted to it and another participant reported the kiwifruit as 
causing more bowel motions at the start of the trial but found these settled down and they 
reported having no problem with this in the last six to seven weeks of the trial.  
5.5 Section one: KIS-Gut Microbiota 
The faecal samples of four participants (one of whom did not complete the trial) were 
excluded from analysis due to starting a course of antibiotics during the trial. For this analysis 
there were 22 participants at week 6 and 21 participants at week 12, due to another participant 
not completing the trial.  
All DNA samples passed quality check and each sample was amplified and barcoded twice to 
reduce the possibility of losing a sample to sequence failure. Only a single amplification 
product failed to sequence (1/152 = 0.7%; well within accepted rate of 4%), however the 
duplicate reaction from this sample sequenced well. Thus, all submitted samples generated 
good sequence data. A total of 5,527,067 sequences were available for further analysis 
following quality-checking procedures. Each sample generated an average of 72,725 
sequences (range 39,216–117,799). 
5.5.1 Taxonomic Results 
The OTU tables were filtered by prevalence (any OTUs not present in at least 25% of the 
sample set were removed). At all taxonomic levels, very low abundance bacteria (<0.1%) 
were not analysed.  
In this study OTUs were assigned taxonomy via the SILVA v. 123 database. Raw sequence 
counts were normalised by conversion to RA and the original OTU table was collapsed to 
each taxonomic level. The species-level data are not presented, as the assignment of 
sequences to species is often not robust using short amplicon data. The results below are 
presented first at the phylum-level and then the lower taxonomic ranks (class, order, family 
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and genus). If a single lineage was observed through multiple taxonomic ranks, only the 
highest taxonomic rank is reported, plus ranks where the taxonomy diverges (thus the author 
reports phylum and then family if there is a single lineage through class and order rankings).  
5.5.1.1 Phylum 
There were six phyla (Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria, Tenericutes 
and Verrucomicrobia) detected with a RA of >0.1%. Only phyla with a RA of >1% 
(Actinobacteria, Bacteroidetes, Firmicutes) are included in this section. The phyla 
Proteobacteria, Tenericutes, Verrucomicrobia were not significantly different at week 6 or 
week 12 compared to baseline (Appendix E). Furthermore, Tenericutes and Verrucomicrobia 
did not split into multiple orders, family or genera in our dataset. Proteobacteria split only at 
the genus-level with two genera (Klebsiella and Escherichia-Shigella) present in the study 
dataset (Appendix E).  
Firmicutes was the dominant taxa comprising around 90% of all bacteria detected (Table 5.7). 
At the phylum-level there was a non-significant positive trend seen from week 0 to week 12 
showing an increase in the RA of Actinobacteria (p=0.058) (Table 5.7).  
Table 5.7: RA of bacteria present at the phylum-level at week 0, 6 and 12. 
RA&of&bacteria&(%)& Week&0&(n=22)& Week&6&(n=22)& Week&12&(n=21)&
Actinobacteria+ 1.06'(0.52Y2.67)' 1.36'(0.80Y2.74)' 2.23'(1.20Y2.91)'
Bacteroidetes+ 3.59'(2.17Y5.56)' 5.52'(2.27Y13.05)' 4.49'(1.71Y6.27)'
Firmicutes+ 93.57'(90.20Y96.06)' 89.47'(80.78Y94.81)' 91.01'(82.84Y94.58)'
Firmicutes'to'
Bacteroidetes'ratio' 25.95'(16.51Y43.53)' 16.81'(6.19Y41.68)' 18.56'(13.95Y56.01)'
Values presented as median and interquartile range (25th to 75th percentiles). 
Wilcoxon Signed Ranks tests were used to compare the phyla between times.  
There were no significant differences.  
 
5.5.1.2 Class 
At the class-level, two phyla (Actinobacteria and Firmicutes) branched into six classes 
(Figures 5.8 and 5.9) with the class Clostridia being the most dominant (Figure 5.10). From 
these six classes, two significant results were seen when comparing the RA of the classes at 
week 6 and week 12, and the RA of the classes at week 0 (Table 5.8).  
The RA of the class Coriobacteriia (from the phylum Actinobacteria) was significantly 
higher after 6 (p=0.001) and 12 weeks of kiwifruit intervention compared with the RA of 
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Coriobacteriia at baseline (p<0.001) (Table 5.8, Figure 5.11 A-B). This figure also shows the 
range in response amongst participants. The RA of Coriobacteriia increased in 18 of the 21 
participants (86%), and the median increase in RA was 0.36% when week 12 was compared 
to baseline (Table 5.8). Five participants had a markedly increased response, whereas three 
participants appeared not to have responded (Figure 5.11 D). This association was not further 
explored at the lower taxonomic levels, as Coriobacteriia did not split into multiple orders, 
family or genera in the study dataset (Figure 5.8). Coriobacteriaceae was the only family 
present for the class Coriobacteriia and the genus was not identified (Figure 5.8).  
The RA of the class Erysipelotrichia (from the phylum Firmicutes) was significantly lower at 
week 6 compared to week 0 (p=0.030) but then increased again from week 6 to week 12, so at 
week 12 the RA of Erysipelotrichia was not significantly different from week 0 (p=0.821) 
(Table 5.8, Figure 5.11 C-D).  
 
Figure 5.8. Bacteria from the phylum Actinobacteria (class, order, family and genus) present in the 
study dataset. 
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Figure 5.9. Bacteria from the phylum Firmicutes (class, order, family and genus) present in the study dataset 
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Figure 5.10. RA of each class at week 0, 6 and 12 in the dataset. 
!
Table 5.8: RA of bacteria present at the class-level at week 0, 6 and 12. 
RA#of#bacteria#(%)# Week#0#(n=22)# Week#6#(n=22)# Week#12#(n=21)#
Actinobacteria;,Actinobacteria, 0.84%(0.23)2.33)% 0.68%(0.32)2.02)% 0.90%(0.52)1.97)%
Actinobacteria;,Coriobacteriia, 0.22%(0.14)0.34)% 0.54%(0.27)0.92)**% 0.58%(0.36)1.48)***%
Firmicutes;,Bacilli, 0.11%(0.03)0.55)% 0.07%(0.03)0.23)% 0.11%(0.03)0.40)%
Firmicutes;,Clostridia, 85.59%(78.24)88.59)% 83.49%(76.10)90.69)% 83.46%(77.77)86.37)%
Firmicutes;,Erysipelotrichia, 5.33%(2.55)7.76)% 2.73%(2.42)5.18)*% 4.25%(2.17)5.45)%
Firmicutes;,Negativicutes, 0.37%(0.05)1.32)% 0.44%(0.05)0.75)% 0.17%(0.02)0.79)%
Values presented as median and interquartile range (25th to 75th percentiles).  
Wilcoxon Signed Ranks tests were used to compare the classes between times.  
*Significant at the 0.05 level, ** significant at the 0.01 level, ***significant at the 0.001 level 
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Figure 5.11. (A and C) RA of Coriobacteriia and Erysipelotrichia (%) in individuals. Bars represent median and interquartile range. (B and D) Individuals’ RA of 
Coriobacteriia and Erysipelotrichia (%) tracked over time. 
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5.5.1.3 Order 
Data are not presented at the order level as all classes contained only a single order.  
5.5.1.4 Family 
At the family-level, five orders (Bacteroidales, Lactobacillales, Clostridiales, 
Erysipelotrichales, and Selenomonadales) branched into 15 families (Figure 5.9 and 5.12). 
From these 15 families, two significant differences were seen when comparing the RA of the 
families at week 6 and week 12 with the RA of the families at week 0. 
The RA of the family Rikenellaceae (from the phylum Bacteroidetes) was significantly higher 
at week 12 compared to baseline (p=0.021) (Table 5.9, Figure 5.13 A-B). Alistipes was the 
only genus in the family Rikenellaceae in the study dataset (Figure 5.12). 
The RA of the family Ruminococcaceae (from the phylum Firmicutes) was significantly 
higher at week 6 compared to baseline (p=0.004) but decreased from week 6 to week 12, and 
the RA at week 12 was not significantly different from baseline (p=0.149) (Table 5.9, Figure 
5.13 C-D).  
In addition to the trends described above, individual changes in the RA of bacteria at the 
family-level were also tracked over the duration of the study. Results show that there are 
changes in the RA of families over time and the changes differ between individuals 
(Appendix F).  
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Table 5.9: RA of bacteria present at the family-level at week 0, 6 and 12. 
RA#of#bacteria#(%)# Week#0#(n=22)# Week#6#(n=22)# Week#12#(n=21)#
Bacteroidetes;,Bacteroidia;,
Bacteroidales;,Bacteroidaceae, 2.60%(1.40)4.47)%
3.25%%
(1.26)11.43)%
3.41%(0.95)5.20)%
Bacteroidetes;,Bacteroidia;,
Bacteroidales;,Porphyromonadaceae, 0.30%(0.10)0.47)% 0.31%(0.16)0.91)% 0.38%(0.16)0.53)%
Bacteroidetes;,Bacteroidia;,
Bacteroidales;,Prevotellaceae,
0.00%(0.00)0.00)% 0.00%(0.00)0.00)% 0.00%(0.00)0.00)%
Bacteroidetes;,Bacteroidia;,
Bacteroidales;,Rikenellaceae,
0.35%(0.11)0.82)% 0.44%(0.22)1.16)%
0.38%%
(0.15)1.07)*%
Firmicutes;,Bacilli;,Lactobacillales;,
Lactobacillaceae,
0.00%(0.00)0.04)% 0.00%(0.00)0.00)% 0.00%(0.00)0.01)%
Firmicutes;,Bacilli;,Lactobacillales;,
Streptococcaceae,
0.10%(0.03)0.17)% 0.05%(0.02)0.20)% 0.11%(0.03)0.24)%
Firmicutes;,Clostridia;,Clostridiales;,
Christensenellaceae, 1.46%(0.45)2.64)% 1.73%(0.32)2.96)% 1.39%(0.52)2.11)%
Firmicutes;,Clostridia;,Clostridiales;,
Clostridiaceae,1, 0.36%(0.01)3.47)% 0.78%(0.08)2.61)% 1.17%(0.02)1.62)%
Firmicutes;,Clostridia;,Clostridiales;,
Family,XIII,
0.11%(0.06)0.41)% 0.16%(0.08)0.34)% 0.11%(0.05)0.26)%
Firmicutes;,Clostridia;,Clostridiales;,
Lachnospiraceae,
56.37%%
(38.30)63.79)%
46.88%%
(39.38)56.42)%
47.05%%
(41.12)57.28)%
Firmicutes;,Clostridia;,Clostridiales;,
Peptostreptococcaceae,
1.09%%
(0.34)8.30)%
1.70%(0.36)5.29)% 1.87%(0.41)8.34)%
Firmicutes;,Clostridia;,Clostridiales;,
Ruminococcaceae,
19.98%%
(17.70)27.30)%
26.41%%
(21.08)30.64)**%%
23.59%%
(19.87)28.95)%
Firmicutes;,Erysipelotrichia;,
Erysipelotrichales;,Erysipelotrichaceae, 5.33%(2.55)7.76)% 2.73%(2.42)5.18)% 4.25%(2.17)5.45)%
Firmicutes;,Negativicutes;,
Selenomonadales;,Acidaminococcaceae,
0.00%%
(0.00)0.19)%%
0.00%(0.00)0.05)% 0.00%(0.00)0.02)%
Firmicutes;,Negativicutes;,
Selenomonadales;,Veillonellaceae,
0.12%%
(0.05)1.08)%
0.10%(0.03)0.68)% 0.09%(0.01)0.59)%
Values presented as median and interquartile range (25th to 75th percentiles).  
Wilcoxon Signed Ranks tests were used to compare the families between times.  
*Significant at the 0.05 level, ** significant at the 0.01 level, ***significant at the 0.001 level 
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Figure 5.12. Bacteria from the phylum Bacteroidetes (class, order, family and genus) present in the study dataset. 
!
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Figure 5.13. (A and C) RA of Rikenellaceae and Ruminococcacea (%) in individuals. Bars represent median and interquartile range. (B and D) Individuals’ RA of 
Rikenellaceae and Ruminococcacea (%) tracked over time. 
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5.5.1.5 Genus 
At the genus-level, five families (Porphyromonadaceae, Family XIII, Lachnospiraceae, 
Ruminococcaceae and Erysipelotrichaceae) all from the phylum Firmicutes branched into 47 
genera (Figure 5.9). From these 49 genera, 13 significant differences were seen (Table 5.10).  
The significant differences in RA observed at week 6, detailed below, were no longer 
significant when compared to baseline at week 12, indicating a temporary shift in the RA of 
the bacteria: 
• The RA of the genus Blautia was significantly lower at week 6 compared to baseline 
(p=0.036) but increased from week 6 to week 12 and so was no longer significantly lower 
at week 12 when compared to baseline (p=0.614) (Table 5.10). The same trend was seen 
for the genus Mogiobacterium at week 6 (p=0.010) and week 12 (p=0.768). 
• The RA of the genus Lachnoclostridium was significantly higher at week 6 compared to 
baseline (p=0.007) but decreased from week 6 to week 12 and so was no longer 
significantly higher at week 12 compared to baseline (p=0.079). The same trend was seen 
for the genera [Eubacterium] xylanophilum group (week 6, p=0.016), Faecalibacterium 
(week 6, p=0.005), Ruminococcaceae UCG-005 (week 6, p=0.007), Ruminococcus 1 
(week 6, p=0.003) and an uncultured genus from the family Lachnospiraceae (week 6,  
p=0.007) (Table 5.10). 
• The RA of Erysipelotrichaceae UCG-003 was significantly lower at week 6 compared to 
baseline (p=0.036) but the RA increased from week 6 to 12 so there was no significant 
difference at week 12 compared to baseline (p=0.566) (Table 5.10).  
Significant differences in RA of bacteria at week 12 compared to baseline: 
• The RA of the genus Lachnospiraceae ND3007 group was significantly higher at week 6 
compared to baseline (p=0.002) but then decreased from week 6 to week 12 and so was 
actually significantly lower at week 12 compared to baseline (p=0.046) (Table 5.10). 
• The RA of Butyricicoccus was significantly higher at week 6 (p=0.010) and week 12 
(p=0.035) compared to baseline (Table 5.10).  
The RA of Ruminicostridium 5 was significantly lower at week 12 (p=0.042) compared to 
baseline. In contrast, the RA of Ruminicostridium 6 and Subdoligranulum were significantly 
higher at week 12 (p=0.008 and p=0.030 respectively) compared to baseline (Table 5.10).
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Table 5.10: Relative abundance (RA) of bacteria present at the genus-level at baseline (week 0), week 6 and on completion of the trial (week 12). 
RA#of#bacteria#(%)# Week#0#(n=22)# Week#6#(n=22)# Week#12#(n=21)#
Bacteroidetes;,Bacteroidia;,Bacteroidales;,Porphyromonadaceae;,Barnesiella, 0.03$(0.00&0.16)$ 0.04$(0.00&0.21)$ 0.04$(0.00&0.14)$
Bacteroidetes;,Bacteroidia;,Bacteroidales;,Porphyromonadaceae;,uncultured, 0.13$(0.02&0.38)$ 0.19$(0.05&0.33)$ 0.17$(0.08&0.42)$
Firmicutes;,Clostridia;,Clostridiales;,Family,XIII;,Family,XIII,AD3011,group, 0.07$(0.04&0.16)$ 0.08$(0.05&0.15)$ 0.08$(0.04&0.13)$
Firmicutes;,Clostridia;,Clostridiales;,Family,XIII;,Mogibacterium, 0.00$(0.00&0.03)$ 0.00$(0.00&0.02)*$ 0.00$(0.00&0.02)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,Anaerostipes, 2.93$(1.59&7.81)$ 2.87$(2.13&7.36)$ 4.51$(1.60&7.20)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,Blautia, 18.58$(8.93&27.19)$ 15.61$(9.49&19.05)*$ 16.71$(10.98&20.92)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,Coprococcus,1, 0.46$(0.25&0.64)$ 0.42$(0.33&0.58)$ 0.36$(0.25&0.52)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,Coprococcus,2, 1.23$(0.16&1.84)$ 0.54$(0.35&3.14)$ 1.50$(0.24&2.04)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,Coprococcus,3, 0.57$(0.18&0.98)$ 0.68$(0.34&0.93)$ 0.74$(0.36&1.31)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,Dorea, 1.97$(0.58&2.77)$ 1.91$(1.00&2.53)$ 1.88$(1.36&2.92)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,Fusicatenibacter, 8.03$(5.67&12.34)$ 8.32$(6.52&11.00)$ 7.67$(6.59&11.02)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,Lachnoclostridium, 0.09$(0.04&0.29)$ 0.28$(0.12&0.64)$**$ 0.11$(0.05&0.19)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,Lachnospiraceae,FCS020,group, 0.23$(0.15&0.37)$$ 0.20$(0.15&0.46)$ 0.24$(0.16&0.35)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,Lachnospiraceae,NC2004,group, 0.74$(0.35&1.30)$$ 0.77$(0.43&1.25)$ 0.67$(0.37&1.50)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,Lachnospiraceae,ND3007,group, 0.03$(0.01&0.14)$$ 0.20$(0.05&0.70)*$ 0.01$(0.00&0.07)*$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,Lachnospiraceae,NK4A136,group, 0.22$(0.04&0.52)$ 0.23$(0.11&0.74)$ 0.28$(0.15&0.81)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,Lachnospiraceae,UCGK008, 1.74$(1.31&2.88)$ 1.95$(0.92&2.81)$ 2.38$(1.59&3.31)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,Roseburia, 0.38$(0.26&0.82)$ 0.95$(0.30&1.52)$ 0.65$(0.26&1.18)$
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RA#of#bacteria#(%)# Week#0#(n=22)# Week#6#(n=22)# Week#12#(n=21)#
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,[Eubacterium],eligens,group, 0.06$(0.03&0.52)$ 0.30$(0.06&0.57)$ 0.22$(0.04&0.48)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,[Eubacterium],oxidoreducens,
group,
0.30$(0.13&0.62)$$ 0.56$(0.22&1.15)$ 0.46$(0.16&0.70)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,[Eubacterium],rectale,group, 1.81$(1.15&5.12)$$ 3.53$(2.01&6.37)$ 2.92$(1.82&5.80)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,[Eubacterium],xylanophilum,group, 0.04$(0.00&0.09)$$ 0.06$(0.01&0.21)*$ 0.03$(0.01&0.08)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,[Ruminococcus],gnavus,group, 0.00$(0.00&0.05)$ 0.00$(0.00&0.03)$ 0.00$(0.00&0.02)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,[Ruminococcus],torques,group, 0.66$(0.26&1.55)$ 0.76$(0.23&1.98)$ 0.59$(0.25&0.90)$
Firmicutes;,Clostridia;,Clostridiales;,Lachnospiraceae;,uncultured, 0.05$(0.02&0.12)$ 0.13$(0.03&0.35)**$ 0.05$(0.03&0.10)$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,Anaerotruncus, 0.04$(0.01&0.10)$ 0.08$(0.03&0.19)$ 0.03$(0.02&0.15)$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,Butyricicoccus, 0.13$(0.03&0.22)$ 0.25$(0.12&0.36)**$ 0.22$(0.16&0.32)*$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,Faecalibacterium, 2.48$(0.93&7.25)$ 6.69$(3.80&9.68)**$ 3.35$(1.99&8.23)$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,Ruminiclostridium,5, 0.73$(0.20&1.14)$ 0.50$(0.30&1.08)$ 0.47$(0.26&0.86)*$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,Ruminiclostridium,6, 0.02$(0.00&0.09)$ 0.02$(0.00&0.16)$ 0.09$(0.01&0.60)**$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,Ruminiclostridium,9, 0.03$(0.01&0.11)$ 0.11$(0.02&0.16)$ 0.05$(0.02&0.13)$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,Ruminococcaceae,NK4A214,
group,
0.07$(0.01&0.63)$ 0.15$(0.02&0.52)$ 0.14$(0.01&0.37)$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,Ruminococcaceae,UCGK002, 0.43$(0.12&1.15)$ 0.62$(0.18&1.45)$ 0.29$(0.23&1.10)$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,Ruminococcaceae,UCGK005, 0.15$(0.07&0.27)$ 0.28$(0.08&0.45)**$ 0.16$(0.09&0.25)$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,Ruminococcaceae,UCGK011, 0.04$(0.01&0.30)$ 0.04$(0.01&0.35)$ 0.05$(0.01&0.24)$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,Ruminococcaceae,UCGK013, 0.23$(0.11&0.42)$ 0.27$(0.11&0.57)$ 0.31$(0.16&0.43)$
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RA#of#bacteria#(%)# Week#0#(n=22)# Week#6#(n=22)# Week#12#(n=21)#
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,Ruminococcaceae,UCGK014, 0.87$(0.16&1.79)$ 0.57$(0.23&1.48)$ 1.28$(0.20&2.20)$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,Ruminococcus,1, 0.29$(0.14&0.80)$ 0.76$(0.24&1.79)**$ 0.73$(0.16&0.89)$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,Ruminococcus,2, 2.58$(0.93&6.37)$ 4.47$(0.60&6.45)$ 3.17$(1.86&5.12)$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,Subdoligranulum, 3.95$(2.15&6.47)$ 4.00$(3.04&8.93)$ 5.52$(3.58&9.03)*$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,[Eubacterium],coprostanoligenes,
group,
1.63$(0.76&2.44)$ 1.82$(1.16&3.17)$ 1.70$(1.23&1.91)$
Firmicutes;,Clostridia;,Clostridiales;,Ruminococcaceae;,uncultured, 0.34$(0.15&0.64)$ 0.42$(0.21&0.74)$ 0.28$(0.17&0.58)$
Firmicutes;,Erysipelotrichia;,Erysipelotrichales;,Erysipelotrichaceae;,Catenibacterium, 0.01$(0.00&0.61)$ 0.01$(0.00&0.25)$ 0.02$(0.00&0.16)$
Firmicutes;,Erysipelotrichia;,Erysipelotrichales;,Erysipelotrichaceae;,
Erysipelatoclostridium,
0.05$(0.00&0.09)$ 0.01$(0.00&0.09)$ 0.03$(0.00&0.10)$
Firmicutes;,Erysipelotrichia;,Erysipelotrichales;,Erysipelotrichaceae;,Erysipelotrichaceae,
UCGK003,
1.51$(0.59&5.19)$ 1.33$(0.88&1.89)*$ 1.83$(1.24&3.14)$
Firmicutes;,Erysipelotrichia;,Erysipelotrichales;,Erysipelotrichaceae;,Holdemanella, 0.00$(0.00&0.78)$$ 0.00$(0.00&2.60)$ 0.00$(0.00&1.73)$
Firmicutes;,Erysipelotrichia;,Erysipelotrichales;,Erysipelotrichaceae;,Turicibacter, 0.05$(0.01&0.44)$ 0.06$(0.01&0.78)$ 0.08$(0.00&0.46)$
Values presented as median and interquartile range (25th to 75th percentiles). Wilcoxon Signed Ranks tests were used to compare the genera between times.  
*Significant at the 0.05 level, ** significant at the 0.01 level, ***significant at the 0.001 level 
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Rarefaction curves showed good coverage of microbiota composition (Figure 5.14).  
 
Figure 5.14. Number of sequences versus number of observed species. Values shown are mean ± SE. 
!
5.5.1.6 Alpha diversity 
Comparison of study time points at a rarefaction level of 35,000 sequences per sample did not 
show a statistically significant difference in alpha diversity (the complexity in composition of 
the microbiota) at week 6 or 12 compared to baseline using a variety of metrics (Table 5.11, 
Figure 5.15). 
Table 5.11: Diversity (at 35,000 sequences/sample) of participants at week 0, 6 and 12. 
Diversity)Measure) Week)0)(n=22)) Week)6)(n=22)) Week)12)(n=21))
Observed(species( 250((2132316)( 279((2322306)( 241((2172283)(
Whole(tree((PD)( 19((17223)( 21((18222)( 20((17222)(
Shannon(index( 5.1((4.625.4)( 5.4((4.725.8)( 5.0((4.925.3)(
Simpson’s(diversity( 0.95((0.9120.96)( 0.96((0.9320.97)( 0.94((0.9320.95)(
Chao(index( 318((2572377)( 367((2882396)( 338((3072389)(
Values presented as median and interquartile range (25th to 75th percentiles).  
Wilcoxon Signed Ranks tests were used to compare the diversity between times.  
There were no significant differences.  
!
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Figure 5.15 Observes species (at 35,000 sequences/sample) of participants at week 0, 6 and 12. Bars 
represent median and interquartile range 
!
5.5.1.7 Beta diversity 
Beta diversity (unique fraction metric (Unifrac) weighted and unweighted) was used to 
compare similarities in microbiota composition over time. A comparison of distances within 
and between time points did not reveal significant changes in community structure with time 
(Figure 5.16-5.17). Unweighted unifrac distances (kinds of bacteria and phylogenetic 
relationships) indicated that the microbiotas of the participants tended to be more similar to 
each other after 12 weeks’ intervention than at baseline or 6 weeks (Figure 5.16). Applying a 
weighting (based on the relative abundance of OTUs) suggested that the microbiota of 
participants are more similar to each other at 6 and 12 weeks than at baseline (Figure 5.17). 
 
Figure 5.16. Unweighted Unifrac (kinds of bacteria and phylogenetic relatedness). Means and SEM 
are shown. 
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Figure 5.17. Weighted Unifrac (kinds of bacteria, phylogenetic relatedness and relative abundances). 
!
5.5.2 Faecal Water Content 
Dietary intervention of two SunGold kiwifruit per day resulted in a significantly greater faecal 
water content at weeks 6 and 12 compared to baseline (Table 5.12 and Figure 5.18).  
Table 5.12: Water content of faecal material at week 0, 6 and 12. 
) Week)0)(n=22)) Week)6)(n=22)) Week)12)(n=21))
Faecal(water(content((%)( 68(±(8( 76(±(7***(( 74(±(7**((
Values presented as mean ± SD.  
Paired sample t-tests were used to compare faecal water content between times.  
*Significant at the 0.05 level, ** significant at the 0.01 level, ***significant at the 0.001 level 
!
 
Figure 5.18. Water content of faecal material at week 0, 6 and 12. 
W
e
e
k  
0
 
W
e
e
k  
6
 
W
e
e
k  
1
2
0
2 0
4 0
6 0
8 0
1 0 0
T i m e
F
a
e
c
a
l 
W
a
te
r 
C
o
n
te
n
t 
(%
)
! 214!
5.5.3 Discussion 
This is the first study to measure changes in the gut microbiota associated with Zespri 
SunGold kiwifruit (Actinidia chinesis var chinesis) consumption in people with prediabetes in 
a free-living situation, while monitoring other indicators of metabolic health and glycaemic 
control.  
In this study, consuming two SunGold kiwifruit per day was associated with a significant 
increase in fasting glucose and a decrease in HbA1c; however, these latter two changes, 
though statistically significant, were small and not clinically significant. Therefore in 
agreement with the hypothesis of this study, results show no clinically significant change in 
glycaemic control. There was a significant reduction in both diastolic and systolic blood 
pressure. A significant reduction in waist circumference and waist-to-hip ratio was also seen, 
even though the reductions in mean BMI and fat mass were small and non-significant. 
In agreement with the hypothesis, this study showed both temporary and enduring shifts in the 
RA of bacteria. However, results from this study did not confirm the reported in vitro effect of 
kiwifruit fermentation (271). In this study population at baseline, the phylum-level Firmicutes 
and Bacteroidetes were the dominant taxa comprising 94% and 4% of all bacterial taxa 
detected respectively. Firmicutes and Bacteroidetes were also the most dominant taxa 
detected in the prediabetes cohort in the observational study (Chapter four) and comprised 
76% and 9.2% respectively.  
Although in this trial there were no significant associations with SunGold kiwifruit 
consumption at the phylum-level, there was a non-significant trend from baseline to week 12 
showing an increase in the RA of Actinobacteria. An increase in the phyla Actinobacteria was 
also seen in an in vitro trial using green kiwifruit as the substrate (277). In the current study, 
at the class-level the increase in Actinobacteria was linked to a significant increase in the RA 
of Coriobacteriia (from the phylum Actinobacteria) after both 6 and 12 weeks of kiwifruit 
consumption compared to baseline. This suggests a longer term increase in the RA of 
Coriobacteriia in response to consuming two SunGold kiwifruit daily as part of participants’ 
usual diet.  
In this dataset, Coriobacteriaceae was the only family present for the class Coriobacteriia 
and the bacterium that fits within the Coriobacteriaceae was not identified. 
Coriobacteriaceae are Gram-positive bacteria that grow as small rods (278). They are strictly 
anaerobic and are usually non-motile, non-sporeforming and non-haemolytic (278). In the gut, 
Coriobacteriaceae carry out functions of importance such as the conversion of bile salts and 
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steroids (278). Another function of Coriobacteriaceae in the gut is the metabolism of dietary 
polyphenols, especially the activation of the isoflavone diadzein to the bioactive metabolite 
equol (278). Dietary polyphenols occur in plants and accordingly foods and beverages such as 
fruits, vegetables, cereals, tea, coffee and wine (279). Because polyphenols represent a wide 
variety of diverse structures from different subclasses (such as flavonoids, phenolic acids, 
lignans, proanthocyanidins), it is difficult to estimate the total polyphenol content (280). 
Although the exact polyphenols have not been identified in SunGold kiwifruit, Dawes and 
Keene (137) investigated the phenolic composition of green kiwifruit juice and reported the 
flavonol glycoside to be the most characteristic feature of the juice. Research suggests that 
kiwifruit contain a moderate amount of polyphenols compared to other fruit (281). However, 
polyphenols are more active in humans in the presence of vitamin C, and saccharides (mainly 
monosaccharides) also enhance their assimilation, with SunGold kiwifruit being an excellent 
source of vitamin C (281). The inter-individual variation in the changes seen for the RA of 
Coriobacteriia at week 6 and 12 may reflect differences between individuals, such as the total 
polyphenol intake at baseline and also during the study.  
It is estimated that 90-95% of dietary polyphenols are not absorbed in the small intestine and 
therefore reach the colon (282). Bacteria digest the polyphenols by various mechanisms 
including hydrolysis, ring-cleavage, reduction, decarboxylation and demethylation (283). The 
antioxidant capacity of phenolics has been associated with potential health benefits of 
polyphenols, including the prevention of diseases associated with oxidative stress such as 
cardiovascular disease, obesity and diabetes (279, 283). For example, increased oxidative 
stress is involved in the development and progression of diabetes and its complications (284, 
285). The bioavailability of phenolic compounds is limited due to covalent linkage to the 
plant cell walls (109). Gut absorption, enhanced by the enzymatic activity of the gut 
microbiota, reduces the polyphenols into smaller phenolic compounds and has been shown to 
be increased in vegans (109).  
Research suggests that the beneficial effects attributed to dietary polyphenols are due more to 
phenolic metabolites formed in the GI tract, resulting from the action of the gut bacteria, than 
the original forms found in the food (286). Brevik et al. (287) carried out a human 
intervention trial with the same cultivar of gold kiwifruit as used in this study (Actinidia 
chinensis). Brevik et al. (287) studied healthy individuals who supplemented their normal diet 
with either one or two gold kiwifruit per day in a cross-over study of two four-week 
intervention periods. They measured markers of antioxidant status, DNA stability, plasma 
lipids and platelet aggregation. They reported increases in plasma vitamin C concentrations 
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along with increases in total antioxidant capacity (increased resistance towards hydrogen 
peroxide-induced DNA damage). They also reported trends towards a decrease in oxidized 
purine and pyrimidine bases, and whole blood platelet aggregation was also reduced. They 
concluded that gold kiwifruit consumption strengthens resistance to endogenous oxidative 
damage. 
Furthermore, prior to digestion and absorption of the polyphenols there is also evidence to 
suggest that diets rich in polyphenols may influence the absorption and metabolism of glucose 
(282, 283). A review on the impact of dietary polyphenols on carbohydrate metabolism 
suggests the following mechanisms (from mainly in vitro and animal models): inhibition of 
carbohydrate digestion and glucose absorption in the intestine, stimulation of insulin secretion 
from the pancreatic β-cells, modulation from glucose release in the liver, activation of insulin 
receptors and glucose uptake in insulin-sensitive tissues, and modulation of hepatic glucose 
output (283, 288). For example, a variety of polyphenols have been shown to inhibit the 
breakdown of starch by α-amylase and α-glucosidase (289-291). Several flavonoids and 
phenolic acids have been shown to inhibit glucose transport across the intestinal brush border 
membrane by inhibiting glucose transporters (SGLT-1 and GLUT2) (292, 293). Polyphenols 
in fruits have also been shown to suppress the postprandial glucose response in humans (294, 
295).  
At the class-level, there was also a significant decrease in the RA of Erysipelotrichia (from 
the phylum Firmicutes) at week 6 compared to baseline; however, at week 12 the RA had 
increased so was no longer significantly different to baseline, indicating a temporary shift in 
the RA of this class of bacteria. This association may be linked to the genus 
Erysipelotrichaceae UCG-003, which showed the same pattern of RA. 
There was a significant increase in the RA of the family Rikenellaceae (from the phylum 
Bacteroidetes) at week 12 compared to baseline. Rikenellaceae is a newly established family 
in the order Bacteroidales that currently comprises the two genera Alistipes and Rikenella 
(296). In this study Alistipes was the only genus present for the family Rikenellaceae. During 
the intervention trial, weight and BMI decreased slightly and waist circumference decreased 
significantly in line with previous research demonstrating an inverse association between 
obesity and the abundance of Alistipes in the gut (297).  
There was a temporary significant increase in the RA of the family Ruminococcaceae at week 
6 compared to baseline. At week 12 the RA had decreased from week 6 but was still higher 
than baseline, although this was not statically significant. There were three genera from the 
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Ruminococcaceae family (Faecalibacterium, Ruminococcaceae UCG-005 and Ruminococcus 
1) that showed the same pattern. The genus Butyricicoccus also had a significantly higher RA 
at week 6 compared to baseline and did decrease from week 6 to week 12, but the RA at week 
12 was still significantly higher than baseline. Blatchford et al. (298) also found 
supplementation with Livaux™, a freeze-dried powder derived entirely from Zespri SunGold 
kiwifruit (Gold3, Actinidia chinensis), significantly increased the RA of Faecalibacterium 
prausnitzii in functionally constipated patients. They concluded that an increased 
F. prausnitzii abundance offers a potential strategy for improving gut microbiota composition, 
as F. prausnitzii produces butyrate, which has been shown to exert anti-inflammatory effects 
in many studies (298). 
Two genera (Ruminiclostridium 6 and Subdoligranulum) from the family Ruminococcaceae 
had a significantly higher RA only at week 12 compared to baseline, and in contrast the genus 
Ruminiclostridium 6 had a significantly lower RA at week 12 compared to baseline. These 
associations may indicate longer-term shifts in the RA of these genera. The increase in the RA 
of the Ruminococcus genus may be due to its ability to degrade the insoluble kiwifruit 
xyloglucan, glucuronoarabinoxylan, galacto-(gluco)-mannan and cellulose (135). 
There were five genera from the family Lachnospiraceae that showed significant changes in 
the RA of bacteria during the trial. The RA of four of these genera (Blautia, 
Lachnoclostridium, [Eubacterium] xylanophilum group and an uncultured genus) showed a 
temporary shift, with the RA being significantly higher at week 6 compared to baseline but 
decreasing after week 6 so that at week 12 the RA was not significantly different to baseline. 
Paturi et al. (299) investigated the effects of kiwifruit on large bowel health in rats and found 
that, consistent with this study, gold kiwifruit significantly promoted the growth of members 
of the family Lachnospiraceae, which have been associated with the production of butyrate; 
this in turn provides an energy source for colonic epithelial cells and plays a key role in 
maintaining human gut health (300). Another genus from the family Lachnospiraceae showed 
a similar trend, but after the RA being significantly higher than baseline at week 6, the RA 
was actually significantly lower than baseline at week 12. 
5.5.3.1 Diversity 
Although there were changes seen in certain taxa as discussed above, in this study population 
the consumption of two SunGold kiwifruit daily did not significantly alter microbial diversity 
after 6 and 12 weeks of consumption.  
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5.5.3.2 Faecal water and gastrointestinal symptoms 
The consumption of two SunGold kiwifruit daily led to a significant increase in faecal water 
content at both 6 and 12 weeks compared to baseline. This indicates a shortened gut transit 
time (laxative effect). A shortened transit time has been linked to decreases in community 
diversity in previous research (301). However, in this study where increased faecal water 
content implied a shorter transit time, community alpha diversity was seen to increase from 0 
to 6 weeks, but was closer to baseline diversity levels at 12 weeks. 
In this study, the observation may be confounded by the fact that kiwifruit contains 
1.4 g/100g of fibre (270), which comprises both soluble and insoluble components at a ratio 
of approximately 1:3 (132). The soluble fibre is made up almost exclusively of pectic 
polysaccharides that have the ability to retain water and form gels, which increases the size 
and softness of the faeces and aids stimulation of peristaltic movements (132). This soluble 
fibre is likely to be the cause of the increase in faecal water seen in this study. Results from 
several clinical trials also show that kiwifruit promotes laxation (302-305).  
Although there were no significant increases seen in the number of daily bowel motions of 
participants at weeks 6 and 12, there were limitations associated with this questionnaire, as 
participants reported their total number of bowel motions over three non-consecutive days. At 
the end of the study 10 participants commented on positive GI effects they noticed during the 
trial, and 10 participants reported changes such as increased bowel motion frequency, reduced 
constipation, reduced irritable bowel syndrome symptoms and improved digestion. The 
average GSRS score at weeks 6 and 12 was not significantly different to baseline, suggesting 
that there was no gastrointestinal discomfort associated with the kiwifruit, with only one 
participant who reported feeling slightly bloated at times during the trial.  
5.5.3.3 Self-reported dietary data 
Participants completed a food diary during the week prior to starting the kiwifruit intervention 
and also during the final week of the trial. Therefore, the baseline food diary data provided a 
measure of their habitual intake, compared to the week 12 data where participants were also 
consuming the two SunGold kiwifruit daily. Analysis of fresh fruit and total fruit intake at 
week 12 was carried out, both including and excluding the kiwifruit, to assess whether 
participants had added the fruit to their usual diet, or if they were replacing with kiwifruit the 
fruit they would have normally eaten.  
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5.5.3.3.1 Fruit intake 
When kiwifruit was included in the analysis of fresh and total fruit intake, results show that 
on average participants were consuming 106 g and 90 g more fresh fruit and total fruit 
respectively at week 12 compared to baseline. This difference equates to approximately one 
kiwifruit (95 g) and therefore suggests that some participants were both adding the kiwifruit 
to their usual diet and replacing the fruit that they would have previously eaten with the 
kiwifruit. This result was verified by a questionnaire participants completed at the end of the 
study, which showed that eleven of the participants reported replacing fruit they had 
previously eaten with the kiwifruit.  
5.5.3.3.2 Macronutrient intake 
Despite the small increase in fruit at week 12, there were no significant differences in energy, 
fibre, protein, total fat and total carbohydrate intake when dietary data at week 12 was 
compared to baseline. This result suggests participants did not make major changes to their 
diet during the trial. The addition of the SunGold kiwifruit also had no significant impact on 
their macronutrient intake as it is relatively low in calories (63 kcal/100g), fibre (1.4 g/100g), 
protein (1.0 g/100g), fat (0.3 g/100g) and carbohydrate (15.8 g/100g)(270). However, 
SunGold kiwifruit does contain 12.3 g/100g of sugar (270) and so this may have contributed 
to the significant higher intake of fructose (increase of 6 g) and glucose (increase of 6 g) at 
week 12 compared to baseline. It was interesting to find no deterioration in glycaemic control 
despite the significant increase in fructose and glucose intake.  
5.5.3.3.3 Vitamins  
SunGold kiwifruit is rich in vitamin C, containing 161.3 mg/100g (127), so predictably 
dietary vitamin C intake was significantly higher at week 12 compared to baseline, in line 
with the significant increase seen with plasma vitamin C and compliance of kiwifruit 
consumption estimated to be 91%. SunGold kiwifruit also contains vitamin E (1.4 mg/100g) 
and folate (31 µg/100g), so will have contributed to the higher intake of these vitamins at 
week 12 compared to baseline.  
5.5.3.3.4 Kiwifruit consumption 
All of the participants said that they found it manageable to consume two SunGold kiwifruit 
every day for three months, and said that they would purchase and continue to consume the 
fruit if there was a health benefit for them. In this free-living situation, half of the participants 
chose to eat both kiwifruit at once. Participants consumed the fruit at a variety of times during 
the day with the most common time being breakfast. Most participants (79%) reported 
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consuming the fruit at the same time every day which suggested they were in a routine. In this 
study all participants were asked not to consume the skin to keep fibre intake between 
participants consistent. Only two participants said it would be more convenient to eat the skin.  
5.5.3.3.5 Blood pressure 
There was a small statistically significant reduction in both diastolic and systolic blood 
pressure over the duration of the study. At week 12, systolic and diastolic blood pressure were 
4 mmHg and 6 mmHg lower than baseline respectively. This result is unlikely to be due to 
changes in blood pressure medication as only two participants reported changes to the dose of 
their blood pressure medication during the study. One of these participants actually had their 
blood pressure medication dose reduced by half between week 6 and 12, and the other 
participant was taking the same dose at week 12 as they were at baseline despite having it 
increased earlier in the study. Results from this study show the overall change in blood 
pressure across the cohort, and also the response of all individuals, with some responding and 
others not. This may be related to their level of oxidative stress as hypertension has been 
related to increased oxidative stress and reduced antioxidant status (306). Kiwifruit contain a 
wide range of natural antioxidants; they are rich in vitamin C, and also contain vitamin E, 
polyphenols and flavonoids, which are all potent antioxidants (268). This result is consistent 
with a RCT of smokers, who are also known to have lower vitamin C concentrations, which 
showed three kiwifruit per day for eight weeks was associated with reductions of 10 mmHg in 
systolic blood pressure and 9 mmHg in diastolic blood pressure (307). 
5.5.3.3.6 Waist circumference 
There was a significant clinically relevant decrease in waist circumference of 3.1 cm at week 
12 compared to baseline. Although, there was only a small non-significant decrease in BMI of 
0.8 kg/m2, waist circumference is used as a marker of abdominal adiposity and so could 
reduce without BMI reducing. Abdominal adiposity is a well-known risk factor for metabolic 
disease and so this result is in agreement with other improvements seen in metabolic health in 
this study cohort such as reduced blood pressure. The RA of the family Ruminococcaceae 
was higher at week 6 and week 12 compared to baseline, with previous research reporting a 
higher RA of this family of bacteria to be negatively associated with visceral adiposity (267).  
5.5.4 Study Strengths 
This was the first study to measure changes in the gut microbiota and vitamin C status 
associated with a whole fruit (SunGold kiwifruit) in people with prediabetes.   
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• The study duration of three months enabled the use of HbA1c as a measure of 
glycaemic control and allowed for investigation of both temporary and longitudinal 
shifts in the microbiota. 
• A free-living situation was used, representing a realistic intervention for the general 
population.  
• Using a whole food rather than an extract/supplement in this study makes it more 
affordable and available for people. Furthermore, the absence of processing maintains 
the natural structure of nutrients which are potentially more bioavailable in whole 
foods (308). 
• In this study plasma vitamin C status corroborated the food diaries as an objective 
measure of compliance. 
5.5.5 Study Limitations 
• The study design was not a randomised cross-over; however, baseline measurements 
were used for comparison. Information on participants’ dietary intake and activity 
levels, supplementation and medication use was collected during the study to ensure 
there were no other significant changes such as eating behaviour that could act as a 
confounder, and thereby contributing to the results seen.  The absence of a control 
group does, however, mean is not possible to attribute cause and effect to the study as 
temporal changes seen in this study may be influenced by individuals being included 
in a nutrition intervention. This was a pilot exploratory study with a limited number of 
participants, which means it may not be sufficient to identify some clinically relevant 
associations with the microbiota. 
• In this study, a 3DEFD was used rather than a weighed food diary that was used in a 
previous study in order to reduce participant burden. A shortened estimated food diary 
was used to check if there were any significant changes in participant intake over the 
duration of the study. It was estimated that a similar percentage of participants were 
under-reporting their energy intake at baseline and week 12 (33% and 25%), similar to 
adults of a similar weight in a New Zealand adult survey which reported 25% of 
overweight adults to be low energy reporters (229). As discussed previously in this 
thesis, it is possible that this is not a limitation as researchers have recently suggested 
that the energy prediction equations overestimate the energy requirements more for 
obesity-susceptible individuals (217).  
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• The number of OTUs (approximately 72) and parameters (approximately 46) explored 
is large, and for the anthropometric data, blood pressure, fasting glucose, GSRS, 
bowel movements, faecal water and microbiota data, two comparisons were made 
(weeks 6 and 12 versus baseline). Given the large number of statistical tests, it is 
highly likely that some of the statistically significant results, particularly at the genus-
level, represent Type I errors. For this reason, the conclusion only includes the results 
of the RA of bacteria if a significant association was seen at the higher taxonomic 
level (phylum and class) for this study.  
• There is some possibility that taking probiotics influenced the results for the three 
participants that consumed the supplement. 
• Limitations on faecal samples, DNA extraction, sequencing and bioinformatics are 
detailed in the Chapter two.  
• All three blood pressure readings were averaged for each participant at each study 
visit. This is a potential limitation as the first reading can often be higher, particularly 
at the first study visit and may therefore have partially contributed to the observation 
seen in this study.  
5.5.6 Conclusions 
This pilot exploratory study showed that the daily consumption of two SunGold kiwifruit in a 
free-living situation for three months caused some change in the gut microbiota in people with 
prediabetes, with no deterioration in HbA1c. The RA of the class Coriobacteriia was higher 
at both week 6 and week 12 compared to baseline levels. It is hypothesised that the 
polyphenols in the SunGold kiwifruit may be acting as an energy source for this class of 
bacteria, with one of their functions being to activate polyphenols.  
The results also showed an increase in faecal water, suggesting a shortened gut transit time. 
Study participants reported finding it manageable to consume the fruit and would continue 
consuming the fruit if there were health benefits for them. The results also showed a reduction 
in blood pressure to be associated with SunGold kiwifruit consumption. As this was a pilot 
trial of a small study cohort, the results need to be interpreted with caution and verified in a 
larger population.  
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5.5.7 Future Research 
The detection of an increased RA of Coriobacteriaceae (from the class Coriobacteriia) in the 
faecal microbiota during the period of SunGold kiwifruit consumption could lead to the 
isolation and characterisation of a new bacterial species. The increased abundance of 
Coriobacteriaceae reflected more pronounced changes in the microbiotas of 5 out of 21 
individuals. Further analysis showed that one bacterium from the Coriobacteriaceae family 
had an increased abundance but has not yet been cultured in the laboratory, and therefore not 
as yet characterised. Future work could be carried out by culturing the Coriobacteriaceae 
from the faecal samples from individuals that had an increased RA of these bacteria and 
characterising their abilities to use kiwifruit components. This could lead to the recognition of 
a new bacterial species particularly adapted to the use of kiwifruit components for growth. It 
will also be important to determine the types and amounts of polyphenols in the SunGold 
kiwifruit as well as phenolics in the faeces to show an association between an increase in 
kiwifruit consumption, chemical transformations/utilization, and an increase in 
Coriobacteriaceae. Measuring phenolics in plasma to show the absorption of compounds 
resulting from bacterial metabolism of phenolics is also suggested. This would help to 
determine if the increase in the RA of Coriobacteriia had a measurable functional impact on 
the human host. 
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Section Two: KIS-Vit C 
5.6 Background 
Consistent with previous research (45, 243, 244, 246, 309), results from Chapters three and 
four have shown that higher plasma vitamin C is associated with reduced insulin resistance 
and better blood glucose control. However, there have been mixed findings reported in RCTs 
investigating whether supplementation with vitamin C had a significant effect on glycaemic 
control and insulin sensitivity (272-274).  
In addition to the microbiota analysis, results from kiwifruit intervention trial provided an 
opportunity to investigate the plasma vitamin C status of the participants at baseline, and also 
the effect of consuming two SunGold kiwifruit per day on plasma vitamin C concentrations in 
a cohort of people with prediabetes in a free-living situation. 
5.7 Aims and Hypothesis 
The aim of this study is to investigate the plasma vitamin C status of the participants at 
baseline, and also the effect of consuming two SunGold kiwifruit per day on plasma vitamin 
C concentrations in a cohort of people with prediabetes in a free-living situation. 
It is hypothesised that: 
• The consumption of two SunGold kiwifruit per day over 12 weeks will increase plasma 
vitamin C concentrations and improve markers of metabolic health.  
5.8 Results 
At baseline there were no participants with deficient plasma vitamin C concentrations 
(<11 µmol/L). There were three participants (13%) with marginal (11–23 µmol/L), and seven 
(29%) with inadequate (24–49 µmol/L) plasma vitamin C concentrations (Figure 5.19). Over 
half of the cohort (n=14) had either adequate (42%, 50–69 µmol/L) or saturating (17%, 
≥70 µmol/L) plasma vitamin C concentrations at baseline (Figure 5.19). 
! 225!
 
Figure 5.19. Plasma vitamin C status of individuals at weeks 0 and 12 classified as having saturating 
(≥70 µmol/L), adequate (50–69 µmol/L), inadequate (24–49 µmol/L) and marginal (11–23 µmol/L) 
plasma vitamin C. There were no participants classified as having deficient (<11 µmol/L) plasma 
vitamin C concentrations. (42)  
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In this study, consuming two SunGold kiwifruit per day resulted in significant increases in 
both plasma and dietary vitamin C (Table 5.13).  
Table 5.13: Dietary and Plasma vitamin C at week 0 and 12. 
) Week)0)(n=24)) Week)12)(n=24)) p)
Dietary(vitamin(C((mg/day)( 79(±(35( 347(±(70( p<0.001(
Plasma(vitamin(C((µmol/L)( 50(±(19( 64(±(13( p<0.001(
!
Of the three participants who had marginal plasma vitamin C concentrations at baseline, two 
participants had adequate and one participant had saturating plasma vitamin C concentrations 
at week 12 (Table 5.14). Of the seven participants who had inadequate plasma vitamin C 
concentrations at baseline, four had adequate plasma vitamin C concentrations at week 12, 
and three remained in the inadequate category (Table 5.14). Of the 10 participants who had 
adequate plasma vitamin C concentrations at baseline, three increased to reach the threshold 
for saturating plasma vitamin C concentrations at week 12 and seven participants remained as 
having adequate levels (Table 5.14). One participant had slightly lower plasma vitamin C 
concentrations at week 12 (68 µmol/L) compared to baseline (89 µmol/L) but still had 
adequate concentrations at week 12 (Table 5.14).  
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Table 5.14: Change in plasma vitamin C concentrations of participants from week 0 to week 12. 
) Week)0) Week)12)
) Plasma)Vitamin)C) Deficient( Marginal( Inadequate( Adequate( Saturating(
)
Deficient( 0( 0( 0( 0( 0(
Marginal( 0( 0( 0( 2( 1(
Inadequate( 0( 0( 3( 4( 0(
Adequate( 0( 0( 0( 7( 3(
Saturating( 0( 0( 0( 1( 3(
!
At baseline the majority of participants (n=20) met the New Zealand RDI for vitamin C of 
45 mg/day (Figure 5.20). There was only one participant who had a dietary intake below the 
New Zealand EAR (30 mg/day), and there were no participants reaching the New Zealand 
MOH SDTs to reduce chronic disease risk, that is 220 mg/day for men and 190 mg/day for 
women (Figure 5.20). At the end of the study the majority of participants (n=22) had dietary 
intakes reaching the SDT, and the other participants had intakes above the RDI (n=2) (Figure 
5.20). 
 
Figure 5.20. Individuals at weeks 0 and week 12 meeting the estimated average requirement (EAR) 
(30 mg/day), recommended dietary intake (RDI) (45 mg/day), and suggested dietary target (SDT) to 
reduce chronic disease risk (220 mg/day for men and 190 mg/day for women). (200) 
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5.8.1 Baseline Correlations 
At baseline, fasting glucose, insulin and waist circumference were significantly negatively 
associated with plasma vitamin C concentrations (Table 5.15). The smoking status of 
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participants (current, ex-smoker, non-smoker) was not significantly associated with plasma 
vitamin C concentrations (p=0.814) or dietary vitamin C intake (p=0.705). There were an 
even number of males and females in this study and gender was not found to be associated 
with plasma vitamin C concentrations (p=0.130) or dietary vitamin C intake (p=0.293). There 
was also no association found between level of education and plasma vitamin C 
concentrations (p=0.121) or dietary vitamin C intake (p=0.418). Ethnicity was not analysed 
with plasma or dietary vitamin C due to the majority of participants being European.  
There was no significant association between plasma vitamin C concentration and dietary 
vitamin C intake (r=0.297, p=0.149). There were no significant associations between dietary 
vitamin C intake and the laboratory, anthropometric and blood pressure measures (Table 
5.15).  
Table 5.15: Pearson correlations of baseline plasma vitamin C and dietary vitamin C, glycaemic 
indices, hormones, lipids, hs-CRP, blood pressure, and anthropometric measures. 
Measure) Plasma)vitamin)C)
Pearson)Correlation)
Dietary)vitamin)C)
Pearson)Correlation)
Fasting(glucose((mmol/L)( 20.450*( 20.223(
HbA1c((mmol/mol)( 20.250( 20.189(
Insulin((pmol/L)( 20.520**( 20.002(
Leptin((ng/mL)( 20.053( 0.247(
Ghrelin((pmol/L)( 0.094( 0.028(
Adiponectin((µg/mL)( 0.273( 20.226(
Total(cholesterol((mmol/L)( 0.046( 20.001(
Triglycerides((mmol/L)( 20.194( 20.181(
HDL2cholesterol((mmol/L)( 0.324( 0.209(
LDL2cholesterol((mmol/L)( 0.090( 0.020(
Cholesterol((total/HDL)(ratio( 20.168( 20.111(
hs2CRP((mg/L)( 20.123( 0.216(
Diastolic(blood(pressure((mmHg)( 20.308( 20.182(
Systolic(blood(pressure((mmHg)( 20.344( 20.172(
Weight((kg)( 20.359( 0.122(
BMI((kg/m2)( 20.328( 0.100(
Fat(mass((%)( 0.060( 0.218(
Waist(circumference((cm)( 20.399*( 0.152(
Waist2to2hip(ratio( 20.315( 20.065(
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5.8.2 Participant Groups by Adequacy  
Participants were grouped by adequacy of plasma vitamin C concentrations at baseline, with 
those with a plasma vitamin C level of ≥ 50 µmol/L considered to be adequate (42). Although 
the increase in vitamin C from week 0 to week 12 was significant for both groups, it was 
greater for those who had a lower plasma vitamin C concentration at baseline (Table 5.16).  
There were 10 participants with plasma vitamin C levels below adequate (<50 µmol/L) at 
baseline (Table 5.16). Of these 10 participants, seven had adequate plasma vitamin C levels 
(≥50 µmol/L) at the end of the kiwifruit intervention. The 14 participants who had adequate 
plasma vitamin C concentrations at baseline also had adequate plasma vitamin C levels at the 
end of the study.  
Table 5.16: Change in vitamin C concentrations (week 12 minus week 0) of participants grouped as 
having adequate and inadequate plasma vitamin C concentrations at baseline. 
Baseline)Plasma)vitamin)C)Groups) Mean)Change)in)Plasma)vitamin)C)
(week)12)minus)week)0))
p)
Inadequate(plasma(vitamin(C((<50(µmol/L)(
(n=10)(
22(µmol/L) 0.004(
Adequate(plasma(vitamin(C((
(≥50(µmol/L)((n=14)(
7(µmol/L( 0.029(
!
Table 5.17 compares the changes (week 12 minus week 0) in laboratory and anthropometric 
measures of participants grouped as having inadequate (<50 µmol/L) and adequate 
(≥50 µmol/L) plasma vitamin C levels at baseline, and also the changes seen in the entire 
cohort. Along with the significant increase in plasma vitamin C, there are improvements in 
several metabolic, inflammatory and anthropometric measures (such as HbA1c, insulin, hs-
CRP, BMI, fat mass and waist circumference) in those with inadequate plasma vitamin C 
levels compared to those with adequate levels; however, these differences are neither 
statistically nor clinically significant. There was a significant difference between the adequacy 
groups for the change in fasting glucose, but the difference is not clinically significant.  
In the overall cohort, there were significant changes in fasting glucose, HbA1c and waist-to-
hip ratio but these changes were small and were not clinically significant. There was a 
significant reduction in both diastolic and systolic blood pressure, and although not 
statistically significant, those with inadequate plasma vitamin C concentrations at baseline 
had a greater reduction in blood pressure than those with adequate vitamin C concentrations.  
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Table 5.17: Change in laboratory and anthropometric measures (week 12 minus week 0) of the whole 
cohort and subgroups of participants grouped by adequacy of plasma vitamin C concentrations at 
baseline. 
Change)in)Measures))
(week)12)minus)week)0))
Total)
(n=24))
p*) <50)µmol/L)
(n=10))
≥50)µmol/L)
(n=14))
p†)
Plasma(vitamin(C((µmol/L)) 14(±(16( <0.001( 22(±(18( 7(±(11( 0.022(
Fasting(glucose((mmol/L)( 0.18(±(0.41( 0.046( 20.03(±(0.42( 0.32(±(0.34( 0.033(
HbA1c((mmol/mol)( 21.2(±(1.9( 0.005( 21.3(±(2.5( 21.1(±(1.5( 0.848(
Insulin((pmol/L)( 0.3(±(22.8( 0.957( 28.7(±(24.3( 6.0(±(20.6( 0.135(
Leptin((ng/mL)( 21.5(±(21.1( 0.728( 20.7(±(32.6( 22.1(±(7.1( 0.871(
Ghrelin((pmol/L)( 5.7(±(34.2( 0.421( 2.3(±(35.0( 8.2(±(34.7( 0.689(
Adiponectin((µg/mL)( 0.9(±(2.1( 0.061( 1.6(±(2.1( 0.3(±(2.0( 0.171(
Total(cholesterol((mmol/L)( 20.1(±(0.5( 0.372( 20.1(±(0.6( 20.1(±(0.5( 0.882(
Triglycerides((mmol/L)( 20.03(±(0.25( 0.580( 20.04(±(0.30( 20.02(±(0.23( 0.865(
HDL2cholesterol((mmol/L)( 0.00(±(0.11( 0.880( 0.03(±(0.07( 20.01(±(0.13( 0.412(
LDL2cholesterol((mmol/L)( 20.08(±(0.49( 0.436( 20.12(±(0.51( 20.05(±(0.49( 0.738(
Cholesterol((total/HDL)(ratio( 20.08(±(0.40( 0.318( 20.19(±(0.34( 20.01(±(0.43( 0.279(
hs2CRP((mg/L)( 20.3(±(1.3( 0.301( 20.5(±(1.7( 20.1(±(1.0(( 0.444(
Diastolic(blood(pressure(
(mmHg)(
24.0(±(8.4( 0.029( 26.5(±(8.7( 22.2(±(8.0( 0.219(
Systolic(blood(pressure(
(mmHg)(
27.2(±(10.7( 0.003( 210.2(±(11.1( 25.1(±(10.2( 0.256(
BMI((kg/m2)( 20.2(±(0.6( 0.070( 20.5(±(0.7( 20.1(±(0.6( 0.132(
Fat(mass((%)( 20.4(±(1.2( 0.108( 20.7(±(1.2( 20.2(±(1.2( 0.368(
Waist(circumference((cm)( 21.7(±(2.2( 0.001( 22.7(±(2.6( 21.0(±(1.4( 0.053(
Waist2to2hip(ratio( 20.01(±(0.02( 0.032( 20.02(±(0.03( 20.01(±(0.02( 0.277(
Values presented as mean ±(SD. 
* p values refer to the change in the total group. 
† p values refer to the comparison of the changes between the two adequacy groups (those with plasma vitamin 
C <50 µmol/L and those with plasma vitamin C ≥50 µmol/L at baseline). 
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5.9 Discussion 
In this study, consuming two SunGold kiwifruit per day (total of 190 g flesh) for three months 
provided approximately 300mg of vitamin C daily from the kiwifruit alone. This increase in 
dietary vitamin C from the SunGold kiwifruit resulted in most participants meeting the New 
Zealand MOH’s SDT to reduce chronic disease risk (200). In agreement with the hypothesis 
for this study, SunGold kiwifruit supplementation resulted in a significant increase in plasma 
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vitamin C concentrations (mean increase of 14 µmol/L) and small improvements in several 
markers of metabolic health. 
When participants were grouped by those with inadequate (<50 µmol/L) and adequate 
(≥50 µmol/L) plasma vitamin C concentrations at baseline, there was a greater and more 
statistically significant increase in plasma vitamin C in those who started with inadequate 
plasma vitamin C concentrations (increase of 22 µmol/L), compared to those who already had 
adequate concentrations at baseline (increase 7 µmol/L). This result is consistent with 
findings from another kiwifruit trial where those with lower baseline plasma vitamin C 
concentrations (mean of 26 µmol/L) showed an earlier and greater response to 
supplementation (half to three kiwifruit per day) causing increases in plasma vitamin C levels 
that ranged from 22 to 43 µmol/L, compared to those with higher plasma vitamin C 
concentrations at baseline (mean of 50 µmol/L) who showed little effect from 
supplementation (195). Three participants (13%) in the current study had only adequate 
plasma vitamin C concentrations at week 12 which may indicate non-compliance or be related 
to some lifestyle factor, such as smoking, or chronic disease (42).  
While all participants met the ADA criteria for prediabetes using HbA1c (39–46 mmol/mol) 
at baseline, there was still a range of anthropometric and laboratory measures for participants. 
For example, fasting glucose ranged from 3.9 to 7.5 mmol/L, insulin ranged from 15 to 
220 pmol/L and waist circumference ranged from 70 to 125 cm. Fasting glucose, insulin and 
waist circumference were all inversely associated with plasma vitamin C concentrations at 
baseline. This result is consistent with previous research (44-46, 243, 244, 309) and is also 
consistent with results from Chapters three and four.  
It has been suggested that vitamin C concentrations at baseline may represent a critical factor 
in predicting the metabolic responses to nutritional interventions tackling oxidative stress and 
may in part explain why there have been inconsistent findings in RCTs investigating 
supplementation with vitamin C and glycaemic control (42, 195). Individuals in this study 
were supplemented with vitamin C-rich kiwifruit; however, there were only three participants 
with marginal vitamin C levels, and no participants with deficient levels at baseline. This may 
explain why no clinically significant differences were seen when changes in anthropometric 
and metabolic markers were calculated (week 12 minus week 0) and compared between those 
with inadequate (<50 µmol/L) and adequate (≥50 µmol/L) plasma vitamin C concentrations. 
Furthermore, the length of an intervention may need to be longer than 12 weeks to see 
biological changes (252). The results do, however, show that even those grouped as having 
inadequate plasma vitamin C concentrations had slightly greater decreases in several markers 
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of metabolic health (such as fasting glucose, HbA1c, insulin and BMI) compared to those 
with adequate vitamin C concentrations. 
As discussed in Section 5.5.3, there was a small statistically significant reduction in both 
diastolic and systolic blood pressure over the duration of the study that did not appear to be 
due to changes in blood pressure medication. Those with inadequate vitamin C levels at 
baseline had a greater reduction in blood pressure (decrease of 7 ± 9 mmHg diastolic and 
10 ± 11 mmHg systolic) compared to those who had adequate levels (decrease of 
2 ± 8 mmHg diastolic and 5 ± 10 mmHg systolic) when week 12 was compared to baseline. 
As discussed in Section 5.5.3 this may be related to their level of oxidative stress as 
hypertension has been related to increased oxidative stress and reduced antioxidant status 
(306).  
In this study, participants were not pre-screened for vitamin C intake or status and, as a result, 
half the study cohort already had adequate plasma vitamin C status at baseline. Furthermore, 
because a study arm with vitamin C supplementation alone was not included, it is difficult to 
ascertain the contribution of the vitamin C content of the fruit to the observed effects. Other 
potentially beneficial or synergistic constituents in kiwifruit may have contributed to the 
results seen. As discussed in Section 5.5.5, all three blood pressure readings were averaged 
for each participant rather than discarding the first reading and averaging the second two 
which may have impacted the blood pressure results. It was estimated that 33% of participants 
were under-reporting their energy intake at baseline. In this study, unlike results from 
Chapters three and four, there was no significant association found between dietary vitamin C 
intake and plasma vitamin C concentrations. However, as discussed in Chapter three, if under-
reporting was related to social desirability, it is unlikely that fruit and vegetable intake, and 
thus dietary vitamin C intake, was affected. It may be that a food diary of a longer duration is 
recommended for analysing dietary intake. Furthermore, food diaries take into account 
vitamin C from diet alone, whereas plasma vitamin C takes into account both intake and 
utilization and may also be impacted by other factors such as illness and smoking.  
5.10 Conclusion 
Supplementation with two SunGold kiwifruit per day significantly increased plasma vitamin 
C concentrations and provided a greater increase in those who had lower plasma vitamin C 
levels at baseline. Small improvements in several markers of metabolic health were associated 
with vitamin C-rich kiwifruit supplementation; however, these were not clinically significant. 
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5.11 Future Research 
In this pilot study of people with prediabetes, there were no participants with deficient, and 
few participants with marginal, vitamin C concentrations at baseline. It is therefore 
recommended that the study is repeated in people with lower plasma vitamin C concentrations 
at baseline. Furthermore, as this was a pilot study of small study numbers, it is recommended 
that a larger cohort of people is used in future research. A food diary of a longer duration is 
recommended for analysing dietary intake as, unlike results from Chapters three and four, in 
this study there were no significant associations found between dietary vitamin C intake and 
plasma vitamin C concentrations. 
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 Chapter Six: Conclusions and Future Research 
Two main areas of research were conducted in this thesis. Associations were investigated 
between the gut microbiota and glycaemic control, as well as between plasma vitamin C and 
glycaemic control.  
6.1 The Gut Microbiota 
To date, few studies have investigated T2DM (or the progression to T2DM) and the gut 
microbiota, and results from those studies which have been carried out are inconsistent (95, 
97, 165, 181). These inconsistencies may in part be due to issues around methodology such as 
heterogeneous cohorts, and lack of control for other factors known to affect the gut 
microbiota. In the observational study in this thesis (Chapter four), some of these 
methodological issues were addressed; for example, participants were carefully stratified 
according to metabolic and clinical criteria to create homogenous groups. Data collected 
included age, sex, ethnicity, education, physical activity, anthropometry, smoking status, 
glycaemic measures, inflammatory marker, lipids and metabolic hormones. Both fasting 
glucose and HbA1c were measured in this thesis, as they reflect different aspects of glucose 
metabolism. Both fasting glucose and HbA1c were also included as continuous variables in 
the observational study due to worldwide discrepancies in the diagnostic criteria for 
prediabetes and T2DM. The study also accounted for other factors known to impact the gut 
microbiota such as gastrointestinal disease, metformin, antibiotic and probiotic use, and 
dietary intake.  
When participants were grouped by glycaemic control (NGT, prediabetes and T2DM), 
concentrations of other markers of metabolic health such as BMI, hormones (insulin, leptin, 
ghrelin) and inflammation (hs-CRP) were associated with glycaemic control, as would be 
expected. For example, BMI, insulin and hs-CRP concentrations all increased from NGT to 
prediabetes to T2DM, suggesting a well-stratified population. 
In this thesis, there was a special emphasis on collecting detailed self-reported dietary data, 
particularly for the observational study when associations between diet and the gut microbiota 
were investigated as potential confounding variables (Chapter four). For this study, weighed 
food diaries were used to allow for precision of portion sizes.  
The self-reported dietary intake of participants with NGT, prediabetes and T2DM from 
Chapters three and four were compared and their macronutrient intake was found to be very 
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similar. It was surprising that in both studies there were no significant differences in total 
energy intake across the study groups, despite BMI being higher in the prediabetes and T2DM 
groups compared to the NGT group. To investigate this further, the percentage of individuals’ 
under-reporting energy intake in each cohort and study group was estimated. The percentage 
of under-reporting was estimated to range from 18-33% for the cohorts included in this thesis. 
The mean percentage of under-reporting energy intake was higher in the prediabetes and 
T2DM groups compared to the NGT group in Chapters three and four. Although this is a 
potential limitation of dietary intake data, there are also several other possible reasons for this 
observation. For example, individuals taking part in research are often motivated and could 
have been currently dieting; recent research has suggested the energy prediction equations 
overestimate the energy requirements more for obesity susceptible individuals (217); and 
individuals with prediabetes and T2DM may have a genetic predisposition to obesity (240). 
Although the known errors associated with dietary assessment are acknowledged in this 
thesis, the methods used in this thesis are perfectly acceptable to measure food consumption 
of individuals in the community. In this thesis, stringent protocols were adhered to, to ensure 
that the diet data collected was as robust as possible. 
In line with previous research (164), results from this thesis also showed that neglecting to 
control for metformin can confound results. Accordingly, individuals with T2DM treated with 
metformin were excluded from the microbiota analysis in this thesis. This resulted in a small 
study group of people with T2DM, as it was very difficult to recruit treatment-naïve 
participants with fasting glucose levels meeting the diagnostic criteria for T2DM. The 
difficulty in recruiting these individuals meant that it was not possible to address the issue of 
small study cohorts in this study. The sequencing data from this study could be combined 
with data from other research groups in collaboration as part of future research.  
In both the observational study (Chapter four) and intervention trial (Chapter five), the only 
phylum found to be associated with glycaemic control and SunGold kiwifruit consumption 
was Actinobacteria.  
6.1.1 Observational Study 
Results from the observational study showed that the RA of the class Actinobacteria (from the 
phylum Actinobacteria) was significantly positively associated with fasting glucose and 
insulin concentrations. The only genus present in the class Actinobacteria in this study’s 
dataset was Bifidobacterium. Previous research has produced conflicting results, with studies 
showing both an increased and decreased RA of Bifidobacterium in people with T2DM 
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compared to those with NGT (181, 265). Further research in larger cohorts is therefore still 
required to validate the findings of this thesis.  
6.1.1.1 Future research 
The observational study in this thesis was a pilot exploratory study and a larger cohort is 
therefore required to validate the microbiota findings due to the large amount of inter-
individual variation. Sequencing data from this study could be combined with data from other 
studies to create a larger dataset for analysis. Furthermore, this research focused on 
characterising the gut microbiota, and so further research is required to investigate the 
function/metabolites of the bacteria. A logical next step would be investigating the bowels of 
those with T2DM to ascertain any factors influencing the gut microbiota, such as increased 
postprandial glucose levels, that may be promoting an increased RA of Actinobacteria.  
6.1.2 Kiwifruit Study 
The intervention trial showed a significant increase in the RA of the class Coriobacteriia 
(from the phylum Actinobacteria) after both 6 and 12 weeks of daily consumption of two 
SunGold kiwifruit. This is the first study to report this finding in humans but is supported by 
an in vitro trial which showed an increase in the phyla Actinobacteria using green kiwifruit as 
the substrate (277). Coriobacteriaceae was the only family present for the class 
Coriobacteriia in this dataset. The bacterium that fits within the Coriobacteriaceae family 
was uncharacterised, suggesting that there are uncultivated bacteria that use substrates 
associated with SunGold kiwifruit in the gut microbiota. One of the functions of 
Coriobacteriaceae is to activate polyphenols, a constituent of SunGold kiwifruit (268). The 
antioxidant capacity of phenolics has been associated with potential health benefits, including 
the prevention of diseases associated with oxidative stress, such as T2DM (310).  
6.1.2.1 Future research 
The detection of an increased RA of Coriobacteriaceae in the faecal microbiota during the 
period of SunGold kiwifruit consumption is an exciting observation that could lead to the 
isolation and characterisation of a new bacterial species. The increased abundance of 
Coriobacteriaceae reflected very pronounced changes in the microbiotas of 5 out of 21 
individuals. Further analysis showed that one bacterium from the Coriobacteriaceae family 
had an increased abundance but has not yet been characterised by culturing in the laboratory. 
Future work should include culturing the Coriobacteriaceae from the faecal samples of 
! 236!
individuals who had an increased RA of these bacteria, to study how these organisms 
metabolize kiwifruit. This could lead to the recognition of a new bacterial species particularly 
adapted to the use of kiwifruit components for growth. Future research should evaluate the 
types and quantities of polyphenols in the SunGold kiwifruit, as well as phenolics in the 
faeces, to show associations between an increase in kiwifruit consumption, chemical 
transformations/utilization, and an increase in Coriobacteriaceae. A further suggestion is to 
measure phenolics in plasma to show the absorption of compounds resulting from bacterial 
metabolism of phenolics. This would determine if the increase in the RA of Coriobacteriia 
seen in Chapter five has a measurable functional impact on the human host.  
6.2 Vitamin C  
Consistent with the previous research (44-46) results from the CHALICE cohort, the 
observational study, and the interventional trial all showed a common theme of plasma 
vitamin C being inversely associated with glycaemic control. Furthermore, BMI and smoking 
history were also independent predictors of plasma vitamin C concentrations, which also 
concurs with previous research (234, 235, 238). Results showed ex-smokers and current-
smokers had lower plasma vitamin C concentrations than non-smokers. Results from this 
thesis showed the concentration of hs-CRP (an inflammatory marker) to increase with the 
deterioration of glycaemic control and an increase in BMI, and the oxidizing properties of 
tobacco smoke resulting in an increased turnover of vitamin C. The lower plasma vitamin C 
concentrations in those with higher BMI, poorer glycaemic control and current smokers is 
consistent with the depletion of vitamin C due to its antioxidant and anti-inflammatory 
activities.  
In addition to the well-documented association between vitamin C deficiency and risk of 
developing the potentially fatal disease of scurvy, there is also growing interest in the role that 
vitamin C may play in countering the development of T2DM and associated complications. 
Furthermore, it is becoming increasingly acknowledged that vitamin C is required at 
concentrations above those needed to prevent scurvy for the maintenance of good health (42, 
43). For example, individuals with marginal vitamin C concentrations are known to present 
with fatigue, depression and deficiencies in wound healing (129, 130).  
In the intervention trial, consuming two SunGold kiwifruit per day provided approximately 
300mg of vitamin C daily. This resulted in a significant increase in plasma vitamin C 
concentrations, with a greater increase seen in those who started with inadequate vitamin C 
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concentrations at baseline. Small improvements were seen in several markers of metabolic 
health; however these were not clinically significant.  
6.2.1 Future Research 
Further research into the possibility of a higher RDI for vitamin C for those with prediabetes 
and T2DM is warranted. As the intervention study in this thesis was a pilot trial with a small 
study cohort, it is recommended that a vitamin C intervention trial is carried out in a larger 
cohort, and in people with T2DM who have marginal or deficient vitamin C levels at baseline. 
This would allow a comparison between an increase in plasma vitamin C concentrations and 
markers of metabolic health.   
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Appendix A 
 
Physical Activity Scoring System (IPAQ)-Short Form 
Continuous score: 
The total minutes of walking, moderate and vigorous intensity activity per week was 
calculated by multiplying the minutes of an activity per day by the number of days per week 
the activity was reported. 
• Walking MET-minutes/week = 3.3 × walking minutes per day × number of days per 
week in which walking was reported. 
• Moderate MET-minutes/week = 4.0 × moderate intensity minutes per day × number of 
days per week in which moderate intensity activity was reported. 
• Vigorous MET-minutes per week = 8.0 × vigorous intensity minutes per day × number 
of days per week in which vigorous intensity activity was reported. 
• Total physical activity MET-minutes/week = walking + moderate + vigorous MET 
minutes/week scores. 
The MET scores of 3.3, 4.0 and 8.0 for walking, moderate and vigorous intensity activity 
were assigned as per the IPAQ scoring protocol (206). 
(
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Appendix B 
 
Procedures followed from raw sequence data to OTU tables  
and diversity analyses for the MHCSS and KIS 
MHCSS workflow 
 
#Join paired ends 
MacQIIME micr_93-mac:~ $ join_paired_ends.py -f 
160930_Lawley_Run2_fastqs/Undetermined_S0_L001_R1_001
.fastq.gz -r 
160930_Lawley_Run2_fastqs/Undetermined_S0_L001_R2_001
.fastq.gz -b 
160930_Lawley_Run2_fastqs/Undetermined_S0_L001_I1_001
.fastq -o 160930_Lawley_Run2_fastqs/fastq_join_run2 
 
#Modify mapping file to remove first base of barcodes 
(this is done as the run has multiple reads with an 
’N’ as the first base of the barcodes and an ’N’ as 
the last base of the joined reads). In excel use 
=RIGHT(B2,11) to remove first base of barcodes in 
column B. Then check mapping file for errors. 
MacQIIME micr_93-mac:160930_Lawley_Run2_fastqs $ 
validate_mapping_file.py -m 
mapping_files_updated/t2d_map_1N.txt -o 
mapping_files_updated/t2d_map_validation 
No errors or warnings were found in mapping file. 
 
#seqtk can be used to trim the first base from each 
read in barcodes.fastq file 
MacQIIME micr_93-mac:160930_Lawley_Run2_fastqs $ 
seqtk trimfq -b 1 
fastq_join_run2/fastqjoin.join_barcodes.fastq > 
fastq_join_run2/fastqjoin.join_barcodes_minus_first.f
astq  
#And the last base from the combined reads.fastq file 
MacQIIME micr_93-mac:~ $ seqtk trimfq -e 1 
160930_Lawley_Run2_fastqs/fastq_join_run2/fastqjoin.j
oin.fastq > 
160930_Lawley_Run2_fastqs/fastq_join_run2/fastqjoin.j
oin_no_last_N.fastq 
 
#Split_libraries_fastq.py using the modified barcode 
file for t2d samples and the trimmed joined reads 
! 268 
MacQIIME micr_93-mac:160930_Lawley_Run2_fastqs $ 
split_libraries_fastq.py -i 
/Users/lawbl09p/160930_Lawley_Run2_fastqs/fastq_join_
run2/fastqjoin.join_no_last_N.fastq -b 
/Users/lawbl09p/160930_Lawley_Run2_fastqs/fastq_join_
run2/fastqjoin.join_barcodes_minus_first.fastq -
m 
/Users/lawbl09p/160930_Lawley_Run2_fastqs/mapping_fil
es_updated/t2d_map_1N_update.txt -q 19 --
barcode_type 11 -o 
/Users/lawbl09p/160930_Lawley_Run2_fastqs/t2d_split_l
ibs_q19_update 
 
#Trim sequences to include those with length 251-
254 bases (use 251 as sequences have had the final 
base trimmed (to remove ’N’ from multiple 
sequences)). 
MacQIIME micr_93-mac:160930_Lawley_Run2_fastqs $ 
prinseq-lite.pl -fasta 
t2d_split_libs_q19_update/seqs.fna -min_len 251 -
max_len 254 
Input and filter stats: 
 Input sequences: 2,607,801 
 Input bases: 659,081,410 
 Input mean length: 252.73 
 Good sequences: 2,579,489 (98.91%) 
 Good bases: 649,790,466 
 Good mean length: 251.91 
 Bad sequences: 28,312 (1.09%) 
 Bad bases: 9,290,944 
 Bad mean length: 328.16 
 Sequences filtered by specified parameters: 
 min_len: 4930 
 max_len: 23382 
 
#Dereplicate sequences filtered to 251-254bp 
MacQIIME micr_93-mac:160930_Lawley_Run2_fastqs $ cd 
t2d_split_libs_q19_update/ 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ 
vsearch --derep_fulllength seqs_prinseq_good.fasta 
--output seqs_u.fasta --sizeout --relabel Unique 
vsearch v1.9.5_osx_x86_64, 8.0GB RAM, 4 cores 
https://github.com/torognes/vsearch 
 
Reading file seqs_prinseq_good.fasta 100%   
! 269 
649790466 nt in 2579489 seqs, min 251, max 254, avg 
252 
Dereplicating 100%   
Sorting 100% 
607578 unique sequences, avg cluster 4.2, median 1, 
max 68208 
Writing output file 100%   
 
#Sort remaining sequences by size of unique clusters 
with a minimum cluster size of 2 (remove singletons) 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ 
vsearch --sortbysize seqs_u.fasta --minsize 2 --
relabel OTU_ --sizeout --output seqs_u_mc2.fasta --
sizein 
vsearch v1.9.5_osx_x86_64, 8.0GB RAM, 4 cores 
https://github.com/torognes/vsearch 
 
Reading file seqs_u.fasta 100%   
153047061 nt in 607578 seqs, min 251, max 254, avg 
252 
Getting sizes 100%   
Sorting 100% 
Median abundance: 2 
Writing output 100%   
 
#Cluster sequences at 97% similarity   
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ 
vsearch --cluster_smallmem seqs_u_mc2.fasta --id 0.97 
--centroids seqs_u_mc2_cent.fasta --uc 
seqs_u_mc2_clust.uc --usersort 
vsearch v1.9.5_osx_x86_64, 8.0GB RAM, 4 cores 
https://github.com/torognes/vsearch 
 
Reading file seqs_u_mc2.fasta 100%   
35168658 nt in 139619 seqs, min 251, max 254, avg 252 
Masking 100% 
Counting unique k-mers 100%   
Clustering 100%   
Sorting clusters 100% 
Writing clusters 100%   
Clusters: 11209 Size min 1, max 4085, avg 12.5 
Singletons: 6067, 4.3% of seqs, 54.1% of clusters 
 
#Chimera detection using a denovo approach 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ 
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vsearch --uchime_denovo seqs_u_mc2_cent.fasta --
uchimeout seqs_u_mc2_cent_uchime.txt --sizeout --
chimeras seqs_u_mc2_cent_chimeras.fasta --nonchimeras 
seqs_u_mc2_cent_nc.fasta 
vsearch v1.9.5_osx_x86_64, 8.0GB RAM, 4 cores 
https://github.com/torognes/vsearch 
 
Reading file seqs_u_mc2_cent.fasta 100%   
2823268 nt in 11209 seqs, min 251, max 254, avg 252 
Sorting by abundance 100% 
Counting unique k-mers 100%   
Detecting chimeras 100%   
Found 9155 (81.7%) chimeras, 2053 (18.3%) non-
chimeras, 
and 1 (0.0%) suspicious candidates in 11209 
sequences. 
 
#Chimera detection using a referece database 
(gold.fa) 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ 
vsearch --uchime_ref seqs_u_mc2_cent_nc.fasta --
uchimeout seqs_u_mc2_cent_nc_dn_ref_uchime.txt --
sizeout --db /Users/lawbl09p/Desktop/gold.fa --
chimeras seqs_u_mc2_cent_nc_dn_ref_chimeras.fasta --
nonchimeras seqs_u_mc2_cent_nc_dn_ref_nc.fasta 
vsearch v1.9.5_osx_x86_64, 8.0GB RAM, 4 cores 
https://github.com/torognes/vsearch 
 
Reading file /Users/lawbl09p/Desktop/gold.fa 100%   
15230724 nt in 10362 seqs, min 1205, max 1655, avg 
1470 
Counting unique k-mers 100%   
Creating index of unique k-mers 100%   
Detecting chimeras 100%   
Found 228 (11.1%) chimeras, 1817 (88.5%) non-
chimeras, 
and 8 (0.4%) suspicious candidates in 2053 sequences. 
 
#Map original fasta sequences onto chimera filtered 
cluster repset 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ 
vsearch --usearch_global seqs_prinseq_good.fasta -db 
seqs_u_mc2_cent_nc_dn_ref_nc.fasta -id 0.97 -uc 
seqs_u_mc2_cent_nc_dn_ref_nc.uc 
vsearch v1.9.5_osx_x86_64, 8.0GB RAM, 4 cores 
! 271 
https://github.com/torognes/vsearch 
 
Reading file seqs_u_mc2_cent_nc_dn_ref_nc.fasta 100%   
457608 nt in 1817 seqs, min 251, max 253, avg 252 
Masking 100% 
Counting unique k-mers 100%   
Creating index of unique k-mers 100%   
Searching 100%   
Matching query sequences: 2313205 of 2579489 (89.68%) 
 
#Convert uc file to OTU table 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ 
python 
/Users/lawbl09p/Bioinformatics/drive5_py/uc2otutab_mo
d.py seqs_u_mc2_cent_nc_dn_ref_nc.uc > 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table.txt 
 
seqs_u_mc2_cent_nc_dn_ref_nc.uc 100.0%  
 
#Assign taxonomy to rep-set seqs (use SILVA 123 
majority 97% taxonomy) method is blast 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ 
assign_taxonomy.py -i 
seqs_u_mc2_cent_nc_dn_ref_nc.fasta -r 
/Users/lawbl09p/Bioinformatics/SILVA123_QIIME_release
/rep_set/rep_set_16S_only/97/97_otus_16S.fasta -t 
/Users/lawbl09p/Bioinformatics/SILVA123_QIIME_release
/taxonomy/16S_only/97/majority_taxonomy_7_levels.txt 
-o SILVA123_majority_97_taxonomy_blast -m blast 
 
#Convert .txt OTU table to .biom format 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ biom 
convert --table-type="OTU table" -i 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table.txt -o 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table.biom --to-hdf5 
 
#Add taxonomy strings to OTU table (try with blast 
taxonomy file first) 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ biom 
add-metadata --sc-separated taxonomy --observation-
header OTUid,taxonomy --observation-metadata-fp 
SILVA123_majority_97_taxonomy_blast/seqs_u_mc2_cent_n
c_dn_ref_nc_tax_assignments.txt -i 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table.biom -o 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table_wtax.biom 
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#Convert taxonomy OTU table to .txt for 
viewing/editing in excel 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ biom 
convert -i 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table_wtax.biom -o 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table_wtax.txt --
table-type="OTU table" --to-tsv --header-key taxonomy 
 
#Align rep-set seqs for tree building 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ 
align_seqs.py -i seqs_u_mc2_cent_nc_dn_ref_nc.fasta -
o pynast_aligned/ 
 
#Filter alignment for tree building 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ 
filter_alignment.py -i 
pynast_aligned/seqs_u_mc2_cent_nc_dn_ref_nc_aligned.f
asta -m /macqiime/greengenes/lanemask_in_1s_and_0s -o 
pynast_aligned/filtered_alignment/ 
 
#Build tree from rep-set seqs 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ 
make_phylogeny.py -i 
pynast_aligned/filtered_alignment/seqs_u_mc2_cent_nc_
dn_ref_nc_aligned_pfiltered.fasta -o 
pynast_aligned/seqs_u_mc2_cent_nc_dn_ref_nc_phylo.tre 
 
#There were several repeats of samples in this data 
set. Use jackknifed clustering to see whether the 
repeated samples cluster together. 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ 
jackknifed_beta_diversity.py -i 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table_wtax.biom -o 
bdiv_jk5000 -e 5000 -m 
../mapping_files_updated/t2d_map_1N.txt -t 
pynast_aligned/seqs_u_mc2_cent_nc_dn_ref_nc_phylo.tre 
--master_tree full -p qiime_parameters.txt 
 
#Modify otu table in excel. Remove samples with <1000 
sequences, OTUs with <10 sequences and taxa not 
considered likely to be bacterial (chloroplasts, no 
blast hit) (trimmed table). Also combine repeats. 
Then convert this trimmed table back to biom (via 
TextWrangler to change carriage returns to Unix line 
! 273 
returns). The biom file is then passed through 
summarize taxa. 
 
#Check taxonomy of high abundance OTUs 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ 
filter_fasta.py -f 
seqs_u_mc2_cent_nc_dn_ref_nc.fasta -s 
10K_or_higher_list.txt -o 10K_or_higher_list.fasta 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ 
filter_fasta.py -f 
seqs_u_mc2_cent_nc_dn_ref_nc.fasta -s 5K_10K_list.txt 
-o 5K_10K_list.fasta 
 
#Convert table from .txt to .biom 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ biom 
convert --table-type="OTU table" -i 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table_wtax_trimmed_u
pdate.txt -o 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table_wtax_trimmed_u
pdate.biom --to-hdf5 --process-obs-metadata taxonomy 
 
#Run core_diversity with an -e value of 6000 and 
include parameters file, focus on ParticipantGroup in 
mapping file 
MacQIIME micr_93-mac:t2d_split_libs_q19_update $ 
core_diversity_analyses.py -i 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table_wtax_trimmed_u
pdate.biom -o core_output_e6000 -m 
/Users/lawbl09p/160930_Lawley_Run2_fastqs/mapping_fil
es_updated/t2d_map_1N_update.txt -t 
pynast_aligned/seqs_u_mc2_cent_nc_dn_ref_nc_phylo.tre 
-e 6000 -p qiime_parameters.txt -c ParticipantGroup 
 
#Files moved to new location, so new folder and paths 
#Run core_diversity with an -e value of 6000 and 
include parameters file (note that the parameters 
file settings over ride command line settings, so 
ensure that -e is set to 6000 in parameters file), 
with focus on ParticipantGroup,HbA1c in mapping file 
MacQIIME micr_93-mac:Renee_Diabetes $ 
core_diversity_analyses.py -i 
t2d_split_libs_q19_update/seqs_u_mc2_cent_nc_dn_ref_n
c_otu_table_wtax_trimmed_update.biom -o 
t2d_split_libs_q19_update/core_output_e6000_update 
-m mapping_files/t2d_map_1N_update.txt -t 
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t2d_split_libs_q19_update/pynast_aligned/seqs_u_mc2_c
ent_nc_dn_ref_nc_phylo.tre -e 6001 -p 
t2d_split_libs_q19_update/qiime_parameters.txt -c 
ParticipantGroup,HbA1c 
 
#Modify mapping file to change headers for HbA1c and 
FG grouping and rerun beta diversity 
MacQIIME micr80BnnockLab:Renee_Diabetes $ 
beta_diversity_through_plots.py -i 
t2d_split_libs_q19_update/seqs_u_mc2_cent_nc_dn_ref_n
c_otu_table_wtax_trimmed_update.biom -m 
mapping_files/t2d_map_1N_update2.txt -o 
t2d_split_libs_q19_update/biv_6K -t 
t2d_split_libs_q19_update/pynast_aligned/seqs_u_mc2_c
ent_nc_dn_ref_nc_phylo.tre -p 
t2d_split_libs_q19_update/qiime_parameters.txt -e 
6000 
 
#Filter OTU table to remove OTUs present in fewer 
than 25% of samples. There are 88 samples in total, 
so set cutoff to be ‘OTU present in at least 22 
samples’. 
MacQIIME micr_93:t2d_split_libs_q19_update $ 
filter_otus_from_otu_table.py -i 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table_wtax_trimmed_u
pdate.biom -o 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table_wtax_trimmed_u
pdate_filtered.biom -s 22 
 
#Convert filtered OTU table to .txt for 
viewing/editing in excel 
MacQIIME micr_93:t2d_split_libs_q19_update $ biom 
convert -i 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table_wtax_trimmed_u
pdate_filtered.biom -o 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table_wtax_trimmed_u
pdate_filtered.txt --table-type="OTU table" --to-tsv 
--header-key taxonomy 
 
#Run summarize taxa on filtered table, keep absolute 
sequence numbers and re-run to obtain relative 
abundance data (RA). 
MacQIIME micr_93:Renee_observational_study $ 
summarize_taxa.py -i taxa_summary/Filtered\ 
tables/0_OTU_table_filtered_by_prevalence.biom -o 
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taxa_summary/Filtered\ tables/taxa_summary -L 
2,3,4,5,6 -a 
MacQIIME micr_93:Renee_observational_study $ 
summarize_taxa.py -i taxa_summary/Filtered\ 
tables/0_OTU_table_filtered_by_prevalence.biom -o 
taxa_summary/Filtered\ tables/taxa_summary_RA -L 
2,3,4,5,6(
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#Join paired ends 
blair@bb1 Renee_Kiwifruit]$ join_paired_ends.py -f 
170227_Lawley_fastqs Undetermined_S0_L001_R1_001.fastq.gz -r 
170227_Lawley_fastqs/Undetermined_S0_L001_R2_001.fastq.gz -b 
170227_Lawley_fastqs/Undetermined_S0_L001_I1_001.fastq.gz -o 
fastq_join 
 
#Validate mapping file 
blair@bb1 Renee_Kiwifruit]$ validate_mapping_file.py -m 
170227_Lawley_fastqs/kiwifruit_mapping_update.txt -o 
170227_Lawley_fastqs/mapping_validation 
No errors or warnings were found in mapping file. 
 
#Run split libraries 
[blair@bb1 Renee_Kiwifruit]$ split_libraries_fastq.py -i 
fastq_join/fastqjoin.join.fastq -b 
fastq_join/fastqjoin.join_barcodes.fastq -m 
170227_Lawley_fastqs/kiwifruit_mapping_update.txt -q 19 --
barcode_type 12 -o split_libs_q19 
 
#Trim sequences to include those with length 252-254bp 
(move prinseq-lite.pl to Renee_Kiwifruit folder in server 
bb1a) 
blair@bb1 Renee_Kiwifruit]$ perl prinseq-lite.pl -fasta 
split_libs_q19/seqs.fna -min_len 252 -max_len 254 
Input and filter stats: 
 Input sequences: 5,527,067 
 Input bases: 1,398,462,325 
 Input mean length: 253.02 
 Good sequences: 5,502,108 (99.55%) 
 Good bases: 1,391,447,556 
 Good mean length: 252.89 
 Bad sequences: 24,959 (0.45%) 
 Bad bases: 7,014,769 
 Bad mean length: 281.05 
 Sequences filtered by specified parameters: 
 min_len: 14763 
 max_len: 10196 
 
#Start vsearch pipeline 
[blair@bb1 Renee_Kiwifruit]$ vsearch --version 
vsearch v2.0.2_linux_x86_64, 503.9GB RAM, 64 cores 
https://github.com/torognes/vsearch 
 
#Dereplicate sequences 
[blair@bb1 Renee_Kiwifruit]$ vsearch --derep_fulllength 
split_libs_q19/seqs_prinseq_good_JUzV.fasta --sizeout --
relabel Unique --output seqs_u.fasta 
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vsearch v2.0.2_linux_x86_64, 503.9GB RAM, 64 cores 
https://github.com/torognes/vsearch 
 
Reading file split_libs_q19/seqs_prinseq_good_JUzV.fasta 
100%   
1391447556 nt in 5502108 seqs, min 252, max 254, avg 253 
Dereplicating 100%   
Sorting 100% 
944716 unique sequences, avg cluster 5.8, median 1, max 
248301 
Writing output file 100% 
 
#Sort remaining sequences by size of unique clusters 
with a minimum cluster size of 2 (remove singletons) 
[blair@bb1 Renee_Kiwifruit]$ vsearch --sortbysize 
seqs_u.fasta --minsize 2 --relabel OTU_ --sizeout --output 
seqs_u_mc2.fasta --sizein 
vsearch v2.0.2_linux_x86_64, 503.9GB RAM, 64 cores 
https://github.com/torognes/vsearch 
 
Reading file seqs_u.fasta 100%   
238901102 nt in 944716 seqs, min 252, max 254, avg 253 
Getting sizes 100%   
Sorting 100% 
Median abundance: 3 
Writing output 100% 
 
#Cluster sequences at 97% similarity   
[blair@bb1 Renee_Kiwifruit]$ vsearch --cluster_smallmem 
seqs_u_mc2.fasta --id 0.97 --centroids 
seqs_u_mc2_cent.fasta --uc seqs_u_mc2_clust.uc --usersort 
vsearch v2.0.2_linux_x86_64, 503.9GB RAM, 64 cores 
https://github.com/torognes/vsearch 
 
Reading file seqs_u_mc2.fasta 100%   
48108274 nt in 190239 seqs, min 252, max 254, avg 253 
Masking 100%   
Counting unique k-mers 100%   
Clustering 100%   
Sorting clusters 100% 
Writing clusters 100%   
Clusters: 5454 Size min 1, max 9901, avg 34.9 
Singletons: 2473, 1.3% of seqs, 45.3% of clusters 
 
#Chimera detection using a denovo approach 
[blair@bb1 Renee_Kiwifruit]$ vsearch --uchime_denovo 
seqs_u_mc2_cent.fasta --uchimeout 
seqs_u_mc2_cent_uchime.txt --sizeout --chimeras 
seqs_u_mc2_cent_chimeras.fasta --nonchimeras 
seqs_u_mc2_cent_nc.fasta 
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vsearch v2.0.2_linux_x86_64, 503.9GB RAM, 64 cores 
https://github.com/torognes/vsearch 
 
Reading file seqs_u_mc2_cent.fasta 100%   
1379254 nt in 5454 seqs, min 252, max 254, avg 253 
Masking 100%   
Sorting by abundance 100% 
Counting unique k-mers 100%   
Detecting chimeras 100%   
Found 4288 (78.6%) chimeras, 1159 (21.3%) non-chimeras, 
and 7 (0.1%) borderline sequences in 5454 unique 
sequences. 
Taking abundance information into account, this 
corresponds to 
19674 (0.8%) chimeras, 2329940 (99.2%) non-chimeras, 
and 32 (0.0%) borderline sequences in 2349646 total 
sequences. 
 
#Chimera detection using a referece database 
(gold.fa) 
[blair@bb1 Renee_Kiwifruit]$ vsearch --uchime_ref 
seqs_u_mc2_cent_nc.fasta --uchimeout 
seqs_u_mc2_cent_nc_dn_ref_uchime.txt --sizeout --db 
gold_db.fna.txt --chimeras 
seqs_u_mc2_cent_nc_dn_ref_chimeras.fasta --nonchimeras 
seqs_u_mc2_cent_nc_dn_ref_nc.fasta 
vsearch v2.0.2_linux_x86_64, 503.9GB RAM, 64 cores 
https://github.com/torognes/vsearch 
 
Reading file gold_db.fna.txt 100%   
29007378 nt in 20098 seqs, min 320, max 2210, avg 1443 
Masking 100%   
Counting unique k-mers 100%   
Creating index of unique k-mers 100%   
Detecting chimeras 100%   
Found 55 (4.7%) chimeras, 1102 (95.1%) non-chimeras, 
and 2 (0.2%) borderline sequences in 1159 unique 
sequences. 
Taking abundance information into account, this 
corresponds to 
17026 (0.7%) chimeras, 2312897 (99.3%) non-chimeras, 
and 17 (0.0%) borderline sequences in 2329940 total 
sequences. 
 
#Map original fasta sequences onto chimera filtered 
cluster repset 
[blair@bb1 Renee_Kiwifruit]$ vsearch --usearch_global 
split_libs_q19/seqs_prinseq_good_JUzV.fasta -db 
seqs_u_mc2_cent_nc_dn_ref_nc.fasta -id 0.97 -uc 
seqs_u_mc2_cent_nc_dn_ref_nc.uc 
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vsearch v2.0.2_linux_x86_64, 503.9GB RAM, 64 cores 
https://github.com/torognes/vsearch 
 
Reading file seqs_u_mc2_cent_nc_dn_ref_nc.fasta 100%   
278619 nt in 1102 seqs, min 252, max 254, avg 253 
Masking 100%   
Counting unique k-mers 100%   
Creating index of unique k-mers 100%   
Searching 100%   
Matching query sequences: 5310754 of 5502108 (96.52%) 
 
#Convert uc file to OTU table 
[blair@bb1 Renee_Kiwifruit]$ python 
/home/blair/drive5_py/uc2otutab_mod.py 
seqs_u_mc2_cent_nc_dn_ref_nc.uc > 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table.txt 
seqs_u_mc2_cent_nc_dn_ref_nc.uc 100.0% 
 
#Assign taxonomy to rep-set seqs (use SILVA128 
majority 97% taxonomy) method is blast 
[blair@bb1 Renee_Kiwifruit]$ assign_taxonomy.py -i 
seqs_u_mc2_cent_nc_dn_ref_nc.fasta -r 
/home/blair/SILVA/SILVA_128_QIIME_release/rep_set/rep_set_
16S_only/97/97_otus_16S.fasta -t 
/home/blair/SILVA/SILVA_128_QIIME_release/taxonomy/16S_onl
y/97/majority_taxonomy_7_levels.txt -o 
SILVA128_majority_97_taxonomy_blast -m blast 
 
#Convert .txt OTU table to .biom format 
[blair@bb1 Renee_Kiwifruit]$ biom convert --table-
type="OTU table" -i 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table.txt -o 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table.biom --to-hdf5 
 
#Add taxonomy strings to OTU table (try with blast 
taxonomy file first) 
[blair@bb1 Renee_Kiwifruit]$ biom add-metadata --sc-
separated taxonomy --observation-header OTUid,taxonomy --
observation-metadata-fp 
SILVA128_majority_97_taxonomy_blast/seqs_u_mc2_cent_nc_dn_
ref_nc_tax_assignments.txt -i 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table.biom -o 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table_wtax.biom 
 
#Convert taxonomy OTU table to .txt for 
viewing/editing in excel 
[blair@bb1 Renee_Kiwifruit]$ biom convert -i 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table_wtax.biom -o 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table_wtax.txt --table-
type="OTU table" --to-tsv --header-key taxonomy 
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#Align rep-set seqs for tree building 
[blair@bb1 Renee_Kiwifruit]$ align_seqs.py -i 
seqs_u_mc2_cent_nc_dn_ref_nc.fasta -o pynast_aligned/ 
 
#Filter alignment for tree building 
[blair@bb1 Renee_Kiwifruit]$ filter_alignment.py -i 
pynast_aligned/seqs_u_mc2_cent_nc_dn_ref_nc_aligned.fasta 
-m lanemask_in_1s_and_0s -o 
pynast_aligned/filtered_alignment/ 
 
#Build tree from rep-set seqs 
[blair@bb1 Renee_Kiwifruit]$ make_phylogeny.py -i 
pynast_aligned/filtered_alignment/seqs_u_mc2_cent_nc_dn_re
f_nc_aligned_pfiltered.fasta -o 
pynast_aligned/seqs_u_mc2_cent_nc_dn_ref_nc_phylo.tre 
 
#Check taxonomy of 
seqs_u_mc2_cent_nc_dn_ref_nc_otu_table_wtax.txt 
through BLAST (Holding off on BLAST checks to 
determine if required), remove no-blast-hit, 
chloroplast and mitochondria OTUs, sum duplicated 
samples, save as tab delimited text (rename to 
otu_table_dupsum), open in BBEdit and save with Unix 
line feed returns. 
 
#Convert .txt file to .biom file 
[blair@bb1 Renee_Kiwifruit]$ biom convert -i 
otu_table_dupsum.txt -o otu_table_dupsum.biom --to-hdf5 --
table-type="OTU table" --process-obs-metadata taxonomy 
 
#Run core_diversity with an -e value of 39000 with 
parameters file. Target metadata = Individual, Time 
and Individual_time (re-run with e = 37000 to include 
further samples). 
[blair@bb1 Renee_Kiwifruit]$ core_diversity_analyses.py -i 
otu_table_dupsum.biom -o core_output_e39K -m 
170227_Lawley_fastqs/kiwifruit_mapping_analysis.txt -t 
pynast_aligned/seqs_u_mc2_cent_nc_dn_ref_nc_phylo.tre -e 
39000 -p qiime_parameters.txt -c 
Individual,Time,Individual_time 
 
#Run core_diversity with an -e value of 35000 with 
parameters file. Target metadata = Individual, Time 
and Individualtime (re-run on desktop reducing e to 
35K). 
MacQIIME micr_93:split_libs_q19 $ 
core_diversity_analyses.py -i otu_table_dupsum.biom -o 
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core_output_e35K_v2 -m 
../170227_Lawley_fastqs/kiwifruit_mapping_analysis.txt -t 
pynast_aligned/seqs_u_mc2_cent_nc_dn_ref_nc_phylo.tre -e 
35000 -p qiime_parameters.txt -c 
Individual,Time,Individualtime 
 
#Run summarize taxa on full table, keep absolute 
sequence numbers and re-run to obtain relative 
abundance data (RA). 
MacQIIME micr_93:Renee_kiwifruit $ summarize_taxa.py -i 
split_libs_q19/otu_table_dupsum.biom -o 
split_libs_q19/taxa_summary -L 2,5,6,7 -a 
MacQIIME micr_93:Renee_kiwifruit $ summarize_taxa.py -i 
split_libs_q19/otu_table_dupsum.biom -o 
split_libs_q19/taxa_summary_RAbund -L 2,5,6,7 
 
#Run make_emperor to generate a biplot. The input 
file for Family level taxonomy comes from the RA 
summary above. This was modified to reduce taxonomy 
to family name alone. Note that modifying the names 
in excel altered the samples numbers. Sample numbers 
needed to be reinstated via BBedit. Repeat as 
necessary for multiple beta diversity metrics. 
Vectors connect sampls by Individual and then by 
Time. 
MacQIIME micr_93:Renee_kiwifruit $ make_emperor.py -i 
split_libs_q19/core_output_e35K_v2/bdiv_even35000/unweight
ed_unifrac_pc.txt -m 
170227_Lawley_fastqs/kiwifruit_mapping_analysis.txt -t 
split_libs_q19/taxa_summary_RAbund/otu_table_dupsum_L5_sim
ple_names.txt -o 
split_libs_q19/core_output_e35K_v2/bdiv_even35000/unweight
ed_unifrac_biplot --add_vectors Individual,Time -n 20 
 
MacQIIME micr_93:Renee_kiwifruit $ make_emperor.py -i 
split_libs_q19/core_output_e35K_v2/bdiv_even35000/weighted
_unifrac_pc.txt -m 
170227_Lawley_fastqs/kiwifruit_mapping_analysis.txt -t 
split_libs_q19/taxa_summary_RAbund/otu_table_dupsum_L5_sim
ple_names.txt -o 
split_libs_q19/core_output_e35K_v2/bdiv_even35000/weighted
_unifrac_biplot --add_vectors Individual,Time -n 20 
 
MacQIIME micr_93:Renee_kiwifruit $ make_emperor.py -i 
split_libs_q19_Renee_Kiwi/core_output_e35K_v2/bdiv_even350
00/bray_curtis_pc.txt -m 
170227_Lawley_fastqs/kiwifruit_mapping_analysis.txt -t 
split_libs_q19_Renee_Kiwi/taxa_summary_RAbund/otu_table_du
psum_L5_simple_names.txt -o 
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split_libs_q19_Renee_Kiwi/core_output_e35K_v2/bdiv_even350
00/bray_curtiss_biplot --add_vectors Individual,Time -n 20 
 
MacQIIME micr_93:Renee_kiwifruit $ make_emperor.py -i 
split_libs_q19_Renee_Kiwi/core_output_e35K_v2/bdiv_even350
00/canberra_pc.txt -m 
170227_Lawley_fastqs/kiwifruit_mapping_analysis.txt -t 
split_libs_q19_Renee_Kiwi/taxa_summary_RAbund/otu_table_du
psum_L5_simple_names.txt -o 
split_libs_q19_Renee_Kiwi/core_output_e35K_v2/bdiv_even350
00/canberra_biplot --add_vectors Individual,Time -n 20 
 
MacQIIME micr_93:Renee_kiwifruit $ make_emperor.py -i 
split_libs_q19_Renee_Kiwi/core_output_e35K_v2/bdiv_even350
00/euclidean_pc.txt -m 
170227_Lawley_fastqs/kiwifruit_mapping_analysis.txt -t 
split_libs_q19_Renee_Kiwi/taxa_summary_RAbund/otu_table_du
psum_L5_simple_names.txt -o 
split_libs_q19_Renee_Kiwi/core_output_e35K_v2/bdiv_even350
00/euclidean_biplot --add_vectors Individual,Time -n 20 
 
#Compare OTU abundance based on “Time” using 
group_significance.py. To do this the OTU table needs 
to be rarefied and then filtered to remove OTUs that 
are present in fewer than 25% of samples (see 
documentation for group_significance.py for details). 
This can be done using the rarefied table from 
core_output_e35K and filter_otus_from_otu_table.py as 
below. First check that table_even35000.biom is the 
correct table to input then filter. 
MacQIIME micr_93:split_libs_q19 $ biom convert -i 
core_output_e35K_v2/table_even35000.biom -o 
core_output_e35K_v2/table_even35000.txt --table-type="OTU 
table" --to-tsv --header-key taxonomy 
MacQIIME micr_93:split_libs_q19 $ 
filter_otus_from_otu_table.py -i 
core_output_e35K_v2/table_even35000.biom -o 
core_output_e35K_v2/table_even35000_filtered.biom -s 19 
 
#Also filter full table (not sure if this will be of 
use). 
MacQIIME micr_93:split_libs_q19 $ 
filter_otus_from_otu_table.py -i otu_table_dupsum.biom -o 
otu_table_dupsum_filtered.biom -s 19 
 
#Convert filtered OTU table to check that filtering 
worked OK. 
MacQIIME micr_93:split_libs_q19 $ biom convert -i 
otu_table_dupsum_filtered.biom -o 
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otu_table_dupsum_filtered.txt --table-type="OTU table" --
to-tsv --header-key taxonomy 
 
#Run group_significance.py on rarefied and filtered 
table. Start with default Kruskal Wallace test using 
Time grouping. 
MacQIIME micr_93:split_libs_q19 $ group_significance.py -i 
core_output_e35K_v2/table_even35000_filtered.biom -m 
../170227_Lawley_fastqs/kiwifruit_mapping_analysis.txt -c 
Time -o core_output_e35K_v2/gpsig_KW.txt 
 
#Run group_significance.py on rarefied and filtered 
table. Use modified mapping file contaiing only 0 and 
6 week samples. Test with default Kruskal Wallace 
test, then use Mann Whitney test using Time grouping. 
MacQIIME micr_93:split_libs_q19 $ group_significance.py -i 
core_output_e35K_v2/table_even35000_filtered.biom -m 
../170227_Lawley_fastqs/kiwifruit_mapping_analysis_time_0_
6.txt -c Time -o core_output_e35K_v2/gpsig_KW_0_6.txt 
MacQIIME micr_93:split_libs_q19 $ group_significance.py -i 
core_output_e35K_v2/table_even35000_filtered.biom -m 
../170227_Lawley_fastqs/kiwifruit_mapping_analysis_time_0_
6.txt -c Time -o core_output_e35K_v2/gpsig_MW_0_6.txt -s 
mann_whitney_u 
 
#Run group_significance.py on rarefied and filtered 
family level table. Use modified mapping file 
contaiing only 0 and 6 week samples and original 
mapping file. Test with default Kruskal Wallace test 
using Time grouping. 
MacQIIME micr_93:split_libs_q19 $ 
filter_otus_from_otu_table.py -i 
core_output_e35K_v2/taxa_plots/table_mc35000_sorted_L5.bio
m -o 
core_output_e35K_v2/taxa_plots/table_mc35000_sorted_L5_fil
tered.biom -s 19 
MacQIIME micr_93:split_libs_q19 $ group_significance.py -i 
core_output_e35K_v2/taxa_plots/table_mc35000_sorted_L5_fil
tered.biom -m 
../170227_Lawley_fastqs/kiwifruit_mapping_analysis_time_0_
6.txt -c Time -o 
core_output_e35K_v2/gpsig_KW_0_6_family.txt 
Warning: No metadata in biom table. Won't alter 
calculations. 
MacQIIME micr_93:split_libs_q19 $ group_significance.py -i 
core_output_e35K_v2/taxa_plots/table_mc35000_sorted_L5_fil
tered.biom -m 
../170227_Lawley_fastqs/kiwifruit_mapping_analysis.txt -c 
Time -o core_output_e35K_v2/gpsig_KW_family.txt 
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Warning: No metadata in biom table. Won't alter 
calculations. 
 
#Run UPGMA clustering using the beta diversity 
distance matrices from core output. This will 
generate trees where samples can be compared by beta 
diversity distance. 
MacQIIME micr_93:split_libs_q19 $ upgma_cluster.py -i 
core_output_e35K_v2/bdiv_even35000/distance_matrices/ -o 
core_output_e35K_v2/bdiv_even35000/UPGMA_trees/ 
 
#Run jackknifed beta diversity on original OTU table 
with a depth of 35000 seqs. This will output 
jackknifed UPGMA trees and beta diversity. 
MacQIIME micr_93:split_libs_q19 $ 
jackknifed_beta_diversity.py -i otu_table_dupsum.biom -o 
core_output_e35K_v2/jackknifed_bdiv -e 35000 -m 
../170227_Lawley_fastqs/kiwifruit_mapping_analysis.txt -t 
pynast_aligned/seqs_u_mc2_cent_nc_dn_ref_nc_phylo.tre -p 
qiime_parameters.txt 
 
#Generate jackknifed UPGMA tree with bootstrap 
values. 
MacQIIME micr_93:split_libs_q19 $ 
make_bootstrapped_tree.py -m 
core_output_e35K_v2/jackknifed_bdiv/unweighted_unifrac/upg
ma_cmp/master_tree.tre -s 
core_output_e35K_v2/jackknifed_bdiv/unweighted_unifrac/upg
ma_cmp/jackknife_support.txt -o 
core_output_e35K_v2/jackknifed_bdiv/unweighted_unifrac/upg
ma_cmp/jackknife_named_nodes.pdf 
 
#Filter out Coriobacteriaceae OTUs for taxonomy check 
via BLAST. Filtered OTU representative sequences will 
be BLASTed against the NCBI nr database. 
MacQIIME micr_93:Renee_kiwifruit $ filter_fasta.py -f 
split_libs_q19_Renee_Kiwi/seqs_u_mc2_cent_nc_dn_ref_nc.fas
ta -s 
split_libs_q19_Renee_Kiwi/coriobacteriacaeae_list.txt -o 
split_libs_q19_Renee_Kiwi/coriobacteriacaeae_list.fasta 
 
#Run summarize taxa on filtered table (keeping only 
OTUs present at >=25% prevalence), keep absolute 
sequence numbers and generate relative abundances 
(RA) in excel. 
MacQIIME micr_93:split_libs_q19_Renee_Kiwi $ 
summarize_taxa.py -i otu_table_dupsum_filtered.biom -o 
taxa_summary_filtered/ -a -L 2,3,4,5,6,7(
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Appendix C 
 
Proteobacteria and Verrucomicrobia 
The below figures and tables show the results for the phyla Verrucomicrobia and 
Proteobacteria (Tables C.1 and C.2, Figure C.1). The results were not included in the main 
text as these phyla were present in low levels (<1%) in the participants studied. However, as 
other researchers (97, 261) have reported the genus Akkermansia when looking at associations 
with T2DM the results from this research are shown below. This study found no association 
with the RA of Verrucomicrobia and as a result no association with the RA of Akkermansia 
and glycaemic control (Tables C.1 and C.2, Figure C.1). This study also found no association 
with the RA of Proteobacteria and as a result no association with the RA of Escherichia-
Shigella as this was the only genus in this dataset (Tables C.1 and C.2, Figure C.1).  
Table C.1: RA of bacteria present by participants grouped by fasting glucose at the phylum-level 
(n=61). 
RA)of)Bacteria)
(%))
NGT))
(n=33))
Prediabetes)
(n=22))
T2DM))
(n=6))
Total)
(n=61))
p)
Proteobacteria* 0.58((0.2621.31)( 0.27((0.1221.17)( 0.26((0.1620.48)( 0.43((0.1721.24)( 0.257(
Verrucomicrobia* 0.83((0.0523.78)( 0.84((0.0122.31)( 0.30((0.0622.06)( 0.77((0.0322.72)( 0.800(
Data presented as median and interquartile range (25th to 75th percentiles). p values from Wilcoxon summed rank 
tests.  
Groups sharing a common superscript letter denotes the study groups that do not differ significantly from each 
other at the 0.05 level from Post Hoc analysis.  
!
Table C.2: Spearman’s correlation coefficient and the RA of bacteria at the phylum-level and 
measures of glycaemic control (n=61). 
( Fasting)Glucose)(mmol/L)) HbA1c)(mmol/mol))
RA)of)Bacteria)(%)( rs( p( rs( p(
Proteobacteria* 20.161( 0.214( 20.063( 0.630(
Verrucomicrobia* 20.150( 0.248( 0.043( 0.742(
!
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Figure C.1. Bacteria for phyla Verrucomicrobia and Proteobacteria (class, order, family, and genus) 
present in the study dataset. 
!
! !
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Appendix D 
 
Associations of Clinical Characteristics and Self-Reported  
Dietary Intake and the Gut Microbiota 
The Gut Microbiota and Participant Characteristics 
Phylum  
In line with the results in the main body of the thesis, only phyla present with a RA of >1% 
(Actinobacteria, Bacteroidetes and Firmicutes) are presented. Weight (r=0.267, p=0.038) and 
fasting insulin concentrations (r=0.314, p=0.014) were positively associated with the phylum 
Actinobacteria and plasma vitamin C concentration was negatively associated with 
Actinobacteria (Table D.1, Figures D.1-D.3). In contrast, plasma vitamin C concentration was 
also positively correlated with Firmicutes (r=0.351, p=0.007) (Table D.1, Figure D.4). 
No significant association with anthropometric measurements (weight, BMI, waist 
circumference, waist-to-hip ratio and fat mass) and the ratio of the RA of the Firmicutes to 
Bacteroidetes was found (Table D.1). There were no significant associations with gender, 
ethnicity or smoking history and bacteria at the phylum-level (Table D.2).  
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Table D.1: Spearman’s correlation coefficients of bacteria at the phylum-level and other characteristics of the study population. 
Phylum' Actinobacteria+ Bacteroidetes+ Firmicutes+
Firmicutes'to'
Bacteroidetes'Ratio'
Characteristics' rs# rs# rs# rs#
Age' $0.144# 0.039# $0.039# $0.027#
Anthropometry' # # # #
Weight#(kg)# 0.267*# $0.125# 0.033# 0.131#
BMI#(kg/m2)# 0.212# $0.124# $0.046# 0.024#
Waist#circumference#(cm)# 0.205# $0.063# 0.002# 0.062#
Waist$to$hip#ratio## 0.169# $0.225# 0.134# 0.227#
Fat#mass#(%)# 0.182# 0.091# $0.183# $0.108#
Laboratory'Measures' # # # #
hs$CRP#(mg/L)## 0.090# $0.104# $0.010# 0.101#
Total#cholesterol#(mmol/L)# $0.047# 0.021# 0.120# $0.007#
HDL$cholesterol#(mmol/L)# $0.180# 0.127# 0.072# $0.107#
LDL$cholesterol#(mmol/L)# $0.023# 0.017# 0.073# $0.011#
Triglycerides#(mmol/L)# 0.245# $0.083# $0.056# 0.066#
Cholesterol#(total/HDL)#ratio# 0.124# $0.070# 0.051# 0.068#
Fasting#insulin#(pmol/L)# 0.314*# $0.166# 0.017# 0.151#
Ghrelin#(pmol/L)## $0.140# $0.030# $0.002# 0.029#
Leptin#(ng/mL)## 0.187# 0.044# $0.077# $0.056#
Adiponectin#(µg/mL)## $0.148# 0.051# $0.102# $0.068#
Plasma#vitamin#C#(µmol/L)# $0.450**# 0.047# 0.351**# $0.002#
*Significant at the 0.05 level, **significant at the 0.01 level  
There are missing data for 5 individuals for waist-to-hip ratio (2 × NGT and 3 × prediabetes) and 3 individuals for plasma vitamin C (2 × NGT and 1 × prediabetes). 
!
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Table D.2: RA of bacteria at the phylum-level and gender, ethnicity and smoking status. 
Phylum' Actinobacteria+ Bacteroidetes+ Firmicutes+
Firmicutes'to'
Bacteroidetes'Ratio'
Characteristics' + + + +
Sex'(n=61)' # # # #
Female#(n=38)# 5.8#(3.1$9.9)# 11.6#(6.5$15.4)# 73.4#(68.2$80.3)# 6.2#(4.5$12.7)#
Male#(n=23)# 5.4#(2.2$15.3)# 8.2#(2.9$13.8)# 77.8#(73.5$84.8)# 9.5#(5.3$32.0)#
Ethnicity'(n=61)' # # # #
Non$European#(n=9)# 10.7#(5.7$25.0)# 2.3#(1.6$19.7)# 72.5#(67.8$76.6)# 32.2#(3.5$54.1)#
European#(n=52)# 5.3#(2.5$10.3)# 10.4#(6.2$14.6)# 76.2#(69.2$82.6)# 7.2#(4.8$13.0)#
Smoking'History'(n=53)' # # # #
Current/ex$smoker#(n=23)# 3.9#(2.2$10.7)# 12.6#(8.5$18.0)# 73.5#(67.8$79.7)# 5.4#(4.1$8.3)#
Non$smoker#(n=30)# 5.9#(4.1$11.4)# 10.0#(4.9$13.9)# 75.4#(70.3$84.3)# 7.9#(5.6$15.4)#
Data presented as median and interquartile range (25th to 75th percentiles). *Significant at the 0.05 level from Mann Whitney U Test.  
There are missing data for 8 individuals for smoking history (4 × NGT and 4 × prediabetes). 
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!
Figure D.1. RA of Actinobacteria (%) with weight. 
 
!
Figure D.2. RA of Actinobacteria (%) with plasma insulin concentrations.  
 
4 0 6 0 8 0 1 0 0 1 2 0 1 4 0
0
1 0
2 0
3 0
4 0
W e ig h t  ( k g )
R
A
 o
f
A
c
ti
n
o
b
a
c
te
ri
a
 (
%
)
r = 0 . 2 6 7 ,  p = 0 . 0 3 8
0 5 0 1 0 0 1 5 0 2 0 0 2 5 0
0
1 0
2 0
3 0
P la s m a  I n s u l in  ( p m o l / L )
R
A
 o
f
A
c
ti
n
o
b
a
c
te
ri
a
 (
,%
)
r = 0 . 3 1 4 ,  p = 0 . 0 1 4
! 291 
!
Figure D.3. RA of Actinobacteria (%) with plasma vitamin C concentrations.  
 
!
Figure D.4. RA of Firmicutes (%) with plasma vitamin C concentrations.  
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Actinobacteria. In contrast, the RA of Coriobacteriia was positively associated with weight 
(r=0.383, p=0.002) and BMI (r=0.255, p=0.047) (Table D.4). Collinsella was the only genus 
in the Coriobacteriia class in this dataset. 
Following from the positive association with the phylum Firmicutes and plasma vitamin C 
levels, the class Clostridia (from the phylum Firmicutes) was positively associated with 
plasma vitamin C concentrations (r=0.379, p=0.003) (Table D.4). Although no significant 
association was seen with the RA of the phylum Firmicutes and ethnicity at the class-level the 
RA of Clostridia was significantly higher in European compared to non-European 
participants (p=0.042) (Table D.3). 
While no significant relationships were seen between the phylum Firmicutes and 
anthropometric measures, at the class-level the RA of Erysipelotrichia (from the phylum 
Firmicutes) was positively associated with weight (r=0.331, p=0.009), waist circumference 
(r=0.314, p=0.014) and waist-to-hip ratio (r=0.330, p=0.013) (Table D.4).  
Table D.3: RA of the class Clostridia and gender, ethnicity and smoking status.  
Phylum;(Class( Firmicutes;(Clostridia(
Characteristics( !
Sex((n=61)( !
Female!(n=38)! 68.7!(62.1275.4)!
Male!(n=23)! 70.3!(63.6277.9)!
Ethnicity((n=61)( !
Non2European!(n=9)! 63.5!(56.7268.7)*!
European!(n=52)! 70.5!(63.7276.7)!
Smoking(History((n=53)( !
Current/ex2smoker!(n=23)! 63.6!(59.4275.0)!
Non2smoker!(n=30)! 70.5!(65.4276.1)!
Data presented as median and interquartile range (25th to 75th percentiles). *Significant at the 0.05 level from 
Mann Whitney U Test.  
There are missing data for 8 individuals for smoking history (4 × NGT and 4 × prediabetes). 
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Table D.4: Spearman’s correlation coefficients of bacteria at the class-level significantly associated with characteristic(s) of the study population. 
Phylum;(Class(
Actinobacteria;,,
Actinobacteria,
Actinobacteria;,,
Coriobacteriia,
Firmicutes;,,
Clostridia,
Firmicutes;,,
Erysipelotrichia,
Characteristics( rs# rs# rs# rs#
Age( $0.117# $0.021# $0.057# 0.057#
Anthropometry( # # # #
Weight#(kg)# 0.206# 0.383**# $0.088# 0.331**#
BMI#(kg/m2)# 0.165# 0.255*# $0.148# 0.153#
Waist#circumference#(cm)# 0.162# 0.219# $0.142# 0.314*#
Waist$to$hip#ratio## 0.150# 0.252# $0.003# 0.330*#
Fat#mass#(%)# 0.160# 0.043# $0.224# 0.025#
Lab(Measures( # # # #
hs$CRP#(mg/L)## 0.053# 0.068# $0.053# 0.114#
Total#cholesterol#(mmol/L)# $0.044# $0.021# 0.081# $0.018#
HDL$cholesterol#(mmol/L)# $0.182# $0.121# 0.099# $0.120#
LDL$cholesterol#(mmol/L)# $0.031# 0.038# 0.030# 0.033#
Triglycerides#(mmol/L)# 0.246# 0.084# $0.144# 0.129#
Cholesterol#(total/HDL)#ratio# 0.139# 0.113# $0.007# 0.112#
Fasting#insulin#(pmol/L)# 0.280*# 0.237# $0.086# 0.219#
Ghrelin#(pmol/L)## $0.124# $0.085# $0.017# $0.002#
Leptin#(ng/mL)## 0.164# 0.066# $0.123# 0.044#
Adiponectin#(µg/mL)## $0.164# 0.050# $0.067# $0.205#
Plasma#vitamin#C#(µmol/L)# $0.427**# $0.221# 0.379**# $0.069#
*Significant at the 0.05 level, ** significant at the 0.01 level 
There are missing data for 5 individuals for waist-to-hip ratio (2 × NGT and 3 × prediabetes) and 3 individuals for plasma vitamin C (2 × NGT and 1 × prediabetes) 
! 294 
Order 
Data are not presented at the order-level as all classes contained only a single order.  
Family  
Two orders (Bacteriodales and Clostridiales) branched into eight families. Of these eight 
families, there were associations between the RA of five families (Rikenellaceae, 
Lachnospiraceae, Ruminococcaceae, Peptostreptococcaceae and an unidentified family 
(‘unknown’)) and participant characteristic(s) (Tables D.5 and D.6). 
The positive association of Clostridia with plasma vitamin C concentration seen at the class-
level is from an unidentified family of bacteria (“unknown”) (r=0.287, p=0.029) (Table D.5).  
There are several new associations with taxa at the family-level that do not follow a pattern 
from phylum or class. From the phylum Bacteroidetes, the RA of the family Rikenellaceae 
was found to be negatively associated with weight (r=−0.311, p=0.015), BMI (r=−0.259,  
p=0.044), waist circumference (r=−0.275, p=0.032), waist-to-hip ratio (r=−0.327, p=0.014), 
triglycerides (r=−0.356, p=0.005), insulin (r=−0.401, p=0.001) and was positively associated 
with adiponectin (r=0.252, p=0.050) (Table D.5). European individuals were found to have a 
lower RA of Rikenellaceae (0.4%) compared to non-European individuals (2.0%) (p=0.023, 
Table D.6). 
From the phylum Firmicutes, the RA of Lachnospiraceae was negatively associated with age 
(r=−0.299, p=0.019). The RA of Ruminococcaceae was negatively associated with waist 
circumference (r=−0.279, p=0.030), waist-to-hip ratio (r=−0.329, p=0.013), and insulin 
(r=−0.265, p=0.029) (Table D.5). In addition to the positive association with vitamin C the 
unidentified (‘unknown’) family of bacteria was also negatively associated with BMI 
(r=−0.338, p=0.008), fat mass (r=−3.01, p=0.018), insulin (r=−0.341, p=0.007) and leptin 
(r=−0.297, p=0.020) (Table D.5). Non-European individuals were also found to have a lower 
RA of the unidentified (‘unknown’) family of bacteria (0.2%) compared to European 
individuals (2.0%) (p=0.003) (Table D.6). Females were found to have a lower RA of 
Peptostreptococcaceae (0.6%) compared to males (1.7%) (p=0.037) (Table D.6). 
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Table D.5: Spearman’s correlation coefficients of bacteria at the family-level significantly associated with other characteristic(s) of the study population. 
Phylum;(Class;(Order;(Family(
Bacteroidetes;,
Bacteroidia;,
Bacteroidales;,
Rikenellaceae,
Firmicutes;,
Clostridia;,
Clostridiales;,,
Lachnospiraceae,
Firmicutes;,
Clostridia;,
Clostridiales;,
Ruminococcaceae,
Firmicutes;,
Clostridia;,
Clostridiales;,,
Unknown,
Characteristics( rs# rs# rs# rs#
Age( 0.190# (0.299*# 0.077# 0.250#
Anthropometry( # # # #
Weight#(kg)# (0.311*# 0.071# (0.180# (0.195#
BMI#(kg/m2)# (0.259*# 0.044# (0.155# (0.338**#
Waist#circumference#(cm)# (0.275*# 0.140# (0.279*# (0.250#
Waist(to(hip#ratio## (0.327*# 0.258# (0.329*# (0.186#
Fat#mass#(%)# (0.045# (0.058# (0.094# (0.301*#
Lab(Measures( # # # #
hs(CRP#(mg/L)## (0.196# 0.073# (0.110# (0.020#
Total#cholesterol#(mmol/L)# (0.035# 0.047# 0.015# 0.024#
HDL(cholesterol#(mmol/L)# 0.249# (0.086# 0.175# 0.114#
LDL(cholesterol#(mmol/L)# (0.029# 0.046# (0.035# (0.025#
Triglycerides#(mmol/L)# (0.356**# 0.137# (0.246# (0.212#
Cholesterol#(total/HDL)#ratio# (0.257*# 0.158# (0.173# (0.107#
Fasting#insulin#(pmol/L)# (0.401**# 0.190# (0.265*# (0.341**#
Ghrelin#(pmol/L)## 0.080# (0.023# 0.064# 0.100#
Leptin#(ng/mL)## (0.092# 0.073# (0.141# (0.297*#
Adiponectin#(µg/mL)## 0.252*# (0.184# 0.114# 0.192#
Plasma#vitamin#C#(µmol/L)# 0.207# 0.172# 0.115# 0.287*#
*Significant at the 0.05 level, **significant at the 0.01 level 
There are missing data for 5 individuals for waist-to-hip ratio (2 × NGT and 3 × prediabetes) and 3 individuals for plasma vitamin C (2 × NGT and 1 × prediabetes). 
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Table D.6: RA of bacteria at the family-level and gender, ethnicity and smoking status. 
Phylum;(Class;(Order;(
Family(
(
Characteristics(
Bacteroidetes;,Bacteroidia;,
Bacteroidales;,
Rikenellaceae,
Firmicutes;,Clostridia;,Clostridiales;,
Peptostreptococcaceae(
Firmicutes;,Clostridia;,Clostridiales;,,
Unknown,
Sex((n=61)( # # #
Female#(n=38)# 2.1#(0.9(4.7)# 0.6#(0.1(2.1)*# 1.2#(0.4(4.0)#
Male#(n=23)# 1.7#(0.4(2.6)# 1.7#(0.5(5.6)# 1.4#(0.2(3.8)#
Ethnicity((n=61)( # # #
Non(European#(n=9)# 0.4#(0.2(1.7)*# 0.6#(0.6(1.7)# 0.2#(0.0(0.4)*#
European#(n=52)# 2.0#(1.0(3.4)# 1.0#(0.2(3.5)# 2.0#(0.5(4.5)#
Smoking(History((n=53)( # # #
Current/ex(smoker#(n=23)# 2.2#(1.4(3.1)# 0.7#(0.1(3.3)# 1.1#(0.2(3.3)#
Non(smoker#(n=30)# 2.0#(0.8(3.7)# 0.8#(0.2(2.6)# 1.5#(0.4(3.9)#
Data presented as median and interquartile range (25th to 75th percentiles). *Significant at the 0.05 level from Mann Whitney U Test.  
There are missing data for 8 individuals for smoking history (4 × NGT and 4 × prediabetes). 
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Genus  
Three families (Ruminococcaceae, Lacnospiraceae and Erysipelotrichia all from the phylum 
Firmicutes) from the classes analysed above contained more than one genus, and these 
branched into 14 genera. Of these 14 genera, 11 were significantly associated with participant 
characteristic(s) (Tables D.7 and D.8).  
At the family-level, the RA of Lacnospiraceae was negatively associated with age and at the 
genus-level the RA of Anaerostripes (r=−0.267, p=0.038), Blautia (r=−0.281, p=0.028) and 
Fusicatenibacter (r=−0.271, p=0.033) from the family Lacnospiraceae were negatively 
associated with age (Table D.7). 
The RA of the genus Blautia was also positively associated with waist circumference 
(r=0.276, p=0.031), waist-to-hip ratio (r=0.329, p=0.031), and fasting insulin (r=0.313, 
p=0.014). The RA of the genus Fusicatenibacter was negatively associated with weight 
(r=−0.264, p=0.040) and BMI (r=−0.259, p=0.044) (Table D.7). 
The RA of Dorea was positively associated with weight (r=0.311, p=0.015), BMI (r=0.323, 
p=0.011), waist circumference (r=0.324, p=0.011), triglycerides (r=0.283, p=0.027), 
cholesterol (total/HDL) ratio (r=0.298, p=0.020), fasting insulin (r=0.439, p<0.001) and leptin 
(r=0.301, p=0.018) (Table D.7). 
From the family Ruminococcaceae, there were six genera significantly associated with 
participant characteristics (Tables D.7 and D.8). The RA of Faecalibacterium was negatively 
associated with hs-CRP (r=−0.292, p=0.022). The RA of Ruminococcaceae UCG-002 was 
negatively associated with weight (r=−0.263, p=0.041), waist-to-hip ratio (r=−0.293, 
p=0.029), triglycerides (r=−0.333, p=0.009), cholesterol (total/HDL) ratio (r=−0.362, 
p=0.004), and plasma insulin concentrations (r=−0.355, p=0.005), and positively associated 
with HDL-cholesterol (r=0.292, p=0.022) (Table D.7). The RA of Ruminococcaceae UCG-
002 was also significantly lower in non-European compared to European participants 
(p=0.008) (Table D.8). The RA of Ruminococcaceae UCG-014 was negatively associated 
with BMI (r=−0.294, p=0.022) and was significantly lower in non-European compared to 
European participants (p=0.009) (Table D.8). The RA of Ruminococcus 2 was also 
significantly lower in non-European compared to European participants (p=0.027, Table D.7). 
The RA of Subdoligranulum was negatively associated with HDL-cholesterol (r=−0.275, 
p=0.032) and ghrelin (r=−0.262, p=0.041) and positively associated with triglycerides 
(r=0.345, p=0.006) and cholesterol (total/HDL) ratio (r=0.360, p=0.004) (Table D.7). The RA 
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of [Eubacterium] coprostanoligenes was negatively associated with cholesterol (total/HDL) 
ratio (r=−0.264, p=0.040) (Table D.7). 
At the class-level, the RA of Erysipelotrichia was positively associated with weight, waist 
circumference and waist-to-hip ratio (Table 3.21). The RA of the genus Holdmanella (from 
the class Erysipelotrichia) was also positively associated with weight (r=0.261, p=0.042) 
(Table D.7). 
The associations seen between the RA of the family Rikenellacaea and anthropometric, 
laboratory measures and ethnicity (Tables D.5 and D.6) were not seen at the genus-level. 
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Table D.7: Spearman’s correlation coefficients of bacteria at the genus-level significantly associated with other characteristic(s) of the study population. 
Phylum;(Class;(Order;(
Family(
Firmicutes;Clostridia;Clostridiales;0
Lachnospiraceae0
Firmicutes;Clostridia;Clostridiales;0
Ruminococcaceae0
Firmicutes;0
Erysipelotrichia;0
Erysipelotrichales;0
Erysipelotrichaceae0
Genus(
Anaerostipes0
Blautia0
D
orea0
Fusicatenibacter0
Faecalibacterium
0
Rum
inococcaceae0
U
CG
>0020
Rum
inococcaceae0
U
CG
>0140
Subdoligranulum
0
0[Eubacterium
]0
coprostanoligenes00
H
oldm
anella0
Characteristics( rs# rs# rs# rs# rs# rs# rs# rs# rs# rs#
Age( $0.267*# $0.281*# 0.027# $0.274*# 0.043# 0.038# 0.029# 0.173# 0.082# 0.024#
Anthropometry( # # # # # # # # # #
Weight#(kg)# $0.113# 0.197# 0.311*# $0.264*# $0.209# $0.263*# $0.174# 0.058# 0.090# 0.261*#
BMI#(kg/m2)# $0.132# 0.224# 0.323*# $0.259*# $0.191# $0.236# $0.294*# 0.075# 0.047# 0.198#
Waist#circumference#(cm)# $0.160# 0.276*# 0.324*# $0.214# $0.211# $0.249# $0.247# 0.156# 0.073# 0.225#
Waist$to$hip#ratio## $0.028# 0.329*# 0.256# 0.021# $0.091# $0.293*# $0.159# 0.130# 0.015# 0.011#
Fat#mass#(%)# $0.110# 0.090# 0.238# $0.209# $0.157# $0.076# $0.200# 0.040# $0.066# 0.193#
Lab(Measures( # # # # # # # # # #
hs$CRP#(mg/L)## $0.110# 0.125# 0.175# $0.196# $0.292*# $0.142# $0.149# $0.018# $0.100# 0.223#
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Phylum;(Class;(Order;(
Family(
Firmicutes;Clostridia;Clostridiales;0
Lachnospiraceae0
Firmicutes;Clostridia;Clostridiales;0
Ruminococcaceae0
Firmicutes;0
Erysipelotrichia;0
Erysipelotrichales;0
Erysipelotrichaceae0
Genus(
Anaerostipes0
Blautia0
D
orea0
Fusicatenibacter0
Faecalibacterium
0
Rum
inococcaceae0
U
CG
>0020
Rum
inococcaceae0
U
CG
>0140
Subdoligranulum
0
0[Eubacterium
]0
coprostanoligenes00
H
oldm
anella0
Characteristics( rs# rs# rs# rs# rs# rs# rs# rs# rs# rs#
Total#cholesterol#
(mmol/L)#
$0.058# $0.007# 0.018# 0.139# 0.020# $0.053# 0.010# 0.046# $0.126# $0.074#
HDL$cholesterol#
(mmol/L)#
0.066# $0.159# $0.199# 0.111# 0.093# 0.292*# $0.045# $0.275*# 0.165# $0.194#
LDL$cholesterol#(mmol/L)# $0.050# 0.027# 0.037# 0.093# 0.026# $0.086# 0.019# 0.066# $0.245# $0.016#
Triglycerides#(mmol/L)# $0.081# 0.149# 0.283*# $0.030# $0.154# $0.333**# $0.174# 0.345**# $0.007# $0.047#
Cholesterol#(total/HDL)#
ratio#
$0.196# 0.143# 0.298*# 0.027# $0.113# $0.362**# $0.053# 0.360**# $0.264*# 0.205#
Fasting#insulin#(pmol/L)# $0.038# 0.313*# 0.439**# $0.013# $0.171# $0.355**# $0.201# 0.209# $0.081# 0.113#
Ghrelin#(pmol/L)## 0.178# 0.009# 0.109# 0.153# $0.003# 0.233# 0.051# $0.262*# 0.092# $0.088#
Leptin#(ng/mL)## 0.001# 0.217# 0.301*# $0.083# $0.157# $0.089# $0.175# 0.060# $0.067# 0.174#
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Phylum;(Class;(Order;(
Family(
Firmicutes;Clostridia;Clostridiales;0
Lachnospiraceae0
Firmicutes;Clostridia;Clostridiales;0
Ruminococcaceae0
Firmicutes;0
Erysipelotrichia;0
Erysipelotrichales;0
Erysipelotrichaceae0
Genus(
Anaerostipes0
Blautia0
D
orea0
Fusicatenibacter0
Faecalibacterium
0
Rum
inococcaceae0
U
CG
>0020
Rum
inococcaceae0
U
CG
>0140
Subdoligranulum
0
0[Eubacterium
]0
coprostanoligenes00
H
oldm
anella0
Characteristics( rs# rs# rs# rs# rs# rs# rs# rs# rs# rs#
Adiponectin#(µg/mL)## 0.015# $0.160# $0.095# $0.109# $0.148# 0.224# 0.216# $0.095# $0.018# $0.175#
Plasma#vitamin#C#
(µmol/L)#
0.231# 0.101# $0.235# 0.175# 0.191# 0.303*# 0.084# 0.059# 0.011# 0.066#
*Significant at the 0.05 level, **significant at the 0.01 level 
There are missing data for 5 individuals for waist-to-hip ratio (2 × NGT and 3 × prediabetes) and 3 individuals for plasma vitamin C (2 × NGT and 1 × prediabetes). 
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Table D.8: RA of bacteria at the genus-level and gender, ethnicity and smoking status. 
Phylum;(Class;(Order;(Family;(
Genus(
(
Characteristics(
Firmicutes;0Clostridia;0Clostridiales;0
Ruminococcaceae;00
Ruminococcaceae0UCG>0020
Firmicutes;0Clostridia;0Clostridiales;0
Ruminococcaceae;00
Ruminococcaceae0UCG>0140
Firmicutes;0Clostridia;0Clostridiales;0
Ruminococcaceae;0Ruminococcus020
Sex((n=61)( # # #
Female#(n=38)# 1.0#(0.5$2.7)# 0.6#(0.0$2.7)# 2.7#(0.5$5.5)#
Male#(n=23)# 0.7#(0.2$1.6)# 0.4#(0.0$1.9)# 2.7#(1.1$4.4)#
Ethnicity((n=61)( # # #
Non$European#(n=9)# 0.3#(0.0$0.5)*# 0.0#(0.0$0.0)*# 0.1#(0.0$2.7)*#
European#(n=52)# 1.0#(0.6$2.5)# 1.0#(0.0$2.6)# 3.1#(1.2$5.3)#
Smoking(History((n=53)( # # #
Current/ex$smoker#(n=23)# 1.0#(0.5$2.5)# 0.0#(0.0$1.8)# 4.1#(1.7$6.3)#
Non$smoker#(n=30)# 1.0#(0.3$2.7)# 1.0#(0.1$2.7)# 2.4#(0.4$3.7)#
Data presented as median and interquartile range (25th to 75th percentiles). *Significant at the 0.05 level from Mann Whitney U Test. 
There are missing data for 8 individuals for smoking history (4 × NGT and 4 × prediabetes) 
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Participant Characteristics and Alpha Diversity  
The main trends seen with alpha diversity were a significantly decreased diversity with higher 
triglyceride concentrations (significant for four of the five diversity measures) (Table D.9 and 
Figure D.5) and a significantly increased diversity with higher plasma vitamin C 
concentrations (significant for three of the five diversity measures) (Table D.9 and Figure 
D.6). European individuals also had a significantly increased diversity compared to non-
European individuals (significant for four of the five diversity measures) (Table D.10, Figure 
D.7). 
There was also a significantly increased diversity (whole tree) with age (r=0.256, p=0.046) 
and a decreased diversity (Shannon index) with waist-to-hip ratio (r=−0.269, p=0.045) and 
insulin (r=−0.300, p=0.019); however, these results did not show a consistent pattern across 
the other measures of diversity (Table D.9). 
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Table D.9: Spearman’s correlation coefficient of alpha diversity (at 6000 sequences/sample) with other characteristic(s) of the study population. 
Characteristics* Observed*Species* Whole*Tree*(PD)* Shannon*Index* Simpson’s*Diversity* Chao*Index*
* rs# p## rs# p# rs# p# rs# p# rs# p#
Age* 0.223# 0.083# 0.256# 0.046# 0.213# 0.099# 0.199# 0.124# 0.064# 0.622#
Anthropometry* # # # # # # # # # #
Weight#(kg)# 70.134# 0.303# 70.128# 0.326# 70.179# 0.167# 70.138# 0.288# 70.043# 0.744#
BMI#(kg/m2)# 70.217# 0.093# 70.224# 0.083# 70.234# 0.070# 70.175# 0.176# 70.047# 0.720#
Waist#circumference#(cm)# 70.161# 0.214# 70.176# 0.174# 70.215# 0.096# 70.145# 0.264# 0.085# 0.516#
Waist7to7hip#ratio## 70.163# 0.229# 70.177# 0.193# 70.269# 0.045# 70.217# 0.108# 0.143# 0.293#
Fat#mass#(%)# 70.093# 0.476# 70.093# 0.478# 70.113# 0.386# 70.064# 0.622# 0.007# 0.959#
Laboratory*Measures* # # # # # # # # # #
hs7CRP#(mg/L)## 70.133# 0.309# 70.123# 0.343# 70.094# 0.471# 70.026# 0.844# 70.150# 0.247#
Total#cholesterol#(mmol/L)# 70.159# 0.222# 70.181# 0.162# 70.064# 0.622# 70.016# 0.901# 0.027# 0.838#
HDL7cholesterol#(mmol/L)# 0.072# 0.579# 0.048# 0.711# 0.141# 0.278# 0.111# 0.396# 70.046# 0.724#
LDL7cholesterol#(mmol/L)# 70.183# 0.158# 70.191# 0.141# 70.077# 0.553# 70.029# 0.823# 0.037# 0.777#
Triglycerides#(mmol/L)# 70.282# 0.028# 70.315# 0.013# 70.356# 0.005# 70.275# 0.032# 0.075# 0.566#
Cholesterol#(total/HDL)#ratio# 70.231# 0.073# 70.248# 0.054# 0.212# 0.100# 70.139# 0.285# 0.022# 0.865#
Fasting#insulin#(pmol/L)# 70.191# 0.140# 70.212# 0.100# 70.300# 0.019# 70.243# 0.059# 70.003# 0.984#
Ghrelin#(pmol/L)## 0.167# 0.198# 0.125# 0.336# 0.137# 0.293# 0.080# 0.538# 70.059# 0.654#
Leptin#(ng/mL)## 70.056# 0.668# 70.070# 0.593# 70.112# 0.389# 70.063# 0.628# 70.035# 0.791#
Adiponectin#(µg/mL)## 0.120# 0.358# 0.143# 0.273# 0.200# 0.121# 0.162# 0.212# 70.094# 0.472#
Plasma#vitamin#C#(µmol/L)# 0.319# 0.015# 0.222# 0.094# 0.319# 0.015# 0.263# 0.046# 0.098# 0.463#
There are missing data for 5 individuals for waist-to-hip ratio (2 × NGT and 3 × prediabetes) and 3 individuals for plasma vitamin C (2 × NGT and 1 × prediabetes). 
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Table D.10: Diversity at 6000 sequences/sample and participants grouped by smoking status, sex and ethnicity.  
# Smoking*Status*(n=53)* Sex*(n=61)* Ethnicity*(n=61)*
Diversity*
Measure*
Current/*
exLsmoker*
(n=23)*
NonLsmoker*
(n=30)*
p**
Female*
(n=38)*
Male*
(n=23)*
p*
NonLEuropean*
(n=9)*
European*
(n=52)*
p*
Observed#species# 225#(1677256)# 237#(1997266)# 0.306# 237#(1937260)# 225#(1857249)# 0.547# 165#(1497170)# 240#(2127261)# 0.000#
Whole#tree#(PD)# 20#(15723)# 20#(17722)# 0.379# 20#(17722)# 20#(17722)# 0.572# 16#(15717)# 21#(18722)# 0.000#
Shannon#index# 5.61#(5.3175.89)# 5.78#(5.2476.09)# 0.389# 5.8#(5.475.9)# 5.4#(5.276.0)# 0.422# 4.7#(4.575.3)# 5.8#(5.476.0)# 0.000#
Simpson’s#
diversity#
0.96#(0.9570.97)# 0.97#(0.9570.97)# 0.370# 0.96#(0.9670.97)# 0.96#(0.9570.97)# 0.484# 0.92#(0.9170.96)# 0.96#(0.9570.97)# 0.001#
Chao#index# 333#(2887374)# 309#(2387368)# 0.184# 317#(2487370)# 325#(2837364)# 0.835# 310#(2387354)# 326#(2767370)# 0.440#
Data presented as median and interquartile range (25th to 75th percentiles). *p values from Mann Whitney U Test. 
There is missing data for 8 individuals for smoking history (4 × NGT and 4 × prediabetes). 
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!
Figure D.5. Observed species (at a rarefaction of 6000 sequences/sample) with triglyceride 
concentrations. 
 
!
Figure D.6. Observed species (at a rarefaction of 6000 sequences/sample) with plasma vitamin C 
concentrations.  
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!
Figure D.7. Observed species (at a rarefaction of 6000 sequences/sample) and participants grouped by 
ethnicity.  
!
Gut Microbiota and Self-Reported Dietary Intake 
Phylum 
In line with the results in the main body of the thesis, only phyla present with a RA of >1% 
are presented. The only significant dietary association at the phylum-level was a positive 
association between non-starchy vegetable intake and the RA of Actinobacteria (r=0.319, 
p=0.012) (Table D.11, Figure D.8).  
!
Figure D.8. RA of Actinobacteria (%) with non-starchy vegetable intake. 
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Table D.11: Spearman’s correlation coefficients of bacteria at the phylum-level and daily dietary intake of the study population. 
Phylum' Actinobacteria+ Bacteroidetes+ Firmicutes+ Firmicutes'to'Bacteroidetes+Ratio'
Daily'Dietary'Intake' rs# rs# rs# rs#
Energy#(kJ)# 0.044# 00.077# 0.211# 0.109#
Fibre#(g)# 00.026# 00.037# 0.053# 0.053#
Protein#(%#of#energy)## 0.001# 0.089# 00.199# 00.115#
Protein#(g)# 0.010# 0.013# 0.066# 00.007#
Total#fat#(%#of#energy)# 00.006# 0.035# 0.125# 00.016#
Total#fat#(g)# 00.010# 00.042# 0.216# 0.075#
Saturated#fat#(%#of#energy)# 00.024# 0.007# 0.152# 0.016#
Saturated#fat#(g)# 00.008# 00.023# 0.205# 0.055#
Monounsaturated#fatty#acids#(MUFA)#(%#of#energy)# 00.072# 0.109# 0.015# 00.089#
MUFA#(g)# 00.031# 0.022# 0.147# 0.010#
Polyunsaturated#fatty#acids#(PUFA)#(%#of#energy)# 0.075# 00.038# 0.049# 0.031#
PUFA#(g)# 0.054# 00.057# 0.154# 0.071#
Total#carbohydrate#(CHO)#(%#of#energy)# 0.053# 00.116# 00.077# 0.093#
Total#CHO#(g)# 0.059# 00.159# 0.190# 0.181#
Sugar#(%#of#energy)# 00.113# 00.002# 0.025# 0.017#
Sugar#(g)# 00.094# 00.011# 0.151# 0.048#
Starch#(%#of#energy)# 0.216# 00.062# 00.245# 0.017#
Starch#(g)# 0.211# 00.134# 0.019# 0.127#
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Phylum' Actinobacteria+ Bacteroidetes+ Firmicutes+
Firmicutes'to'
Bacteroidetes+Ratio'
Daily'Dietary'Intake' rs# rs# rs# rs#
Dietary#vitamin#C#(mg)# 00.111# 00.024# 0.214# 0.058#
Fresh#fruit#(g)# 00.175# 0.025# 0.108# 0.003#
Kiwifruit#(g)# 00.184# 0.007# 0.169# 0.025#
Total#fruit#(g)# 00.220# 0.044# 0.144# 00.009#
Total#vegetables#(g)# 00.082# 0.098# 0.003# 00.078#
Non0starchy#vegetables#(g)# 0.346*# 00.087# 00.176# 0.055#
Starchy#vegetables#(g)# 00.066# 0.031# 00.066# 00.034#
Total#fruit#and#vegetables#(g)# 00.197# 0.048# 0.102# 00.020#
Probiotics#(g)# 00.055# 0.201# 00.029# 00.177#
Grainy#foods#(g)# 0.208# 0.005# 00.105# 00.030#
Nuts#and#seeds#(g)# 00.065# 0.195# 00.084# 00.186#
*Significant at the 0.05 level.  
There are no missing data.  
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In line with the results in the main body of the thesis when reporting results at the class, order, 
family and genus levels, lineages that did not show any divergence between levels are not 
presented. Very low abundance taxa (RA of <0.1%) were also not analysed. Taxa are also 
presented only if a significant result is found for one of the self-reported dietary intake 
measures.  
Class  
The RA of Actinobacteria, Clostridia and Erysipelotrichia were associated with dietary intake 
(Table D.12). The positive association seen with non-starchy vegetables and Actinobacteria at 
the phylum-level is linked with the class Actinobacteria (r=0.319, p=0.012) (Table D.12).  
Although there were no significant associations between the RA of the phylum Firmicutes, at 
the class-level Clostridia was positively associated with dietary vitamin C intake (r=0.253,  
p=0.049) and negatively associated with non-starchy vegetable intake (r=−0.265, p=0.039) 
(Table D.12). Additionally Erysipelotrichia (from the phylum Firmicutes) was negatively 
associated with fibre (r=−0.379, p=0.003), fresh fruit (r=−0.341, p=0.007), total fruit  
(r=−0.316, p=0.013) and nuts and seeds (r=−0.413, p=0.001), and positively associated with 
total fat (as % of energy) (r=0.256, p=0.046) and saturated fat (as % of energy) (r=0.369,  
p=0.003) (Table D.12). 
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Table D.12: Spearman’s correlation coefficients of bacteria at the class-level and the daily dietary intake of the study population.  
Phylum;(Class( Actinobacteria;,Actinobacteria, Firmicutes;,Clostridia, Firmicutes;,Erysipelotrichia,
Daily(Dietary(Intake( rs# rs# rs#
Energy#(kJ)# 0.025# 0.131# 0.104#
Fibre#(g)# 70.014# 0.153# 70.379**#
Protein#(%#of#energy)## 0.032# 70.082# 70.101#
Protein#(g)# 0.041# 0.107# 70.030#
Total#fat#(%#of#energy)# 70.047# 0.002# 0.256*#
Total#fat#(g)# 70.034# 0.120# 0.153#
Saturated#fat#(%#of#energy)# 70.042# 0.033# 0.369**#
Saturated#fat#(g)# 70.023# 0.100# 0.248#
MUFA#(%#of#energy)# 70.091# 70.067# 0.104#
MUFA#(g)# 70.046# 0.067# 0.085#
PUFA#(%#of#energy)# 0.008# 0.019# 70.059#
PUFA#(g)# 0.008# 0.097# 70.023#
Total#CHO#(%#of#energy)# 0.048# 70.050# 70.152#
Total#CHO#(g)# 0.035# 0.124# 70.024#
Sugar#(%#of#energy)# 70.123# 0.028# 70.071#
Sugar#(g)# 70.114# 0.101# 70.041#
Starch#(%#of#energy)# 0.212# 70.211# 70.090#
Starch#(g)# 0.201# 70.037# 0.027#
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Phylum;(Class( Actinobacteria;,Actinobacteria, Firmicutes;,Clostridia, Firmicutes;,Erysipelotrichia,
Daily(Dietary(Intake( rs# rs# rs#
Dietary#vitamin#C#(mg)# 70.103# 0.253*# 70.141#
Fresh#fruit#(g)# 70.176# 0.230# 70.341**#
Kiwifruit#(g)# 70.189# 0.183# 70.056#
Total#fruit#(g)# 70.226# 0.235# 70.316*#
Total#vegetables#(g)# 70.090# 0.039# 70.074#
Non7starchy#vegetables#(g)# 0.319*# 70.265*# 0.234#
Starchy#vegetables#(g)# 70.075# 70.136# 0.227#
Total#fruit#and#vegetables#(g)# 70.212# 0.179# 70.216#
Probiotics#(g)# 70.033# 0.037# 70.103#
Grainy#foods#(g)# 0.248# 70.055# 70.145#
Nuts#and#seeds#(g)# 70.029# 0.041# 70.413**#
*Significant at the 0.05 level, ** significant at the 0.01 level 
There are no missing data. 
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Family 
The RA of six families (Bacteroidaceae, Rikenellaceae, Clostridiaceae1, 
Peptostreptococcaceae, Ruminococcaceae and an unidentified family (‘unknown’)) were 
significantly associated with dietary intake (Table D.13). 
The positive association between the RA of the class Clostridia and dietary vitamin C is 
linked to the RA of two families of bacteria, Clostridiaceae1 (r=0.267, p=0.037) and 
Peptostreptococcaceae (r=0283, p=0.027) (Table D.13). Additionally, the negative 
association of the class Clostridia and non-starchy vegetable intake is linked to the RA of the 
Clostridiaceae1 family (r=−0.254, p=0.048) (Table D.13).  
Clostridiaceae1 was also positively associated with fresh fruit, (r=0.336 p=0.008), and total 
fruit (r=0.274, p=0.032), and is negatively associated with starchy (r=−0.269, p=0.036) and 
non-starchy vegetable intake (r=−0.254, p=0.048) (Table D.13).  
Ruminococcaceae (from the class Clostridia) was positively associated with kiwifruit intake 
(r=0.322, p=0.011) (Table D.13). 
Bacteroidaceae (from the phylum Bacteroidetes) was negatively associated with total 
carbohydrate intake (g/day) (r=−0.293, p=0.022) and positively associated with probiotic 
intake (r=0.253, p=0.049) (Table D.13). Rikenellaceae (from the phylum Bacteroidetes) was 
also positively associated with probiotic intake (r=0.263, p=0.041) (Table D.13).  
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Table D.13 Spearman’s correlation coefficients of bacteria at the family-level and the daily dietary intake of the study population. 
Phylum;(Class;(Order( Bacteroidetes;,Bacteroidia;,
Bacteroidales;,
Firmicutes;,Clostridia;,Clostridiales;,
Family( Bacteroidaceae, Rikenellaceae, Clostridiaceae1, Peptostreptococcaceae, Ruminococcaceae, Unknown,
Daily(Dietary(Intake( rs# rs# rs# rs# rs# rs#
Energy#(kJ)# -0.192# -0.126# 0.127# 0.201# 0.027# 0.062#
Fibre#(g)# -0.104# 0.066# 0.116# 0.058# 0.132# 0.120#
Protein#(%#of#energy)## 0.194# 0.046# -0.064# -0.068# 0.092# -0.001#
Protein#(g)# -0.051# -0.022# 0.066# 0.113# 0.055# 0.057#
Total#fat#(%#of#energy)# 0.013# -0.026# 0.098# 0.068# 0.115# -0.141#
Total#fat#(g)# -0.141# -0.082# 0.127# 0.172# 0.115# 0.012#
Saturated#fat#(%#of#energy)# 0.027# -0.073# -0.026# 0.030# 0.072# -0.227#
Saturated#fat#(g)# -0.088# -0.102# 0.044# 0.118# 0.064# -0.108#
MUFA#(%#of#energy)# 0.028# 0.047# 0.099# 0.015# 0.118# -0.156#
MUFA#(g)# -0.092# -0.044# 0.121# 0.134# 0.125# -0.007#
PUFA#(%#of#energy)# -0.028# -0.078# 0.129# -0.011# -0.092# 0.114#
PUFA#(g)# -0.149# -0.101# 0.154# 0.115# -0.004# 0.146#
Total#CHO#(%#of#energy)# -0.149# -0.015# -0.003# -0.037# -0.114# -0.015#
Total#CHO#(g)# -0.293*# -0.185# 0.062# 0.112# -0.128# -0.007#
Sugar#(%#of#energy)# -0.071# 0.178# 0.137# 0.084# -0.110# 0.041#
Sugar#(g)# -0.183# 0.079# 0.142# 0.137# -0.094# -0.007#
Starch#(%#of#energy)# -0.050# -0.151# -0.117# -0.121# -0.175# -0.043#
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Phylum;(Class;(Order( Bacteroidetes;,Bacteroidia;,
Bacteroidales;,
Firmicutes;,Clostridia;,Clostridiales;,
Family( Bacteroidaceae, Rikenellaceae, Clostridiaceae1, Peptostreptococcaceae, Ruminococcaceae, Unknown,
Daily(Dietary(Intake( rs# rs# rs# rs# rs# rs#
Starch#(g)# -0.215# -0.249# -0.006# 0.044# -0.137# -0.073#
Dietary#vitamin#C#(mg)# -0.064# 0.218# 0.267*# 0.283*# 0.227# 0.168#
Fresh#fruit#(g)# -0.008# 0.177# 0.336**# 0.185# 0.095# 0.266*#
Kiwifruit#(g)# -0.024# 0.157# 0.102# 0.206# 0.322*# 0.100#
Total#fruit#(g)# 0.001# 0.133# 0.274*# 0.184# 0.095# 0.196#
Total#vegetables#(g)# 0.129# 0.211# -0.029# -0.029# 0.234# 0.126#
Non-starchy#vegetables#(g)# -0.083# -0.089# -0.254*# -0.118# -0.165# -0.116#
Starchy#vegetables#(g)# 0.072# 0.012# -0.269*# -0.197# -0.084# 0.147#
Total#fruit#and#vegetables#(g)# 0.050# 0.192# 0.099# 0.043# 0.237# 0.159#
Probiotics#(g)# 0.253*# 0.263*# 0.011# 0.020# 0.224# 0.152#
Grainy#foods#(g)# -0.106# -0.091# -0.059# 0.010# -0.147# 0.055#
Nuts#and#seeds#(g)# 0.116# 0.144# -0.042# -0.176# 0.099# 0.174#
*Significant at the 0.05 level.  
There are no missing data.  
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Genus 
There were nine genera significantly associated with dietary intake (Table D.14). At the 
family-level, Ruminococcaceae was positively associated with kiwifruit consumption; 
however, at the genus-level Subdoligranulum (from the family Ruminococcaceae) was 
negatively associated with kiwifruit consumption (r=−0.265, p=0.039) (Table D.14). There 
were several other associations seen with genera from the family Ruminococcaceae which 
were not seen at the family-level. The RA of Ruminococcaceae UCG-002, was positively 
associated with dietary vitamin C (r=0.276, p=0.031) and probiotic intake (r=0.298, p=0.020). 
The RA of Ruminococcaceae UCG-014 was positively associated with probiotic (r=0.276, 
p=0.031) and nuts and seeds (r=0.271, p=0.035) intake (Table 3.28). The RA of 
Ruminococcus 2 was positively associated with total fat (as % of energy) (r=0.386, p=0.002), 
saturated fat (as % of energy) (r=0.355, p=0.005), MUFA (as % of energy) (r=0.277, 
p=0.031) and negatively associated with carbohydrate intake (as % of energy) (r=−0.283, 
p=0.027) (Table D.14). 
Holdmanella (from the class Erysipelotrichia) was negatively associated with fibre intake 
(r=−0.316, p=0.013) (Table D.14). 
There were no significant associations seen with the family Lachnospiraceae but there were 
several significant associations seen with genera linked to this family (Anaerostipes, Dorea, 
Eubacterium, Roseburia) (Table 3.28). Anaerostipes were negatively associated with MUFA 
intake both as grams per day (r=−0.263, p=0.041) and as a percentage of energy (r=−0.299, 
p=0.019) (Table D.14). Dorea was negatively associated with fibre (r=−0.288, p=0.024), total 
vegetable (r=−0.453, p<0.001), total fruit and vegetable (r=−0.318, p=0.012) and probiotic 
intake (r=−0.340, p=0.007) (Table D.14). Eubacterium was positively associated with starch 
(g/day) (r=0.253, p=0.049), and Roseburia was negatively associated with non-starchy 
vegetable intake (r=−0.304, p=0.017) (Table D.14). 
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Table D.14: Spearman’s correlation coefficients of bacteria at the genus-level and the daily dietary intake of the study population. 
Phylum;(Class;(Order;(Family(
Firmicutes;Clostridia;Clostridiales;0
Lachnospiraceae;0
Firmicutes;Clostridia;Clostridiales;0
Ruminococcaceae;0
Firmicutes;0
Erysipelotrichia;0
Erysipelotrichales;0
Erysipelotrichaceae;(
Genus(
Anaerostipes0
D
orea0
Eubacterium
0
Roseburia0
Rum
inococcaceae00
U
CG
=0020
Rum
inococcaceae00
U
CG
=0140
Rum
inococcus020
Subdoligranulum
0
H
oldm
anella0
Daily(Dietary(Intake! rs! rs! rs! rs! rs! rs! rs! rs! rs!
Energy!(kJ)! -0.146! -0.008! 0.079! 0.030! -0.036! -0.090! 0.071! -0.022! 0.062!
Fibre!(g)! 0.044! -0.288*! 0.147! -0.035! 0.019! 0.103! -0.155! 0.056! -0.316*!
Protein!(%!of!energy)!! -0.004! 0.048! 0.066! -0.036! 0.059! 0.240! -0.127! -0.010! 0.051!
Protein!(g)! -0.045! 0.030! 0.160! 0.045! 0.029! 0.099! -0.053! 0.000! 0.063!
Total!fat!(%!of!energy)! -0.232! 0.068! -0.046! -0.100! 0.001! -0.162! 0.386**! -0.046! 0.116!
Total!fat!(g)! -0.192! -0.021! 0.032! -0.027! 0.030! -0.105! 0.251! -0.054! 0.064!
Saturated!fat!(%!of!energy)! -0.047! 0.073! 0.087! -0.059! -0.027! -0.249! 0.355**! -0.201! 0.120!
Saturated!fat!(g)! -0.116! 0.032! 0.123! -0.009! -0.031! -0.185! 0.230! -0.130! 0.097!
MUFA!(%!of!energy)! -0.299*! 0.032! -0.100! -0.080! 0.037! -0.132! 0.277*! -0.048! 0.110!
MUFA!(g)! -0.263*! -0.019! -0.004! -0.038! 0.056! -0.110! 0.220! -0.046! 0.085!
PUFA!(%!of!energy)! -0.172! -0.059! -0.040! -0.020! -0.033! -0.074! 0.100! 0.212! -0.006!
 
!
318 
Phylum;(Class;(Order;(Family(
Firmicutes;Clostridia;Clostridiales;0
Lachnospiraceae;0
Firmicutes;Clostridia;Clostridiales;0
Ruminococcaceae;0
Firmicutes;0
Erysipelotrichia;0
Erysipelotrichales;0
Erysipelotrichaceae;(
Genus(
Anaerostipes0
D
orea0
Eubacterium
0
Roseburia0
Rum
inococcaceae00
U
CG
=0020
Rum
inococcaceae00
U
CG
=0140
Rum
inococcus020
Subdoligranulum
0
H
oldm
anella0
Daily(Dietary(Intake! rs! rs! rs! rs! rs! rs! rs! rs! rs!
PUFA!(g)! -0.183! -0.104! 0.015! -0.039! 0.008! -0.084! 0.141! 0.096! 0.009!
Total!CHO!(%!of!energy)! 0.148! -0.121! 0.035! -0.070! -0.040! 0.024! -0.283*! 0.102! -0.077!
Total!carbohydrate!(g)! -0.051! 0.039! 0.225! 0.005! -0.213! -0.143! -0.171! 0.027! 0.051!
Sugar!(%!of!energy)! 0.203! 0.005! -0.107! -0.022! 0.021! 0.108! -0.211! -0.021! -0.018!
Sugar!(g)! 0.087! 0.087! 0.036! -0.037! -0.042! -0.015! -0.153! -0.067! 0.060!
Starch!(%!of!energy)! -0.039! -0.200! 0.131! -0.126! -0.120! -0.088! -0.100! 0.120! -0.017!
Starch!(g)! -0.129! -0.069! 0.253*! -0.075! -0.215! -0.186! -0.058! 0.047! 0.056!
Dietary!vitamin!C!(mg)! 0.139! -0.171! -0.169! 0.074! 0.276*! 0.099! -0.040! -0.086! -0.132!
Fresh!fruit!(g)! 0.096! -0.079! -0.082! 0.077! 0.109! 0.001! -0.057! 0.065! -0.050!
Kiwifruit!(g)! 0.060! -0.030! -0.159! 0.080! 0.181! -0.011! -0.020! -0.265*! -0.003!
Total!fruit!(g)! 0.073! -0.056! -0.104! 0.117! 0.065! 0.022! -0.096! 0.082! -0.062!
Total!vegetables!(g)! 0.029! -0.453**! 0.014! -0.111! 0.210! 0.216! 0.050! -0.074! -0.145!
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Phylum;(Class;(Order;(Family(
Firmicutes;Clostridia;Clostridiales;0
Lachnospiraceae;0
Firmicutes;Clostridia;Clostridiales;0
Ruminococcaceae;0
Firmicutes;0
Erysipelotrichia;0
Erysipelotrichales;0
Erysipelotrichaceae;(
Genus(
Anaerostipes0
D
orea0
Eubacterium
0
Roseburia0
Rum
inococcaceae00
U
CG
=0020
Rum
inococcaceae00
U
CG
=0140
Rum
inococcus020
Subdoligranulum
0
H
oldm
anella0
Daily(Dietary(Intake! rs! rs! rs! rs! rs! rs! rs! rs! rs!
Non-starchy!vegetables!(g)! 0.227! -0.137! 0.136! -0.304*! -0.163! -0.036! 0.073! -0.111! -0.219!
Starchy!vegetables!(g)! 0.100! -0.167! 0.010! 0.110! 0.006! 0.063! -0.081! 0.020! 0.091!
Total!fruit!and!vegetables!(g)! 0.095! -0.318*! -0.024! -0.024! 0.163! 0.141! -0.015! -0.005! -0.215!
Probiotics!(g)! 0.036! -0.340**! -0.121! 0.072! 0.298*! 0.276*! 0.008! -0.003! -0.012!
Grainy!foods!(g)! 0.051! -0.126! 0.192! 0.069! -0.134! -0.050! -0.215! 0.150! -0.006!
Nuts!and!seeds!(g)! -0.071! -0.105! -0.013! -0.053! 0.022! 0.271*! -0.085! 0.062! -0.196!
*Significant at the 0.05 level, **significant at the 0.01 level 
There are no missing data 
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Dietary Intake and Alpha Diversity  
The main trends seen with alpha diversity were a significantly decreased diversity with higher 
intakes of total carbohydrates (g/day) (significant for three of the five diversity measures), 
starch (g/day) (significant for four of the five diversity measures) and non-starchy vegetables 
(significant for three of the five diversity measures) (Table D.15, Figures D.9-D.11). 
There was also a significant increase in diversity with a higher intake of protein (g/day and as 
% of energy), dietary vitamin C and fresh fruit, but these results were only significant for one 
to two diversity measures each and so did not show a consistent pattern (Table D.15).  
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Table D.15: Spearman’s correlation coefficient of alpha diversity (at 6000 sequences/sample) with dietary intake. 
Characteristics* Observed*Species* Whole*Tree*(PD)* Shannon*Index* Simpson’s*Diversity* Chao*Index*
Daily*Dietary*Intake* rs# p# rs# p# rs# p# rs# p# rs# p#
Energy#(kJ)# -0.167# 0.199# -0.180# 0.166# -0.100# 0.445# -0.057# 0.664# -0.031# 0.814#
Fibre#(g)# -0.111# 0.395# -0.093# 0.477# 0.026# 0.843# 0.023# 0.861# 0.087# 0.504#
Protein#(%#of#energy)## 0.248# 0.054# 0.295# 0.021# 0.205# 0.113# 0.193# 0.137# 0.378# 0.003#
Protein#(g)# 0.066# 0.614# 0.081# 0.536# 0.093# 0.478# 0.119# 0.363# 0.254# 0.048#
Total#fat#(%#of#energy)# -0.131# 0.315# -0.182# 0.160# -0.103# 0.432# -0.089# 0.495# -0.115# 0.378#
Total#fat#(g)# -0.143# 0.272# -0.191# 0.141# -0.077# 0.556# -0.050# 0.704# -0.065# 0.617#
Saturated#fat#(%#of#energy)# -0.131# 0.314# -0.193# 0.135# -0.176# 0.176# -0.156# 0.231# -0.076# 0.558#
Saturated#fat#(g)# -0.167# 0.198# -0.216# 0.095# -0.147# 0.259# -0.114# 0.383# -0.022# 0.867#
MUFA#(%#of#energy)# -0.118# 0.364# -0.166# 0.202# -0.053# 0.685# -0.052# 0.693# -0.186# 0.151#
MUFA#(g)# -0.129# 0.322# -0.183# 0.158# -0.047# 0.717# -0.026# 0.844# -0.103# 0.428#
PUFA#(%#of#energy)# -0.161# 0.214# -0.179# 0.169# -0.062# 0.635# -0.076# 0.562# 0.038# 0.770#
PUFA#(g)# -0.176# 0.175# -0.207# 0.110# -0.076# 0.561# -0.067# 0.607# 0.016# 0.903#
Total#carbohydrate#(%#of#energy)# -0.093# 0.475# -0.064# 0.623# -0.133# 0.306# -0.154# 0.236# -0.011# 0.931#
Total#carbohydrate#(g)# -0.287# 0.025# -0.285# 0.026# -0.268# 0.037# -0.240# 0.062# -0.050# 0.702#
Sugar#(%#of#energy)# 0.081# 0.536# 0.085# 0.517# 0.081# 0.533# 0.073# 0.574# -0.082# 0.530#
Sugar#(g)# -0.039# 0.768# -0.043# 0.743# -0.017# 0.895# -0.003# 0.985# -0.089# 0.494#
Starch#(%#of#energy)# -0.228# 0.077# -0.189# 0.144# -0.264# 0.040# -0.289# 0.024# 0.084# 0.519#
Starch#(g)# -0.357# 0.005# -0.340# 0.007# -0.359# 0.005# -0.341# 0.007# 0.018# 0.890#
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Characteristics* Observed*Species* Whole*Tree*(PD)* Shannon*Index* Simpson’s*Diversity* Chao*Index*
Daily*Dietary*Intake* rs# p# rs# p# rs# p# rs# p# rs# p#
Dietary#vitamin#C#intake#(mg)# 0.175# 0.176# 0.107# 0.412# 0.243# 0.059# 0.254# 0.048# 0.003# 0.984#
Fresh#fruit#(g)# 0.184# 0.157# 0.142# 0.273# 0.283# 0.027# 0.273# 0.034# 0.015# 0.908#
Kiwifruit#(g)# 0.187# 0.150# 0.120# 0.357# 0.197# 0.129# 0.197# 0.128# 0.054# 0.682#
Total#fruit#(g)# 0.139# 0.287# 0.119# 0.362# 0.243# 0.059# 0.245# 0.057# 0.052# 0.689#
Total#vegetables#(g)# 0.041# 0.752# 0.044# 0.734# 0.098# 0.454# 0.087# 0.503# 0.089# 0.493#
Non-starchy#vegetables#(g)# -0.297# 0.020# -0.226# 0.081# -0.301# 0.018# -0.298# 0.020# 0.048# 0.716#
Starchy#vegetables#(g)# -0.018# 0.893# -0.012# 0.930# -0.034# 0.794# -0.037# 0.777# 0.238# 0.064#
Total#fruit#and#vegetables#(g)# 0.099# 0.450# 0.068# 0.603# 0.142# 0.275# 0.123# 0.346# 0.129# 0.323#
Probiotics#(g)# 0.244# 0.058# 0.178# 0.169# 0.221# 0.087# 0.204# 0.115# 0.239# 0.064#
Grainy#foods#(g)# -0.202# 0.118# -0.163# 0.210# -0.187# 0.149# -0.176# 0.176# 0.073# 0.578#
Nuts#and#seeds#(g)# 0.097# 0.458# 0.098# 0.451# 0.137# 0.292# 0.145# 0.266# 0.219# 0.090#
 
! 323 
!
Figure D.9. Observed species (at a rarefaction of 6000 sequences/sample) with non-starchy vegetable 
intake. 
 
!
Figure D.10. Observed species (at a rarefaction of 6000 sequences/sample) with starch intake. 
 
0 1 0 0 2 0 0 3 0 0 4 0 0
0
1 0 0
2 0 0
3 0 0
4 0 0
N o n - S t a r c h y  V e g e t a b le  I n t a k e  ( g / d a y )
O
b
s
e
rv
e
d
 S
p
e
c
ie
s
r = - 0 . 2 9 7 ,  p = 0 . 0 2 0
0 5 0 1 0 0 1 5 0 2 0 0 2 5 0
0
1 0 0
2 0 0
3 0 0
4 0 0
S t a r c h  I n t a k e  ( g / d a y )
O
b
s
e
rv
e
d
 S
p
e
c
ie
s
r = - 0 . 3 5 7 ,  p = 0 . 0 0 5
! 324 
!
Figure D.11. Observed species (at a rarefaction of 6000 sequences/sample) with carbohydrate intake. 
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Appendix E 
 
Tenericutes, Verrucomicrobia and Proteobacteria 
At the phylum-level the RA of Tenericutes and Verrucomicrobia were not significantly 
different at week 6 (p=1.000 and p=0.520 respectively) and week 12 (p=0.753 and p=0.094 
respectively) when compared to week 0 (Table E.1).  These phyla were not further explored, 
because at the lower taxonomic levels (class, order, family and genus) the phyla do not split 
into multiple orders, family or genera in the study dataset (Figure E.1).  
At the phylum-level the RA of Proteobacteria was also not significantly different at weeks 6 
(p=0.485) and 12 (p=0.931) when compared to week 0 (Table E.1). Due to the low RA, 
Proteobacteria was not explored further and split only at the genus-level to two genera 
(Figure E.2) present in the study dataset. 
Table E.1: RA of bacteria present at the phylum-level at week 0, 6 and 12. 
RA#of#bacteria#(%)# Week#0# Week#6# Week#12#
Proteobacteria* 0.12%(0.03(0.26)% 0.08%(0.03(0.13)% 0.06%(0.02(0.26)%
Tenericutes* 0.00%(0.00(0.13)% 0.00%(0.00(0.06)% 0.00%(0.00(0.01)%
Verrucomicrobia* 0.01%(0.00(0.14)% 0.00%(0.00(0.20)% 0.00%(0.00(0.17)%
Data presented median and interquartile range (25th to 75th percentiles).  
There were no significant differences from post hoc analyses.   
!
 
Figure E.1. Bacteria from the phyla Tenericutes and Verrucomicrobia (class, order, family and genus) 
present in the study dataset. 
!
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Figure E.2. Bacteria from the phylum Proteobacteria (class, order, family and genus) present in the 
study dataset. 
!
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Appendix F 
 
Summary of the Family-Level Taxonomic Groups  
The figures below show the RA of bacteria at the family-level for each individual at weeks 0, 
6 and 12. The families shown in the figures below represent a >99.5% coverage of the 
available sequence data. The figures show how the microbiota composition changed in 
individuals over time and the changes differ between individuals (Figures F.1-F.3). 
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Figure F.1. Summary of family-level taxonomic groups at week 0, 6 and 12. Each individual is shown 
as a separate figure. 
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Figure F.2. Summary of family-level taxonomic groups at week 0, 6 and 12. Each individual is shown 
as a separate figure. 
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Figure F.3. Summary of family-level taxonomic groups at week 0, 6 and 12. Each individual is shown 
as a separate figure. 
!
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